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Abstract
Immunosuppressive therapy for kidney transplantation in
children and adolescents: systematic review and
economic evaluation
Marcela Haasova,1* Tristan Snowsill,1 Tracey Jones-Hughes,1
Louise Crathorne,1 Chris Cooper,1 Jo Varley-Campbell,1
Ruben Mujica-Mota,1 Helen Coelho,1 Nicola Huxley,1 Jenny Lowe,1
Jan Dudley,2 Stephen Marks,3 Chris Hyde,1 Mary Bond1
and Rob Anderson1
1Peninsula Technology Assessment Group (PenTAG), Evidence Synthesis & Modelling for Health
Improvement, University of Exeter, Exeter, UK
2Department of Paediatric Nephrology, Bristol Royal Hospital for Children (University Hospitals
Bristol NHS Foundation Trust), Bristol, UK
3Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS
Foundation Trust, London, UK
*Corresponding author M.Haasova@exeter.ac.uk
Background: End-stage renal disease is a long-term irreversible decline in kidney function requiring kidney
transplantation, haemodialysis or peritoneal dialysis. The preferred option is kidney transplantation
followed by induction and maintenance immunosuppressive therapy to reduce the risk of kidney rejection
and prolong graft survival.
Objectives: To systematically review and update the evidence for the clinical effectiveness and
cost-effectiveness of basiliximab (BAS) (Simulect,® Novartis Pharmaceuticals) and rabbit antihuman thymocyte
immunoglobulin (Thymoglobuline,® Sanofi) as induction therapy and immediate-release tacrolimus [Adoport®
(Sandoz); Capexion® (Mylan); Modigraf® (Astellas Pharma); Perixis® (Accord Healthcare); Prograf® (Astellas
Pharma); Tacni® (Teva); Vivadex® (Dexcel Pharma)], prolonged-release tacrolimus (Advagraf,® Astellas Pharma);
belatacept (BEL) (Nulojix,® Bristol-Myers Squibb), mycophenolate mofetil (MMF) [Arzip® (Zentiva), CellCept®
(Roche Products), Myfenax® (Teva), generic MMF is manufactured by Accord Healthcare, Actavis, Arrow
Pharmaceuticals, Dr Reddy’s Laboratories, Mylan, Sandoz and Wockhardt], mycophenolate sodium, sirolimus
(Rapamune,® Pfizer) and everolimus (Certican,® Novartis Pharmaceuticals) as maintenance therapy in children
and adolescents undergoing renal transplantation.
Data sources: Clinical effectiveness searches were conducted to 7 January 2015 in MEDLINE (via Ovid),
EMBASE (via Ovid), Cochrane Central Register of Controlled Trials (via Wiley Online Library) and Web of
Science [via Institute for Scientific Information (ISI)], Cochrane Database of Systematic Reviews, Database of
Abstracts of Reviews of Effects and Health Technology Assessment (HTA) (The Cochrane Library via Wiley
Online Library) and Health Management Information Consortium (via Ovid). Cost-effectiveness searches
were conducted to 15 January 2015 using a costs or economic literature search filter in MEDLINE
(via Ovid), EMBASE (via Ovid), NHS Economic Evaluation Databases (via Wiley Online Library), Web of
Science (via ISI), Health Economic Evaluations Database (via Wiley Online Library) and EconLit
(via EBSCOhost).
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Review methods: Titles and abstracts were screened according to predefined inclusion criteria, as
were full texts of identified studies. Included studies were extracted and quality appraised. Data were
meta-analysed when appropriate. A new discrete time state transition economic model (semi-Markov) was
developed; graft function, and incidences of acute rejection and new-onset diabetes mellitus were used to
extrapolate graft survival. Recipients were assumed to be in one of three health states: functioning graft,
graft loss or death.
Results: Three randomised controlled trials (RCTs) and four non-RCTs were included. The RCTs only
evaluated BAS and tacrolimus (TAC). No statistically significant differences in key outcomes were found
between BAS and placebo/no induction. Statistically significantly higher graft function (p< 0.01) and
less biopsy-proven acute rejection (odds ratio 0.29, 95% confidence interval 0.15 to 0.57) was found
between TAC and ciclosporin (CSA). Only one cost-effectiveness study was identified, which informed
NICE guidance TA99. BAS [with TAC and azathioprine (AZA)] was predicted to be cost-effective at
£20,000–30,000 per quality-adjusted life year (QALY) versus no induction (BAS was dominant). BAS (with
CSA and MMF) was not predicted to be cost-effective at £20,000–30,000 per QALY versus no induction
(BAS was dominated). TAC (with AZA) was predicted to be cost-effective at £20,000–30,000 per QALY
versus CSA (TAC was dominant). A model based on adult evidence suggests that at a cost-effectiveness
threshold of £20,000–30,000 per QALY, BAS and TAC are cost-effective in all considered combinations;
MMF was also cost-effective with CSA but not TAC.
Limitations: The RCT evidence is very limited; analyses comparing all interventions need to rely on
adult evidence.
Conclusions: TAC is likely to be cost-effective (vs. CSA, in combination with AZA) at £20,000–30,000 per
QALY. Analysis based on one RCT found BAS to be dominant, but analysis based on another RCT found
BAS to be dominated. BAS plus TAC and AZA was predicted to be cost-effective at £20,000–30,000 per
QALY when all regimens were compared using extrapolated adult evidence. High-quality primary
effectiveness research is needed. The UK Renal Registry could form the basis for a prospective primary study.
Study registration: This study is registered as PROSPERO CRD42014013544.
Funding: The National Institute for Health Research HTA programme.
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Glossary
Acute rejection Process by which the graft recipient’s immune system attempts to destroy the graft,
usually within the first 3 months of transplantation.
Cadaveric transplant A transplant kidney removed from someone who has died.
Calcineurin inhibitor Ciclosporin or tacrolimus.
Cytomegalovirus A virus that normally causes only a mild ‘flu-like’ illness. In people with a kidney
transplant, cytomegalovirus can cause a more serious illness, affecting the lungs, liver and blood.
Donation after brain death A donation from people in whom the heart is still beating after brain death
has occurred (heart-beating donors). Most, but not all, cadaveric transplants. The extended criteria donor
kidneys include donations from heart-beating donors who would not normally meet the criteria for
transplantation and are likely to have a lower chance of long-term success.
Donation after circulatory death A donation from people who cannot be diagnosed as brainstem dead
but whose death is verified by the absence of a heart beat (non-heart-beating donors).
Donor A person who donates an organ to another person (the recipient).
Glomerular filtration rate Flow rate of filtered fluid through the kidney, measured directly by injecting a
harmless chemical (e.g. inulin) into the blood and then measuring how much of the chemical is filtered in
a given unit of time.
Graft function A measure of the efficiency of the graft by various markers, for example glomerular
filtration rate and serum creatinine levels.
Graft loss Absence of kidney function occurring any time after transplantation requiring chronic dialysis
and/or retransplantation (excluding loss caused by death).
Haemodialysis Removal of waste products by passing blood out of the body, through a filtering system
(dialyser) and then back to the body.
1-Haplotype identical Human leucocyte antigens are inherited as a set called a ‘haplotype’ from one or
both parents. 1-Haplotype identical is not a ‘perfect’ human leucocyte antigen match; a 2-haplotype
identical is a perfect human leucocyte antigen match.
Living related transplant A kidney donated by a living relative of the recipient. A well-matched living
related transplant is likely to last longer than either a living unrelated transplant or a cadaveric transplant.
Living unrelated transplant A kidney transplant from a living person who is biologically unrelated to
the recipient.
Mycophenolic acid Mycophenolate mofetil or mycophenolate sodium.
Nephritis A general term for inflammation of the kidneys. This is also used as an abbreviation
for glomerulonephritis.
OKT3 A murine monoclonal antibody muromonab-CD3.
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Peritoneal dialysis Removal of waste products using the peritoneum as a filter. Dialysis fluid is pumped
into the peritoneal cavity and waste products and excess fluid are moved from the blood into the dialysis
fluid, which is then drained from the cavity.
Recipient In the context of transplantation, a person who receives an organ from another person
(the donor).
Rejection The process whereby a patient’s immune system recognises a transplant kidney as foreign and
tries to destroy it. Rejection can be acute or chronic.
Renal replacement therapy Dialysis or kidney transplantation.
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Plain English summary
K idney transplantation is the preferred treatment for people with end-stage kidney disease. Withoutimmune-suppressing medications, the transplanted kidney would be rejected or lost. To prevent
rejection and loss, a combination of medications to dampen the immune system are used. The aim of this
assessment was to evaluate the clinical benefits and cost-effectiveness of nine immune-suppressing drugs
in children and adolescents. We searched for relevant studies in major databases, trial registries, systematic
reviews and references of included studies. All included studies were assessed for their quality.
The review included three randomised trials and four non-randomised studies. The randomised trials
evaluated two drugs [basiliximab (BAS) (Simulect,® Novartis Pharmaceuticals) and tacrolimus (TAC)] and
their results were used in cost-effectiveness analyses. No child/adolescent randomised trials were found for
the other immune-suppressing drugs. We found statistically significant improvements in transplanted
kidney function and proven acute rejection for TAC compared with ciclosporin (CSA) in one trial.
The cost-effectiveness analyses suggested that TAC is cost-effective when compared with CSA. BAS was
found to be cost-effective in one trial-based analysis but not to be cost-effective in another. An economic
model, based on evidence from adults, indicated that only one drug combination (BAS followed by
immediate-release TAC and azathioprine) would be cost-effective.
In summary, there is very limited evidence for how effective immune-suppressing drugs are in children and
adolescents, and cost-effective analyses comparing all immune-suppressing medications may need to rely
on results from studies in adults.
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Scientific summary
Background
Chronic kidney disease in childhood leads to lifelong health complications. A long-term progression of
irreversible decline in kidney function to end-stage renal disease will require renal replacement therapy
(kidney transplant, haemodialysis or peritoneal dialysis) for a child or adolescent to survive. The preferred
option is kidney transplantation (transfer of a healthy kidney from a donor to a recipient). Kidneys for
transplantation may be obtained via living donation (related or unrelated), donation after brain death or
donation after circulatory death. Between April 2013 and March 2014, 125 kidney transplant operations
were performed on children and adolescents in the UK.
Following kidney transplantation in children and adolescents, major clinical concerns are acute kidney
rejection, graft loss and growth. Acute kidney rejection occurs when the immune system attempts to
destroy the graft. Immunosuppressive therapy is then implemented to reduce the risk of kidney rejection
and prolong graft survival. Immunosuppression comprises induction and maintenance therapy; induction
involves powerful antirejection drugs taken at the time of transplantation, when the risk of rejection is
highest, and maintenance drugs are less powerful and are used as both initial and long-term therapy.
Objectives
To review and update the evidence for the clinical effectiveness and cost-effectiveness of basiliximab
(BAS) (Simulect,® Novartis Pharmaceuticals) and rabbit antihuman thymocyte immunoglobulin (r-ATG)
(Thymoglobuline,® Sanofi) as induction immunosuppressive therapy and immediate-release tacrolimus
(TAC-IR) [Adoport® (Sandoz); Capexion® (Mylan); Modigraf® (Astellas Pharma); Perixis® (Accord Healthcare);
Prograf® (Astellas Pharma); Tacni® (Teva); Vivadex® (Dexcel Pharma)]; prolonged-release tacrolimus
(TAC-PR) (Advagraf,® Astellas Pharma); belatacept (BEL) (Nulojix,® Bristol-Myers Squibb); mycophenolate
mofetil (MMF) [Arzip® (Zentiva), CellCept® (Roche Products), Myfenax® (Teva), generic MMF is
manufactured by Accord Healthcare, Actavis, Arrow Pharmaceuticals, Dr Reddy’s Laboratories, Mylan,
Sandoz and Wockhardt], mycophenolate sodium (MPS) (Myfortic,® Novartis Pharmaceuticals), sirolimus
(SRL) (Rapamune,® Pfizer), everolimus (EVL) Certican,® Novartis Pharmaceuticals) as maintenance
immunosuppressive therapy in children and adolescents undergoing renal transplantation.
Methods
Clinical effectiveness systematic review
Bibliographic literature searching was conducted on 14 April 2014 (updated 7 January 2015). The searches
for individual studies [randomised controlled trials (RCTs) and controlled clinical trials] took the following
form: (terms for kidney or renal transplant or kidney or renal graft) AND (terms for the interventions under
review) AND (a study design limited to RCTs or controlled trials). Literature searches were not restricted to
child or young adult populations, primarily to preserve the sensitivity of the searches. In order to update
the previous assessment by Yao et al. [Yao G, Albon E, Adi Y, Milford D, Bayliss S, Ready A, et al.
A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive
therapy for renal transplantation in children. Health Technol Assess 2006;10(49)] the searches were date
limited (2002–current). The following databases were searched: MEDLINE and MEDLINE In-Process & Other
Non-Indexed Citations (via Ovid), EMBASE (via Ovid), Cochrane Central Register of Controlled Trials
(via Wiley Online Library) and Web of Science [via Institute for Scientific Information (ISI) – including
conference proceedings]. In addition, the following trials registries were hand-searched in January 2015:
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Current Controlled Trials, ClinicalTrials.gov, Food and Drug Administration website, European Medicines
Agency website (European Public Assessment Reports).
Separate searches were undertaken to identify systematic reviews of RCTs and non-randomised controlled
studies, run from database inception in MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations
(via Ovid), EMBASE (via Ovid), Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts of
Reviews of Effects (DARE) and Health Technology Assessment (HTA) (The Cochrane Library via Wiley Online
Library) and Health Management Information Consortium (via Ovid). These searches took the following
form: (terms for kidney or renal transplant or kidney or renal graft) AND (terms for the interventions under
review) AND (a pragmatic limit to systematic reviews).
Records and subsequent full papers were dual screened for inclusion independently by two researchers.
Disagreements were resolved by discussion, with involvement of a third reviewer. Data were extracted
if appropriate and quality appraisal conducted based on Centre for Reviews and Dissemination
(CRD) guidance.
Data were tabulated and discussed in a narrative review and, when data permitted, meta-analysis was
conducted. Estimates of overall treatment effect and assessment of heterogeneity were performed using a
random-effects model. Odds ratios (ORs) and mean differences were calculated (for binary and continuous
data, respectively).
Cost-effectiveness systematic review
Bibliographic literature searching was conducted on 8 April 2014 (updated 15 January 2015) in MEDLINE
(via Ovid), EMBASE (via Ovid), NHS Economic Evaluation Database (via Wiley Online Library), Web of
Science (via ISI – including conference proceedings), Health Economic Evaluations Database (HEED)
(via Wiley Online Library) and EconLit (EBSCOhost). The searches took the following form: (terms for kidney
or renal transplant or kidney or renal graft) AND (terms for the interventions under review) AND (a costs
or economic literature search filter). The search was date limited 2002–current in line with the previous
assessment, but was not limited by language or to human-only studies.
Records were dual screened by two reviewers (disagreements resolved by discussion). Studies meeting the
criteria for inclusion were assessed by one reviewer using the Evers checklist. Studies were based on
decision models were quality assessed using the Philips checklist.
Economic studies were extracted, summarised and synthesised using tabulated data and narrative synthesis.
Appraisal of company submissions
The appraisal of company submissions focused on their model-based economic analyses. Their systematic
reviews were primarily assessed to establish whether or not any includable RCTs were missed by our
searches. None were found.
Assessment group economic model
A new economic model was developed to address the decision problem in a cost–utility analysis. A discrete
time state transition model (semi-Markov) was employed in which transition probabilities were dependent
on age and time since initial transplantation. A cycle length of one-quarter year was used and transitions
were assumed to occur mid-cycle. A time horizon of 50 years was adopted. Costs were included from a NHS
and Personal Social Services perspective. Health effects were measured in quality-adjusted life-years (QALYs)
and calculated by assuming health state-specific utility decrements from a baseline utility, which was
age-dependent and derived from the Health Survey for England (Health and Social Care Information Centre.
Health Survey for England – 2012. London: Health and Social Care Information Centre; 2013). Costs and
QALYs were discounted at 3.5% per annum and costs were inflated as necessary to 2014/15 prices.
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxx
Model structure
Kidney transplant recipients were assumed to be in one of three health states at any time: functioning
graft (not dependent on dialysis), graft loss (dialysis dependent) or death. In addition to these health states,
for each regimen the incidence of acute rejection (AR), cytomegalovirus (CMV) infection, dyslipidaemia and
new-onset diabetes mellitus after transplantation (NODAT) were estimated, with corresponding costs
(one-off for AR and CMV infection; ongoing for dyslipidaemia and NODAT). NODAT was also associated
with a utility decrement. The incidences of AR and NODAT (and graft function after 12 months) were
used as surrogate determinants of graft survival and the rate of death with functioning graft (DWFG)
(NODAT only).
Up to three retransplantations were modelled, which could take place from the graft loss state.
Pre-emptive retransplantation was also modelled for the initial graft, allowing retransplantation from the
first functioning graft state. Kidney transplant recipients would transition to the next functioning graft state
if retransplantation was successful or to the next graft loss state if it was unsuccessful.
Results
Clinical effectiveness systematic review
Three RCTs are included in the clinical effectiveness systematic review: one new RCT and two RCTs from
the previous assessment.
Four non-RCTs are included in our review, all of which were also included in the previous assessment by
Yao et al. (2006).
Induction therapy
Two RCTs of induction therapy evaluating BAS in children and adolescents were identified in the review.
No RCTs were identified that evaluated r-ATG in children and adolescents. No non-RCTs in the child and
adolescent population evaluated induction therapies.
We found no significant difference in survival, graft loss, graft function and incidences of biopsy-proven
acute rejection (BPAR) and time to BPAR between BAS and placebo (PBO)/no induction.
The results of the current review are similar to the previous HTA (Yao et al. 2006).
Maintenance therapy
One RCT of maintenance therapy in children and adolescents was identified, evaluating tacrolimus (TAC)
compared with ciclosporin (CSA). No RCTs were identified for the other maintenance treatments.
Three non-RCTs evaluating MMF [compared with azathioprine (AZA)] in children and adolescents were
identified. One non-RCT compared TAC+AZA with CSA+MMF. No non-RCTs were identified for the
other maintenance treatments.
From the RCTs, we found no significant difference in survival or graft loss between TAC and CSA.
However, a significantly higher graft function [mean estimated glomerular filtration rate (eGFR) of 71.5
(standard deviation 22.9) ml/minute/1.73m2 in TAC vs. mean eGFR of 53.0 (21.6) ml/minute/1.73 m2 in
CSA, t-test= 4.03; p< 0.01 at 4-year follow-up] and less BPAR [OR 0.29, favours TAC, 95% confidence
interval (CI) 0.15 to 0.57 at 6-month follow-up] was found in TAC compared with CSA.
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The results of the current review for survival, graft function and BPAR are similar to the previous HTA.
However, the child and adolescent RCT evidence identified in the previous HTA review concluded that TAC
lowered graft loss at 2- and 4-year follow-up. The difference in these results is because we excluded graft
loss due to death from all analyses to avoid double counting with another key outcome (mortality) and
because death-censored graft survival is a well-established clinical outcome (to which DWFG is intrinsically
related). After the removal of graft loss due to death from the analyses, the evidence from the RCT
suggested statistically non-significant lower graft loss with TAC compared with CSA (OR 0.41, 95% CI
0.16 to 1.00, and OR 0.43, 95% CI 0.18 to 1.01 at 2 and 4 years’ follow-up, respectively).
Adverse events
More infections were found in children treated with BAS than those treated with PBO (OR 2.23, favours
PBO; 95% CI 1.03 to 4.68) and Grenda et al. (Grenda R, Watson A, Vondrak K, Webb NJ, Beattie J,
Fitzpatrick M, et al. A prospective, randomized, multicenter trial of TAC-based therapy with or without
basiliximab in pediatric renal transplantation. Am J Transplant 2006;6:1666–72) found that toxic
nephropathy and abdominal pain was higher with BAS compared with no induction (p= 0.03 and
p= 0.02, respectively). In one RCT, no statistically significant differences were found between TAC and
CSA for a range of adverse events. In addition, there were no statistically significant differences identified
between MMF and AZA, or between TAC+AZA and CSA+MMF, in the non-randomised evidence.
Cost-effectiveness systematic review
Only one previous cost-effectiveness study of immunosuppressive regimens in children and adolescents
was identified. The study evaluated the cost-effectiveness of adding BAS induction to maintenance therapy
with TAC or CSA combined with AZA and corticosteroids (CCSs). The study also compared CSA with TAC
when given in combination with AZA and CCSs, and, separately, MMF versus AZA as part of the triple
therapy containing CSA and CCSs.
The analysis was conducted using a Markov model of a cohort with starting age ranging between 3 and
13 years and a 10-year horizon, and found that BAS induction resulted in higher costs and more QALYs
than no induction in both the TAC and CSA containing regimens. TAC was found to have a base-case
incremental cost-effectiveness ratio (ICER) (incremental cost per QALY) of £145,000/QALY relative to CSA,
while MMF had an ICER of £195,000/QALY relative to AZA when given as part of a CSA-containing triple
therapy. The sensitivity analysis showed that these results were subject to a high degree of uncertainty.
Analyses based on randomised controlled trial evidence in children
and adolescents
Base-case analysis
Compared with no induction, BAS was predicted to be cost-effective at £20,000–30,000 per QALY when
used with TAC and AZA [based on Grenda et al. (2006), BAS was dominant], but not when used with CSA
and MMF [based on Offner et al. (2008), BAS was dominated].
Based on Trompeter et al. (Trompeter R, Filler G, Webb NJA, Watson AR, Milford DV, Tyden G, et al.
Randomized trial of tracolimus versus cyclosporin microemulsion in renal transplantation. Pediatric
Nephrology 2002;17:141–9), TAC (when used with AZA) was predicted to be cost-effective at
£20,000–30,000 per QALY versus CSA (TAC was dominant).
Scenario analyses
Results were robust to removal of the surrogate relationship between AR and graft survival and/or to
assuming weight would follow the ninth centile for age instead of the median.
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Analyses based on randomised controlled trial evidence in adults
Base case
In the base-case deterministic and probabilistic analyses, BAS, TAC, MMF (only when used with CSA) and
AZA (only when used with TAC) were predicted to be cost-effective at £20,000–30,000 per QALY. When
all regimens were simultaneously compared, only BAS+ TAC+AZA was cost-effective at £20,000–30,000
per QALY.
Scenario analyses
Results were robust to removal of the surrogate relationship between AR and graft survival. When it was
assumed that weight would follow the ninth centile for age instead of the median, BAS and TAC were still
predicted to be cost-effective at £20,000–30,000 per QALY. However, when used with BAS, MPS was
predicted to be cost-effective at £30,000 per QALY (ICER £27,000 per QALY) and MMF was predicted to
be cost-effective at £20,000 per QALY.
Limitations
The number of included randomised trials is low (also comparative non-RCTs may have been missed); only
RCT evidence evaluating BAS and TAC and non-RCT evidence on the use of TAC and MMF was identified.
In addition, no studies reporting on quality of life, adherence, growth or supporting the subgroup analyses
specified in the review protocol were identified. Significantly, cost-effectiveness analyses comparing all
interventions rely on effectiveness estimates from the adult RCTs (which may or may not generalise to
children and adolescents). Finally, some of the newer immunosuppressive drugs, such as EVL and SRL,
would normally be given to children and adolescents after an initial maintenance therapy that consists of
more conventional drugs. This makes it challenging to compare the clinical effectiveness of such regimens
because only children and adolescents who are well maintained on their initial maintenance therapy would
be given such drugs.
Conclusions
There is limited high-quality evidence for the effectiveness of immunosuppressive agents in children and
adolescents. A RCT comparing TAC with CSA demonstrated that TAC resulted in statistically significant
improvements in graft function and AR. No other outcomes in that RCT or the other two included RCTs
were statistically significant.
Based on effectiveness estimates from the adult population, BAS and TAC are cost-effective at a threshold
of £20,000–30,000 per QALY in all considered combinations, while MMF is cost-effective only if used with
CSA. Effectiveness estimates in children and adolescents are only available for BAS and TAC. Based on
these, TAC (used with AZA and compared with CSA) is cost-effective at £20,000–30,000 per QALY,
whereas cost-effectiveness results for BAS are mixed.
Implications for health care
BAS, TAC, MMF and AZA are all used regularly in the NHS. It is not clear whether or not changes to
induction agents used in the NHS would significantly affect costs. However, replacing TAC with TAC-PR,
SRL, BEL or CSA would likely result in increased costs.
It is possible that replacing MMF with AZA (when used with TAC) will result in reduced costs, while it is
likely that replacing these with SRL, EVL or MPS would increase costs.
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Recommendations for research
High-quality primary effectiveness research in children and adolescents is needed. Potentially, the UK Renal
Registry could form the basis for a prospective study. This may require collection of some information not
currently held, but could include health-related quality of life and growth measurements. In addition,
given the perceived importance of adherence to immunosuppression in this population, an objective and
practical measure of adherence is needed. Furthermore, a systematic review of non-RCTs is recommended.
Study registration
The protocol for the HTA is available on National Institute for Health and Care Excellence (NICE) website
[NICE. PROTOCOL: Immunosuppressive therapy for kidney transplantation in children and adolescents
(review of technology appraisal guidance TA99). London: NICE, 2014]. This study is also registered as
PROSPERO CRD42014013544.
Funding
Funding for this study was provided by the HTA programme of the National Institute for Health Research.
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxxiv
Chapter 1 Background
The aim of this assessment is to review and update the evidence of the clinical effectiveness andcost-effectiveness of immunosuppressive regimens for renal transplantation in children and adolescents
[a review of National Institute for Health and Care Excellence (NICE) guidance TA99].1 Two therapy stages
are assessed: induction therapy [regimens including basiliximab (BAS) (Simulect,® Novartis Pharmaceuticals)
or rabbit antihuman thymocyte immunoglobulin (r-ATG) (Thymoglobuline,® Sanofi)] and maintenance
therapy [regimens including immediate-release tacrolimus (TAC-IR) [Adoport® (Sandoz); Capexion® (Mylan),
Modigraf® (Astellas Pharma); Perixis® (Accord Healthcare); Prograf® (Astellas Pharma); Tacni® (Teva);
Vivadex® (Dexcel Pharma)], prolonged-released tacrolimus (TAC-PR) (Advagraf,® Astellas Pharma),
belatacept (BEL) (Nulojix,® Bristol-Myers Squibb), mycophenolate mofetil (MMF) [Arzip® (Zentiva), CellCept®
(Roche Products), Myfenax® (Teva), generic MMF is manufactured by Accord Healthcare, Actavis, Arrow
Pharmaceuticals, Dr Reddy’s Laboratories, Mylan, Sandoz and Wockhardt], mycophenolate sodium (MPS)
(Myfortic,® Novartis Pharmaceuticals), sirolimus (SRL) (Rapamune,® Pfizer) and everolimus (EVL) (Certican,®
Novartis Pharmaceuticals), alone or in combination].
The systematic review and economic evaluation developed to support the current NICE guidance TA99 was
published by Yao et al. in 2006.2 This assessment incorporated relevant evidence presented in the previous
report and report new evidence.
Description of health problem
End-stage renal disease
Chronic kidney disease (CKD) in childhood leads to lifelong health complications, often resulting in the
need of a kidney transplant.3 In 2013, 891 children and adolescents < 18 years of age were receiving
treatment at paediatric nephrology centres for end-stage renal disease (ESRD).4 ESRD is a long-term
irreversible decline in kidney function, for which renal replacement therapy (RRT) is required if the
individual is to survive. ESRD is often the result of an acute kidney injury or primarily a progression from
CKD, which describes abnormal kidney function and/or structure. Although RRT can take a number of
forms (kidney transplantation, haemodialysis and peritoneal dialysis), the preferred option for people with
ESRD is kidney transplantation, rather than dialysis, owing to improved duration and quality of life with
transplantation compared with dialysis.5
Transplantation
Kidney transplantation is the transfer of a healthy kidney from a donor to a recipient. Kidneys for
transplantation may be obtained via living donation (related or unrelated), donation after brain death
(DBD; those with deceased heart-beating who are maintained on a ventilator in an intensive care unit,
with death diagnosed using brain stem tests) or donation after circulatory death [DCD; non-heart-beating
donors who cannot be diagnosed as brainstem dead but whose death is verified by the absence of a heart
beat (cardiac arrest)].
Children and adolescents represent a distinct group of transplant recipients and can differ from adults in
several important aspects, including the cause of established renal failure, the complexity of the surgical
procedure, the metabolism and pharmacokinetic properties of immunosuppressants, the developing
immune system and immune response following organ transplantation, the measures of success of
the transplant procedure, the number and the degree of comorbid conditions, the susceptibility to
post-transplant complications, and the degree of adherence to treatment.6,7 The metabolism of many
immunosuppressive medications substantially differs in young children compared with adults and drug
metabolism changes as children grow and develop.
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Following kidney transplantation, major clinical concerns for children and adolescents are acute kidney
rejection, graft loss and diminished growth. Acute kidney rejection occurs when the immune response
of the graft recipient attempts to destroy the graft as the graft is deemed foreign tissue.5 Therefore,
immunosuppressive therapy is implemented to reduce the risk of kidney rejection and prolong survival of
the graft. Prior to renal transplantation, growth retardation in children and adolescents with CKD may
already be an issue owing to a combination of inadequate nutritional intake, acidosis, renal osteodystrophy
and alterations to the growth hormone insulin-like growth factor.8 However, post transplant, the steroidal
therapy often included in immunosuppression regimens can affect longitudinal growth and calcium/
phosphorous metabolism.9,10
Aetiology, pathology and prognosis
Aetiology
In children, ESRD is usually due to innate structural abnormalities or genetic causes or is acquired in
childhood through glomerulonephritis.11 Figure 1 displays the causative diagnoses for children and
adolescents (< 16 years old) with primary renal disease in 2013.
Pathology
Table 1 displays the distribution of the UK primary renal diagnosis for end-stage renal failure over time,
reported from 1999 to 2003, 2004 to 2008 and 2008 to 2013 in children and adolescents aged
< 16 years. Renal dysplasia, which is abnormal tissue development in the kidney, is the primary renal
disease diagnosis in approximately one-third of all children and adolescents with ESRD.
When chronic renal failure occurs, children and adolescents may experience malaise, nausea, loss of
appetite, change in mental alertness, bone pain, headaches, stunted growth, change in urine outputs,
urinary incontinence, pale skin, bad breath, poor muscle tone, tissue swelling and hearing deficit.
Treatment of chronic renal failure depends on the degree of kidney function that remains and the age of
the child/adolescent. Treatment may include dialysis, kidney transplantation, diet restrictions, diuretic
therapy and medications (to help with growth and prevent bone density losses).12
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FIGURE 1 Causative diagnoses for children and adolescents; primary renal disease percentage in incident and
prevalent children and adolescents with established renal failure patients < 16 years old in 2013. Reproduced with
permission from UK Renal Registry 17th Annual Report (figure 4.3, p. 99).4 The data reported here have been
supplied by the UK Renal Registry of the Renal Association. The interpretation and reporting of these data are the
responsibility of the authors and in no way should be seen as an official policy or interpretation of the UK Renal
Registry or the Renal Association.
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Acute rejection
In patients who survive transplantation, acute rejection (AR) may occur when the immune response of the
host attempts to destroy the graft as the graft is identified as foreign tissue.5 AR is treated by modifying
the immunosuppressive regimen (increasing doses or switching treatments). Untreated AR will ultimately
result in destruction of the graft; however, high levels of immunosuppression may also increase the risk of
other infections and malignancy.5 AR is primarily measured following a biopsy and graded according to
Banff criteria (grades I–III, for which grade III indicates the most severe). The Banff classification13 is:
l Banff grade I: tubulointerstitial inflammation only.
l Banff grade IA: interstitial inflammation moderate–severe and/or tubulitis moderate.
l Banff grade IB: tubulitis severe.
l Banff grade II: intimal arteritis.
l Banff grade IIA: intimal arteritis mild–moderate.
l Banff grade IIB: intimal arteritis severe.
l Banff grade III: transmural arteritis and/or fibrinoid necrosis.
Although the incidence of AR following a transplant is included in this appraisal, its treatment is outside
the scope. In addition to AR affecting the survival of the graft, other reasons which may instigate graft
loss include blood clots, narrowing of an artery, fluid retention around the kidney, side effects of other
medications and recurrent kidney disease.14
It is important to note that failing to stay on the immunosuppression regime prescribed following a kidney
transplant will also significantly increase the risk of AR and/or graft loss.15 If the kidney is lost, ultimately
the patient will need to return/start on dialysis, for which the quality of life is reduced and overall costs
are higher.5
TABLE 1 Number and percentage of children and adolescents under 16 years for whom a primary renal diagnosis
had been reported as a cause of ERF, by 5-year time period and observed change in proportion of children and
adolescents in each diagnostic group
1999–2003 2004–8 2009–13 1999–2013
Primary renal diagnosis n % n % n % % change
Renal dysplasia+ reflux 157 29.1 191 33.7 182 33.7 4.6
Obstructive uropathy 80 14.8 75 13.3 97 18 3.1
Glomerular disease 130 24.1 112 19.8 83 15.4 –8.7
Tubulointerstitial diseases 42 7.8 46 8.1 41 7.6 –0.2
Congenital nephrotic syndrome 27 5 33 5.8 35 6.5 1.5
Metabolic 29 5.4 25 4.4 31 5.7 0.4
Uncertain aetiology 12 2.2 32 5.7 29 5.4 3.1
Renovascular disease 23 4.3 19 3.4 19 3.5 –0.7
Polycystic kidney disease 16 3 19 3.4 19 3.5 0.6
Malignancy and associated disease 10 1.9 9 1.6 4 0.7 –1.1
Drug nephrotoxicity 14 2.6 5 0.9 0 0 –2.6
Note
Six children in 1999–2003, nine in 2004–8 and 20 in 2009–13 with no primary renal diagnosis recorded are excluded from
this table.
Reproduced with permission from UK Renal Registry 17th Annual Report (table. 4.13. p. 102).4 The data reported here have
been supplied by the UK Renal Registry of the Renal Association. The interpretation and reporting of these data are the
responsibility of the authors and in no way should be seen as an official policy or interpretation of the UK Renal Registry or
the Renal Association.
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Graft function
Glomerular filtration rate (GFR) describes the flow rate of filtered fluid through the kidney. GFR is
expressed in terms of volume filtered per unit time [sometimes this is also expressed per average surface
area (1.73m2)]. There are various methods used to calculate GFR [estimated glomerular filtration rate
(eGFR)] from serum creatinine levels, age, sex and ethnic group (e.g. Modification of Diet in Renal Disease,
Cockcroft–Gault, and Nankivell). Different methods are used for children and adolescents (e.g. Schwartz
and Counahan–Barratt equations). Levels of eGFR represent the level of kidney function and Table 2
presents the NICE cut-off values for classification of CKD (NICE guidelines CG182).16 These values apply to
children aged > 2 years and up to (and including) adulthood.17
Some children and adolescents may experience delayed graft function (DGF) after transplantation and
Figure 2 shows a hypothetical graph to explain the relationship between normally functioning grafts, DGF
and primary non-functioning (PNF) grafts. At 7 days post transplant, some of the children and adolescents
who need dialysis and whose grafts are therefore classified as DGF will have grafts that never function.
When this has been established, these grafts are classified as PNF.
Growth
Normal growth is often affected in children and adolescents with ESRD; short stature is diagnosed if the
height standard deviation score (SDS) is < 2.5 of the target height.19 There are three main factors that may
impact post-transplant growth:
l Age at transplantation. Following a transplant, post-transplantation catch-up growth is not uncommon;
however, it is unlikely to be sufficient to compensate for the pre-transplant accrued deficit.20 Data from
the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) indicated that children
< 6 years of age exhibit catch-up growth whereas children > 6 years at the time of transplantation
exhibit limited to no catch-up growth.
l Allograft function. An increase of 1.0mg/dl in serum creatinine level (indicating a decrease in kidney
function) has been associated with a decrease of 0.17 in SDS.21
l Corticosteroid (CCS) dose. For example, reducing steroids to every other day22 and withdrawing or
avoiding steroids23 have been associated with improved growth. Similarly, Grenda et al.24 reported an
increase of 0.13 in SDS in a group of primarily pre-pubertal children who withdrew from steroids on
day 5 compared with those in whom the dose was tapered to 10mg/m2.
TABLE 2 Glomerular filtration rate categories
GFR category GFR (ml/minute/1.73m2) Terms
1 > 90 Normal or high
2 60–89 Mildly decreased
3a 45–59 Mildly to moderately decreased
3b 30–44 Moderately to severely decreased
4 15–29 Severely decreased
5 < 15 Kidney failure
Notes
The eGFR and level of serum creatinine following a transplant can guide postoperative care as indicators of AR, recurrence
of original kidney disease or development of de novo kidney disease.
Reproduced from NICE guidelines CG182.16 © NICE 2014. All rights reserved. NICE copyright material can be downloaded
for private research and study, and may be reproduced for educational and not-for-profit purposes. No reproduction by or
for commercial organisations, or for commercial purposes, is allowed without the written permission of NICE.
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UK data are not available on growth changes following kidney transplant in children and adolescents;
however, data from the NAPRTCS are available. The NAPRTCS 2010 annual report indicates that at
transplantation, the mean height deficits for all children and adolescents is –1.75 SDS (–1.78 for boys and
–1.70 for girls).25 For children and adolescents who have reached their adult height following kidney
transplant (n= 2867), the average SDS is –1.40, with 25% having a SDS of –2.2 or worse and 10% are
> 3.24 SDS below the population average.25 In addition, German data reported by Nissel et al.,26 who
followed 37 children for a mean duration of 8.5 years to monitor their growth, showed that those children
who received their transplant before the start of puberty attained an adult height that was on average
5.2 cm (boys) and 13.0 cm (girls) lower than predicted while those who received their transplant after the
onset of puberty had a final adult height that was on average 12.6 cm (both boys and girls) lower than
the target.
Prognosis
Data collected for survival rates of children and adolescents < 16 years of age starting RRT between 1999
and 2012 were collected from UK paediatric centres.4 The median follow-up time was 3.5 years (ranging
from 1 day to 15 years). There were a total of 99 deaths reported. Table 3 shows the survival hazard ratios
(HRs) (following adjustment for age at start of RRT, sex and RRT modality) and highlights that children
starting RRT at < 2 years of age, compared with 12- to 16-year-olds starting RRT, had a worse survival
outcome with a HR of 5.0.
Various factors may influence survival following a kidney transplant. A study of 1189 child/adolescent
kidney transplants in England between April 2001 and March 2012 found that 33 children and adolescents
did not survive.27 The most common causes of these 33 deaths were renal (n= 8; classified as ESRD, renal
dysplasia and disorder of kidney/ureter), infections (n= 6) and malignancy (n= 5).27 The age of the recipient
was not found to significantly impact patient survival: age 0–1 years (100% survival), age 2–5 years
(96% survival), age 6–12 years (97.5% survival) and age 13–18 years (97.4% survival).27
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FIGURE 2 Hypothetical graph to explain graft function, DGF and primary non-functioning graft. Reproduced with
permission from Bond et al.18 Contains information licensed under the Non-Commercial Government Licence v1.0.
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Important prognostic factors
A number of important factors have been identified within the research literature that may influence
overall survival and graft survival. These factors are summarised below:
l Age: both the age of the recipient and the age of the donor will influence the survival of the
transplant. The number of kidney transplants performed is much lower in infants and small children
than in older children. This has been attributed to some centres keeping a child on dialysis until they
reach an arbitrary age when they are deemed suitable for a transplant.28
l Recipient ethnicity: black patients tend to have worse graft function, shorter graft survival and higher
rates of chronic allograft nephropathy than white patients.29 Racial differences have also been indicated
in American children, with poorer outcomes in black children following a kidney transplant than in
white or Hispanic children.30
l Waiting time to transplant: the longer a person is on dialysis waiting for a kidney transplant, the poorer
their outcomes post transplantation.31
l Cold ischaemia time: the shorter this time (≤ 20 hours), the better the immediate and long-term outcomes.32
l Donor type: receiving a donated kidney from a live donor will probably result in better outcomes than
receiving a kidney from a deceased donor.29 Similarly, receiving a kidney from extended criteria donors
(donors who may for example be older, have a history of diabetes mellitus or hypertension or have an
increased risk of passing on an infection or malignancy) will have inferior graft survival rates and
increased incidences of AR when compared with receiving a standard donated kidney.33
l Immunological risk, to include human leucocyte antigen (HLA) and blood group incompatibility: if the
number of mismatches from the donor to the recipient are higher, there is an increased likelihood of
AR and graft loss.29
l Comorbidities, for example diabetes mellitus, cancer and cardiovascular disease (CVD): the higher a
patient score on the Charlson Comorbidity Index, the lower the patient and graft survival is likely to be.
AR is not significantly correlated to the Charlson Comorbidity Index.34
TABLE 3 Survival hazard ratio during childhood and adolescence for RRT patients
Hazard ratio Confidence interval p-value
Age
0–< 2 years 5.0 2.8–8.8 < 0.0001
2–< 4 years 2.9 1.4–5.7 0.003
4–< 8 years 2.2 1.3–4 0.006
8–< 12 years 1.4 0.7–2.9 0.400
12–< 16 years 1.0 – –
Sex
Female 1.2 0.7–1.9 0.5
Male 1.0 – –
Modality
Dialysis 7.1 4.7–10.7 < 0.0001
Transplant 1.0 – –
Modality, RRT modality.
Note
Survival hazard ratios are adjusted for age at start of RRT, gender and RRT modality; results are presented for children
under 16 years of age because data for the 16- to 18-year-old patients were incomplete.
Reproduced with permission from UK Renal Registry 17th Annual Report (table 4.16, p. 104).4 The data reported here have
been supplied by the UK Renal Registry of the Renal Association. The interpretation and reporting of these data are the
responsibility of the authors and in no way should be seen as an official policy or interpretation of the UK Renal Registry or
the Renal Association.
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Incidence and/or prevalence
In 2013, 891 children and young people < 18 years of age were receiving treatment for ESRD at UK
paediatric nephrology centres, of whom 80.2% had a functioning kidney transplant, 11.7% were receiving
haemodialysis and 8.1% were receiving peritoneal dialysis.4 When comparing RRT data from the most
recent 5-year period (2009–13) with the two previous periods (1999–2003 and 2004–8), a sustained
increase in the number of younger children (aged 0 to < 8 years when starting RRT) can be seen, while the
number of older children (8 to < 16 years when starting RRT) has decreased. Consequently, the total
number of children starting RRT has remained relatively constant; 546 children between 1999 and 2003,
575 children between 2004 and 2008, and 560 children between 2008 and 2013.4
Table 4 presents the number of children and adolescents commencing RRT in 2013 with data presented by
age and by sex.
Although the number of children and adolescents starting RRT has not changed significantly, the number
of children and adolescents actively waiting for a kidney transplant fell from 112 in 2005 to 70 in 2014.
Figure 3 displays the number of children and adolescents on the transplant list both active and suspended
over time from 2005 to March 2014 (when suspension from the list may occur if the transplant cannot go
ahead, e.g. further medical problems making the operation unsafe).
One hundred and twenty five kidney transplant operations were performed on children and adolescents
in the UK between April 2013 and March 2014.32 The total number of transplants in children and
adolescents and the graft type (living, DBD and DCD) performed each year from 2004 to 2014 are
displayed in Figure 4. In children and adolescents, most donated kidneys are from living and DBD donors,
with very few kidneys being form DCD donors.
Overall survival reported in children and adolescents following kidney transplants from deceased and living
donors is similar at both 1- and 5-year follow-up; however, graft survival at 5 years is improved if the
donors are living (Table 5).32
Data on incidence and prevalence of AR in children and adolescents are not available for the UK. However,
they are likely to be similar to those reported in the NAPRTCS, which indicates that for transplants
occurring between 1987 and 2010, the prevalence in children and adolescents of at least one episode of
AR following a kidney transplant is 46% (41% in live donors and 51% in deceased donors).25
TABLE 4 The 2013 UK incidence of established renal failure by age group and sex
Age group All patients n (pmarp) Male n (pmarp) Female n (pmarp) M : F ratio
0–< 2 years 19 (11.8) 13 (15.7) 6 (7.6) 2.1
2–< 4 years 17 (10.6) 11 (13.4) 6 (7.6) 1.7
4–< 8 years 14 (4.5) 4 (2.5) 10 (6.6) 0.4
8–< 12 years 31 (11.0) 20 (13.9) 11 (8.0) 1.7
12–< 16 years 31 (10.7) 12 (8.1) 19 (13.4) 0.6
Under 16 years 112 (9.3) 60 (9.7) 52 (8.8) 1.1
F, female; M, male; pmarp, per million age-related population.
Note
Results are presented for children under 16 years old because data for the 16- to 18-year-old patients were incomplete.
Reproduced with permission from UK Renal Registry 17th Annual Report (table 4.7, p. 100).4 The data reported here have
been supplied by the UK Renal Registry of the Renal Association. The interpretation and reporting of these data are the
responsibility of the authors and in no way should be seen as an official policy or interpretation of the UK Renal Registry or
the Renal Association.
DOI: 10.3310/hta20610 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 61
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Haasova et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
7
2005
0
20
40
60
80
100
120
140
160
180
200
2006 2007 2008 2009 2010 2011 2012 2013 2014
Year
N
u
m
b
er
133 135
118
147
137
149
123
111
103
96
112 115
102
117
105
116
93 88
75 70
21 20 16
30 32 33 30
23 28 26
Active
Suspended
Total
FIGURE 3 Children and adolescents on the kidney-only transplant waiting list at March 2013. Reproduced with
permission from NHS Blood and Transplant.32
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FIGURE 4 Kidney-only transplants in children and adolescents 2004–2014. Reproduced with permission from NHS
Blood and Transplant.32
TABLE 5 Kidney graft and overall survival in children and adolescents in the UK
Kidney graft survival Patient survival
1 year,a % (95% CI) 5 years,b % (95% CI) 1 year,a % (95% CI) 5 years,b % (95% CI)
Deceased donors 96 (93 to 98) 84 (79 to 88) 99 (97 to 100) 99 (96 to 100)
Living donors 95 (92 to 97) 94 (89 to 96) 99 (97 to 100) 99 (96 to 100)
CI, confidence interval.
a Includes transplants performed between 1 April 2009 and 31 March 2013.
b Includes transplants performed between 1 April 2005 and 31 March 2009.
Data source: NHS Blood and Transplant.32
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Impact of kidney transplantation
Significance for patients
Living with ESRD may substantially challenge the well-being of children and adolescents. Not only will the
disease impact physical health, but mental and social health may also be affected owing to increased
hospital visits and the child or adolescent’s inability to take part in the same activities as their peers.35
However, having a kidney transplant will improve the symptoms associated with ESRD and dialysis and
reduce the time spent in hospital.36 The median wait time for a child/adolescent requiring a kidney
transplant in the UK is 342 days.32
Kidney transplantation requires a lifelong regimen of immunosuppressive medication. Immunosuppressants
may produce unpleasant side effects (including possible skin cancer, crumbling bones, fatigue, body hair
growth, swollen gums and weight gain).37 Nevertheless, favourable social and professional outcomes have
been observed from a long-term follow-up (15.6 years± 3 years) of people who had a kidney transplant
as a child (aged 10 years± 5 years).38 Adherence to post-transplant immunosuppressive regimens is
important for favourable clinical outcomes in children and adolescents39 and has been suggested as a core
strategy to improve clinical outcomes.40 In addition, failing to follow treatment may result in an increase in
medical costs.41
Acute rejection is common in the first year after kidney transplantation and treatment of AR involves
a more intensive drug treatment than standard maintenance regimens, which in turn increases the
possibility of adverse events (AEs). Should a graft be lost, the child/adolescent will face another wait for
transplantation (if appropriate) and will need to undergo dialysis while waiting for transplantation
(although a pre-emptive transplantation may be available), or need to undergo dialysis for life where
transplantation is not possible.
The impact on a child/adolescent returning to or starting dialysis (of the psychological burden of graft
failure and going back to a previous treatment) is little researched, but necessarily includes the impact of
being on dialysis per se: dialysis is time-consuming and may affect education and normal family life and
require changes in diet and fluid intake. Common side effects of dialysis (either haemodialysis or peritoneal
dialysis) include fatigue, low blood pressure, invasive staphylococcal infections, muscle cramps, itchy skin,
peritonitis, hernia and weight gain.42
Finally, growth retardation in children and adolescents with ESRD is thought to be a combination of
inadequate nutritional intake, acidosis, renal osteodystrophy and alterations to the growth hormone
insulin-like growth factor.8 Ensuring optimal growth or optimisation of final height is a major concern
for children and adolescents with ESRD, as short stature may have an impact on social development,
self-esteem and quality of life and is associated with an increase in the number of hospitalisations
and behavioural and cognitive disorders, and a decrease in the level of education and employment
in adulthood.20,43–45
Unfortunately, data relating specifically to quality of life are currently available only in the adult population,
among whom there are clear quality-of-life improvements from having a functioning kidney transplant
compared with being on dialysis.46–52
Significance for the NHS
Treatment for ESRD is considered resource-intensive for the NHS because current costs have been
estimated to use 1–2% of the total NHS budget to treat 0.05% of the population (both adult and
child/adolescent).53 Based on data from the Department of Health, it is estimated that in 2008/9, the total
expenditure on ‘renal problems’ in England was £1.3B, representing 1.4% of the NHS expenditure.53
An economic evaluation of treatments for ESRD by de Wit et al.54 showed that transplantation is the most
cost-effective form of RRT with increased quality of life and independence for an individual.
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There are no apparent reasons why RRT demand may dramatically increase in children and adolescents.
However, it is projected that an increasingly overweight population will increase the demand for RRT, with
a consequent increase in pressure on services from renal units and other health-care providers dealing
with comorbidities. Increased resources may be needed for dialysis, surgery, pathology, immunology,
tissue typing, histopathology, radiology, pharmacy and hospital beds. Demand is likely to be particularly
significant in areas where there are large South Asian, African and African Caribbean communities and in
areas of social deprivation, where people are more susceptible to kidney disease.4
Measurement of disease
The outcome of kidney transplants (and of the success of immunosuppressive regimens) can be measured
in a variety of ways. These include:
Short term
l Immediate graft function: the graft works immediately following transplantation, removing the need
for further dialysis.
l Delayed graft function: the graft does not work immediately and dialysis is required during the first
week post transplant. Dialysis has to continue until graft function recovers sufficiently to make it
unnecessary. This period may last up to 12 weeks in some cases.
l Primary non-function: the graft never works after transplantation.
Long term
l Rejection rates: the percentage of grafts that are rejected by the recipients’ bodies; rejection can be
acute or chronic.
l Graft survival: the length of time that a graft functions in the recipient.
l Graft function: a measure of the efficiency of the graft by various markers, for example GFR and serum
creatinine levels.
l Patient survival: how long the recipient survives.
l Quality of life: how a person’s well-being is affected by the transplant.
Current service provision
Management of end-stage kidney disease
End-stage renal disease is primarily managed by RRT. The patient pathway leading to RRT for those with
ESRD can be seen in Figure 5. Once a child/adolescent has been diagnosed with ESRD, the RRT options
are a transplant (from a living or deceased donor) or dialysis (haemodialysis and peritoneal dialysis).
If suitable, the option of a pre-emptive kidney transplant (when transplantation is performed without the
child/adolescent spending any time on dialysis) is also available.
The form of treatment modality at the start of RRT changed from 1999 to 2013 (Figure 6). The primary
changes are an increase in the number of kidney transplants from living donors and a simultaneous
decrease in donations from deceased donors. In addition, an increase in haemodialysis and a concurrent
decrease in peritoneal dialysis are seen (see Figure 6).
The 2013 data suggest that most children and adolescents receive a kidney transplant (78%) and that the
proportion of living and deceased kidney donations is equal: 50% and 50%, respectively (Figure 7).
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FIGURE 5 The care pathway for RRT. Reproduced with permission from The National Service Framework for Renal
Services. Part One: Dialysis and Transplantation.11 © Crown Copyright 2004. Contains public sector information
licensed under the Open Government Licence v3.0.
DOI: 10.3310/hta20610 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 61
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Haasova et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
11
Management of kidney transplants
If transplantation is the chosen method for RRT for a child/adolescent with ESRD then there are three main
service provision steps required for the management of the transplant.
The first of these is organ procurement, which includes the identification and management of potential
donors and assessment of donor suitability. HLAs are carried on cells within the body, enabling the body to
distinguish between its ‘self’ or to recognise ‘non-self’ that should be attacked. The closer the HLA
matching, the less vigorously the body will attack the foreign transplant and, consequently, the chances of
graft survival are improved. HLA mismatch refers to the number of mismatches between the donor and the
recipient at the A, B and DR loci, with a maximum of two mismatches at each locus.32 Therefore, a match
would have a score of zero and a complete mismatch would have a score of six. However, it should be noted
that with the improvements in immunosuppressants, the significance of HLA matching has diminished.55
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FIGURE 6 Type of treatment at start of RRT for incident children and adolescents < 16 years old by 5-year time
period. HD, haemodialysis; PD, peritoneal dialysis. Reproduced with permission from UK Renal Registry 17th
Annual Report (figure 4.4. p. 102).4 The data reported here have been supplied by the UK Renal Registry of the
Renal Association. The interpretation and reporting of these data are the responsibility of the authors and in no
way should be seen as an official policy or interpretation of the UK Renal Registry or the Renal Association.
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FIGURE 7 Renal replacement therapy treatment used by prevalent children and adolescents < 16 years old in 2013.
HD, haemodialysis; PD, peritoneal dialysis. Reproduced with permission from UK Renal Registry 17th Annual Report
(figure 4.1. p. 98).4 The data reported here have been supplied by the UK Renal Registry of the Renal Association.
The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen
as an official policy or interpretation of the UK Renal Registry or the Renal Association.
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The second step is the provision of immunosuppressive therapy. Immunosuppressants are the drugs taken
around the time of, and following, an organ transplant. They are aimed at reducing the body’s ability to
reject the transplant and thus at increasing patient and graft survival and preventing acute and/or chronic
rejection (while minimising associated toxicity, infection and malignancy). Immunosuppressants are
required in some form for all kidney transplant recipients (KTRs), except potentially when the donor is an
identical twin.
The final service provision step is short- and long-term follow-up following transplantation. This step
involves looking for indications of any kidney graft dysfunction and other complications. Complications fall
into four categories.
1. Medical follow-ups to include rejections, nephrotoxicity of calcineurin inhibitors (CNIs) and recurrence of
the native kidney diseases.
2. Anatomic complications of surgery to include renal artery thrombosis, renal artery stenosis, urine leaks
from disruption of the anastomosis, ureteral stenosis and obstruction and lymphocele.
3. Other complications include infection, malignancy, new-onset of diabetes mellitus, liver disease,
hypertension, CVD.
4. Ensuring growth is not impeded and maximal ‘catch-up’ growth is achieved. The 2010 NAPRTCS report
suggests that the average final adult height of a renal transplant recipient has increased significantly
from –1.93 SDS between 1987 and 1991 to –0.94 SDS between 2002 and 2010.25
If the kidney loses its function, many of the physiological changes that occur mimic those seen with
progressive renal diseases from other causes. Therefore, these symptoms should be managed in a similar
way to the non-transplant population. However, it should be noted that the loss of a kidney transplant
carries increased susceptibility to bruising and infection compared with pre-transplant kidney failure.56
Once the kidney is confirmed to have been lost, the graft may or may not need to be surgically removed.
The decision of whether or not the graft is removed is often made on a case-by-case basis taking into
consideration all perceived benefits and risks. The immunosuppression regimen can then be tapered and
withdrawn while the patient returns to dialysis and waits for a new kidney to become available.
Current service cost
The overall cost of CKD to the NHS in England was estimated as £1.45B in 2009–10, with more than half
of total estimated expenditure for RRT.57 The costs of RRT can be divided into costs associated with the
transplantation and costs associated with dialysis. Transplantation costs can include the cost of workup for
transplantation (assessing recipient suitability), maintaining and co-ordinating the waiting list, obtaining
donor kidneys (harvesting, storage and transport for deceased donors; nephrectomy procedure for living
donors), cross-matching for donor–recipient compatibility, the transplantation procedure, induction
immunosuppression, hospital inpatient stay following procedure, initial and long-term maintenance
immunosuppression, prophylaxis and monitoring for infections, monitoring of graft function and general
health, adjustment of immunosuppressant dosages, treatment of AR, and treatment of associated AEs.
Should the kidney be lost, the costs of restarting dialysis (dialysis costs, the cost of treatment for AEs
attributable to dialysis and the cost of dialysis access surgery) would be incurred.
Data from the NHS Reference Costs 2013 to 2014 indicated that the cost of kidney transplantation in those
< 19 years of age is, on average, £20,576.58 Paediatric nephrology outpatient clinics are, on average, £249
and the cost of haemodialysis and peritoneal dialysis is, on average, £79,807 and £41,382, respectively.58
Variation in services
There are currently 13 paediatric renal centres in the UK, nine that offer dialysis and perform
transplantations [Birmingham, Bristol, Glasgow, Leeds, London (Guys and Great Ormond Street),
Nottingham, Belfast and Manchester] and four that offer renal care but not transplantations
(Cardiff, Liverpool, Newcastle and Southampton).
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After kidney transplantation, recipients are prescribed an immunosuppression regimen consisting of both
induction and maintenance therapy. Following this, they are offered check-up appointments with their
clinic (consultant nephrologist) to monitor general health, kidney function, immunosuppressive drugs,
infections (prophylaxis and treatment) and to address any social or psychological concerns. The Renal
Association Guidelines59 suggest the following frequency of clinic appointments:59
l two to three times weekly for the first month after transplantation
l one to two times weekly for months 2 to 3 after transplantation
l every 1 to 2 weeks for months 4 to 6 after transplantation
l every 4 to 6 weeks for months 6 to 12 after transplantation
l once every 3–6 months thereafter
l detailed annual post-operative reviews.
Clinician estimations of average frequency of outpatient visits have been reported as 34.3, 6.3 and
4.7 visits for the first, second and third years post transplant, respectively, with UK database figures
suggesting 39.7, 11.0 and 9.2 visits for the first, second and third years post transplant, respectively.60
Service provision (clinic appointments or other services) is likely to increase if AR occurs (possibly requiring
hospital admission and escalating treatment) and when there is declining graft function (which might
necessitate more regular clinic visits, blood tests and other investigations and changes to treatment
regimens). Patients may also present to their general practitioner (GP) or accident and emergency
department with AEs related to kidney transplantation or immunosuppressive regimen and this may be
followed by an additional referral to the consultant nephrologist or other appropriate specialist (e.g. renal
dietitian), followed by management as required (e.g. additional prescribing and monitoring).
In addition to these services, The Renal Association Guidelines59 also recommend that recipients of a
transplant should have the following:59
l online access to their results via the ‘Renal Patient View’ service
l open access to the renal transplant outpatient service
l an established point of contact for enquiries
l access to patient information (which should be available in both written and electronic formats).
Current National Institute for Health and Care Excellence guidance
Current NICE guidance on immunosuppressive therapy for renal transplantation in children and
adolescents (NICE technology appraisal guidance, TA99) has the following recommendations for induction
and maintenance therapy.1
Induction therapy
Basiliximab or daclizumab (DAC), used as part of a ciclosporin (CSA)-based immunosuppressive regimen,
is recommended as an option for induction therapy in the prophylaxis of acute organ rejection in children
and adolescents undergoing renal transplantation, irrespective of immunological risk. The induction
therapy (BAS or DAC) with the lowest acquisition cost should be used, unless it is contraindicated.1
The marketing authorisation for DAC has been withdrawn at the request of the manufacturer.
Maintenance therapy
Tacrolimus (TAC) is recommended as an alternative option to CSA when a CNI is indicated as part of an
initial or a maintenance immunosuppressive regimen for renal transplantation in children and adolescents.
The initial choice of TAC or CSA should be based on the relative importance of their side effect profiles for
the individual patient.1
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Mycophenolate mofetil is recommended as an option as part of an immunosuppressive regimen for child
and adolescent renal transplant recipients only when:
l there is proven intolerance to CNIs, particularly nephrotoxicity which could lead to risk of chronic
allograft dysfunction or
l there is a very high risk of nephrotoxicity necessitating the minimisation or avoidance of a CNI until the
period of high risk has passed.1
The use of MMF in CCS reduction or withdrawal strategies for child and adolescent renal transplant
recipients is recommended only within the context of randomised clinical trials.1
Mycophenolate sodium is currently not recommended for use as part of an immunosuppressive regimen in
child or adolescent renal transplant recipients.1
Sirolimus is not recommended for children or adolescents undergoing renal transplantation except
when proven intolerance to CNIs (including nephrotoxicity) necessitates the complete withdrawal of
these treatments.1
As a consequence of following this guidance, some medicines may be prescribed outside the terms of their
UK marketing authorisation. Health-care professionals prescribing these medicines should ensure that
children and adolescents receiving renal transplants and/or their legal guardians are aware of this and that
they consent to the use of these medicines in these circumstances.1
Description of technology under assessment
Summary of intervention
This technology assessment report considers nine pharmaceutical interventions. Two are used as induction
therapy and seven are used as a part of maintenance therapy in renal transplantation. The two interventions
considered for induction therapy are BAS and r-ATG. The seven interventions considered for maintenance
therapy are TAC-IR and TAC-PR, MMF, MPS, BEL, SRL and EVL.
Induction therapy
Basiliximab (Simulect,® Novartis Pharmaceuticals) is a monoclonal antibody which acts as an interleukin
2 receptor antagonist. It has a UK marketing authorisation for prophylaxis of AR in allogeneic renal
transplantation in children (aged 1–17 years). The summary of product characteristics (SPC) states it is to
be used concomitantly with CSA for microemulsion- and CCS-based immunosuppression, in patients with
panel reactive antibodies < 80%, or in a triple maintenance immunosuppressive regimen containing CSA
for microemulsion, CCSs and either azathioprine (AZA) or MMF.7
Rabbit antihuman thymocyte immunoglobulin is a gamma immunoglobulin. It has a UK marketing
authorisation for the prevention of graft rejection in renal transplantation. The SPC states it is usually used
in combination with other immunosuppressive drugs. It is administered intravenously. The UK marketing
authorisation is not restricted to adults only.7
Maintenance therapy
Tacrolimus is a CNI that is available in an immediate-release formulation (Adoport,® Sandoz; Capexion,®
Mylan; Modigraf,® Astellas Pharma; Perixis,® Accord Healthcare; Prograf,® Astellas Pharma; Tacni,®
Teva; Vivadex,® Dexcel Pharma). All of these formulations of TAC have UK marketing authorisations for
prophylaxis of transplant rejection in kidney allograft recipients. The marketing authorisations include
adults and children.7 TAC (Modigraf®, Astellas Pharma) is available in a granule form which can be
suspended in liquid and may be more suitable for those who struggle swallowing pills.
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Tacrolimus is also available in a prolonged-release formulation (Advagraf,® Astellas Pharma). It has a UK
marketing authorisation for prophylaxis of transplant rejection in kidney allograft recipients. The marketing
authorisation is restricted to adults. The Commission on Human Medicines advises that all oral TAC
(including both TAC-IR and TAC-PR) medicines in the UK should be prescribed and dispensed by brand
name only.7
Belatacept is designed to selectively inhibit CD28-mediated co-stimulation of T-cells. BEL has a UK
marketing authorisation for prophylaxis of graft rejection in adults receiving a renal transplant, in
combination with CCSs and a mycophenolic acid (MPA; Myfortic,® Novartis Pharmaceuticals). The SPC
recommends that an interleukin 2 receptor antagonist for induction therapy is added to this BEL-based
regimen. The SPC states that the safety and efficacy of BEL in children and adolescents aged 0–18 years
have not yet been established. This formulation does not have a UK marketing authorisation for the
prophylaxis of transplant rejection in renal transplantation in children and adolescents.7
Mycophenolate mofetil is a prodrug of MPA which acts as an antiproliferative agent (Arzip,® Zentiva;
CellCept,® Roche Products; Myfenax,® Teva); generic MMF is manufactured by Accord Healthcare, Actavis,
Arrow Pharmaceuticals, Dr Reddy’s Laboratories, Mylan, Sandoz and Wockhardt). It has a UK marketing
authorisation for use in combination with CSA and CCSs for the prophylaxis of acute transplant rejection
in people undergoing kidney transplantation. The UK marketing authorisation is not restricted to adults
(dosage recommendations for children aged 2–18 years are included in the SPC).7
Mycophenolate sodium is an enteric-coated formulation of MPA. This formulation has the same UK
marketing authorisation as MMF; however, this is restricted to adults. This formulation does not have a
UK marketing authorisation for the prophylaxis of transplant rejection in renal transplantation in children
and adolescents.7
Sirolimus (Rapamune,® Pfizer) is an antiproliferative with a non-calcineurin-inhibiting action. It has a UK
marketing authorisation for the prophylaxis of organ rejection in adult patients at low to moderate
immunological risk receiving a renal transplant. It is recommended to be used initially in combination
with CSA and CCSs for 2–3 months. It may be continued as maintenance therapy with CCSs only if CSA
can be progressively discontinued. This formulation does not have a UK marketing authorisation for the
prophylaxis of transplant rejection in renal transplantation in children and adolescents.7
Everolimus (Certican,® Novartis Pharmaceuticals) is a proliferation signal inhibitor and is an analogue of
SRL. EVL does not currently have a UK marketing authorisation for immunosuppressive treatment in kidney
transplantation in children and adolescents.7
Current usage in the NHS
There is a variation in the use of induction and maintenance therapy in the UK. Table 6 provides an
overview of immunosuppression regimens for low-risk first renal transplants (e.g. blood group and HLA
compatible) in the 10 paediatric transplant centres in the UK. Four out of the 10 centres use BAS as a
part of induction therapy. Apart from the use of antibody induction, all centres use a single dose of
methylprednisolone at the time of transplantation. The table also illustrates the difference in the use of the
two proliferative agents (MMF and AZA), the agreement in the use of CNI across all centres (TAC; usually
Adoport), and the use of steroids as a part of maintenance therapy. The current NICE guidelines are
followed by using TAC+AZA+CCS± BAS regimens.1 However, the use of MMF is not limited to proven
intolerance to CNIs, or to a very high risk of nephrotoxicity necessitating a temporary minimisation or
avoidance of CNI (see Current National Institute for Health and Care Excellence guidance for more details).
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Anticipated costs associated with intervention
The cost of the intervention (immunosuppressive regimen) is determined primarily by the choice and
combination of the drugs and their dosages. Indicative costs for different immunosuppressive agents are
given in Table 7. Caution should be exercised in interpreting these as dosages are commonly titrated and
may differ from those indicated.
In addition, drug administration costs are also incurred for some maintenance agents. CSA, TAC, SRL and
EVL are routinely titrated using therapeutic drug monitoring, which is estimated to cost approximately
£26 per test (testing frequency is reduced as patients become stabilised in dosage), and BEL requires
intravenous (i.v.) infusion, entailing catheterisation and nursing time. The cost of this is difficult to estimate
but estimates range from £15466 to £320.11
TABLE 6 The use of immunosuppressive agents in paediatric centres in the UK
Hospital
Antibody used for
induction therapy Maintenance therapy
Birmingham Children’s Hospital BAS TWIST protocol: TAC+MMF+CCS
Bristol Children’s Hospital Nonea Triple therapy: TAC+AZA+CCS
Glasgow, Yorkhill BAS TWIST protocol: TAC+MMF+CCS
Leeds, Paediatric Unitb Nonec Triple therapy: TAC+AZA+CCSd
London, Evelina Children’s Hospital BAS Triple therapy: TAC+AZA+CCSe
London, Great Ormond Street None Triple therapy: TAC+AZA+CCS
Newcastle Great North Children’s Hospital None Triple therapy: TAC+AZA+CCS
Nottingham Children’s Unit Nonef Triple therapy: TAC+AZA+CCSg
Royal Belfast Hospital for Sick Children Nonec Triple therapy: TAC+MMF+CCSh
Royal Manchester’s Children’s Hospital BAS TWIST protocol: TAC+MMF+CCS
The TWIST study, A Randomized Trial to Assess the Impact of Early Steroid Withdrawal on Growth in Pediatric
Renal Transplantation.
a BAS is used for second and subsequent transplants when the previous transplant was lost as a result of AR.
b 16- to 18-year-old patients follow adult protocol of antibody+ TAC+MMF+CCS.
c BAS is used if there are high levels of panel reactive antibodies.
d MMF for second transplantation or post rejection.
e Early CCS withdrawal in certain cases (e.g. risk of diabetes mellitus, etc.).
f BAS for high-risk patients.
g Low thresholds for MMF switching.
h For children who have bony problems (e.g. slipped upper femoral epiphysis) or obesity (e.g. Bardet–Biedl syndrome),
BAS with rapid steroid withdrawal is used.
Notes
The TWIST study protocol is based on a European study of an early steroid withdrawal study – the TWIST Study,24 with two
doses of antibody (day zero and day four) and only five doses of steroids (day zero to day four), TAC, and MMF.
Source: Dr Jan Dudley, Bristol Royal Hospital for Children, 2015, personal communication; and Dr Stephen Marks, Great
Ormond Street Hospital in London, 2015, personal communication.
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TABLE 7 Overview of costs and dose for different immunosuppressive agents
Compound Unit cost Recommended dose
Estimated weekly cost for 31.5 kg
body weight, surface area 1.1m2
(10-year-old male)a
AZA Hospital pharmacy:
0.1 p per mgb
Community
pharmacy: 0.1 p
per mgd
1–3mg/kg per day, adjusted according
to responsec
Hospital pharmacy: 22.05 p to
66.15 p
Community pharmacy: 22.05 p to
66.15 p
BAS £75.87 per mg
(10-mg vial) and
£42.12 per mg
(20-mg vial)c
Child > 1 year, body weight < 35 kg, 10mg
within 2 hours before transplant surgery
and 10mg 4 days after surgery
Child body weight ≥ 35 kg, 20mg within
2 hours before transplant surgery and 20mg
4 days after surgeryc
Cost calculated based on
recommended dose:
Child < 35 kg: £1517.38 (induction
period only)
Child ≥ 35 kg: £842.38
(induction period)
BEL £1.42 per mgc Not licensed for use in childrenc
Adult dose 5mg/kg per 4 weeks
£55.83 (adult, weight-based dose)
CSA Hospital pharmacy:
1.65 p per mgb
Community
pharmacy: 2.55 p
per mgc
8–12mg/kg/daye Hospital pharmacy: £29.10–43.66
Community pharmacy:
£44.98–67.47
CCSs Hospital pharmacy:
0.3 p per mgb
Community
pharmacy: 0.9 p
per mgd
Methylprednisolone: 10–20mg/kg or
400–600mg/m2 (maximum 1g) once daily
for 3 daysc
Prednisolone: consult local treatment
protocols for details.c An example:
60mg/m2/day during first week, eventually
weaned down to < 10mg/m2 on
alternate days
Hospital pharmacy: £2.83–5.67
Community pharmacy:
£8.49–17.01
EVL £9.90 per mgf Not licensed for use in childrenc
Adult dose of 1.5mg per day
g
£103.95 (adult non-weight-based dose)
TAC-IR Hospital pharmacy:
52.0 p per mgb
Community
pharmacy: 118.6 p
per mgc,d
150 µg/kg twice daily, adjusted according to
whole blood concentration
Hospital pharmacy: £34.40
Community pharmacy: £78.45
MMF Hospital pharmacy:
37.74 p per gb
Community
pharmacy: 40.44 p
per gd
300mg/m2 twice daily (maximum 2g) if in
addition with TAC and CCSsc
600mg/m2 twice daily (maximum 2g) if in
addition with CSA and CCSsc
Hospital pharmacy: £1.74
Community pharmacy: £1.86
Hospital pharmacy: £3.48
Community pharmacy: £3.73
MPS 0.5 p per mgc Not licensed for use in childrenc
Adult dose 1440mg per dayc
£50.4 (adult non-weight-based dose)
TAC-PR 106.8 p per mgc Not licensed for use in childrenc
Adult dose 0.2mg/kg per day
£47.10 (adult weight-based dose)
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TABLE 7 Overview of costs and dose for different immunosuppressive agents (continued )
Compound Unit cost Recommended dose
Estimated weekly cost for 31.5 kg
body weight, surface area 1.1m2
(10-year-old male)a
r-ATG £6.35 per mgc Not licensed for use in childrenc
1.5mg/kg/day administered by intravenous
infusion for 7–14 daysh
£2100.52 (induction period only)
SRL £2.88 per mgc,d Not licensed for use in childrenc
Adult dose 2mg per dayc
£40.36 (adult non-weight-based dose)
a Weight to age taken from Astellas’ submission and weight to surface area calculated using the Boyd61 formula
(www.ouh.nhs.uk/oxparc/professionals/documents/Body-surfaceareaCCLGChart1.pdf).
b Commercial Medicines Unit electronic market information tool.62
c British National Formulary volume 68 (January 2015 online update).63
d NHS Business Services Authority, NHS Drug Tariff for England and Wales (2015).
e Drugs.com.64
f Novartis’ submission.
g MHRA SPC.
h Drugs.com.65
Note
Costs are estimated based on units of mg or g, which may not be appropriate if fine dosing is not possible, or if fine dosing
products are substantially more expensive per unit; in particular, for BEL, it assumes that perfect vial sharing is employed
(in which one vial may be used by more than one patient to eliminate wastage).
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Chapter 2 Definition of the decision problem
Decision problem
The purpose of this assessment is to answer the following question:
What is the clinical effectiveness and cost-effectiveness of the following immunosuppressive therapies in
renal transplantation in children and adolescents:
l Basiliximab and r-ATG as an induction therapy, and
l TAC-IR, TAC-PR, MMF, MPS, BEL, SRL, and EVL as a maintenance therapy
l including a review of TA99.
The project was undertaken based on a published scope7 and in accordance with a protocol.67
Interventions
A total of nine interventions are considered, two for induction therapy and seven for initial and long-term
maintenance therapy.
The two induction treatments are:
l BAS
l r-ATG.
The seven maintenance treatments are:
l TAC-PR formulation (Advagraf,® Astellas Pharma)
l TAC-IR formulations [Adoport® (Sandoz); Capexion® (Mylan); Modigraf® (Astellas Pharma); Perixis®
(Accord Healthcare); Prograf® (Astellas Pharma); Tacni® (Teva); Vivadex® (Dexcel Pharma)]
l BEL MMF
l MPS SRL
l EVL.
These treatments are described in Chapter 1, Summary of Intervention. Several of the drugs being assessed
are used in the NHS outside the terms of their UK marketing authorisation, for example in children and
adolescents, or in high-risk people, or in unlicensed drug combinations. Specifically EVL, TAC-PR, BEL, MPS
and SRL are not currently licensed for the prophylaxis of transplant rejection in renal transplantation in
children and adolescents.
Under an exceptional directive from the Department of Health, the Appraisal Committee may consider
making recommendations about the use of drugs outside the terms of their existing marketing
authorisation when there is compelling evidence of their safety and effectiveness. Accordingly, the review
included controlled studies that used drugs outside the terms of their marketing authorisations.
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Populations including subgroups
The population being assessed are children and adolescents aged 0–18 years (inclusive) undergoing kidney
transplantation. Patients receiving multiorgan transplants and those who have received transplants and
immunosuppression previously were excluded.
If data allow, the following subgroups were considered:
l different age groups
l level of immunological risk (including HLA compatibility and blood group compatibility)
l people at high risk of rejection within the first 6 months
l people who have had a retransplant within 2 years
l previous AR
l people at high risk of complications from immunosuppression (including new-onset diabetes mellitus).
Relevant comparators
For induction therapy, the treatments are to be compared with each other, as data permit, or with other
regimens that do not include monoclonal or polyclonal antibodies. For maintenance therapy, each
treatment or regimen (combination of treatments) is to be compared with the other treatments or
regimens as data permit, or with a CNI with or without an antiproliferative agent and/or CCSs.
Outcomes
The health-related outcomes to be included in this technology assessment are:
l patient survival
l graft survival
l graft function
l time to and incidence of AR
l severity of AR
l growth
l adverse effects of treatment
l health-related quality of life (HRQoL).
Key issues
A number of factors may influence the survival and function of transplanted kidney and the survival of
the recipient.
The viability of the kidney may depend on the type of donor (living related, living unrelated, DBD, DCD or
expanded criteria donor), the age of the donor, whether or not they had comorbidities such as diabetes
mellitus, and the length of cold ischaemia. Furthermore, the age, sex, ethnicity and health of the recipient,
and the length of time the recipient is on dialysis prior to transplantation may affect the outcome of
transplantation. These issues have been discussed in more detail in Chapter 1, Important prognostic factors.
Overall aims and objectives of assessment
This assessment reviewed and updated the evidence for the clinical effectiveness and cost-effectiveness of
immunosuppressive therapies in children and adolescents renal transplantation. This was to be done by
conducting a systematic review of clinical effectiveness studies and a model-based economic evaluation
of induction and maintenance immunosuppressive regimens to update the current guidance (TA99).
We have incorporated relevant evidence presented in this previous report and report new evidence.
This included a new decision-analytic model of kidney transplantation outcomes to investigate which
regimen is the most cost-effective option.
DEFINITION OF THE DECISION PROBLEM
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Chapter 3 Assessment of clinical effectiveness
Methods for reviewing effectiveness
This report contains reference to confidential information provided as part of the NICE appraisal process.
This information has been removed from the report and the results, discussions and conclusions of the
report do not include the confidential information. These sections are clearly marked in the report.
This systematic review was commissioned by NICE to update the previous guidance (TA99).1 The systematic
review and economic evaluation developed to support current NICE guidance TA99, was published by Yao
et al. in 2006.2 The differences between the remit of the previous review and the protocol of the current
one are discussed in The previous assessment report.
There was one departure from the protocol:67 the age of population eligibility criterion was changed from
< 18 years (a common definition of children and adolescents) to ≤ 18 years [the age inclusion criterion
applied by the three eligible randomised controlled trial (RCTs)].
The aim was to systematically review the clinical effectiveness of immunosuppressive therapies in child and
adolescent (≤ 18 years) renal transplantation; that is to determine their effect on patient survival, graft
survival, graft function, time to and incidence of AR, severity of AR and quality of life, growth, and their
impact on AEs.
Identification of studies
Bibliographic literature database searching was conducted on 14 April 2014 and updated on 7 January 2015.
The searches for individual effectiveness studies (RCTs and controlled clinical trials) took the following form:
(terms for kidney or renal transplant or kidney or renal graft) AND (terms for the interventions under review)
AND [a study design limit to randomised control trials (RCT) or controlled trials]. In order to update the
previous assessment,2 the searches were date limited (2002–current). These searches were not limited by
language or to human-only studies because such a limit may have blocked retrieval of includable studies for
R-ATG (line 8 of the MEDLINE search). The following databases were searched: MEDLINE and MEDLINE
In-Process & Other Non-Indexed Citations (via Ovid), EMBASE (via Ovid), Cochrane Central Register of
Controlled Trials (CENTRAL) (via Wiley Online Library) and Web of Science [via Institute for Scientific
Information (ISI) – including conference proceedings]. In addition, the following trials registries were
hand-searched in January 2015: Current Controlled Trials, ClinicalTrials.gov, FDA website, EMA website
(European Public Assessment Reports).
Separate searches were undertaken to identify systematic reviews of RCTs and non-randomised studies.
These searches took the following form: (terms for kidney or renal transplant or kidney or renal graft)
AND (terms for the interventions under review) AND (a pragmatic limit to systematic reviews). The same
population and intervention search terms were used as in the individual studies search. A pragmatic,
methodological search filter was used to limit by study design. No other limits (e.g. language) were applied
to this search. The search was run from database inception in the following databases: MEDLINE and
MEDLINE In-Process & Other Non-Indexed Citations (via Ovid), EMBASE (via Ovid), Cochrane Database of
Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects (DARE) and Health Technology
Assessment (HTA) (The Cochrane Library via Wiley Online Library) and Health Management Information
Consortium (HMIC) (via Ovid).
The search strategies are recorded in Appendix 1.
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The database search results were exported to, and deduplicated using, EndNote (X5) (Thomson Reuters,
CA, USA). Deduplication was also performed manually.
Furthermore, the following websites were searched for background information.
Renal societies (UK)
l British Renal Society (www.britishrenal.org/).
l Renal Association (www.renal.org/).
l UK Renal Registry (www.renalreg.com/).
l Kidney Research UK (www.kidneyresearchuk.org/).
l British Kidney Patient Association (www.britishkidney-pa.co.uk/).
l National Kidney Federation (www.kidney.org.uk/).
Renal societies (international)
l American Society of Nephrology (www.asn-online.org/).
l American Association of Kidney Patients (www.aakp.org/).
l National Kidney Foundation (US; www.kidney.org/).
l Canadian Society of Nephrology (www.csnscn.ca/).
l Kidney Foundation of Canada (www.kidney.ca/).
l Australian and New Zealand Society of Nephrology (www.nephrology.edu.au/).
l Kidney Health Australia (www.kidney.org.au/).
l Kidney Society Auckland (www.kidneysociety.co.nz/).
Previous Health Technology Assessment review
Studies included in the previous HTA review (Yao et al.2) were screened using the inclusion criteria for the
Peninsula Technology Assessment Group (PenTAG) review (Inclusion and exclusion criteria).
Reference lists
Reference lists of included guidelines, systematic reviews, company submissions and clinical trials were
scrutinised in order to identify additional studies.
Ongoing trials
Searches for ongoing trials were also undertaken. Terms for the intervention and condition of interest were
used to search the following trial registers for ongoing trials: ClinicalTrials.gov and Controlled Trials
(ISRCTN). Trials that did not relate to immunosuppressive therapies for kidney transplantation in children
and adolescents were removed by hand-sorting. All searches for ongoing trials were carried out in January
2015. The search strategies can be found in Appendix 1.
Adult randomised controlled trial evidence
In addition, as specified in the review protocol, all child/adolescents RCT and non-RCT evidence included
in this review was compared with adult evidence identified from parallel HTA 09/46/01 appraisal.68 This
parallel HTA was conducted by PenTAG to inform the ongoing technology appraisal of immunosuppressive
therapy for kidney transplantation in adults (review of technology appraisal guidance 85; NICE appraisal
ID 456). The NIHR Evaluation, Trials and Studies Coordinating Centre reference for the adult report is 09/46/01
(www.nice.org.uk/guidance/indevelopment/gid-tag348/documents).
Inclusion and exclusion criteria
Studies retrieved from the literature searches were selected for inclusion according to the inclusion/
exclusion criteria specified below. Studies available only as abstracts were included provided sufficient
methodological details were reported to allow critical appraisal of study quality. We also contacted authors
for additional data.
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Study design
The clinical effectiveness review included:
l eligible studies – RCTs in children and adolescents (≤ 18 years), RCTs of adults and children/adolescents
in which a subgroup analysis of children and adolescents is reported, and non-randomised controlled
studies (comparative quasi-experimental and observational studies were considered)
l search strategy – databases were searched to identify RCTs, systematic reviews of RCTs and systematic
reviews of non-randomised controlled studies. Individual non-randomised controlled studies were
identified via the bibliographies of systematic reviews (i.e. individual non-randomised controlled studies
were not searched for directly).
For the purpose of this review, a systematic review was defined as one that has:
l a focused research question
l explicit search criteria that are available to review, either in the document or on application
l explicit inclusion/exclusion criteria, defining the population(s), intervention(s), comparator(s),
and outcome(s) of interest
l a critical appraisal of included studies, including consideration of internal and external validity of
the research
l a synthesis of the included evidence, whether narrative or quantitative.
Interventions
Studies evaluating the use of the following immunosuppressive therapies for renal transplantation
were included.
Induction therapy
l Basiliximab.
l Rabbit antihuman thymocyte immunoglobulin.
Maintenance therapy
l TAC-PR formulation.
l TAC-IR formulations.
l Belatacept.
l MMF (generic MMF manufactured by Accord Healthcare, Actavis, Arrow Pharmaceuticals, Dr Reddy’s
Laboratories, Mylan, Sandoz and Wockhardt).
l Mycophenolate sodium.
l Sirolimus.
l Everolimus.
All treatments are described in detail in Chapter 1, Summary of intervention.
In addition (as evidence allows), adherence to treatment and the use of treatments in conjunction with
either CCS or CNI reduction or withdrawal strategies is considered. To achieve this, only studies that meet
the inclusion criteria are examined. As such, studies in which the intervention is identical in both study
arms, but dose reduction or withdrawal of CCSs or CNIs occurs in one arm, were excluded.
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Comparator
Studies using the following comparators were included.
Induction therapy
l Regimens without monoclonal or polyclonal antibodies, for example regimens that include
methylprednisolone or placebo (PBO).
l Interventions should also be compared with each other.
Maintenance therapy
l A CNI with or without an antiproliferative agent and/or CCSs.
l Interventions should also be compared with each other.
In addition, when appropriate, the interventions were appraised as part of combination regimens.
Population
The population is children and adolescents aged ≤ 18 years undergoing kidney transplantation. The kidney
donor may be living related, living unrelated or deceased. Patients receiving multiorgan transplants and
those who have received transplants and immunosuppression previously were excluded.
Outcomes
The outcome measures to be considered are:
l patient survival
l graft survival
l graft function
l time to and incidence of AR
l severity of AR
l growth
l adverse effects (AE) of treatment
l HRQoL.
Screening
All records were dual screened. First, titles and abstracts returned by the search strategy were screened for
inclusion. The screening was distributed across a team of five researchers (TJ-H, LC, MHa, MB and HC).
Update searches were screened by two reviewers (MHa and JV-C) and disagreements were resolved by
discussion, with involvement of a third reviewer (TJ-H or MHa) if necessary. Full texts of identified studies
were obtained and screened in the same way. Studies reported only as abstracts were included provided
sufficient methodological details were reported to allow critical appraisal of study quality. In addition,
studies included in the review conducted by Yao et al.2 were screened for inclusion.
As specified in the review protocol, the searches for systematic reviews were separately screened to
identify systematic reviews of non-randomised studies and these in turn were screened to identify
non-randomised studies for inclusion in the review.
Data extraction
Information from new studies (not included in TA99) was extracted and tabulated; information included
details of the study design and methodology, baseline characteristics of participants and results including
HRQoL and any AEs if reported (see Appendix 1). All included studies (including those in TA99) were
quality appraised.
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If we identified several publications for one study, we evaluated the effectiveness data from the most
recent publication and amended this with information from other publications. For quality appraisal
purposes, all publications relating to a study were assessed together.
Critical appraisal strategy
Randomised control trials
Four reviewers (LC, MHa, HC and TJ-H) independently assessed the quality of all studies included in the
clinical effectiveness review. The internal and external validity of RCTs was assessed according to criteria
based on Centre for Reviews and Dissemination (CRD) guidance69 (Table 8).
Non-randomised control trials
There is no agreed recommended appraisal tool for the assessment of non-randomised studies.70 The CRD
handbook suggests considering the study design, risk of bias, other issues related to study quality, choice
of outcome measure, statistical issues, quality of reporting, quality of the intervention and generalisability.69
Therefore, the internal and external validity of non-RCTs was assessed according to criteria based on CRD
guidance69 (Table 9).
Methods of data synthesis
Data were tabulated and discussed in a narrative review. The subgroups defined in Chapter 2, Populations
including subgroups, were considered in the analyses.
TABLE 8 Critical appraisal checklist for randomised control studies
Bias Criteria for assessment of risk of bias
Treatment allocation 1. Was the assignment to the treatment groups really random?
2. Was treatment allocation concealed?
Similarity of groups 3. Were the groups similar at baseline in terms of prognostic factors?
Implementation of masking 4. Were the care providers blinded to the treatment allocation?
5. Were the outcome assessors blinded to the treatment allocation?
6. Were the participants blinded to the treatment allocation?
Outcomes 7. Were all a priori outcomes reported?
8. Were complete data reported, e.g. was attrition and exclusion (including reasons)
reported for all outcomes?
9. Did the analyses include an ITT analysis?
Generalisability 10. Are there any specific limitations which might limit the applicability of this study’s
findings to the current NHS in England?
ITT, intention to treat.
Note
Criteria were based on CRD guidance.69
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Meta-analyses
When data permitted, the results of individual studies comparing the same regimens were pooled using
the methods described below.
A random-effects model was assumed for all meta-analyses. For binary data, an odds ratio (OR) was
used as a measure of treatment effect and the DerSimonian–Laird method was used for pooling.71
For continuous data (e.g. graft function), mean differences were calculated if the outcome was measured
on the same scale in all trials. If applicable, publication bias was assessed using funnel plots, the Harbord
test was used for binary outcomes [OR, log-standard error (SE)] and the Egger test for continuous data.
All analyses were performed in Stata 13 (StataCorp LP, College Station, TX, USA).
For studies with more than one intervention arm (that were separately compared with the same control
arm), the number of events and the total sample size in the control arm were divided equally across
the comparisons, and when pooling mean differences the total sample size in the control arm was adjusted
and divided equally across the comparisons. However, if only one experimental arm was eligible for the
analysis, all participants and events assigned to the control arm were included. If the number of events was
zero in one of the studies arms, a value of 0.5 was added to all study arms to allow for statistical analyses.
Results of the systematic review
Quantity and quality of research available
The current review summarises both randomised and non-randomised controlled evidence. The assessment
of clinical effectiveness is reported separately for induction and maintenance regimens.
Randomised control trials
Our searches returned 5079 unique titles and abstracts, with 784 papers retrieved for detailed
consideration. To ensure the inclusion of trials with mixed child/adolescent and adult populations that
reported separate results for children and adolescents, the searches and title and abstract screening were
not limited to children and adolescents. Update searches conducted on 7 January 2015 returned 416
unique titles and abstracts. Forty papers were retrieved for detailed consideration.
TABLE 9 Critical appraisal checklist for non-randomised control studies
Bias Criteria for assessment of risk of bias
Treatment allocation 1. Was the method of allocation reported?
2. Is the allocation to groups or to the study a source of selection bias?
Similarity of groups 3. Were the groups similar at baseline in terms of prognostic factors?
Implementation of masking 4. Were the care providers blinded to the treatment allocation?
5. Were the outcome assessors blinded to the treatment allocation?
6. Were the participants blinded to the treatment allocation?
Outcomes 7. Was follow-up long enough for outcomes to occur?
8. Were complete data reported, e.g. was attrition and exclusion (including reasons)
reported for all outcomes?
9. Were statistical analyses adjusted to account for any between-group differences?
Generalisability 10. Was the group(s) representative of NHS renal transplant patients?
Note
Criteria were based on CRD guidance.69
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Of the 824 full-text papers retrieved, 793 were excluded (a list of these records with reasons for their
exclusion can be found in Appendix 2, Table 135). Although RCTs in mixed populations were identified,
none included subgroup analysis by age – providing separate results for children/adolescents and adults –
and were therefore excluded from the review (a list of these records can be found in Appendix 2, Table 136).
Three RCTs (published in one abstract72 and seven papers73–79) met the inclusion criteria.
Only one abstract72 was included in the review. This abstract included new data related to Offner et al.73 and
sufficient methodological information to inform the quality appraisal. In addition, there were 23 articles that
were systematic reviews and all eligible systematic reviews were tabulated (see Appendix 3, Table 137).
The process is illustrated in detail in Figure 8.
In summary, three RCTs (published in seven papers73–79 and one abstract72) were found eligible and are
included in this review (Table 10).
Records identified through database searching
(n = 5079; including 189 records identified
through SRs searching)
Records after duplicates
removed
(n = 4459)
Records screened
(n = 4459)
Records excluded
(n = 3675)
Full-text articles
excluded with reasons
(n = 793)
Full text assessed for
eligibility
(n = 784)
Full text assessed for
eligibility
(n = 40)
Records identified
through update
searching
(n = 416; including 43
records identified
through SRs searching)
Eligible studies
(n = 31; 3 RCTs reported in
7 papers and 1 abstract,
and 23 SRs)
RCTs included (n = 3)
• RCTs included in Yao et al.,1 n = 2
• New RCTs, n = 1
• Non RCTs included in Yao et al.,1 n = 4
• New non-RCTs, n = 0
Non-RCTs included (n = 4)
• Abstract, n = 332
• Population, n = 210
• Study design, n = 149
• No usable data, n = 18
• Duplicate, n = 9
• Intervention, n = 10
• Comparator, n = 28
• Outcome, n = 26
• Language, n = 7
• Unobtainable, n = 4
FIGURE 8 Clinical effectiveness review: Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) flow diagram. SR, systematic review.
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Non-randomised trials
The systematic reviews were used to identify non-RCTs. We screened the titles and abstracts of 226 unique
references identified by the PenTAG systematic review searches (including 43 records from update
searches) and retrieved 38 papers for detailed consideration. All eligible systematic reviews were tabulated
(see Appendix 3, Table 137).
In total, four non-RCTs met the inclusion criteria and were considered eligible for inclusion (Table 11).
All of these were included in the previous HTA by Yao et al.2 so no new non-RCTs were identified.
However, in 2007 one of the four non-RCT studies83 published 5-year follow-up data85 that were not
included in the previous HTA.
TABLE 10 Summary table of included randomised controlled studies
Study na Agent (n) Control (n) Outcomes
Multiple
publications
Induction therapy
Offner et al.73 192 BAS+CSA+MMF+CCS
(100)
PBO+CSA+MMF+CCS
(92)
Mortality, graft
loss, graft
function, BPAR, AE
Höcker et al.,74
Jungraithmayr
et al.72
Grenda et al.75 192 BAS+ TAC+AZA+CCS
(99)
NI+ TAC+AZA+CCS
(93)
Mortality, graft
loss, graft
function, BPAR, AE
Webb et al.76
Maintenance therapy
Trompeter et al.77 196 TAC+AZA+CCS (103) CSA+AZA+CCS (93) Mortality, graft
loss, graft
function, BPAR, AE
Filler et al.,78
Filler et al.79
BPAR, biopsy-proven acute rejection; NI; no induction.
a Intention-to-treat population.
TABLE 11 Summary table of included non-randomised studies
Study na Treatment Outcomes Multiple publications
Induction and maintenance therapy
Garcia et al80 24 BAS+ TAC+AZA+CCS
vs. BAS+CSA+MMF+CCS
Mortality, graft loss,
graft function, BPAR, AE
N/A
Maintenance therapy
Antoniadis et al.81 14 CSA+MMF+CCS
vs. CSA+AZA+CCSb
Graft function, BPAR, AE N/A
cBenfield et al.82 67 (OKT3 or CSA)+MMF+CCS vs.
(OKT3 or CSA)+AZA+CCS
Mortality, graft loss,
graft function, BPAR
N/A
Staskewitz et al.83 139d CSA+MMF+CCSe
vs. CSA+AZA+CCS
Mortality, graft loss,
graft function, BPAR, AE
Jungraithmayr et al.,84
Jungraithmayr et al.85
BPAR, biopsy-proven acute rejection; N/A, not applicable; OKT3, a murine monoclonal antibody muromonab-CD3.
a Intention-to-treat population.
b Methylprednisolone induction in all participants.
c This was a randomised trial of OKT3 vs. CSA at the time of transplantation. First 31 participants were given AZA and
subsequent 36 participants were given MMF. In addition, participants were randomly assigned to receive two different
CSA preparations: (Sandimmun®, Novartis) and (Neoral®, Novartis). Only a subgroup of participants was considered in
this review.
d Staskiewitz et al.83 reported results for 65 MMF and 54 AZA participants; however, the following two publications
(Jungraithmayr et al.84 and Jungraithmayr et al.85) report on 85 MMF and 54 AZA participants.
e Participants received prednisone/methylprednisolone induction in this arm, no induction reported for the historical
control arm (CSA+AZA+CCS).
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Ongoing studies
Eleven ongoing trials were considered relevant to this review and were investigated further. An overview of
the 11 trials with reasons for inclusion/exclusion in PenTAG review is provided in Appendix 4, Table 138.
Only one of these ongoing trials was identified as potentially eligible for inclusion. The methods and
design of this trial (A2314) were reported as conference abstracts.86–89 This international trial investigates
the efficacy, tolerability and safety of early introduction of EVL, reduced CNIs and early steroid elimination
compared with standard CNI, MMF and steroid regimen in paediatric renal transplant recipients and is
sponsored by Novartis. The estimated date of completion is December 2016, so it was not included in this
review. The search of ongoing studies in trial registries did not identify any additional RCTs for inclusion in
the PenTAG systematic review.
The previous assessment report
The assessment report published as Yao et al.2 informed the current NICE guidance TA99.1 The aim of
the previous HTA was to establish the clinical effectiveness (harms and benefits) and cost-effectiveness
of four of the newer immunosuppressive drugs for renal transplantation, namely BAS, DAC, TAC and
mycophenolate (mofetil and sodium), and of SRL in children and adolescents.
The previous HTA review adopted the following approach of three evidence levels:
l Level 1 evidence: findings from RCTs carried out in children and adolescents with kidney transplants.
This could include RCTs undertaken solely in children and adolescents, or RCTs where a subgroup
analysis in children and adolescents was reported.
l Level 2 evidence: when level 1 evidence was not available, use of findings from RCTs undertaken in
adults with kidney transplants.
l Level 3 evidence: findings from non-randomised comparative evidence collected in children and
adolescents with kidney transplants. Level 3 evidence was used to complement and check the
consistency of level 2 evidence (if level 1 evidence was not available).
The current PenTAG systematic review aims to establish the clinical effectiveness and cost-effectiveness of
immunosuppressive regimens including BAS and r-ATG as an induction therapy in renal transplantation in
children and adolescents, and of immunosuppressive regimens including TAC-IR, TAC-PR, MMF, MPS, BEL,
SRL, and EVL as a maintenance therapy in renal transplantation in children and adolescents (including
review of TA99).
The current PenTAG review included:
l RCTs in children and adolescents (≤ 18 years), and RCTs of adults and children and adolescents in
which a subgroup analysis of children and adolescents is reported
l systematic reviews which include non-randomised studies evaluating the interventions of interest in
children and adolescents (≤ 18 years).
In addition, the PenTAG review compares results in children and adolescents with those from the parallel
HTA 09/46/01 appraisal ‘Immunosuppressive therapy for kidney transplantation in adults’.68
In the sections below we summarise the evidence included in TA99 and highlight the differences between
the PenTAG review and the previous review.
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Randomised control trials
Children and adolescents
The previous TA991 included three paediatric RCTs: the unpublished Wyeth 0468E1–217-US study
(Wyeth submission 2005), Trompeter et al.,77 and an abstract by Grenda et al.90 (Table 12). The Wyeth
submission 2005 compared an addition of SRL to a CNI maintenance therapy [(CSA or TAC)+CCS], with a
triple maintenance therapy [(CSA or TAC)+ (MMF or AZA)+CCS] in children and adolescents (≤ 20 years
of age) who experienced one or more episodes of AR or chronic rejection after kidney transplantation.2
Because of the trial design (treatment combinations were allowed) and population characteristics (age and
time from transplantation) this study is not eligible to be included in the current review. The other two
paediatric RCTs included in Yao et al.2 are included in the PenTAG review.77,90 Additional publications of
Grenda et al.90 were identified in our searches (the previous HTA included only 6-month follow-up data;
see Table 12). We identified one new RCT73 that was not included in Yao et al.2
Non-randomised studies
An overview of the nine non-randomised studies included in Yao et al.2 with reasons for inclusion/
exclusion in the current review is provided in Table 13. Five studies were excluded from the PenTAG review
(see Table 13):
l Duzova et al.91 (compared BAS with no induction) administered triple therapy of (CSA or TAC)+
(AZA or MMF)+CCS; however, a breakdown of the numbers (and results) in each combination was
not reported and the mean recipient age was 14.9± 3.6 years (range 7–21 years).
l Pape et al.92 recruited a child with a combined kidney–liver transplantation.
l Swiatecka-Urban et al.93 included children, adolescents and adults (inclusion criteria aged < 21 years).
l Neu et al.94 included children, adolescents and adults (inclusion criteria aged > 2 years and < 21 years)
and the use of induction therapy varied in the study.
l Steffen et al.95 was published as an abstract only and did not include enough information to allow
critical appraisal.
In summary, four non-randomised studies were included in the PenTAG review and all were also included
in the previous HTA review by Yao et al.2 No new non-randomised studies were identified in PenTAG
systematic review searches.
TABLE 12 Previous HTA review included children and adolescents RCTs
Number Study Multiple publications Treatments Published
Included in PenTAG
(reason)
1 Grenda et al.90 Fijusawa/Astellas 2005 BAS vs. PBO Abstract only; full trial
provided in Fujusawa/
Astellas’ submission
Yes, trial was published
as Grenda et al.75 and
Webb et al.76
2 Trompeter et al.77 Filler et al.78,79 TAC vs. CSA Yes Yes
3 Wyeth submission
2005
0468E1–217-US,
NCT00005113
(study was terminated)
Addition of SRL No; full trial provided
in Fujusawa/Astellas’
submission
No (population, design)
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Adults
The previous TA99 included evidence from 25 adult RCTs. In comparison, the updated HTA 09/46/01
appraisal ‘Immunosuppressive therapy for kidney transplantation in adults’ included 86 trials: 11 induction
studies, 73 maintenance studies and two studies of both induction and maintenance treatment. An
overview of the 25 adult RCTs included in Yao et al.2 with reasons for inclusion/exclusion in the parallel
HTA review68 is provided in Appendix 5 (see Table 139).
If relevant, the adult evidence from the HTA 09/46/01 appraisal was summarised and compared with
child/adolescent evidence included in the PenTAG review.
Quality of included studies
We appraised both newly identified trials and those included in the previous HTA review.2 The reasons for
reappraising trials were first to ensure consistency with appraisal of the new study and, second, because
we have access to new information from papers published after the inclusion date for the previous review.
Only primary research studies were appraised (i.e. not systematic reviews). If a trial was reported in multiple
publications, only one quality assessment of the trial was conducted (all publications for that trial were
assessed together).
Randomised controlled trials
In total, three RCTs were assessed: two induction studies and one maintenance study.73,75,77
TABLE 13 Previous HTA review included children and adolescents non-randomised studies
Number ID na Treatments
Included in PenTAG
(reason)
Induction therapy
1 Duzova et al.91 43 BAS+ (CSA or TAC)+ (AZA or MMF)+CCS vs.
(CSA or TAC)+ (AZA or MMF)+CCS
No (design and population)
2 Pape et al.92 77 BAS+CSA+CCS vs. CSA+CS No (population)b
3 Swiatecka-Urban et al.93 32 BAS+ TAC+CCS vs. TAC+CCSc No (population)
Maintenance therapy
4 Garcia et al.80 24 BAS+ TAC+AZA+CCS
vs. BAS+CSA+MMF+CCS
Yes
5 Neu et al.94 986 TAC+MMF+CCS vs. CSA+MMF+CS No (population)
6 Antoniadis et al.81 14 CSA+MMF+CCS vs. CSA+AZA+CCSd Yes
7 Steffen et al.95 NR No (abstract)
8 Staskewitz et al.83
(Jungraithmayr et al.84)
120 CSA+MMF+CCSe vs. CSA+AZA+CCS Yes
9 fBenfield et al.82 678 (OKT3 or CSA)+MMF+CCS vs. (OKT3
or CSA)+AZA+CCS
Yes
ID, identification; NR, not reported; OKT3, a murine monoclonal antibody muromonab-CD3.
a An intention-to-treat population.
b One child had a combined kidney–liver transplantation.
c A single AZA dose perioperatively in seven out of eight participants in the non-BAS group.
d Methylprednisolone induction in all participants.
e Participants received prednisone/methylprednisolone induction in this arm, no induction reported for the historical
control arm (CSA+AZA+CCS).
f This was randomised trial of OKT3 vs. CSA at the time of transplantation. First 31 participants were given AZA and
subsequent 36 participants were given MMF. In addition participants were randomly assigned to receive Sandimmun or
Neoral CSA preparations.
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Overall assessment
For all three RCTs, fewer than half of the items constituting the quality appraisal assessment were rated as
being of ‘adequate’ quality (Table 14). All of these trials either did not report, or lacked clarity on, at least
5 out of the 10 quality appraisal items. It is possible that items that were not clearly reported in the papers
were in fact adequately conducted in the trials. Nevertheless, all three RCTs were rated as ‘inadequate’
for at least one item of the quality appraisal assessment.
Treatment allocation
Random allocation: the method of random allocation, including the method of sequence generation, was
clearly stated and adequate in only one trial73 and unclear in the other two trials.75,77
Concealment of allocation: the method of concealment of allocation was clearly reported in only one trial77
and unclear in the other two trials.73,75
Similarity of groups
Baseline characteristics: all three RCTs stated that baseline characteristics were similar between treatments
arms on a range of prognostic factors (see Table 16 for a summary of baseline characteristics). However,
one trial appeared to have a higher percentage of males in the PBO arm than the BAS arm (67.4% vs.
56%, respectively).73
Implementation of masking
Treatment allocation masked from providers: the method was clearly stated and adequate in only one
trial.73 In the other two trials,75,77 care providers were not blinded to treatment allocation.
Treatment allocation masked from outcome assessors: none of the three trials clearly reported whether or
not treatment allocation was masked from outcome assessors.73,75,77
Treatment allocation masked from participants: the method was clearly stated and adequate in only one
trial.73 In the other two trials, participants were not blinded to treatment allocation.
Completeness of trials
In all three studies,73,75,77 it was not clear whether or not all reported outcomes were the same as those
in the trial protocol and the reporting of loss to follow-up, withdrawals and dropouts was also not
clearly reported.
Intention-to-treat (ITT) analysis: none of the trials was rated as adequate. One induction trial investigating
the effectiveness of BAS excluded eight participants who received a ‘commercially available formulation of
the drug instead of the blinded study drug Simulect’ and was, therefore, rated as ‘inadequate’ for this item
of the quality appraisal assessment.73 Similarly, one study excluded participants who did not receive study
medication and excluded an additional four participants because of reporting issues and so was also
rated as ‘inadequate’ for this item.77 The remaining study75 did not clearly report the initial number of
participants who were randomised, so it was unclear whether or not all randomised and transplanted
participants were included in the analyses.
Applicability of trials to the NHS
Applicability to the current NHS in England: all three studies were considered to be applicable to the NHS
because no specific limitations with regards applicability were found in the study.73,75,77 All three trials
were conducted in Europe, patient and donor characteristics were largely representative of the NHS in
England and doses of the drug under investigation were similar to current recommended doses,
although Trompeter et al.77 administered 10mg of BAS for participants who were < 40 kg, and 20mg for
participants who were ≥ 40 kg, whereas the recommended cut-off for increasing the dose from 10mg to
20mg is currently 35 kg.
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Non-randomised trials
In total, four non-randomised studies were assessed.80–83
Overall assessment
For all four non-randomised studies, fewer than half of the items constituting the quality appraisal
assessment were adequately addressed (Table 15). However, for all studies, at least 5 out of the 10 quality
appraisal items were either not applicable (owing to study design), not reported, or not clearly reported.
It is possible that items that were not clearly reported in the papers were in fact adequately conducted in
the studies.
Treatment allocation
Allocation to groups: three of the non-randomised studies adequately described what the treatment and
control groups were and the general basis for allocating participants to a particular treatment.80,82,83 In two
studies,82,83 allocation to groups was dictated by changes to the treatment protocol in the study centres
(i.e. they were historically controlled studies). One study compared two retrospective cohorts (for which
treatment allocation was unrelated to the study design).80 Despite being a prospective non-randomised,
controlled trial, the remaining study did not report the basis for allocation to treatment groups.81
Avoidance of selection bias: none of the four studies provided evidence that selection bias (to the study
overall and to treatment groups) was minimised within the context of the study design. All four studies
were rated as ‘unclear’ with regards minimisation of selection bias. Two studies did not confirm whether or
not all eligible participants were recruited for either group.82,83 The other two studies did state that all
transplanted children and adolescents were included in the study but did not clearly describe how
participants were allocated to treatment groups, so the extent of possible selection bias to groups is
not clear.80,81
Similarity of groups
Baseline characteristics: three out of the four studies did not clearly report whether or not treatment
groups were similar at baseline on a range of prognostic factors and they omitted descriptive statistical
information (see Table 17 for a summary of baseline characteristics).80–82 In two studies,80,83 the age of
participants statistically significantly differed between treatment groups. In addition, although the groups
were reported not to be significantly different for gender, the percentages of males appeared to be
different (6/12, 50% and 8/12, 66.7%, respectively) in one small study.83
Implementation of masking
None of the four non-randomised studies reported whether or not treatment allocation was masked from
treatment providers, outcome assessors or participants. However, for three of the studies this was not
applicable, because blinding could not be reasonably expected given the study design.80,82,83 The remaining
study was a prospective non-RCT, therefore, masking of care providers, outcome assessors (by using
independent assessors) and participants could be done but was not reported.81
Length of follow-up
Three of the non-randomised studies had an adequate length of follow-up, with all participants followed
for at least 6 months.81–83 The remaining study was rated as ‘partial’ because not all participants were
followed for at least 6 months but DGF was included as an outcome (this outcome would usually be
assessed within the first month of transplantation).80
Completeness of trials
All four of the non-randomised studies adequately described the completeness of the study, either by
describing withdrawals or drop-outs (including reasons) or by making it clear that all enrolled participants
completed the study.
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Adjustment for bias in non-randomised studies
This item of the quality appraisal assessment was applicable to all four studies. However, two of the
studies did not perform any adjustment for bias in their analyses.82,83 For the other two studies, analyses
were not fully reported, so this could not be assessed.80,81
Applicability of trials to the current NHS in England
None of the non-randomised studies was considered to be clearly applicable to the NHS in England.
Two studies were rated as inadequate because the study population was not representative of the current
NHS in England. In one of these studies, all kidneys were from living related donors81 and in the other,
> 90% of kidneys were from cadaveric donors.83 The other two studies were both rated as unclear
because the populations were not recruited from the European Union, but it was not clear to what extent
the population characteristics could generalise to the NHS in England.80,82
Baseline characteristics
Randomised controlled studies
Baseline characteristics of the three included RCTs73,75,77 are summarised in Table 16. All three studies were
conducted over multicentres in Europe. Only Offner et al.73 reported the countries involved (Germany,
France and Switzerland).73 Mean age across the studies’ arms ranged from 10.1 years to 11.5 years. The
proportion of adolescents (with 12 or 13 years old being the cut-off point for adolescence in the three
studies; see Table 16 for details) is 36.6% to 54.4% across the study arms. Boys represented 56.0–67.4%
of participants. Two studies had a high proportion of white participants (87–95%),73,77 with one trial not
reporting ethnicity.75 The proportion of living donors across the study arms ranges from 15.5% to 35.8%.
The proportion of first transplants is high, ranging from 85% to 96% across the arms. Finally, HLA antigen
mismatch ranges from 2.3 to 2.7 across the three trials. A close antigen match is no longer considered
critical owing to the more effective immunosuppressive therapy, but a better HLA match may lead to
longer graft survival.
Non-randomised studies
Similarly, baseline characteristics of the four included non-randomised studies [Antoniadis et al.81
(non-RCT), Benfield et al.82 (historically controlled study), Garcia et al.80 (retrospective cohort study) and
Staskewitz et al. 200183 (historically controlled study)] are summarised in Table 17.80–83 The Antoniadis
et al.81 study was conducted in one Greek centre, the Benfield et al.82 study was conducted in two centres
in the USA and the Staskewitz et al.83 study was conducted in 12 German centres. Garcia et al.80 did not
report where or within how many centres their study was performed, but the authors are all based in
Brazil and, therefore, it is likely that this study was completed in Brazil. Not surprisingly, the baseline
characteristics of the non-RCTs vary not only across the studies, but also within the studies. Mean age
across the study arms ranges from 9.0 years to 11.5 years; however, none of the non-RCTs reports the
proportion of adolescents included. Boys represented 50.0–66.7% of participants. Two studies had a high
proportion of white participants (75–100%),80,83 one study reported that between 19% and 25% of
participants were black (dependent on treatment group),82 while one study did not report ethnicity.81 Most
studies included a high proportion of living donors (75 –100%). However, one study reported only 6%
living donors in one treatment group and 9% in the other treatment group.83 This was the only study
reporting mean HLA mismatches (2.69–2.89).83
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Results of the included studies
No studies were identified that evaluated growth or HRQoL in the use of induction immunosuppression
therapy in renal transplantation in children and adolescents. In addition, no studies that would allow
analyses of adherence to treatment and the use of treatments in conjunction with either CCS or CNI
reduction or withdrawal strategies were identified.
A summary comparing our results with those of the adult kidney transplant population (using evidence
from parallel HTA appraisal ‘Immunosuppressive therapy for kidney transplantation in adults’68) is made at
the end of this section. Briefly, 11 induction trials, 73 maintenance trials and two trials of both induction
and maintenance were included in the parallel HTA.
Induction therapy
Two RCTs of induction therapy73,75 (reported in four publications73–76 and one abstract72) in children and
adolescents were identified in the review; the population characteristics are summarised in Table 16.
Offner et al.73 compared BAS induction therapy with PBO: BAS+CSA+MMF+CCS versus
PBO+CSA+MMF+CCS. Grenda et al.75 compared BAS induction therapy with no induction:
BAS+ TAC+AZA+CCS versus TAC+AZA+CCS. No RCTs were identified that evaluated r-ATG in
children and adolescents.
No non-RCTs in the child/adolescent population evaluated induction therapies.
Mortality
Both RCTs73,75 provided data on mortality for BAS versus no induction or PBO (Table 18). Grenda et al.75
reported the longest follow-up data at 2 years post transplant. No evidence of a statistically significant
difference in overall survival between BAS and comparator arms was reported at any time point.
Summary
In summary, there was no evidence that BAS improved survival when compared with PBO or no induction.
This is similar to the conclusions of the previous HTA.2
Graft loss
Both RCTs73,75 provided data on graft loss for BAS versus no induction or PBO (Table 19). Grenda et al.75
reported the longest follow-up data of 2 years. No evidence of a significant difference between the BAS
and control arms was reported for any data point.
The pooled results at 6-month follow-up did not find any significant difference between BAS and control
arms for graft loss [OR= 93 favours BAS; 95% confidence interval (CI) 0.29 to 2.97, I2= 0%, τ2= 0;
Figure 9].
Summary
In summary, there was no evidence that BAS lowered graft loss when compared with PBO or no induction.
This is similar to the conclusions of the previous HTA.2
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Graft function
Both RCTs73,75 reported graft function estimated using the Schwartz equation (ml/minute/1.73m2; Table 20).
There were no statistically significant differences between BAS and control arms at any data point (between
6 months and 2 years). Both RCTs reported 6-month and 2-year follow-ups, no standard deviation (SD) was
reported at 2 years by Offner et al.73 and no SD was reported at 6 months or 2 years by Grenda et al.75
To allow for combining the results at 6-month and 2-year follow-ups, a SD of 26ml/minute/1.73 m2 was
used (‘average’ SD calculated from SD available at 6-month and 2-year follow-ups; Figure 10). The pooled
results do not suggest any difference for eGFR between BAS and control arms: weighted mean difference
(WMD)= –4.20 (favours controls; 95% CI –9.60 to 1.20, I2= 0%) at 6 months and WMD= –1.38
(favours controls; 95% CI –7.20 to 4.44, I2= 0%) at 2 years. Grenda et al.75 also reported incidences of
DGF (defined as requiring dialysis for more than 1 day during the first study week). The rate of DGF was
not statistically significantly different between the two arms: 11 out of 99 participants (11%) and 5 out
of 93 participants (5%) in BAS and no induction arms, respectively (p-value was not reported).75
Note: weights are from random-effects analysis
Overall (I 2 = 0.0%; p = 0.991)
Grenda et al., 200671
Offner et al., 200869
Study ID
0.93 (0.29 to 2.97)
OR (95% CI)
0.94 (0.26 to 3.34)
0.92 (0.06 to 14.91)
100.00
82.73
17.27
% weight
Favours BAS  Favours control
0.0567 1 17.6
FIGURE 9 Graft loss: randomised control trials. Control, no induction/PBO control arms. τ2= 0. Studies included
were Offner et al.73 and Grenda et al.75
TABLE 20 Graft function (eGFR): RCTs
Study Treatment
6 months 1 year 2 years
Mean
(SD)
t-test
(p-value)
Mean
(SD)
t-test
(p-value)
Mean
(SD)
t-test
(p-value)
aOffner et al.73 BAS+CSA+MMF+CCS 80 (27) –1.73 (0.08) 79 (23) –0.88 (0.38) 80 (NR) –0.92 (0.36)
PBO+CSA+MMF+CCS 87 (29) 82 (24) 84 (NR)
bGrenda et al.75 BAS+ TAC+AZA+CCS 77.6 (NR) –0.48 (0.63) NR N/A 66.7 (NR) 0.22 (0.82)
NI+ TAC+AZA+CCS 79.4 (NR) NR 65.8 (NR)
N/A, not applicable; NI; no induction; NR, not reported; SD, standard deviation.
a The number of participants evaluated at 2-year follow-up was 79 in BAS arm and 65 in PBO arm.
b The number of participants evaluated at 2-year follow-up was 84 in BAS arm and 80 in NI arm. t-tests were calculated
by PenTAG, for data points with no SD reported a SD of 26 was used. Graft function was estimated using the Schwartz
equation (ml/minute/1.73m2).
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Summary
In summary, there was no evidence that BAS lowered graft function when compared with PBO or no
induction. The child/adolescent RCT evidence identified in the previous HTA review2 concluded that BAS
did not increase serum creatinine levels at 1-year follow-up when compared with no induction.
Acute rejection
Both RCTs73,75 provided data on biopsy-proven acute rejection (BPAR) for BAS versus no induction or PBO
(Table 21). Grenda et al.75 reported the longest follow-up data of 2 years. No evidence of a statistically
significant difference between the BAS and the comparators arms was reported for any data point. The
pooled results at 6 months did not find any difference between BAS and control arms for BPAR: OR= 0.71
(favours BAS; 95% CI 0.40 to 1.27, I2= 15.7%, τ2= 0.03; Figure 11).
In addition, Grenda et al.75 also reported BPAR separately for younger and older age groups (< 12 years
and ≥ 12 years, respectively). The incidence of BPAR was lower in the patients < 12 years in the no
induction arm (4/42, 10%) than the same age group with BAS (6/46, 13%), although this difference was
not statistically significant (Wilcoxon–Gehan test, p-value was not reported). Conversely, incidences of
BPAR were higher for the patients ≥ 12 years with no induction (15/51, 29%) than the same age group
with BAS (13/53, 25%); however, again, this difference was not statistically significant (Wilcoxon–Gehan
test, p-value was not reported).
Finally, the data from Offner et al.75 of 79 BAS and 65 PBO on study participants (reported in an abstract
by Jungraithmayr et al.72) found a cumulative AR rate of 33% versus 35% in the BAS and PBO arms,
respectively, at 2 years and a cumulative AR rate of 41% versus 45% in the BAS and PBO arms, respectively,
at 5 years. Results were not statistically significant at either data point.72
Note: weights are from random-effects analysis
6 months
Offner et al., 200869
Grenda et al., 200671
Subtotal (I 2 = 0.0%; p = 0.347)
2 years
Offner et al., 200869
Grenda et al., 200671
Subtotal (I 2 = 0.0%; p = 0.411)
– 7.00 (– 14.94 to 0.94)
– 1.80 (– 9.16 to 5.56)
– 4.20 (– 9.60 to 1.20)
– 4.00 (– 12.53 to 4.53)
0.90 (– 7.06 to 8.86)
– 1.38 (– 7.20 to 4.44)
46.18
53.82
100.00
46.53
53.47
100.00
Favours BAS  Favours control
– 14.9 0 14.9
Study ID WMD (95% CI) % weight
FIGURE 10 Graft function (eGFR): randomised control trials. Control, no induction/PBO control arms. For data
points with no SD reported, a SD of 26 was used. Graft function was estimated using the Schwartz equation
(ml/minute/1.73m2). Studies included were Offner et al.73 and Grenda et al.75
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Time to BPAR (Table 22) was only reported by Grenda et al.75 The median time to BPAR appears to be similar
between the two arms (p-values were not reported in the study).75 Time to first BPAR episode or treatment
failure within the first 6 months post transplant was the primary efficacy end point in Offner et al.73 The
proportion of children and adolescents (Kaplan–Meier estimates) achieving this efficacy point was 16.7%
in the BAS arm and 21.7% in the PBO arm. The difference was not statistically significant; HR of 0.72
(favours BAS; 95% CI 0.42 to 1.26).73
Severity of BPAR was reported by Offner et al.73 and Grenda et al.75 (Table 23). All BPAR episodes in BAS
treated patients were mild (grade IA or IB), whereas 8 out of 18 episodes in the PBO group were moderate
(grade IIA) in Offner et al.73 Similarly, there seemed to be more moderate BPAR episodes (Banff 2) in the
no induction group than the BAS group in Grenda et al.75 However, Offner et al.73 also performed biopsies
in children who had not recently experienced clinical signs of rejection or undergone biopsy (at 6 months,
n= 64 and n= 60 in BAS and PBO groups, respectively) to identify subclinical rejections. The rate
(p= 0.055) and severity (p-value not reported) of subclinical rejections was higher in the BAS group
(25.0%) than in the PBO group (11.7%).73
Summary
In summary, there was no evidence that BAS reduced incidences of, severity and time to BPAR when
compared with PBO or no induction. This is similar to the conclusions of the previous HTA; no significant
differences in BPAR for BAS versus no therapy in children were found.2
Note: weights are from random-effects analysis
Overall (I 2 = 15.7%; p = 0.276)
Grenda et al., 200671
Offner et al., 200869
0.71 (0.40 to 1.27)
0.93 (0.45 to 1.88)
0.51 (0.23 to 1.14)
100.00
55.56
44.44
Favours BAS  Favours control
0.226 1 4.43
Study ID OR (95% CI) % weight
FIGURE 11 Biopsy-proven acute rejection: RCTs. Control, no induction/PBO control arms. τ2= 0.03. Studies included
were Offner et al.73 and Grenda et al.75
TABLE 22 Time to BPAR: RCTs
Study Treatment Time to AR median (range), days
Grenda et al.75 BAS+ TAC+AZA+CCS 41 (2–176)
NI+ TAC+AZA+CCS 43 (1–150)
NI, no induction.
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Adverse events
Two RCTs73,75 provided data on AEs for BAS versus no induction or PBO. Offner et al.73 reported AEs that
occurred in at least 10% of the safety population. Grenda et al.75 reported AEs that occurred in at least
10% in either treatment arm. The AEs reported in these trials are summarised in Table 24.
In one trial,73 more infections were found with BAS than with PBO (OR= 2.23; favours PBO; 95% CI 1.03
to 4.68).73 In Grenda et al.75 toxic nephropathy was higher in the BAS arm than in the no induction arm
(14.1% vs. 4.3%, respectively; p= 0.03). Similarly, abdominal pain was higher in the BAS arm than no
induction (11.1% vs. 2.2%, respectively; p= 0.02).75
Grenda et al.75 also reported changes in glucose metabolism disorders. None of the children and
adolescents had a glucose metabolism disorder {described as glucose tolerance decreased, hyperglycaemia
or diabetes mellitus using the modified coding symbols for a thesaurus of adverse reaction terms [The
Coding Symbols for a Thesaurus of Adverse Reaction Terms (COSTART) dictionary]} at baseline. However,
during the study, 13 patients (13.1%) in the BAS arm and 10 patients (10.8%) in the no induction arm
developed a glucose metabolism disorder within the first 6 months. One new case of impaired glucose
metabolism was noted at 1 year; this new case resolved at 2 years.
Summary
In summary, more infections were found with BAS than with PBO (OR= 2.23, favours PBO; 95% CI 1.03
to 4.68).73 In addition, Grenda et al.75 found that toxic nephropathy and abdominal pain were higher in
the BAS arm than in the no induction arm (p= 0.03 and p= 0.02, respectively). The previous HTA reported
post-transplant diabetes mellitus in only one study90 and the rest of the data were confidential and were,
therefore, omitted from the report.
Maintenance therapy
One RCT77 and four non-RCTs80–83 of maintenance therapy in children and adolescents were included in the
review. RCT evidence evaluating TAC and non-RCT evidence on the use of TAC and MMF was identified.
The population characteristics from the one RCT of maintenance treatment identified in the review are
summarised in Table 16. Trompeter et al.77 compared the use of TAC+AZA+CCS with CSA+AZA+CCS.77
No RCTs evaluated TAC-PR, MMF, MPS, EVL, SRL and BEL in children and adolescents.
TABLE 23 Severity of AR: RCTs
BAS+CSA+MMF+CCS n events/
N participants (%)
PBO/NI+CSA+MMF+CCS n events/
N participants (%)
Study BPAR Banff 1 Banff 2 Banff 3 BPAR Banff 1 Banff 2 Banff 3 p-value
Grenda et al.75 19/99 (19.2) 15/99 (15) 3/99 (3) 1/99 (1) 19/93 (20.4) 11/93 (12) 7/93 (8) 1/93 (1) NR
aOffner et al.73 11/100 (11) Grade IA:
8/100 (8)
Grade IIA:
0/100 (0)
0/100 (0) 18/92 (19.6) Grade IA:
9/92 (10)
Grade IIA:
8/92 (9)
0/92 (0) 0.308b
Grade IB:
3/100 (3)
Grade IIB:
0/100 (0)
Grade IB:
1/92 (1)
Grade IIB:
0/92 (0)
NI, no induction.
a One patient in the PBO group experienced two episodes of BPAR.
b Wilcoxon signed-rank test.73,96
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The population characteristics from the four non-RCTs of maintenance treatment identified in the
review80–83 are summarised in Table 17. Garcia et al.80 compared the use of BAS+ TAC+AZA+CC with
BAS+CSA+MMF+CCS in a retrospective cohort study. Antoniadis et al.81 compared the use of
CSA+MMF+CCS with CSA+AZA+CCS in a non-RCT. Benfield et al.82 reported retrospective analyses of
a randomised, multicentre trial of OKT3 (a murine monoclonal antibody muromonab-CD3) versus CSA
induction therapy with two types of maintenance therapies, but only the comparison of CSA+MMF+CCS
with CSA+AZA+CCS was included in this review. Finally, Staskewitz et al.83 compared the use of
CSA+MMF+CCS with CSA+AZA+CCS in a historically controlled study. No non-randomised evidence
was identified regarding the use of TAC-PR, MPS, EVL, SRL and BEL in the child/adolescent population.
Mortality
Randomised controlled trials
Trompeter et al.77 compared the use of TAC+AZA+CCS with CSA+AZA+CCS. The trial reported similar
survival rates in both arms, which were not significantly different at 6 months, 1 year, 2 years or 4 years
(Table 25).
Non-randomised controlled trials
Three non-RCTs80,81,83 provided data on mortality (Table 26) and two trials compared MMF with AZA.81,83
The remaining study80 compared TAC+AZA with CSA+MMF. Staskewitz et al.83 reported long-term
follow-up of up to 5 years, but no further deaths were recorded in either arm. No statistically significant
difference in child/adolescent survival between MMF and AZA and between TAC+AZA and CSA+MMF
was reported.
Summary
In summary, no difference in survival was found between TAC and CSA from the child/adolescent RCT.
In addition, no difference was found between TAC and CSA, and between MMF and AZA, in the
child/adolescent non-RCT evidence. This is similar to the conclusions of the previous HTA.2
TABLE 25 Mortality: RCTs
Follow-up
Trompeter et al.77
TAC+AZA+CCS n events/
N participants, %
CSA+AZA+CCS n events/
N participants, % OR (95% CI)
6 months 3/103, 3 3/93, 3 0.90 (0.18 to 4.58)
1 year 3/103, 3 3/93, 3 0.90 (0.18 to 4.58)
2 years 3/103, 3 4/93, 4 0.67 (0.15 to 3.07)
4 years 5/103, 5 4/93, 4 1.14 (0.30 to 4.36)
NR, not reported.
Note
All ORs were calculated by PenTAG.
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Graft loss
Randomised controlled trials
Trompeter et al.77 compared the use of TAC+AZA+CCS with CSA+AZA+CCS. Graft loss appeared to
be higher in the CSA arm than in the TAC arm, especially at the longer follow-up (2–4 years), but the
difference was not statistically significant (Table 27).
Non-randomised controlled trials
Three non-RCTs80,81,83 provided data on graft loss (Table 28). Two trials compared MMF with AZA.81,83 The
remaining study80 compared TAC+AZA with CSA+MMF. Staskewitz et al.83 found better graft survival in
MMF than with AZA in up to a 5-year follow-up,83 while Antoniadis et al.81 did not find a statistically
significant difference in graft loss between MMF and AZA. No statistically significant difference in graft loss
between TAC+AZA and CSA+MMF regimens was reported.80
Summary
In summary, no statistically significant difference was found between TAC and CSA for graft loss.
However, the RCT child/adolescent evidence identified in the previous HTA review2 concluded that TAC
lowered graft loss at 2- (10/103 vs. 19/93; p= 0.03) and 4-year follow-ups (11/103 vs. 20/93; p= 0.03).
This discrepancy in result is because we have excluded graft loss due to death from our analyses. This was,
first, to avoid double counting with another key outcome (mortality) and, second, because death-censored
graft survival is a well-established clinical outcome to which death with functioning graft (DWFG) is
intrinsically related, just as mortality is to overall survival. It should be noted that after the removal of graft
loss due to death from the analyses, the evidence from Trompeter et al.77 suggested borderline statistically
non-significantly lower graft loss in TAC than CSA (OR= 0.41, 95% CI 0.16 to 1.00, and OR= 0.43,
95% CI 0.18 to 1.01 at 2- and 4-year follow-ups, respectively). In addition, the current review and the
previous HTA2 found better graft survival in MMF than in AZA (up to 5-year follow-up) in one non-RCT.83
TABLE 27 Graft loss: RCTs
Follow-up
Trompeter et al.77
TAC+AZA+CCS n events/
N participants, %
CSA+AZA+CCS n events/
N participants, % OR (95% CI)
6 months 6/103, 6 13/93, 14 0.38 (0.14 to 1.05)
1 year 8/103, 8 15/93, 16 0.44 (0.18 to 1.09)
2 years 8/103, 8 16/93, 17 0.41 (0.16 to 1.00)
4 years 9/103, 9 17/93, 18 0.43 (0.18 to 1.01)
Note
All ORs were calculated by PenTAG.
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Graft function
Randomised controlled trials
Trompeter et al.77 compared the use of TAC+AZA+CCS with CSA+AZA+CCS and reported graft
function estimated using the Schwartz equation (ml/minute/1.73 m2). Significantly higher graft function in
the TAC arm than in the AZA arm was reported (Table 29). No data on DGF were reported.77
Non-randomised controlled trials
Only one non-RCT provided data on graft function. Garcia et al.80 compared TAC+AZA with CSA+MMF
and reported graft function at a 3-month follow-up (Table 30). There were no significant differences between
the arms for graft function [eGFR, creatinine clearance (ml/minute)]. Garcia et al.80 also reported incidences of
DGF. The same rate of DGF was reported in the two arms [1/12 (8%) and 1/12 (8%), respectively].80
Summary
In summary, lower graft function was associated with TAC compared with CSA in the child/adolescent
RCT. This is similar to the conclusions of the previous HTA.2 In addition, no difference in graft function
between TAC+AZA and CSA+MMF regimens was reported in the one non-RCT.80 However, the previous
HTA included a non-RCT by Neu et al.94 which found significantly better graft function at 1- and 2-year
follow-ups (p< 0.01).
TABLE 29 Graft function (eGFR): RCTs
Follow-up
Trompeter et al.77
TAC+AZA+CCS, mean (SD),
n participants
CSA+AZA+CCS, mean (SD),
n participants t-test (p-value)
6 months 65.6 (19.9), 91 61.2 (15.8), 86 1.62 (0.11)
1 yeara 64.9 (20.7), 84 57.8 (21.9), 77 2.11 (0.04)
2 years 64.9 (19.8), 71 51.7 (20.3), 66 3.85 (< 0.01)
3 years 66.7 (26.4), 81 53.0 (23.3), 55 3.11 (< 0.01)
4 years 71.5 (22.9), 51 53.0 (21.6), 44 4.03 (< 0.01)
a N values reported in Trompeter et al.77 and Filler et al.79 differed; values from Filler et al.79 were used. t-tests were
calculated by PenTAG.
Evidence suggesting a statistically significant difference between treatments is highlighted in bold.
Graft function estimated using the Schwartz equation (ml/minute/1.73m2).
TABLE 30 Graft function (eGFR): non-randomised studies
Study ID Treatment
3 months
Mean (SD) t-test (p-value)
Garcia et al. 200280 BAS+ TAC+AZA+CCS 71 (23) –1.28 (0.21)
BAS+CSA+MMF+CCS 82 (19)
Note
t-tests were calculated by PenTAG; graft function was estimated by measuring creatinine clearance (ml/minute).
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Acute rejection
Randomised controlled trials
Trompeter et al.77 compared the use of TAC+AZA+CCS with CSA+AZA+CCS, reporting statistically
significantly higher BPAR at a 6-month follow-up, and AR (which was not biopsy proven) at 6-month and
1-year follow-ups in the CSA arm compared with the TAC arm (Table 31). In addition, 2- and 4-year
follow-up data are available for Trompeter et al.77 in Filler et al.79 However, these analyses do not take into
account those who were lost to follow-up and those who died. In the second year of the trial, 7 out of
77 patients in the TAC group and 9 out of 71 patients in the CSA group experienced AR (p= 0.6041,
Fisher’s exact test).79 In the third year, 2 out of 70 patients in the TAC group and 6 out of 57 patients in
the CSA group experienced AR (p= 0.1454, Fisher’s exact test).79 Finally, in the fourth year, 2 out of
57 patients in the TAC group and 6 out of 42 patients in the CSA group experienced AR (p= 0.1359,
Fisher’s exact test).79 Rejection episodes frequently occurred in the same patients that experienced AR
previously. Although overall treatment group differences were maintained after the first year, the annual
differences in AR were not statistically significant for years 2, 3 and 4.79 Time to, and severity of, AR were
not reported in Trompeter et al.77
Non-randomised controlled trials
Four non-RCTs80–83 provided data on BPAR (Table 32)80–83 and three studies compared MMF with AZA.81–83
The remaining study80 compared TAC+AZA with CSA+MMF. No statistically significant difference in
BPAR was found between the MMF arm and AZA arms, and between TAC+AZA and CSA+MMF.
The pooled results at a 6-month follow-up suggested borderline statistically non-significantly lower BPAR in
MMF compared with AZA (OR= 0.48, 95% CI 0.23 to 1.02, I2= 0%, τ2= 0; Figure 12).
In addition, Garcia et al.80 reported the severity of AR (Table 33); one Banff 3 episode was reported in
TAC+AZA and two Banff 1 episodes were reported in CSA+MMF. No study reported time to BPAR.
TABLE 31 Acute rejection: RCTs
Study ID
Acute
rejection Treatment
6 months 1 yeara
n events/N
participants, % OR (95% CI)
n events/N
participants, % OR (95% CI)
Trompeter et al. 200277 BPARb TAC+AZA+CCS 17/94, 18 0.29
(0.15 to 0.57)
NR N/A
CSA+AZA+CCS 37/86, 43 NR
AR TAC+AZA+CCS 38/103, 37 0.40
(0.23 to 0.71)
42/103, 41 0.43
(0.25 to 0.76)
CSA+AZA+CCS 55/93, 59 57/93, 62.3
N/A, not applicable; NR, not reported.
a 1-year follow-up reported in Trompeter et al.77 Between months 6 and 12, four TAC patients and two CSA patients
experienced a first AR.
b 94 TAC and 86 CSA participants had renal biopsies; 13 out of 18 centres reported biopsy findings. In addition, biopsies
were not mandatory in case of clinically suspected AR.
All ORs were calculated by PenTAG.
Evidence suggesting a statistically significant difference between treatments is highlighted in bold.
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TABLE 32 Biopsy-proven acute rejection: non-randomised studies
Study Treatment
3 months 6 months
n events/N
participants, % OR (95% CI)
n events/N
participants, % OR (95% CI)
Garcia et al. 200280 BAS+ TAC+AZA+CCS 1/12, 8 0.45
(0.04 to 5.78)
NR N/A
BAS+CSA+MMF+CCS 2/12, 17 NR
Antoniadis et al. 199881 CSA+MMF+CCS NR N/A 0/7, 0 0.08
(0.003 to 1.94)
CSA+AZA+CCS NR 3/7, 43
Staskewitz et al. 200183 CSA+MMF+CCS NR N/A 10/65, 15 0.52
(0.21 to 1.29)
CSA+AZA+CCS NR 14/54, 26
Benfield et al. 199982 CSA+MMF+CCS NR N/A 4/17, 24a 0.56
(0.13 to 2.47)
CSA+AZA+CCS NR 6/17, 35
N/A, not applicable; NR, not reported.
a Reported in text as 4 out of 17, 23%.
All ORs were calculated by PenTAG.
Note: weights are from random-effects analysis
Overall (I 2 = 0.0%; p = 0.547)
Benfield et al., 199978
Antoniadis et al., 199877
Staskewitz et al., 200179
0.48 (0.23 to 1.02)
0.56 (0.13 to 2.52)
0.09 (0.00 to 2.07)
0.52 (0.21 to 1.29)
100.00
25.35
5.61
69.04
Favours MMF  Favours AZA 
0.00355 1 282
Study ID OR (95% CI) % weight
FIGURE 12 Biopsy-proven acute rejection: non-randomised studies. τ2= 0. Studies included were Antoniadis et al.,81
Staskewitz et al.83 and Benfield et al.82
TABLE 33 Severity of AR: non-randomised studies
Study Treatment
3 month n events/N participants, %
Banff 1 Banff 2 Banff 3
Garcia et al. 200280 BAS+ TAC+AZA+CCS 0/12, 0 0/12, 0 1/12, 8
BAS+CSA+MMF+CCS 2/12, 17 0/12, 0 0/12, 0
Note
No Banff 2 AR was reported, assumed 0 and 0 events of Banff 2 in each arm.
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Summary
In summary, higher rates of BPAR were found in CSA than TAC in the one included child/adolescent RCT
with 6-month data.77 The RCT child/adolescent evidence identified in the previous HTA review2 also
concluded more BPAR in the CSA arm than the TAC.77 However, the limited longer follow-up data from
this study did not find statistically significant differences in AR between TAC and CSA at 2- and 4-year
follow-ups.79 In addition, no statistically significant difference in BPAR was found between the MMF arm
and AZA arms, and between TAC+AZA and CSA+MMF arms in the non-randomised evidence. The
pooled non-RCT child/adolescent evidence identified in the previous HTA review suggested less BPAR with
MMF compared with AZA [relative risk (RR)= 0.39 favours MMF; 95% CI 0.19 to 0.79]. Similarly, our
analyses suggested borderline statistically non-significantly lower BPAR in MMF than AZA at 6-month
follow-up (OR= 0.48, 95% CI 0.23; 1.02, I2= 0%, τ2= 0).
Adverse events
Randomised controlled trials
One child/adolescent RCT77 provided data on AE for maintenance treatments. This study compared the use
of TAC+AZA+CCS with CSA+AZA+CCS and reported no statistically significant differences between
TAC and CSA for a range of AEs (Table 34). In addition, the incidence of new-onset diabetes mellitus after
transplantation (NODAT) (defined as insulin use for > 30 consecutive days in previously non-diabetic
patients) was not significantly different between TAC and CSA; NODAT was reported for 3 out of 100
children and adolescents (3.0%) in the TAC group and 2 out of 93 children and adolescents (2.2%) in the
CSA group.77 The proportion of children and adolescents withdrawing owing to AEs was 10% (10/103) in
TAC and 15% (14/93) in CSA arms (OR= 0.61; favours TAC; 95% CI 0.25 to 1.44). Finally, Trompeter
et al.77 reported that a deficiency of magnesium in the blood and diarrhoea were more common with TAC
than with CSA [34.0% compared with 12.9% (p= 0.001) and 13.6% compared with 3.2% (p= 0.011),
respectively], while excessive hair growth, flu syndrome and swollen gums were less common with TAC
than with CSA [0.0% compared with 7.5% (p= 0.005), 0.0% compared with 5.4% (p= 0.023) and 0.0%
compared with 5.4% (p= 0.023), respectively].77
TABLE 34 Adverse events, maintenance studies: RCTs
Adverse events
AE n events/N participants, %
aTrompeter et al.77
TAC+AZA+CCS CSA+AZA+CCS OR (95% CI)
Any infections 71/103, 69 60/93, 65 0.88 (0.45 to 1.67)
UTI 30/103, 30 31/93, 33 0.82 (0.45 to 1.49)
Bacterial infections 43/103, 42 38/93, 41 1.04 (0.60 to 1.80)
Viral infections 23/103, 22 23/93, 25 0.88 (0.45 to 1.69)
PTLD 1/103, 1 2/93, 2 0.45 (0.04 to 5.01)
Solid tumour 1/103, 1 0/93, 0 2.73 (0.11 to 67.99)
Hypertension 71/103, 69 57/93, 61 1.40 (0.83 to 2.36)
Any AE 98/103, 95 93/93, 100 0.10 (0.01 to 1.57)
PTLD, post-transplant lymphoproliferative disease; UTI, urinary tract infection.
Note
a All ORs were calculated by PenTAG.
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Non-randomised controlled trials
Three non-RCTs provided data on AEs (Table 35)80,81,83 and two trials compared MMF with AZA.81,83
The remaining study80 compared TAC+AZA with CSA+MMF.80 Staskewitz et al.83 reported AEs only for
the MMF group and not for the historic control AZA group. No statistically significant between-group
differences in AEs were found (see Table 35) in the non-RCTs that did compare treatment groups.
In addition, Staskewitz et al.83 reported AEs up to 5 years of follow-up for the MMF group (see Appendix 5,
Table 140).84,85
TABLE 35 Adverse events, maintenance studies: non-randomised studies
Adverse
events
AE n events/N participants, %
Garcia et al.80 Antoniadis et al.81
Staskewitz
et al.83
Follow-up TAC+AZA CSA+MMF OR (95% CI) MMF AZA OR (95% CI) MMF
UTI 3 months NR NR N/A NR NR N/A 13/65, 20
6 months NR NR N/A 2/7, 28 5/7, 71 0.16
(0.02 to 1.55)
14/65, 22
CMV
infections
3 months 4/12, 33.3 0/12, 0 13.80
(0.67 to 286.1)
NR NR N/A 9/65, 14
6 months NR NR N/A 3/7, 43 5/7, 71 0.30
(0.04 to 2.51)
10/65, 15
Respiratory
infections
3 months NR NR N/A NR NR N/A 15/65, 23
6 months NR NR N/A 1/7, 14 3/7, 42 0.22
(0.02 to 2.92)
20/65, 31
Herpes
simplex
3 months NR NR N/A NR NR N/A 6/65, 9
6 months NR NR N/A 2/7, 28 1/7, 14 2.40
(0.17 to 33.52)
8/65, 12
Oral thrush 3 months NR NR N/A NR NR N/A 2/65, 3
6 months NR NR N/A 1/7, 14 1/7, 14 N/A 2/65, 3
Diarrhoea 3 months NR NR N/A NR NR N/A 11/65, 17
6 months NR NR N/A 1/7, 14 0/7, 0 3.55
(0.12
to 103.51)
13/65, 20
Abdominal
pain
3 months NR NR N/A NR NR N/A 14/65, 22
6 months NR NR N/A NR NR N/A 16/65, 25
NODAT 3 months 1/12, 8.3 0/12, 0 3.29
(0.12 to 89.20)
NR NR N/A NR
CMV, cytomegalovirus; N/A, not applicable; NR, not reported; UTI, urinary tract infection.
Notes
Staskewitz et al.83 did not report any AE for the historic control AZA group; only AE for MMF group were reported.
All ORs were calculated by PenTAG.
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Summary
The RCT results suggested no statistically significant differences between TAC and CSA for a range of
AEs [any infections, urinary tract infections (UTIs), bacterial infections, viral infections, post-transplant
lymphoproliferative disease (PTLD), solid tumour, hypertension, any AE and NODAT].77 This is similar to the
conclusions of the previous HTA.2 In addition, no statistically significant differences between MMF and AZA
for UTI, cytomegalovirus (CMV) infections, respiratory infections, herpes simplex, oral thrush and diarrhoea
were identified in the non-randomised evidence.81 Similarly, no statistically significant differences between
TAC+AZA and CSA+MMF in CMV infections and NODAT were identified in the non-randomised
evidence.80 In contrast, the previous HTA found significantly more CMV infection in TAC+AZA than
CSA+MMF (4/12 vs. 0/12, respectively; p= 0.04) in the same non-RCT.80 This discrepancy in results is
due to different statistical analyses used as the current review calculated OR (OR= 13.80, favours
CSA+MMF; 95% CI 0.67 to 286.10). This inconsistency highlights the small size of this study80 (n= 24)
and the uncertainties of its results.
Comparing children and adolescents, and adult evidence
The results from the current review are contrasted with those from the parallel HTA appraisal
‘Immunosuppressive therapy for kidney transplantation in adults’.68
Induction therapy
The current review identified two RCTs73,75 evaluating BAS induction therapy in children and adolescents.
Offner et al.73 compared BAS induction therapy with PBO and Grenda et al.75 compared BAS induction
therapy with no induction.
Mortality
Adult randomised controlled trial evidence
In the adult evidence identified by the parallel HTA, three RCTs comparing BAS and no induction
reported mortality97–99 and four studies compared BAS with PBO.100–103 Six studies reported results at 1-year
follow-up.98–103 The pooled results at 1 year with four studies98,100–102 suggest no difference between BAS
and PBO or no induction: OR= 0.95 (favours BAS; 95% CI 0.49 to 1.87, I2= 0.7%, τ2= 0.004);98,100–102
two studies reported zero events in both arms.99,103
Summary
In summary, there was no evidence that BAS improved survival when compared with PBO or no induction
in the adult evidence. The child/adolescent RCT evidence is consistent with the adult RCT evidence
identified in the parallel HTA.
Graft loss
Adult randomised controlled trial evidence
In the adult evidence identified by the parallel HTA, three studies comparing BAS and no induction
reported graft loss97–99 and four studies compared BAS with PBO.100–103 Six studies reported results at 1-year
follow-up.98–103 The pooled results at 1 year with five studies98,100–103 suggest no difference between BAS
and PBO or no induction: OR= 0.82 (favours BAS; 95% CI 0.56 to 1.21, I2= 0.0%, τ2= 0.0);98,100–103 one
study reported zero events in both arms.99
Summary
In summary, there was no evidence that BAS lowered graft loss when compared with PBO or no induction
in the adult evidence. The child/adolescent RCT evidence is consistent with the adult RCT evidence
identified in the parallel HTA.
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Graft function
Adult randomised controlled trial evidence
In the adult evidence identified by the parallel HTA, graft function was reported by four studies at 1 year
comparing BAS with PBO.99–102 The pooled analysis for graft function implied no beneficial effect of BAS
compared with controls: WMD= 1.93 (favours BAS; 95% CI –0.97 to 4.83, I2= 23.9%).99–102 One study
comparing BAS and no induction reported data on graft function from 1 year to 10 years.99 It was
summarised that up to 7 years, graft function appeared to be slightly better for participants who received
BAS; however, the effect reduced over time and the reverse was true at 10 years. Furthermore, the
difference across all time points was not statistically significant.99
Summary
In summary, there was no significant evidence that BAS increased graft function when compared with PBO
or no induction in the adult evidence. The child/adolescent RCT evidence is consistent with the adult RCT
evidence identified in the parallel HTA.
Acute rejection
Adult randomised controlled trial evidence
In the adult evidence identified by the parallel HTA, three studies comparing BAS and no induction97–99
and four studies comparing BAS with PBO reported AR.100–103 The pooled results at 1 year with five
studies98,100–103 suggest less BPAR in BAS than PBO or no induction (OR= 0.53; favours BAS; 95% CI 0.40
to 0.70, I2= 0.0%, τ2= 0.0). Furthermore, Sheashaa et al.99 reported BPAR at 10 years, at which time BAS
continues to show a beneficial effect compared with no induction (OR= 0.41, 95% CI 0.18 to 0.96).
In addition, six studies reported severity of BPAR.97,99–103 The results do not suggest that BAS is associated
with more severe BPAR than no induction or PBO (Table 36).
TABLE 36 Adult RCT evidence: severity of AR BAS versus PBO/no induction
Study
Time
point
(years)
BAS PBO/no induction
n BPAR Banff 1 Banff 2 Banff 3 n BPAR Banff 1 Banff 2 Banff 3
Albano et al. 201397 0.5 283 36 16 18 2 302 31 13 15 3
aLawen et al. 2003103 0.5 59 9 5 1 2 64 17 4 11 1
Nashan et al. 1997101 0.5 190 51 20 26 5 186 73 31 31 11
Ponticelli et al. 2001102 0.5 168 31 15 12 4 172 49 16 25 8
Kahan et al. 1999100 1 173 61 26 31 4 173 85 38 37 10
bSheashaa et al. 200399 1 50 29 27 2 50 45 35 10
bSheashaa et al. 200399 5 50 27 24 3 50 36 25 11
bSheashaa et al. 200399 7 50 41 3 2 50 55 44 11
bSheashaa et al. 200399 10 50 41 3 2 50 55 44 11
a In addition to reported Banff 1–3, there was one BPAR of unknown classification in both study arms.
b Numbers of BPAR episodes were reported and Banff 2 and 3 were reported together, while episodes recorded as Banff
1 also included borderline BPAR.
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Summary
In summary, the adult evidence suggested less BPAR in BAS than PBO or no induction, but no difference in
severity of BPAR was found. Similarly, there was no evidence that BAS reduced incidences of, severity and
time to BPAR when compared with PBO or no induction in the child/adolescent RCTs.73,75
Adverse events
Adult randomised controlled trial evidence
Five adult RCTs comparing BAS with PBO or no induction identified by the parallel HTA reported AEs at
1-year follow-up.98,100,101,103,104 No significant differences in NODAT, PTLD, malignancy, infections and CMV
infections were found between BAS and PBO or no induction arms (Table 37).
Summary
In summary, the adult RCT evidence identified in the parallel HTA did not find any significant differences
in NODAT, PTLD, malignancy, infections and CMV infections between BAS and PBO or no induction
conditions. However, the child/adolescent RCTs found more infections with BAS than with PBO in one
study (OR= 2.23, favours PBO; 95% CI 1.03 to 4.68).73
Maintenance therapy
The current review identified one RCT77 and four non-RCTs80–83 evaluating maintenance therapy in children
and adolescents. Trompeter et al.77 compared the use of TAC and CSA. Garcia et al.80 compared the use of
TAC+AZA and CSA+MMF. Antoniadis et al.,81 Benfield et al.82 and Staskewitz et al. 200183 compared the
use of MMF and AZA.
TABLE 37 Adults induction therapy RCTs: pooled results at 1-year follow-up
AE Studies OR 95% CI I2 t2
NODATa Kyllönen et al. 200798 3.79 0.43 to 33.64 N/A N/A
Malignancyb Kahan et al. 1999100 0.62 0.22 to 1.76 0% 0
Kyllönen et al. 200798
Nashan et al. 1997101
PTLDb Nashan et al. 1997101 0.98 0.06 to 15.77 N/A N/A
Infectionsa Kahan et al. 1999100 0.98 0.80 to 1.20 0% 0
Nashan et al. 1997101
Lawen et al. 2003103
CMVa Kahan et al. 1999100 0.8 0.56 to 1.13 0% 0
Kyllönen et al. 200798
Nashan et al. 1997101
Lawen et al. 2003103
N/A, not applicable.
a Bingyi et al.104 reported zero events in each arm.
b Bingyi et al.104 and Lawen et al.103 reported zero events in each arm.
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Mortality
Parallel Health Technology Assessment adult randomised controlled trial evidence
Ten adult RCTs comparing TAC+AZA with CSA+AZA identified by the parallel HTA reported
mortality.105–114 The pooled results at 1 year with eight studies106–111,113,114 found no statistically significant
difference between TAC and CSA (OR= 1.51; favours CSA; 95% CI 0.75 to 3.06, I2= 14.8%). One study107
reported mortality up to 5 years, but the results are consistent with earlier time points and indicated no
statistically significant difference between arms (OR 1.20; favours CSA; 95% CI 0.69 to 2.07).107
Seven adult RCTs comparing MMF+CSA and AZA+CSA identified by the parallel HTA reported
mortality.114–120 The pooled results at 1 year with five studies114,116–119 suggest no significant difference
between MMF and AZA (OR= 1.19; favours AZA; 95% CI 0.47 to 3.02, I2= 0%, τ2= 0). In addition,
two studies reported mortality at a 3-year follow-up, suggesting no difference between MMF and AZA
(OR= 0.56 favours MMF; 95% CI 0.23 to 1.23, I2= 0%, τ2= 0).115,118 The study reported by Tuncer et al.118
provided data at 5 years, which also indicated no preference for either MMF or AZA (OR 0.73, 95% CI
0.15 to 3.50).
Summary
In summary, no difference in survival was found between TAC and CSA and between MMF and AZA in
the adult evidence. The child/adolescent RCT and child/adolescent non-RCT evidence is consistent with the
adult RCT evidence identified in the parallel HTA.
Graft loss
Parallel Health Technology Assessment adult randomised controlled trial evidence
Eleven adult RCTs comparing TAC+AZA with CSA+AZA identified by the parallel HTA reported graft
loss.105–114,121 The pooled results at 1 year with eight studies107–111,113,114,121 found no significant difference
between TAC and CSA (OR= 0.83; favours TAC; 95% CI 0.54 to 1.27, I2= 12.3%; in addition, one study
reported zero events in both arms108). As with mortality, the results for graft loss suggest no statistically
significant difference between TAC and CSA. This lack of preference for either treatment remained at
2- (OR 0.71, 95% CI 0.40 to 1.25)107,121, 4- (OR 0.96, 95% CI 0.62 to 1.48)107 and 5-year follow-ups
(OR 0.92, 95% CI 0.61 to 1.40).107 However, the pooling of two trials at 6 months gives an OR of 0.45
with 95% CI 0.24 to 0.84, which is statistically significant in favour of TAC.110,112
Five adult RCTs comparing MMF+CSA with AZA+CSA identified by the parallel HTA reported graft
loss.114–117,120 The pooled results at 1 year with four studies114–117 suggest no significant difference between
MMF and AZA (OR= 0.76; favours MMF; 95% CI 0.38 to 1.50, I2= 32.3%, τ2= 0.120).
Summary
In summary, 1-year follow-up data found no statistically significant difference in graft loss between TAC
and CSA and between MMF and AZA in the adult evidence. Similarly, no statistically significant difference
was found between TAC and CSA for graft loss in the child/adolescent RCT evidence. However, it should
be noted that the evidence from Trompeter et al.77 suggested borderline statistically non-significantly lower
in graft loss with TAC compared with CSA (OR= 0.41, 95% CI 0.16 to 1.00, and OR= 0.43, 95% CI 0.18
to 1.01 at 2- and 4-year follow-ups, respectively). In addition, the current review found better graft survival
in MMF than in AZA in a 5-year follow-up from one child/adolescent non-RCT.83
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Graft function
Parallel Health Technology Assessment adult randomised controlled trial evidence
Four adult RCTs comparing TAC with CSA identified by the parallel HTA reported graft function.105,110,122,123
No meta-analysis was conducted because the results were presented in a number of ways and were not
appropriate for pooling. One study110 suggested lower graft function for TAC, as opposed to CSA at
1- and 2-year follow-ups, but not at a 3-year follow-up. Another study122 did not find statistically
significant difference between TAC and CSA at 1-year follow-up. Conflicting results were reported by all
four trials across all time points (1 month to 3 years).
Summary
In summary, conflicting adult evidence was reported in the parallel HTA across all time points (1 month to
3 years) and it is not clear if there is any difference between TAC and CSA with regard to graft function.
In contrast, better graft function was associated with TAC compared with CSA in the one child/adolescent
RCT.77 In addition, no difference in graft function between TAC+AZA and CSA+MMF regimens was
reported in the one non-RCT.80
Acute rejection
Parallel Health Technology Assessment adult randomised controlled trial evidence
TAC versus CSA Nine adult RCTs comparing TAC with CSA identified by the parallel HTA reported AR at
1 year.107–111,113,114,121,124 The pooled results at 1 year with all nine studies found significantly higher BPAR in
the CSA arm than the TAC arm (OR= 0.50; favours TAC; 95% CI 0.39 to 0.64, I2= 8.1%).107–111,113,114,121,124
In addition, Mayer et al.107 reported BPAR at 4 years, for which the beneficial effect of TAC appeared to be
maintained (OR 0.38 favours TAC, 95% CI 0.25 to 0.57).
Time to first BPAR was reported by two studies109,121 which suggested that BPAR may occur quicker for
participants receiving TAC (35 days, SD 13) than CSA (59 days, SD 38); however, no statistical tests were
reported.121 Campos et al.109 reported that the mean time to BPAR was comparable between the TAC and
CSA groups (14.5 days, SD 47.3, and 12.0 days, SD 21.0, respectively).
Severity of BPAR was reported by four studies (Table 38).110,112,113,121 At 6 months, Charpentier et al.112
report the proportion of people with BPAR classified as Banff 3 as 10.7% for TAC and 15.4% for CSA and
by 2 years Margreiter et al.110 report 6.4% and 16.8% of people with BPAR experiencing Banff 3, for TAC
and CSA, respectively.
TABLE 38 Adult RCT evidence: severity of AR TAC+AZA versus CSA+AZA
Study
Time
point
(years)
TAC+AZA CSA+AZA
n BPAR Banff 1 Banff 2 Banff 3 n BPAR Banff 1 Banff 2 Banff 3
Margreiter et al. 2002 110 0.5 286 56 21 31 4 271 101 34 49 18
Charpentier et al. 2003112 0.5 186 28 18 7 3 184 39 14 19 6
Baboolal et al. 2002121 1 27 5 3 2 0 24 8 5 3 0
Hardinger et al. 2005113 1 134 6 3 3 0 66 4 1 3 0
aMargreiter et al. 2002110 1 286 60 23 33 4 271 111 39 54 18
aMargreiter et al. 2002110 2 286 62 23 35 4 271 113 40 54 19
a Recorded Banff 1 BPAR include two and one borderline BPAR in TAC+AZA and CSA+AZA groups, respectively.
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MMF versus AZA Six adult RCTs comparing MMF and AZA identified by the parallel HTA reported
BPAR.114–117,119,120 The pooled results from three studies115,119,120 at 6-month follow-up suggested less BPAR
in the MMF than the AZA arm (OR= 0.50; favours MMF; 95% CI 0.35 to 0.72, I2= 35.1%, τ2= 0.036),
while pooled results of four RCTs114–117 at 1-year follow-up suggested no statistically significant
between-group differences for BPAR (OR= 0.67; 95% CI 0.37 to 1.22, I2= 58.3%, τ2= 0.198).
In addition, three RCTs identified by the parallel HTA reported severity of BPAR (Table 39).115,117,120 Overall,
at 0.5 years, the more severe classification of Banff 3 appears to be more likely in the AZA arm for people
with BPAR (CSA 9.1%, AZA 15.9% for Sollinger et al.120 and CSA 5.9%, AZA 11.9% for the Tricontinental
Group 1996115).
Insufficient data were provided for time to BPAR to allow pooled analysis as only Merville et al.117 reported
time to BPAR as 48.5 days for MMF and 43.7 days for AZA.
Summary
In summary, pooled results of nine adult RCTs identified by the parallel HTA at 1-year follow-up suggested
less BPAR with TAC compared with CSA. Similarly, higher rates of BPAR were found in CSA compared
with TAC in the one included child/adolescent RCT at a 6-month follow-up.77 No statistically significant
differences were found between TAC and CSA in the adult RCT evidence with regard to time to BPAR,
and severity of BPAR. No child/adolescent evidence on severity and time to BPAR was identified.
In addition, pooled results of three adult RCTs identified by the parallel HTA at 6-months follow-up
suggested less BPAR with MMF than AZA (OR= 0.50; favours MMF; 95% CI 0.35 to 0.72, I2= 35.1%);
however, the pooled results of four adult RCTs at 1-year follow-up suggested no statistical significance
between-group differences (OR= 0.67; 95% CI 0.37 to 1.22, I2= 58.3%). Similarly in the child/adolescent
non-randomised evidence, no statistically significant differences in BPAR were found between the MMF
and AZA arms, and between TAC+AZA and CSA+MMF.
Adverse events
Parallel Health Technology Assessment adult randomised controlled trial evidence
Ten adult RCTs comparing TAC with CSA identified by the parallel HTA reported AEs at 1-year
follow-up,106–109,113,114,121,125–127 six studies compared TAC+AZA+CCS with CSA+AZA+CCS
regimens,106–109,113,121 two studies compared TAC+MMF+CCS with CSA+MMF+CCS regimens,114,125
one study compared TAC+ SRL+CCS with CSA+ SRL+CCS regimens,126 and one study (Symphony study
comparing four regimens127) compared low TAC+MMF+CCS with low CSA+MMF+CCS regimens.127
No difference in PTLD, malignancy, infections and CMV infection was found between TAC and CSA
regimens at 1-year follow-up. The meta-analysis (including eight studies106–109,113,125–127) suggested more
cases of NODAT in TAC regimens compared with CSA (OR= 2.22; favours CSA; 95% CI 1.42 to 3.46,
I2= 0%). All meta-analyses are summarised in Table 40.
TABLE 39 Adult RCT evidence: severity of AR MMF+CSA versus AZA+CSA
Study
Time
point
(years)
MMF+CSA AZA+CSA
n BPAR Banff 1 Banff 2 Banff 3 n BPAR Banff 1 Banff 2 Banff 3
Sollinger et al. 1995120 0.5 167 33 18 12 3 166 63 29 24 10
Tricontinental study 1996115 0.5 173 34 16 16 2 166 59 26 26 7
aMerville et al. 2004117 1 37 5 4 1 0 34 7 2 3 2
a Incidences of BPAR were reported.
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Three adult RCTs that compared MMF with AZA reported AEs; one study compared MMF+CSA+CCS
with AZA+CSA+CCS regimens,117 and two three-arm studies compared MMF+CSA+CCS with
AZA+CSA+CCS regimens.114,116 No difference in infections and CMV infection were found between
MMF and AZA regimens at 1-year follow-up. However, only two studies114,117 reported CMV infection and
only one study reported infections.116
Summary
The result suggested no difference between TAC and CSA for mortality, graft loss and AEs, although more
BPAR and AR, and worse graft function was reported in CSA compared with TAC.77 The child/adolescent
RCT found no statistically significant differences between TAC and CSA for a range of AEs including
NODAT (e.g. any infections, UTIs, bacterial infections, viral infections, PTLD and solid tumour).
TABLE 40 Adults maintenance therapy RCTs: pooled results at 1-year follow-up
AE Study OR 95% CI I2 t2
NODAT Laskow et al. 1996106 2.22 1.42 to 3.46 0% 0
Mayer et al. 1997107
Jarzembowski et al. 2005108
Campos et al. 2002109
Hardinger et al. 2005113
Yang et al. 1999 125
Symphony127
Chen et al. 2008126
Malignancy Mayer et al. 1997107 1.36 0.54 to 3.39 0% 0.57
Hardinger et al. 2005113
Yang et al. 1999125
Symphony127
Infections Mayer et al. 1997107 1.12 0.84 to 1.49 0% 0.46
Chen et al. 2008126
Yang et al. 1999125
Symphony127
CMV Baboolal et al. 2002121 0.8 0.59 to 1.09 0% 0.6
Mayer et al. 1997107
Jarzembowski et al. 2005108
Weimer et al. 2006114
Symphony127
Yang et al. 1999125
Hardinger et al. 2005113
N/A, not applicable.
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Summary
Three RCTs are included in the clinical effectiveness systematic review presented in this report: one new
RCT73 and two RCTs from the previous assessment.75,77
Four non-RCTs are included in our review. All of these were also included in the previous assessment by
Yao et al.2 No new non-randomised studies were identified in our searches.
Induction therapy
Two RCTs of induction therapy (reported in four publications and one abstract) evaluating BAS in children
and adolescents were identified in the review.73,75 No RCTs were identified that evaluated r-ATG in
children and adolescents.
No non-RCTs in the child and adolescents population evaluated induction therapies.
We found no significant difference in survival, graft loss, graft function, incidences of BPAR, severity of
BPAR and time to BPAR between BAS and PBO/no induction.73,75
Comparison with the previous Health Technology Assessment and the parallel
Health Technology Assessment in adults
The results of the current review are similar to the previous HTA.2
In addition, the child RCT evidence is similar to the conclusions of the parallel HTA in adults. However, the
adult evidence found less BPAR in BAS than PBO or no induction (OR= 0.53; favours BAS; 95% CI 0.40 to
0.70, I2= 0.0%, τ2= 0.0; pooled results at 1-year follow-up with five studies).
The comparison of the child/adolescent RCT evidence with the previous HTA and the parallel HTA in adults
is summarised in Table 41.
Maintenance therapy
Randomised controlled trial evidence
One RCT of maintenance therapy (reported in three publications) evaluating TAC (compared with CSA) in
children and adolescents was identified.77 No RCTs were identified that evaluated TAC-PR, MMF, MPA,
SRL, EVL or BEL in children and adolescents.
From the RCTs, we found no significant difference in survival or graft loss between TAC and CSA.77
However, a significantly higher graft function (mean eGFR of 71.5ml/minute/1.73 m2, SD 22.9ml/minute/
1.73m2, in TAC vs. mean eGFR of 53.0ml/minute/1.73 m2, SD 21.6ml/minute/1.73 m2, in CSA; t-test= 4.03;
p< 0.01 at 4-year follow-up), and less BPAR (OR= 0.29, favours TAC, 95% CI 0.15 to 0.57 at 6-month
follow-up) was found in TAC compared with CSA.77
Comparison with the previous Health Technology Assessment and the parallel
Health Technology Assessment in adults
The results of the current review for survival, graft function and BPAR are similar to the previous HTA.2
However, the RCT child and adolescent evidence identified in the previous HTA review2 concluded that TAC
lowered graft loss at 2- and 4-year follow-ups. The difference in these results is because we excluded graft loss
due to death from all analyses. This was, first, to avoid double counting with another key outcome (mortality)
and, second, because death-censored graft survival is a well-established clinical outcome, to which DWFG is
intrinsically related. After the removal of graft loss due to death from the analyses, the evidence from
Trompeter et al.77 suggested a borderline (statistically non-significant) lower graft loss with TAC than CSA
(OR= 0.41, 95% CI 0.16 to 1.00, and OR= 0.43, 95% CI 0.18 to 1.01 at 2- and 4-year follow-ups,
respectively). In addition, while there were statistically significant treatment group differences in BPAR and AR
at 6 months, the annual differences in AR were not statistically significant for years 2, 3 and 4.77,79
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In addition, the child RCT evidence is similar to the conclusions of the parallel HTA in adults. The pooled
result of nine studies at 1-year follow-up found less BPAR in TAC than CSA (OR= 0.50, favours TAC;
95% CI 0.39 to 0.64, I2= 8.1%). The comparison of the child/adolescent RCT evidence with the previous
HTA and the parallel HTA in adults is summarised in Table 42.
Non-randomised controlled trial evidence
Three non-RCTs evaluating MMF (compared with AZA) in children and adolescents were identified.81–83
One non-RCT compared TAC+AZA with CSA+MMF.80 No non-RCTs were identified that evaluated
TAC-PR, MPA, SRL, EVL or BEL in children and adolescents.
TABLE 41 Summary of RCT evidence comparing BAS with PBO and no induction
Outcome Follow-up
PenTAG RCTs BAS
vs. control
Yao et al.2 RCTs BAS
vs. control
Parallel HTA adult RCTs BAS vs.
control (meta-analysis at 1-year
follow-up)
OR (95% CI) RR (95% CI) OR (95% CI)
Mortality 3 months 2.79 (0.11 to 69.31)73
6 months 4.69 (0.22 to 99.10)73
No deaths in either arm75
No deaths in either arm75
1 year 6.64 (0.34 to 130.33)73 0.95 (0.49 to 1.87); I2=0.7%98,100–102
No deaths in either arm99,103
2 years 0.33 (0.01 to 8.20)75
Graft Loss 6 months 0.93 (0.29 to 2.97);
I2= 0%73,75
0.93
(95% CI 0.28 to 3.12)75
1 year 0.92 (0.06 to 14.92)73 0.82 (0.56 to 1.21); I2= 0%98,100–103
No deaths in either arm99
2 years 0.50 (0.16 to 1.54)75
BPAR 3 months 0.39 (0.14 to 1.07)73
6 months 0.71 (0.40 to 1.27);
I2= 15.7%73,75
0.93
(95% CI 0.53 to 1.65)75
1 year 0.51 (0.24 to 1.08)73 0.53 (0.40 to 0.70); I2= 0%98,100–103
2 years 0.74 (0.39 to 1.40)75
eGFR 6 months WMDa –4.20 (–9.60 to 1.20);
I2= 0%73,75
WMDb 4.5
(95% CI –6.26 to 5.26)75
1 year Mean (SD)a: 79(23) vs. 82
(24); p= 0.38d,73
WMDc 1.93 (–0.97 to 4.83);
I2= 23.9%99–102
2 years WMDa –1.38 (–7.20 to 4.44);
I2= 0%73,75
a eGFR estimated using Schwartz equation (ml/minute/1.73m2).
b Serum creatinine (mmol/l).
c Various equations (ml/minute).
d Result of t-test comparing means and SDs.
Notes
The previous HTA by Yao et al.2 had only 6 months follow-up data for Grenda et al.75 (as included in Fujusawa/Astellas’
submission and an abstract by Grenda et al.90).
Evidence suggesting a statistically significant difference between treatments highlighted in bold. OR > 1 favours BAS;
RR > 1 favours BAS; WMD > 0 favours BAS.
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TABLE 42 Summary of RCT evidence comparing TAC with CSA
Outcome Follow-up
PenTAG RCTs TAC
vs. CSA
Yao et al.2 RCTs TAC
vs. CSA
Parallel HTA adult RCTs TAC vs.
CSA (meta-analysis at 1 year
follow-up)
OR (95% CI) RR (95% CI) OR (95% CI)
Mortality 6 months 0.9 (0.18 to 4.58)77 0.9 (0.21 to 3.84)77
1 year 0.9 (0.18 to 4.58)77 n/N: 3/103 vs. 3/93
(p= 0.90)77
1.51 (0.75 to 3.06);
I2= 14.8%106–111,113,114
2 years 0.67 (0.15 to 3.07)77 n/N: 3/103 vs. 4/93 (NS)77
4 years 1.14 (0.30 to 4.36)77 n/N: 5/103 vs. 4/93
(p= 0.90)
Graft lossa 6 months 0.38 (0.14 to 1.05)77 0.48 (0.22 to 1.08)77
1 year 0.44 (0.18 to 1.09)77 n/N: 10/103 vs. 17/93
(p= 0.082)77
10.83 (0.542 to 1.27);
I2= 12.3%106,107,109–111,113,114,121
2 years 0.41 (0.16 to 1.00)77 n/N: 10/103 vs. 19/93
(p= 0.03)77
4 years 0.43 (0.18 to 1.01)77 n/N: 11/103 vs. 20/93
(p= 0.03)77
BPAR 6 months 0.29 (0.15 to 0.57)77 0.42 (0.26 to 0.69)77
1 year 0.50 (0.39 to 0.64);
I2= 8.1%107–111,113,114,121,124
eGFRb 6 months Mean (SD):c 65.6 (19.9)
vs. 61.2(15.8); dp= 0.1177
Mean (SD):c 90.91 (34.2)
vs. 86.09 (26.8)77;
dp= 0.0977
No meta-analysis was performed;
conflicting results were reported by
all four trials across all time points
(1 month to 3 years)99–102
1 year Mean (SD):c 64.9 (20.7)
vs. 57.8 (21.9); dp= 0.0477
Mean (SD):c 62.5 vs. 56.4;
dp< 0.0177
2 years Mean (SD):c 64.9 (19.8)
vs. 51.7 (20.3); dp< 0.0177
Mean (SD):c 64.9 vs. 51.7;
dp< 0.0177
3 years Mean (SD):c 66.7 (26.4)
vs. 53.0 (23.3); dp< 0.0177
4 years Mean (SD):c 71.5 (22.9)
vs. 53.0 (21.6); dp< 0.0177
Mean (SD):c 71.5 vs. 53.0;
dp< 0.0177
NS, not significant.
a The discrepancy in graft loss result between PenTAG and the previous HTA is because we have excluded graft loss
owing to death from our analyses. This was, first, to avoid double counting with another key outcome (mortality) and,
second, because death-censored graft survival is a well-established clinical outcome, to which DWFG is intrinsically
related just as mortality is to overall survival. It should be noted that after the removal of graft loss owing to death from
the analyses the child/adolescent RCT evidence suggested borderline statistically non-significantly lower graft loss in TAC
compared with CSA.
b eGFR values reported in Trompeter et al.77 and the 4-year follow-up paper by Filler et al.79 differ, we used data reported
in Filler et al.79
c eGFR estimated using Schwartz equation (ml/minute/1.73m2).
d Result of t-test comparing means and SDs.
Note
Evidence suggesting a statistically significant difference between treatments highlighted in bold. OR > 1 favours TAC;
RR > 1 favours TAC; WMD > 0 favours TAC.
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Tacrolimus versus ciclosporin
We found no statistically significant difference in survival between MMF and AZA in the non-RCTs.81,83
Similarly, no statistically significant difference in BPAR between MMF and AZA in the non-RCTs was
identified.81–83 A significantly lower graft loss was found in MMF compared with AZA at 1- to 5- year
follow-ups in one of the two non-RCTs83 (OR= 0.24 at 5-year follow-up; favours MMF; 95% CI 0.09 to
0.63). However, this was not confirmed by the other non-RCT at 1-year follow-up.81 Graft function (eGFR)
was not measured in the three included non-RCTs comparing MMF and AZA.81–83
In addition, conflicting evidence was found in the parallel HTA in adults. No difference in graft loss was
found between MMF and AZA in the adult evidence; OR= 0.76 (favours MMF; 95% CI 0.38 to 1.50,
I2= 32.3%, τ2= 0.120; pooled results of four studies a 1-year follow-up).114–117,120 The pooled results of
three adult RCTs at 6-month follow-up suggested less BPAR with MMF than AZA (OR= 0.50; favours
MMF; 95% CI 0.35 to 0.72, I2= 35.1%);115,119,120 however, the pooled results of four adult RCTs at 1-year
follow-up suggested no statistically significant between-group differences (OR= 0.67; 95% CI 0.37 to
1.22, I2= 58.3%).114,116–119 Finally no significant difference in survival between MMF and AZA was found in
the adult evidence (OR= 1.19; favours AZA; 95% CI 0.47 to 3.02, I2= 0%, τ2= 0; pooled results of five
studies at 1-year follow-up).114,116–119
Tacrolimus ± azathioprine versus ciclosporin ±mycophenolate mofetil
We found no statistically significant difference in survival, graft loss, BPAR, graft function and DGF
between TAC+AZA and CSA+MMF in the non-RCT.80
No adult evidence comparing TAC+AZA and CSA+MMF was identified in the parallel HTA in adults.
Adverse events
Induction
More infections were found in children treated with BAS than in those treated with PBO (OR= 2.23,
favours PBO; 95% CI 1.03 to 4.68).73 In addition, Grenda et al.75 found that toxic nephropathy and
abdominal pain was higher in the BAS arm than no induction (p= 0.03 and p= 0.02, respectively).75
The previous HTA reported only post-transplant diabetes mellitus90 and the rest of the data were
confidential and were omitted from the report.2
In addition, the child RCT evidence is largely similar to the conclusions of the parallel HTA in adults. The adult
1-year follow-up RCT evidence identified in the parallel HTA did not find any significant differences in
NODAT, PTLD, malignancy, infections and CMV infections between BAS and PBO or no induction.98,100,101,103,104
Maintenance therapy
There were no statistically significant differences between TAC and CSA for a range of AEs (any infections,
UTIs, bacterial infections, viral infections, PTLD, solid tumour, hypertension, any AEs and NODAT).77
This is similar to the conclusions of the previous HTA.2 However, Trompeter et al.77 also reported that a
deficiency of magnesium in the blood and diarrhoea were more common with TAC than with CSA, while
excessive hair growth, flu syndrome and swollen gums were less common with TAC than with CSA.77 In
addition, there were no statistically significant differences between MMF and AZA for UTI, CMV infections,
respiratory infections, herpes simplex, oral thrush and diarrhoea identified in the non-randomised
evidence.81 Similarly, no statistically significant differences between TAC+AZA and CSA+MMF in CMV
infections and NODAT were identified in the non-randomised evidence.80
However, the parallel HTA in adults found more cases of NODAT in TAC than CSA (OR= 2.22; favours
CSA; 95% CI 1.42 to 3.46, I2= 0%; pooled results of eight studies at 1-year follow-up).106–109,113,125–127
In addition, no difference in CMV infections114,117 and infection116 were found between MMF and AZA
regimens in the adult evidence at 1-year follow-up.
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Companies’ reviews of clinical effectiveness
One submission (Astellas) was presented summarising evidence on the effectiveness of immunosuppressive
therapies in child/adolescent renal transplantation.
Astellas submitted a systematic review summarising evidence on the clinical effectiveness and safety of
TAC-IR therapy compared with current alternative treatments [TAC-PR (Advagraf), CSA, SRL, BEL, and EVL]
as primary immunosuppressive therapies in patients undergoing renal transplantation. The submission did
not address the study question in full.
The literature searches were conducted in the key bibliographic databases: MEDLINE, EMBASE, The
Cochrane Library and Cochrane NHS Economic Evaluation Database (NHS EED). The literature search was
limited from 2002 to June 2014. The literature searches use minimal free-text search terms without the use
of truncation or controlled indexing and selective synonyms are used for the interventions/comparators.
This reflects poor sensitivity and, combined with the fact that searching has been conducted on only the
abstracts of potential studies, it is possible that studies may have been missed. In addition, although
the submission states that evidence will be assessed from RCTs and non-RCTs, a RCT study design filter
was applied. It is unclear from the search strategies provided how the referenced non-RCT data would
have been captured.
Only one child/adolescent RCT77 and two child/adolescent non-RCTs80,94 were included in the company
submission. In addition, adult RCT evidence was summarised; an overview of adult RCTs included
in Astellas’ submission with reasons for inclusion/exclusion in the PenTAG parallel review is provided in
Appendix 6, Table 141.
Tacrolimus versus ciclosporin
Trompeter et al.77 is the only child/adolescent RCT comparing TAC with CSA that is included both in
the Astellas submission and in the PenTAG review. Astellas reported a significantly higher graft function,
BPAR and better graft survival in TAC than AZA.77 However, we have excluded graft loss due to death
from our analyses. This was, first, to avoid double counting with another key outcome (mortality) and,
second, because death-censored graft survival is a well-established clinical outcome to which DWFG is
intrinsically related, just as mortality is to overall survival. After the removal of graft loss due to death from
the analyses, the evidence from Trompeter et al.77 suggested borderline statistically non-significantly lower
graft loss in TAC than in CSA (OR= 0.41, 95% CI 0.16 to 1.00, and OR= 0.43, 95% CI 0.18 to 1.01,
at 2- and 4-year follow-ups, respectively).
Astellas’ clinical effectiveness results from adult RCTs suggest less AR and more NODAT for TAC than for
CSA. The findings from the adult RCTs were similar to the conclusions in the parallel HTA: more BPAR and
more NODAT were found for TAC than for CSA, but it was not clear whether or not TAC improved graft
function when compared with CSA.
Tacrolimus versus sirolimus
No child/adolescent evidence comparing TAC and SRL was identified. Astellas’ clinical effectiveness results
from adult RCTs suggest better graft survival and less AR with TAC compared with SRL, but they included
a trial comparing TAC and no induction-based regimen with SRL+ r-ATG induction regimen.128 The parallel
PenTAG review found fewer incidences of BPAR for TAC compared with SRL. In addition, Astellas pooled
results from studies comparing SRL with MMF in TAC-based regimens and significantly more drug
discontinuations were found in the SRL+ TAC regimen than in the MMF+ TAC regimen.
Immediate-release tacrolimus versus prolonged-release tacrolimus
No child/adolescent evidence comparing immediate-release TAC and prolonged-release TAC formulations
was identified. Astellas’ clinical effectiveness results from adult RCTs suggest no difference between TAC
and TAC-PR. The results do not conflict with conclusions in the parallel HTA review.68
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Tacrolimus versus belatacept
No child/adolescent evidence comparing TAC and BEL was identified. In addition, no adult RCTs comparing
TAC and BEL were identified. Astellas performed an indirect treatment comparison to compare Advagraf
with Prograf, with more intensive and less intensive BEL regimens. Evidence of less AR with Prograf
compared with both BEL regimens was presented. In addition, better graft survival was found with
Prograf compared with the more intensive BEL regimen, and better survival was found with Prograf
compared with the less intensive BEL regimen. Finally, evidence of less AR with Advagraf compared
with the less intensive BEL regimen was presented. However, it was not clear what TAC evidence was
included and the results presented seem to be conflicted. The parallel HTA network meta-analyses results
suggested that BEL+MMF may be more effective at reducing the odds of mortality than TAC+MMF
and SRL+MMF. In addition, a study directly comparing BEL and TAC regimens was identified in the
parallel HTA.129
Tacrolimus versus everolimus
No child/adolescent evidence comparing TAC and EVL was identified. In addition, no adult RCTs
comparing TAC and EVL were identified. Astellas performed an indirect treatment comparison to compare
TAC with EVL. It is not clear what TAC evidence was included and why the results were not reported
separately for TAC and TAC-PR (as they were presented in the TAC vs. BEL comparison). No statistically
significant differences between TAC and EVL were identified in the submission. The parallel HTA
network meta-analyses results did not find any difference between TAC and EVL regimens for clinical
effectiveness outcomes.
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Chapter 4 Assessment of cost-effectiveness
Systematic review of existing cost-effectiveness evidence
The purpose of this section of the report is to review existing evidence on the cost-effectiveness of
immunosuppressive regimens [BAS and r-ATG as induction therapies, and TAC-IR, TAC-PR, MMF, MPS,
SRL, EVL and BEL as maintenance therapies (including a review of TA99)] in renal transplantation in
children and adolescents.
Methods
Searches
Bibliographic literature searching was conducted on 8 April 2014. The searches took the following form:
(terms for kidney or renal transplant or kidney or renal graft) AND (terms for the interventions under
review) AND (a costs or economic literature search filter). The search was date limited 2002–current in line
with the previous assessment and the searches were updated on 15 January 2015. The search was not
limited by language and it was not limited to human-only studies.
The following databases were searched: MEDLINE and MEDLINE In-Process (via Ovid), EMBASE (via Ovid),
NHS EED (via Wiley Online Library), Web of Science (ISI – including conference proceedings), Health
Economic Evaluations Database (HEED) (via Wiley) and EconLit (via EBSCOhost). The search strategies are
recorded in Appendix 1.
Screening
Inclusion and exclusion criteria were the same as for the clinical effectiveness systematic review
(see Chapter 3, Inclusion and exclusion criteria), with the following exceptions (as specified in the
appraisal protocol):
l Non-randomised studies were included (e.g. decision model-based analyses, or analyses of patient-level
cost and effectiveness data alongside observational studies).
l Full cost-effectiveness analyses, cost–utility analyses and cost–benefit analyses were included
(economic evaluations that report only average cost-effectiveness ratios were included only if the
incremental ratios can be easily calculated from the published data).
l Studies that measure only costs but not health benefits were excluded except for stand-alone cost
analyses from the perspective of the UK NHS.
l Only economic evaluations from the UK, the USA, Canada, Australia and western Europe were
included as these settings may include data generalisable to the UK.
All records were dual screened. Titles and abstracts were screened for relevance by two reviewers
(RMM and LC), with disagreements resolved by discussion. Full texts were retrieved for references judged
to be relevant and were screened for eligibility by the same reviewers, with disagreements resolved
by discussion.
The bibliographies of review articles not judged eligible for inclusion were examined by one reviewer (LC)
to identify other potentially relevant references. These references were retrieved and checked for eligibility
in the same way as full texts from database searches.
Quality assessment
Studies meeting the criteria for inclusion were assessed by one reviewer (RMM) using the checklist
developed by Evers et al.130 When studies were based on decision models they were also quality assessed
using the checklist developed by Philips et al.131,132
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Synthesis
Economic studies were summarised and synthesised using tabulated data and narrative synthesis.
Results
Identified studies
The electronic database search for cost-effectiveness evidence, including update searches conducted on
18 November 2014, identified 2090 records. After deduplication 1378 records remained, all of which were
screened by title and abstract. Of these, 86 full texts were assessed for eligibility. Thirty-eight full texts
were deemed to meet the eligibility criteria for the review. The process is illustrated in detail in Figure 13.
Records identified through
database searching
(n = 2090)
Records after duplicates
removed
(n = 1378)
Records screened
(n = 1378)
Records excluded
(n = 1392)
Full-text articles
excluded with reasons
(n = 68)
• Population, n = 7
• Intervention, n = 14
• Comparator, n = 8
• Outcomes, n = 6
• Study design, n = 20
• No usable data, n = 1
• Language, n = 2
• Duplicates, n = 9
• Not obtainable, n = 1
Full text assessed for
eligibility
(n = 86)
Records identified
through update
searching
(n = 247)
Full text assessed for
eligibility
(n = 20)
Adult population
(n = 37)
Eligible publications
(n = 38)
Children and adolescents
population
(n = 1)
CEA/CUA
(n = 1)a
FIGURE 13 Cost-effectiveness review: PRISMA flow diagram. CEA, cost-effectiveness analyses; CUA, cost–utility
analyses. a, The previous HTA review by Yao et al.;2 includes child, adolescent and adult evidence.
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Only one study2 was identified that met the inclusion criteria. This was the HTA report of the previous NICE
appraisal on the topic in children or adolescent patients. The rest of the subsection is devoted to reviewing
this study.
Yao et al.2 reports the methods and results of economic analyses submitted to the previous NICE appraisal
on the topic by three sponsoring companies. All of these analyses used an equation estimated from
regression analysis (meta-model) of child/adolescent simulation outcomes of immunosuppressive regimens
derived from a model originally developed by one company (Novartis) for informing its submission to the
corresponding NICE review on adult patients. The adult metamodel was developed by the Technology
Assessment Group at Birmingham and the individual companies adapted it to children and adolescents.
After critically appraising the evidence submitted by the companies, the group at Birmingham then
produced its own analysis by adapting the metamodel to children and adolescents.
Briefly, the Birmingham model was a Markov model spanning a 10-year horizon after the initial transplant.
It consisted of three states: functioning graft, graft failed (dialysis) and death. In common with models in
this clinical area, surrogate outcomes were used to extrapolate beyond the end of follow-up in the RCT
evaluating the relative effects of immunosuppressive regimens in terms of BPAR. The model used a HR
of 1.41 for graft failure up to 7 years post transplant for children and adolescents (≤ 18 years) treated
for an AR before discharge versus those not treated. The Birmingham group then used this surrogate
relationship to translate 12-month differences in BPAR rates between immunosuppressive regimens from
RCT studies in children and adolescents for therapies other than MMF and DAC, for which adult RCT data
were used, into 10-year graft survival differences. The study also adjusted the resource use and costs for
age–weight immunosuppressive doses in children and adolescents.
Table 43 presents the characteristics of the analysis by Yao et al.2 Results were presented for two
pairwise comparisons of induction regimens and two pairwise comparisons of initial and maintenance
immunosuppressive regimens. In the comparisons of induction therapy regimens, BAS was found to result
in lower total costs and higher quality-adjusted life-years (QALYs) than no induction in patients managed
with either TAC or CSA in a CNI-containing triple immunosuppressive therapy including AZA and steroids.
In terms of the initial and maintenance immunosuppressive regimens, TAC was found to have an
incremental cost per QALY gained of £145,540 relative to CSA, while the corresponding figure for MMF
relative to AZA was £194,559 when these therapies were combined with CSA and steroids. It is worth
noting that the latter comparison was based on efficacy data from studies on MMF use in adults. Table 44
summarises the base-case results. However, altering the hazard (risk) ratio of graft loss with AR from
1.41 (which was based on a single observational study in children and adolescents) to a HR of 1.96
(derived from a pooled analysis of adult observational studies) and arbitrarily increasing the cost of dialysis
from the base-case value of £21,000 (which was estimated from data on adults) to £50,000, as a way of
accounting for the higher staff-to-patient ratios in children and adolescents, resulted in a cost per QALY
gained of £34,000.2
The technology assessment review team at Birmingham developed these analyses after considering
evidence submitted by three companies using the Birmingham original model, which related to adult
patients. The companies had found their sponsored drugs to result in lower total costs and higher QALYs,
when compared with the triple therapy of CSA, AZA and steroids (CSA+AZA+CCS). Although
the independent assessment by the Birmingham group confirmed the companies’ finding that BAS
induction was expected to reduce total costs and increase QALYs, its results for initial and maintenance
immunosuppression were contrary to those obtained by the companies, as TAC, AZA and steroids had an
incremental cost-effectiveness ratio (ICER) above £30,000 relative to CAS and the same was found for CSA
with MMF and steroids. Moreover, the technology assessment team at Birmingham found these results
robust to uncertainty in the hazard rate used to extrapolate differences in AR rates to long-term estimates
of health benefit.
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These analyses represent the only available evidence about the costs and benefits of immunosuppressive
regimens in recipients of kidney transplants aged ≤ 18. However, this evidence is based on regimens that
may no longer represent routine practice in terms of therapies used (MMF has become part of standard
immunosuppressive therapy) and dosages (lower doses of TAC are being used as they are perceived to
have a better efficacy and safety profile).
As for the methodology behind this evidence, the assessment was based on a meta-analysis of the
evidence on AR rates, although for MMF this included studies in adult patients. The study did not account
for costs and HRQoL effects of changes in graft function and omitted the effect of differences between
regimens in terms of the graft function on longer-term prognosis. Recent evidence from studies in adults
suggest that quality of life133 and costs60 do vary significantly with renal function and this casts some doubt
on the conclusion by the Birmingham group that small QALY differences are generally found between
regimens. It is also questionable whether or not the surrogate relationship between AR and graft survival
was validly implemented, because the estimated HR used to predict graft survival was estimated from AR
rates occurring before discharge post transplantation, while the efficacy data used to model treatment
differences were based on 12-month outcomes post transplantation. In addition, lack of data prevented
the analysis from accounting for side effect differences between regimens, to which results were found to
be sensitive. The quality assessment of these analyses are summarised in Table 45.
Critical appraisal of company submissions
Astellas’ submission
The submission compared
l twice-daily TAC-IR (Prograf) with
l once-daily TAC-PR,
and, using a different modelled relationship between efficacy and effectiveness to that used by the
previous comparison, it separately compared
l twice-daily TAC-IR (Prograf) with
l Modigraf (TAC granules for oral solution – for 3 years, then switch to Prograf)
l TAC specials (oral suspensions)
l EVL
TABLE 44 Base-case results of analyses presented by Yao et al.2
Regimens compared BTAS vs. TAS BCAS vs. CAS TAS vs. CAS CMS vs. CAS
Initial age range 3–13 years
Time horizon 10 years
Discounted incremental QALYs 0.038 0.074 0.090 0.049
Discounted incremental costs (£) –451 –1103 13,716 9543
ICER, incremental cost per
QALY gained
Dominant Dominant 145,540 194,559
Notes Costs discounted at 6%; QALYs discounted at
1.5%, costs are in 2005 prices
Cost discounted at 6%, QALYS
1.5%. Efficacy data were based on
meta-analysis that included studies
of MMF in adults
ICER, incremental cost-effectiveness ratio.
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l BEL
l SRL with low-dose CSA (CNI minimisation)
l SRL with MMF (CNI avoidance).
Prograf was considered to be the standard treatment of choice in adult renal transplantation
immunosuppression based on its UK market share, while the comparators investigated were deemed to be
used infrequently. The submission cites evidence of improved outcomes for Advagraf relative to the current
standard regimen, Prograf, since the former became available in 2009. In addition, as requested by the
NICE scope, EVL, BEL and SRL were included in the evaluation despite their lack of market authorisation in
the UK.
Astellas’ analysis found that Prograf was cost-effective compared with all comparators, except SRL
(avoidance), which the company argues is not a treatment option that is routinely considered of use for
children and adolescents in general. Further, Advagraf was considered cost-effective relative to Prograf
and recommended by the company to be adopted as the new standard of care. Owing to limited
information on children and adolescents, the model was populated with information from adult KTRs
from a meta-analysis and network meta-analysis of evidence on short-term outcomes from comparative
clinical studies in adults.
TABLE 45 Quality assessment Evers checklist2,130
Item Yao et al.2
1. Is the study population clearly described? Y
2. Are competing alternatives clearly described? Y
3. Is a well-defined research question posed in answerable form? Y
4. Is the economic study design appropriate to the stated objective? Y
5. Is the chosen time horizon appropriate to include relevant costs and consequences? N
6. Is the actual perspective chosen appropriate? Y
7. Are all important and relevant costs for each alternative identified? Y
8. Are all costs measured appropriately in physical units? ?
9. Are costs valued appropriately? ?
10. Are all important and relevant outcomes for each alternative identified? N
11. Are all outcomes measured appropriately? ?
12. Are outcomes valued appropriately? ?
13. Is an incremental analysis of costs and outcomes of alternatives performed? Y
14. Are all future costs and outcomes discounted appropriately? Y
15. Are all important variables, whose values are uncertain, appropriately subjected to sensitivity analysis? N
16. Do the conclusions follow from the data reported? Y
17. Does the study discuss the generalisability of the results to other settings and patient/client groups? N
18. Does the article indicate that there is no potential conflict of interest of study researcher(s) and funder(s)? Y
19. Are ethical and distributional issues discussed appropriately? N
Y, Yes; N, No; ?, unclear.
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The submission pointed to evidence on the relationship between adherence, acute and long-term graft
rejection, and graft failure. In particular, it is stated that adherence to immunosuppressant regimens
positively affects graft survival by preventing the development of de novo donor specific antibodies, which
have been associated with a reduction in 10-year graft survival.134 This is the stated justification for
translating the observed improvement in adherence with once-daily TAC relative to twice-daily TAC135 into
graft and patient survival benefits in the Astellas model.135 In addition, the company claims that once-daily
TAC-PR has a better pharmacokinetic profile than twice-daily TAC (lower intra-patient variability,136 which
results in a lower risk of long-term graft failure137). The company also cites analyses from the Collaborative
Transplant Study for Europe (2011–13 data) presented at the 2014 World Transplant Congress, which
shows that Advagraf-treated patients had higher patient and graft survival rates than Prograf-treated
patients over the 12 months following renal transplantation. However, this observation was not robust to
the adjustment for multiple confounders (HR 0.76; p= 0.14, 95% CI was not stated).
The submission also cites the results of a meta-analysis pointing to increased risk of NODAT with TAC
(RR at 12 months 1.72, 95% CI 1.17 to 2.52; RR at 36 months 2.71, 95% CI 1.61 to 4.57) relative to CSA
and acknowledges the evidence on the association between NODAT and reduced graft survival (RR 1.63,
95% CI 1.46 to 1.84).138 The company argues that these estimates may have been the result of patients
treated with high doses of TAC relative to current practice. To support this claim, the submission cites the
results of a Phase III study comparing Advagraf with Prograf,139 which used lower doses of TAC and found
lower incidence rates of NODAT than those in the studies included in the meta-analysis report.139 However,
it is noted that the Krämer et al.139 evidence is not relevant to the meta-analysis finding of a higher RR of
NODAT with TAC than CSA.
Review of economic models and their results in the submission
The submission provides an overview of model structures and conclusions of previous cost-effectiveness
analyses of renal transplantation immunosuppressive regimes. From searches of electronic databases
(NHS EED, The Cochrane Library, MEDLINE and other sources not specified) it identified and included
12 studies in its review (although the Astellas submission states that 11 studies were included). No details
were provided about the inclusion criteria for the review of economic studies but all of the reviewed
studies were conducted in adults.
One of the included studies compared TAC-IR with TAC-PR (US study140); four studies compared TAC with
CSA (two in continental Europe,141,142 one in the UK143 and the remaining study was from the USA and
measured only costs of medication113); seven studied SRL in CNI avoidance or minimisation strategies
versus TAC (one from the USA,144 another from the UK,145 two more from Germany146,147 and three studies
from Colombia, Mexico and Poland148–150).
The submission briefly described the main results of these studies without critically assessing their validity
and applicability to a UK setting, although it mentions the limited transferability of results from non-UK
studies (10 out of the 12). It concludes that the evidence supports the view that TAC is cost-effective when
compared with CSA, but that it is ambiguous in relation to the comparison against SRL in a CNI avoidance
or minimisation strategy. The submission also includes a section where three published models are
described.144,148,149 No assessment of their strengths and weakness was presented. These models are all of
adult patient populations and are therefore not included in the review of cost-effectiveness studies of
this monograph.144,148,149
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Economic evaluation by the company
The cost-effectiveness analysis submitted by Astellas is an adaptation of a published Markov model-based
assessment of the cost-effectiveness of TAC, in either its extended release formulation, Advagraf, or the
current standard therapy of immediate-release (Prograf151) in adult KTRs. The model describes the annual
transitions between four health states starting from kidney-only transplantation: functioning graft without
history of AR, functioning graft having experienced AR, graft failure (dialysis) and death (Table 46). Owing to
the lack of child/adolescent data, the Astellas submission is based on a review of short-term safety and
efficacy outcomes of immunosuppression in adults, reported by RCTs published study until June 2014. These
were then extrapolated using registry data on child/adolescent graft and patient survival. The base-case
analyses submitted by the company discount costs and QALY outcomes at an annual rate of 3.5%.
Efficacy data
The model accounts for differences in outcomes between regimens that originate in their differing impact
on BPAR at 12 months post transplant. These differences in BPAR between the regimens evaluated were
estimated from RCTS of adult KTRs (Table 47). The model was based on the assumption that the effects of
treatment on this surrogate outcome lasted for only the first year post transplantation. In fact, the model
allowed BPAR to occur only in the first 12 months post transplantation. This assumption was combined
with (1) the estimated RR of graft failure for a functioning graft with previous BPAR versus no previous
BPAR and (2) the 1-year post-transplant BPAR frequency, both from estimates reported by Opelz et al.,153
to derive the graft survival curves for grafts without prior AR and grafts with history of AR from the child
5-year graft survival profile in UK registry data (including graft survival rates for years 3 and 4 derived by
linear interpolation32). The model extrapolation was complemented by using exponential survival curves to
extend graft survival from 5 years up to 16 years post transplantation.
With regard to patient survival, the model used the 1-, 2- and 5-year post-transplantation survival rates in
children and adolescents from the NHS Blood and Transplant (NHSBT) Report 2013–201432 as the
estimated survival rates with a functioning graft. To populate survival probabilities in the state of graft
failure, the model used annual survival rates of adult patients on dialysis followed for 10 years from the UK
Renal Registry.154 The patient survival rates were extrapolated until 18 years of age (i.e. 10 years post
transplant in the base case) by linear extrapolation of the available data, projecting survival rates from the
last observed rate. There is no mention in the submission about adjusting survival for increases in
background mortality as the cohort in the model ages. For patients in the state of graft failure, which was
assumed to be associated with the use of dialysis, the probability of receiving a retransplant was populated
with data from adults treated at a centre in Cardiff, Wales.155
In addition to the difference in efficacy, measured in terms of AR rates (see Table 47), the model allowed
for differences in effectiveness between the TAC arms through the differences in adherence associated
with the once daily, prolonged-release formulations of the drug (Advagraf) versus the twice-daily
immediate-release formulations of the drug (Prograf). The model employed comparative estimates on
adherence with Advagraf versus Prograf of 88.2% versus 78.8% from a published randomised study135
and combined them with an estimated RR of graft failure in non-adherent versus adherent patients of
3.47 derived from a meta-analysis15 to obtain a RR of graft failure of 0.848, which was applied to the graft
survival curves (until year 5 and, by exponential curve extrapolation, thereafter) that were common to all
other immunosuppressive treatment strategies in the model.15,135
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Adverse events
The model allows for seven types of AE following transplantation: malignancy, diabetes mellitus, anaemia,
CMV infection, hypertension, wound-healing disorders and the need for 3-hydroxy-3-methylglutaryl-
coenzyme A. These events were assigned costs (except for the last type of event which had zero cost and,
thus, was effectively omitted from the analysis) but no disutility. The AE incidence rates used in the model,
reproduced in Table 48, differed across immunosuppressant treatment arms, although these had no
influence on the probability of graft failure and patient death. Such differences only affected the costs
differences between the treatments.
The incidence rates of AEs were derived from a systematic review and meta-analysis published in 2006,156
the values adopted by the published economic model for adults in Germany by Jurgensen et al.146 and trial
outcomes from the BENEFIT and BENEFIT-EXT trials.157,158
The rates of AEs were assumed to be the same with Advagraf and Prograf and for the two SRL regimens
(CNI avoidance and CNI minimisation). According to the incidence rates figures in this model, TAC has the
lowest annual incidence of malignancy (except for SRL from the third post-transplantation year onwards),
CMV, anaemia (except for BEL which had the same annual incidence rates as those of TAC), dyslipidaemia
and hypertension, but was associated with an excess incidence of NODAT over the other options.
Utilities
Health-related quality of life and QALY outcomes were calculated from time spent in the graft functioning
state and the graft failure state, which involved dialysis. Based on published European Quality of Life-5
Dimensions (EQ-5D) estimates,159 the functioning state was associated with a utility value of 0.71,
regardless of any prior experience of AR, and the graft failure state was associated with a utility of 0.459,
which was equal to the weighted average of the utility of haemodialysis (0.44), experienced by 82% of
dialysis patients, and peritoneal dialysis (0.53), received by the rest.159
Retransplantation
The model allows for the occurrence and effects of retransplantation, using the time to retransplantation
data reported by McEwan et al.145,155 for adult patients. However, the states following the first
retransplantation (i.e. functioning graft with prior AR on the current retransplant, functioning graft
without prior AR on the current retransplant – regardless of AR of any previous transplant and graft failure)
face the same transition probabilities, utility values and costs as the corresponding states before
retransplantation. This is likely biasing the analysis in favour of treatments with higher rejection rates in
the model (as higher AR rates imply higher graft failure rates in this model) and may be interpreted as a
conservative assumption of the relative effectiveness and incremental costs advantage of TAC over
the comparators.
TABLE 47 Acute graft rejection rates used in the Astellas model
Product Rate, % Comment
Prograf (base comparator) 12.6 Silva et al.,152 Albano et al.,97 Krämer et al.139
Modigraf/TAC specials 12.6 Assumed the same as Prograf owing to lack of data
Advagraf 14.6 Silva et al.,152 Albano et al.,97 Krämer et al.139 and meta-analysis
BEL 30.7 Silva et al.,152 Albano et al.,97 Krämer et al.139 and meta-analysis
EVL (CNI minimisation) 18.0 Silva et al.,152 Albano et al.,97 Krämer et al.139 and meta-analysis
SRL (CNI minimisation) 16.5 Silva et al.,152 Albano et al.,97 Krämer et al.139 and meta-analysis
SRL (CNI avoidance) 28.7 Silva et al.,152 Albano et al.,97 Krämer et al.139 and meta-analysis
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TABLE 48 Adverse events used in the Astellas model (%)
Product AE Year 1 Year 2 Year 3 and later
Advagraf/Prograf/Modigraf/TAC specials Malignancies 0.00 0.00 0.43
CMV infections 3.62 3.62 0.04
NODAT 6.07 6.07 6.27
Wound-healing disorders 4.12 4.12 0.00
Anaemia 14.71 14.71 14.71
HMGCoA 13.84 13.84 3.46
Hypertension 9.17 9.17 9.17
EVL Malignancies 2.43 2.43 0.64
CMV infections 3.19 3.19 0.04
NODAT 5.58 5.58 5.77
Wound-healing disorders 10.72 10.72 0.00
Anaemia 27.30 27.30 27.30
HMGCoA 29.47 29.47 7.37
Hypertension 31.63 31.63 31.63
SRL (CNI minimisation and avoidance regimens) Malignancies 0.20 0.20 0.05
CMV infections 2.11 2.11 0.03
NODAT 5.88 5.88 6.07
Wound-healing disorders 10.72 10.72 0.00
Anaemia 18.68 18.68 18.68
HMGCoA 21.77 21.77 5.44
Hypertension 15.08 15.08 15.08
BEL Malignancies 2.32 2.32 0.61
CMV infections 7.65 7.65 0.09
NODAT 4.00 4.00 4.19
Wound-healing disorders 4.12 4.12 0.00
Anaemia 14.71 14.71 14.71
HMGCoA 18.88 18.88 18.88
Hypertension 31.12 31.12 31.12
HMGCoA, 3-hydroxy-3-methylglutaryl-coenzyme A.
Source: Webster et al.,156 Jürgensen et al.,146 Vincenti et al.157 and Durrbach et al.158
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Resource utilisation and unit costs
The amount of drug use for TAC was age dependent and imputed according to weight by age
distributions in observational data by associating body surface area with mean weight by age statistics
from UK growth charts.160,161 Dosages per kg of body weight for all medications were based on adult
dosages as detailed in the British National Formulary (BNF)162 and the corresponding Summary Product
Characteristics, with the exception of MMF, which was based on body surface area parameters, and EVL,
which was based on data from a study in children and adolescents.163
The model used BNF prices for both interventions and comparators. The cost per mg of Advagraf used was
23% lower than that of Prograf, based on the BNF list prices and information on the market share of pack
sizes for Prograf. [The authors present sensitivity analyses of discounts on TAC list prices limited to the first
(commercial-in-confidence information has been removed) days post transplantation.] Prices for other
immunosuppressant regimens were based on BNF prices. Table 49 reproduces table 38 in the submission,
which details the prices used by the Astellas model. The submission says that TAC prices were not available
in the electronic market information tool (eMIT), apparently to justify its deviation from the NICE methods
guide (section 5.5.2)165 which specifies that, if available, reduced prices should be used in the reference
case, that is, eMIT prices reflecting the prices paid by NHS trusts. The submission does not give any further
reason for their using list prices for TAC and all the other drug regimens.
TABLE 49 Unit costs of immunosuppressive therapies in the Astellas model (£)
Variable Value Comment
Cost per mg: Simulect® £42.12 Injection, powder for reconstitution, BAS, net price 10-mg vial= £758.69, 20-mg
vial= £842.38 (both with water for injections). For i.v. infusion
Cost per mg: Prograf® £1.62 Concentrate for i.v. infusion, 5mg/ml of TAC, net price 1-ml ampoule=£58.45.
Capsules, TAC (as monohydrate) 500 µg (yellow), net price 50-capsule pack=£61.88;
1mg (white), 50-capsule pack=£80.28, 100-capsule pack=£160.54; 5mg (greyish-red),
50-capsule pack=£296.58 and using market distribution of pack sizes
Cost per mg: Advagraf® £1.24 Capsules, m/r, TAC (as monohydrate) 500 µg (yellow/orange), net price 50-capsule
pack= £35.79; 1mg (white/orange), 50-capsule pack= £71.59, 100-capsule
pack= £143.17; 3mg (orange), 50-capsule pack= £214.76; 5mg (red/orange),
50-capsule pack= £266.92
Cost per mg: BEL £1.42 i.v. infusion, powder for reconstitution, BEL, net price 250-mg vial= £354.52
Cost per mg: EVL £5.87 No UK price available price at the time of this submission. Estimated price of EVL
based on the price of Afinitor® (EVL) white-yellow, EVL, 5mg, net price 30-tablet
pack= £2250.00; 10mg, 30-tablet pack= £2970.00 and assuming use of cheapest in
terms of cost per mg
Cost per mg: Modigraf £7.22 Granules, TAC (as monohydrate), 200 µg, net price 50-sachet pack= £71.30; 1mg,
50-sachet pack= £356.65
Cost per mg: specials £3.83 TAC 2.5mg/5ml oral suspension, 100ml= £232.44; TAC 5mg/5ml oral
suspension, 100ml= £301.96164
Cost per mg: SRL
(Rapamune®)
£3.45 Tablets, coated, SRL 500 µg (tan), net price 30-tablet pack= £69.00; 1mg (white),
30-tablet pack= £86.49; 2mg (yellow), 30-tablet pack= £172.98
Cost per mg: BEL
(Nulojix®)
£1.42 i.v. infusion, powder for reconstitution, BEL, net price 250-mg vial= £354.52
Cost per mg: Neoral £0.03 Capsules, 10mg of CSA (yellow/white), net price 60-capsule pack= £19.40; 25mg
(blue/grey), 30-capsule pack=£19.52; 50mg (yellow/white), 30-capsule pack=£38.23;
100mg (blue/grey), 30-capsule pack= £72.57
Cost per mg: CellCept £0.003 Capsules, blue/brown, MMF 250mg, net price 100-capsule pack= £82.26
Cost per mg:
Thymoglobuline®
£6.35 i.v. infusion, powder for reconstitution, r-ATG, net price 25-mg vial= £158.77
Reproduced from Astellas’ submission to NICE, Patel S, Astellas Pharma Ltd, 2014, unpublished data.
Note
Prices of pharmaceutical products from BNF.162
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Treatment of AR was assigned costs of i.v. steroids and, for the 20% of steroid-resistant BPAR cases, a
regimen of r-ATG and the cost of an inpatient hospital stay for acute kidney injury without complications
(£1737 overall mean cost). This assumed zero medical management costs for the 80% of patients with
steroid-sensitive AR, which ignores any follow-up costs to monitor treatment efficacy. The cost per year of
dialysis was £31,806 and the cost of retransplant was £26,639. Although the latter was based on UK
NHS Reference Costs 2013 to 2014,58 the former was based on a microcosting study in seven hospital
units in the UK.166 The study measured the average costs of dialysis per year for a ‘typical patient’, who is
likely to be an adult. These costs were measured from the service provider’s perspective and included
direct costs and the costs of transport and medication usage. They excluded the costs of access surgery
and managing dialysis complications. In addition, capital costs of the hospital building were not included.
The costs of AEs adopted are presented in Table 50, which reproduces table 35 in the Astellas submission
to NICE. The major elements of costs are summarised in Table 51.
Results
The base-case results presented by Astellas are displayed in Table 52. The expected discounted (at 3.5%)
QALYs (censored after 10 years) were 5.569 for TAC-IR (Prograf), 5.565 for SRL CNI minimisation, 5.564
for EVL, 5.553 for SRL CNI avoidance, and 5.551 for BEL, in a cohort of patients of mean age 8 years. For
TAC once-daily prolonged-release formulation (Advagraf), discounted QALYs were 5.569. The Modigraf
and TAC specials regimens were assumed to result in the same health outcomes as Prograf.
In the base-case results, results comparing TAC immediate-release (Prograf) with non-TAC
immunosuppressive regimens, Prograf produced more QALYs than any of the comparators and lower costs
than BEL and EVL, SRL avoidance, Modigraf and TAC specials whereas it had higher cost than the SRL
minimisation regimen. The ICER against SRL CNI minimisation strategy was in excess of £1M. In the
comparison of TAC regimens, Advagraf dominated Prograf, given its lower costs and higher QALYs (both
discounted and undiscounted).
TABLE 50 Costs of AEs used in the Astellas model (per year)
Variable Value Comment
Malignancies £1388 to £4452 depending
on body surface area (m2)
PTLD/skin/non-Hodgkin’s lymphoma. Mabthera concentrate for i.v.
infusion, 10mg/ml of rituximab, net price 10-ml vial= £174.63, 50-ml
vial= £873.15. No costs included of other treatment modalities
CMV infections £221 to £1151 depending on
weight (kg)
i.v. ganciclovir 14–21 days then maintenance for 8 weeks. Cymevene®
i.v. infusion, powder for reconstitution, ganciclovir (as sodium salt).
Net price 500-mg vial= £29.77
NODAT £17.38 Tablets, coated, metformin hydrochloride 500mg, net price 28-tablet
pack= 87p, 84-tablet pack= £1.00; 850mg, 56-tablet pack= £1.36
Wound-healing
disorders
£0.00 –
Anaemia £16.88/kg Binocrit® injection maintenance dose 17–33 units/kg three times
weekly, prefilled syringe, epoetin alfa, net price 1000 units= £4.33;
2000 units= £8.65; 3000 units= £12.98; 4000 units= £17.31;
5000 units= £21.64; 6000 units= £25.96; 8000 units= £40.73;
10,000 units= £43.27
LDL cholesterol £235.03 Zocor® tablets, all f/c, simvastatin 10mg (peach), net price 28-tablet
pack= £18.03; 20mg (tan), 28-tablet pack= £29.69; 40mg (red),
28-tablet pack= £29.69; 80mg (red), 28-tablet pack= £29.69
Hypertension £15.51 Capsules, Ramipril 1.25mg, net price 28-capsule pack= 99p; 2.5mg,
28-capsule pack= £1.05; 5mg, 28-capsule pack= £1.12; 10mg,
28-capsule pack= £1.19
Reproduced from Astellas’ submission to NICE, Patel S, Astellas Pharma Ltd, 2014, unpublished data.
Source: BNF 2014.162
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TABLE 51 Major cost elements in the Astellas model (£)
Cost elements Astellasa
TAC-IR therapy (per year) 1559 (first year)
1366 (second year+)b
TAC-PR therapy (per year) 1322 (first year)
1112 (second year+)
Modigraf 13,654 (first year)
13,580 (second year+)
TAC administration 0
MMF therapy (per year) 1326c
CSA therapy N/Ad
EVL (per year) 5086
EVL administration 0
SRL (per year) 2536 (first year)
2522 (second year+)
SRL administration 0
BEL (per year) 4018 (first year)
2374 (second year+)
BEL administration 0
CCSs 176 (first year)
139 (second year+)
AR (event) 889e
Dialysis (per year) 31,806f
Retransplantation 26,639
g
Retransplantation: organ procurement 0
a Adopted a 11–12 kg weight and body-surface area for representative patient in the model. The cost of BAS induction
(20mg within 2 hours before transplantation and at 4 days post transplant; BNF 2014 prices162 £1685) was included in
all arms.
b Prograf.
c Based on 600 mg/m2 twice daily, valued at £82.26 price for 500mg, 50-capsule pack from BNF 2014.162
d Astellas does not evaluate CSA with MMF in their submission. The model only includes CSA as part of the SRL
(minimisation) comparator regimen.
e Based on BNF prices.162
f From Baboolal et al.166 and included direct costs and the costs of transport and medication usage. They excluded the
costs of access surgery and managing dialysis complications. In addition, capital costs of the hospital building were
not included.
g NHS Reference Costs – Renal Transplant and Dialysis.167
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The results were found to be sensitive to the starting age (base case started at 8 years, while sensitivity
analyses started at 2, 10 and 13 years) and the discount rate, AEs and half-cycle corrections. The results
against SRL were found to change significantly when graft survival parameters in the model were
populated with data from the Symphony study127 instead of the NHSBT Service data32 used in the
base-case analyses: low dose TAC was found to dominate SRL as CNI avoidance regimen when both were
given with DAC induction, 2 g of MMF and steroids. In discussing these findings, the authors note that
the Symphony study127 has reported outcomes up to 3 years and is the largest prospective study in the de
novo kidney transplantation to date, which showed TAC to result in lower AR, better renal function and
graft survival outcomes at 1 year than the SRL regimen.
On the basis of these results, the company submission concludes that TAC is cost-effective and that
Advagraf should become the standard of care as it produces lower costs and better health outcomes than
Prograf. The latter statement is further supported, the submission claims, by the expected benefits (not
accounted for in the Astellas model) arising from the improved pharmacokinetic profile of Advagraf relative
to Prograf. Despite the apparent cost-effectiveness of its CNI minimisation mode, the submission states
that the results of the Symphony trial have discouraged the general use of SRL and that BEL’s high cost
and high AR rate may do likewise, citing a report by the All Wales Medicines Strategy Group168 as
supportive evidence for this assertion.
Critical appraisal
The analysis presented by Astellas (Table 53 shows the quality checklist) covers a number of appropriate
comparators, including new regimens BEL and regimens with modes of action different from that of CNIs
(i.e. EVL and SRL), as well alternative TAC formulations that are believed by the company to be used in
routine practice (i.e. Modigraf and specials). However, it omits one relevant comparator: CSA. There is no
justification in the submission as to why this drug regimen was not considered. This suggests that the
results presented may be misleading owing to the exclusion of a relevant comparator. In addition, all of
the regimens analysed by Astellas were evaluated in combination with MMF. This seems to contradict the
assertion in the company’s submission that ‘Most children in the UK receive triple immunosuppression
therapy with a CNI (CSA or TAC), a DNA proliferation inhibitor (usually azathioprine), and a CCS following
kidney transplantation’ (Astellas’ submission, page 1). Astellas also reported the results of sensitivity
TABLE 52 Results of model-based analyses submitted by Astellas
Submission
Regimens
compared
Patient
characteristics
Time horizon
(years)
Life-years
(undiscounted)
Discounted
costs (£)
Discounted
QALYs
ICER
incremental
cost per QALY
Astellas 2003 TAC-IR
(Prograf)
Mean age
8 years
Weight
11.3–12.2
10 9.472 58,471 5.569 Prograf vs.
SRL: 1,576,937
TAC
(Modigraf)
9.472 88,915 5.569
TAC
specials
9.472 72,945 5.569
SRL I 9.468 52,339 5.565
EVL 9.467 90,168 5.564
SRL II 9.456 61,490 5.553
BEL 9.455 75,726 5.551
TAC-PR
(Advagraf)
9.502 53,395 5.604 Advagraf
dominates
TAC-IR
(Prograf)
9.472 58,471 5.569
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analyses that varied the mean starting age of patients in the cohort modelled, but as the analysis was
censored/stopped at age 18 years, it is difficult to assign any meaningful interpretation to their findings
that the results were sensitive to such variation.
There are two logical concerns with the Astellas model-based analysis. First, by accounting for the
advantages in adherence of Advagraf in its comparison with Prograf, it makes the comparison of outcomes
of Advagraf with those of other immunosuppressive regimens in the model invalid, as no allowance was
made for any effects of adherence on graft survival for the other regimens analysed in the model. Indeed
this undermines the fundamental assumption in the model that all significant differences in any drug
regimen comparison may be accounted for by the effect through the surrogate, in this case the rate of
AR.169 Thus, regardless of the validity of the comparative analysis of Advagraf and Prograf, indirect
comparisons of model results between advagraf and SRL, and EVL and BEL are invalid. Second, although
the model was adjusted to include the effect of adherence on graft survival in the Advagraf versus Prograf
comparison, the patient survival curves (for the functioning and failed graft states) were left unchanged,
thus the same set of patient survival curves was applied to all immunosuppressive options analysed. This
implies the empirically questionable assumption that improvements in graft survival, such as those obtained
with Advagraf relative to Prograf (and indeed relative to all other model arms), do not translate in direct
patient survival benefits. This inconsistent logic in turn leads to underestimating the benefits of Advagraf
and overestimating its costs.
TABLE 53 Quality assessment Evers checklist;130 Astellas’ submission
Item
Astellas’
submission
1. Is the study population clearly described? Y
2. Are competing alternatives clearly described? Y
3. Is a well-defined research question posed in answerable form? Y
4. Is the economic study design appropriate to the stated objective? Y
5. Is the chosen time horizon appropriate to include relevant costs and consequences? Y
6. Is the actual perspective chosen appropriate? Y
7. Are all important and relevant costs for each alternative identified? Y
8. Are all costs measured appropriately in physical units? Y
9. Are costs valued appropriately? Y
10. Are all important and relevant outcomes for each alternative identified? N
11. Are all outcomes measured appropriately? Y
12. Are outcomes valued appropriately? Y
13. Is an incremental analysis of costs and outcomes of alternatives performed? Y
14. Are all future costs and outcomes discounted appropriately? Y
15. Are all important variables, whose values are uncertain, appropriately subjected to sensitivity analysis? Y
16. Do the conclusions follow from the data reported? Y
17. Does the study discuss the generalisability of the results to other settings and patient/client groups? N
18. Does the article indicate that there is no potential conflict of interest of study researcher(s) and
funder(s)?
N
19. Are ethical and distributional issues discussed appropriately? N
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Inspection of the Microsoft Excel® 2010 (Microsoft Corporation, Redmond, WA, USA) model spreadsheets
revealed that the TAC drug regimen options (Advagraf and Prograf) and EVL were the only treatment arms
populated by actual data on immunosuppressive drug use from the RCT sample that served as the source
for the respective efficacy data; drug consumption values for BEL and SRL regimens were based on
treatment guidelines (BNF or SPC). Adult dosages (per kg body weight) of these treatments were used to
estimate costs in the model. The only therapies for which child-specific doses were used in calculating
resource utilisation in the analysis were MMF and EVL. There are important distinctions with adults that are
likely to cast doubt on these drug dosage values. In particular, as acknowledged by the authors in relation
to TAC pharmacokinetic studies, children and adolescents appear to eliminate the drug more rapidly than
older adults. Further, in relation to steroids, there are concerns about the effects of the medication on
growth, which are likely to lead to its more limited use in children and adolescents than in adults.
There is inadequate use of the registry data used to extrapolate short-term efficacy outcomes from RCT
in the model. The model used the data from the NHSBT report 2013–1432 on patient survival rates for
kidney-only transplant recipients in the UK (table 28, p. 35, Astellas’ submission) to populate the patient
survival parameters of patients with a functioning graft, ignoring the fact that such data on survival rates
were likely to include deaths from both patients with a functioning and a failed graft. Instead, the
probability of death in the graft functioning state should have been calculated as the remainder of
the annual probability of death from the NHSBT patient survival data minus the product of probability of
mortality in the graft failure state and the proportion of patients with a failed graft. In other words,
the Astellas model is likely to overestimate mortality in the functioning graft states, which, in turn,
underestimates the benefits of gains in efficacy (i.e. reductions in AR in the model) that any regimen may
have over another, for example TAC over the comparators. Thus, the results reported by Astellas in the
submission may be treated as conservative estimates of the costs and benefits of its TAC regimes. In
relation to the evidence presented in support of Advagraf, its quality is limited by the omission of CSA as a
comparator therapy and the fact that the Advagraf versus Prograf comparison is based on what is, in
effect, a different model of the outcomes of renal transplantation from that used to compare Prograf with
all the other regimens. In fact, the model used for comparing Advagraf with Prograf contradicts the
fundamental premise of the model used to compare Prograf with all regimens other than Advagraf:
that AR captures all important drivers of clinically meaningful outcomes.
One other issue relates to the way the model was structured. Although the model allowed repeat
transplantation to occur for a given individual, only for the first transplantation were the costs and HRQoL
of subsequent dialysis accounted for. Although the proportion of patients with more than one
retransplantation may be small, this assumption could have been important to the conclusions derived
from the comparison with CSA, had such comparator been included.
In addition, Astellas chose to use values of time to retransplantation for patients on dialysis that were
obtained from adult studies, whose mean wait for a retransplant was 3 years.155 This was in contradiction
with the company’s submission, which stated that ‘Children tend to be prioritised in deceased donor organ
allocation systems: the median wait for a kidney in the UK during 2003–2006 for patients aged < 18 years
was 277 days’.170
There is also an anomaly with regards to the timing of transplantation. Markov models typically imply that
transitions occur at the end of the period represented by each cycle. In the present case, the cycle length
was 1 year and the authors of the Astellas model correctly decided on using half-cycle corrections to
reduce the inaccuracy in expected costs and QALY calculations arising from more frequent average state
transitions. However, the model assumed that a proportion of patients undergo retransplantation in the
very first cycle and that these made a transition from the failed graft state to a functioning graft post
retransplantation state as if the retransplant had occurred at the start of the period so that they spent
the whole cycle length (6 months, owing to the half-cycle correction) with a functioning graft after
retransplantation in the first cycle. However, this is incorrect as in a cohort of de novo kidney transplant
patients, the discrete Markov process transition from a functioning first graft to a functioning retransplant
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requires two sequential intervening events to occur (i.e. graft failure and retransplantation) and a minimum
of two cycles, one for each event.
In terms of the values used to populate the model, the costs of dialysis – one of the most influential
parameters in the analysis – was derived from a microcosting study of the treatment pathway of a typical
(i.e. adult) patient at six hospital units. This study166 sought to inform the introduction of Payment by
Results in the NHS.171 It did not include the costs of access surgery, managing dialysis complications and
capital building costs. Reference costs for dialysis are now available that may reflect more representative
data.58 On this basis of this feature and the observation that children and adolescents tend to require
higher staff-to-patient ratios than adults,2 it is expected that the costs of dialysis have been underestimated
by the Astellas analysis.
The analysis does not account for discounts in price paid by hospitals for TAC-IR (Prograf), MMF, steroids
and CSA (in the SRL CNI minimisation regimen), which were found to be one-third, one-tenth, one-tenth
and a half of the list prices, respectively (see Tables 49 and 97). The implications of these differences are
further explored in the next section (see Chapter 5).
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Chapter 5 Independent economic assessment
Introduction
The objective of this independent economic assessment was to answer the following study question in line
with the NICE reference case:165
What is the cost-effectiveness of immunosuppressive regimens in renal transplantation in children and
adolescents, of BAS and r-ATG as an induction therapy and TAC-IR, TAC-PR, MMF, MPS, SRL, EVL and BEL
as a maintenance therapy?
We are aware of only one published economic evaluation that partially addresses the study question,
which is the economic evaluation conducted to support current NICE guidance TA99, published by
Yao et al.2 This evaluation did not include the interventions rabbit antihuman thymocyte, EVL or BEL.
Astellas submitted an economic evaluation which also does not address the study question in full.
No economic evaluation has independently addressed the full study question in line with the NICE
reference case and, therefore, a new economic assessment was required.
The economic assessment was conducted in parallel with an economic assessment of the same study
question in the adult population (review of NICE guidance TA85) and the decision-analytic model
developed in Microsoft Excel for the parallel assessment was used as the basis for answering the study
question in this assessment in a cost–utility analysis with modifications to make it more relevant to the
child/adolescent population.
Methods
Summary of changes from Peninsula Technology Assessment Group model
for adults
This economic assessment was conducted using an economic model originally developed by PenTAG to
evaluate the cost-effectiveness of immunosuppressive agents in adult KTRs. A summary of changes is
provided here as a reference for readers familiar with the original model for adult KTRs (Table 54).
Modelling approach
Target population and subgroups
The target population was children and adolescents undergoing kidney-only transplantation (i.e. people
receiving multiorgan transplants are not included). The upper age limit for the population ‘children and
adolescents’ is not always clear as young people aged 16–18 years may receive their treatment in
child/adolescent or adult centres.172 Although some data sets include only young people aged < 16 years,
the population for the economic assessment is children and adolescents aged < 18 years. The vast majority
of transplant kidneys for this population come from DBD and living related donors (UK Transplant Registry
standard data set, see Appendix 10 for further details) (Cathy Hopkinson, NHSBT, 15 October 2014,
personal communication).
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TABLE 54 Summary of changes from PenTAG model for adults
Type of change Description
Detailed description and
justification in Chapter 5
Structural Addition of two new arms: BAS+ TAC+AZA and
r-ATG+ TAC+AZA
Interventions and comparators
Change of assumed baseline regimen from BAS+ TAC+MMF
to BAS+ TAC+AZA
Model structure
Removal of DCD and living unrelated donors for first graft Graft survival, Baseline
Addition of extra retransplantation Markov model
Inclusion of six new arms (three pairs), based on child/adolescent
RCTs identified in Chapter 3 (summarised in Table 10)
Decision tree
Inclusion of body weight and surface area as age-dependent
variables affecting doses
Target population and
subgroups
Natural history
parameters
Baseline graft survival re-estimated for those under 18 years and
according to age group (< 6 years, 6–12 years, > 12 years)
Graft survival, Baseline
Increased rate of retransplantation while < 18 years Interventions and comparators
Surrogate relationship between eGFR and graft survival re-estimated
from a child/adolescent study
Graft survival, Graft function
at 12 months
Baseline eGFR at 12 months re-estimated from a child/adolescent
study
Graft survival, Graft function
at 12 months
Probability of pre-emptive retransplantation at loss of first graft set
to 20%
Graft survival, Use of graft
survival in the model
Re-estimated baseline risks of AR, cytomegalovirus infection
and NODAT
Adverse events
Re-estimated risk profiles for cytomegalovirus and Epstein–Barr virus Tables 91 and 93
Mortality rate while receiving dialysis estimated for those < 18 years Overall survival, Mortality after
graft loss
Cost parameters
(resource use)
Dosages for TAC-IR, CSA, MMF, AZA and prednisolone updated with
estimates from child/adolescent studies
Resource use, Maintenance
therapy
Cytomegalovirus prophylaxis resource use updated Resource use, Infection
prophylaxis
Post-transplant monitoring resource use updated Resource use, Monitoring
Mix of haemodialysis and peritoneal dialysis estimated for those
< 18 years
Resource use, Dialysis
Cost parameters
(unit costs)
Cost of temporary access for haemodialysis estimated for those
< 19 yearsa
Unit cost, Dialysis
Ongoing costs of haemodialysis and peritoneal dialysis updated for
those < 19 years
Unit cost, Dialysis
Cost of 10mg of BAS dose added for KTRs who weigh < 35 kg Unit cost, Induction
Costs estimated for differing severity of AR (spontaneously resolving,
steroid sensitive and steroid resistant)
Unit costs, Acute rejection
Cost of PTLD estimated Unit costs, Post-transplant
lymphoproliferative disease
Costs of hypertension and hypomagnesaemia estimated Unit costs, Hypomagnesaemia
and Hypertension
Costs of explant surgery estimated for those < 19 years Unit costs, Explant surgery
Costs of pre-transplant workup and transplantation estimated for
those < 19 years
Unit costs,
Subsequent transplant
a Costs are estimated for those < 19 years rather than those < 18 years as this is how NHS Reference Costs 2013 to 201458
are reported.
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The UK Transplant Registry standard data set contains data on all solid organ transplants in the UK
between 1995 and 2012. It allows linkage of multiple transplants for a single recipient and includes graft
and patient survival (measured in days). A total of 34,803 records refer to kidney-only transplants, of which
29,759 recorded both graft and patient survival, 4937 recorded graft survival only (although it may be
inferred that the patient survived at least as long as the graft), 24 recorded patient survival only, and 83
recorded neither graft nor patient survival.
The population modelled is incident KTRs and did not include prevalent KTRs (i.e. people who received a
kidney transplant in the past) or those suffering from AR (although a number of the interventions
separately have marketing authorisation for the treatment of AR).
To explore the impact of age at time of transplantation on cost-effectiveness, subgroups were identified by
age (Table 55). In addition to this, the average cost-effectiveness of interventions was calculated by
determining weighted average total discounted costs and QALYs for each year of age. It was assumed that
the same number of transplants would be conducted in 16- and 17-year-olds as for 15-year-olds in order
to estimate the cost-effectiveness for those under 18 years. No other subgroups were analysed as there
was no evidence from child/adolescent RCTs identified in the systematic review of clinical effectiveness to
support economic evaluation of these subgroups.
The weight and body surface area of child/adolescent KTRs are important for dosing and are highly
dependent on age. It was assumed that the weight of child/adolescent KTRs would follow the median
weight of UK children and adolescents160,161 (Figure 14). In scenario analyses it was assumed instead that
the weight of child/adolescent KTRs would follow the ninth centile weight of UK children and adolescents
to reflect the possibility that child/adolescent KTRs may have had their growth impaired by renal failure.
TABLE 55 Age distribution of child/adolescent KTRs in the UK
Age (years) Number of transplants (2000–13) Proportion of transplants (2000–13)
1 30 2.2%
2 77 5.5%
3 89 6.4%
4 83 6.0%
5 80 5.8%
6 66 4.7%
7 65 4.7%
8 80 5.8%
9 84 6.0%
10 91 6.5%
11 97 7.0%
12 120 8.6%
13 117 8.4%
14 151 10.9%
15 161 11.6%
Source: UK Renal Registry. The data reported here have been supplied by the UK Renal Registry of the Renal Association
(Anna Casula, UK Renal Registry, personal communication, 26 February 2015). The interpretation and reporting of these
data are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the
UK Renal Registry or the Renal Association.
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Body surface area was then calculated from weight based on the table for body surface area estimation in
the BNF for Children,173,174 as shown in Table 56.
Setting and location
The NHS in England (although some data sources have been UK-wide, particularly the UK Renal Registry
and the UK Transplant Registry standard data set).
Study perspective
In line with the NICE reference case,165 the perspective adopted on outcomes was all direct health effects
for patients (and, when relevant, carers) and the perspective adopted on costs was that of the NHS and
Personal Social Services.
TABLE 56 Estimated body surface area for given weight
Weight (kg) BSA (m2)
1.0 0.10
1.5 0.13
2.0 0.16
2.5 0.19
3.0 0.21
3.5 0.24
4.0 0.26
4.5 0.28
5.0 0.30
5.5 0.32
6.0 0.34
6.5 0.36
7.0 0.38
7.5 0.40
8.0 0.42
8.5 0.44
9.0 0.46
9.5 0.47
0
10
20
30
40
50
60
70
0 5 10 15
M
ed
ia
n
 w
ei
g
h
t 
(k
g
)
Age (years)
Combined
Male
Female
FIGURE 14 Median weight of UK children and adolescents according to age.
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TABLE 56 Estimated body surface area for
given weight (continued )
Weight (kg) BSA (m2)
10.0 0.49
11.0 0.53
12.0 0.56
13.0 0.59
14.0 0.62
15.0 0.65
16.0 0.68
17.0 0.71
18.0 0.74
19.0 0.77
20.0 0.79
21.0 0.82
22.0 0.85
23.0 0.87
24.0 0.90
25.0 0.92
26.0 0.95
27.0 0.97
28.0–29.0 1.00
30.0–34.0 1.10
35.0–38.0 1.20
39.0–43.0 1.30
44.0–48.0 1.40
49.0–53.0 1.50
54.0–58.0 1.60
59.0–64.0 1.70
65.0–69.0 1.80
70.0–75.0 1.90
76.0–81.0 2.00
82.0–87.0 2.10
88.0–90.0 2.20
BSA, body surface area.
Source: BNF for Children.173
Adapted by permission from Macmillan Publishers Ltd on
behalf of Cancer Research UK: Journal of Cancer, Sharkey I,
Boddy AV, Wallace H, Mycroft J, Hollis R, Picton S. Body
surface area estimation in children using weight alone:
application in paediatric oncology. British Journal of Cancer
2001;85(1):23,174 copyright 2001.
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Interventions and comparators
As the immunosuppressive agents are used in combination and in sequence, we used treatment regimens
as interventions and comparators rather than individual agents, although the cost-effectiveness of an
individual agent versus another individual agent can then be evaluated by considering the cost-effectiveness
of regimens which are identical but for the use of the intervention agent or the comparator.
Regimens were included as interventions or comparators if they were in current use in the NHS or if they
would plausibly be used in the NHS and there was sufficient clinical evidence to estimate the costs and
outcomes for KTRs receiving those regimens. It was necessary to include regimens that are not in current
clinical practice to allow all the interventions being appraised to have their cost-effectiveness appraised.
The only regimen which is a pure ‘comparator regimen’ (in that it contains no agents listed as interventions
in the scope) is CSA+AZA.
Two regimens were included which were not included in the economic assessment for adults:
BAS+ TAC+AZA and r-ATG+ TAC+AZA. The first was added as it is in common use in the NHS and the
second was added to allow comparison of BAS and r-ATG in combination with TAC-IR and AZA.
Table 57 presents the regimens considered in this analysis as well as an indication of whether or not the
Assessment Group believes the regimen to be a licensed combination for children and adolescents
(however, no warranty or representation is given as to the correctness of the information presented in this
regard, which reflects the Assessment Group’s understanding of the marketing authorisation as stated in
the summaries of product characteristics; this understanding has not been confirmed by a clinician or
pharmacist and, therefore, its accuracy cannot be guaranteed, particularly as regards drug combinations).
TABLE 57 Immunosuppressive regimens included in independent economic assessment
Identifier Induction therapy Maintenance therapya Licensed
CSA+MMF None CSA and MMF Y
TAC+MMF None TAC-IR and MMF U
CSA+AZA None CSA and AZA Y
TAC+AZA None TAC-IR and AZA Y
CSA+ EVL None CSA and EVL N
TAC+ SRL None TAC-IR and SRL N
TAC-PR+MMF None TAC-PR and MMF N
BAS+CSA+MMF BAS CSA and MMF Y
BAS+ TAC+MMF BAS TAC-IR and MMF U
BAS+CSA+AZA BAS CSA and AZA Y
BAS+ TAC+AZA BAS TAC-IR and AZA U
BAS+ SRL+MMF BAS SRL and MMF U
BAS+ BEL+MMF BAS BEL and MMF N
BAS+CSA+MPS BAS CSA and MPS N
r-ATG+CSA+MMF R-ATG CSA and MMF Y
r-ATG+ TAC+MMF R-ATG TAC-IR and MMF U
r-ATG+CSA+AZA R-ATG CSA and AZA Y
r-ATG+ TAC+AZA R-ATG TAC-IR and AZA Y
N, no; Y, yes; U, uncertain.
a All maintenance regimens also included CCSs.
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In its submission, Astellas also included the following regimens, which we have not modelled:
l SRL and CSA (with BAS induction) – note that we have modelled SRL and TAC without BAS induction
(although the SPC for SRL specifies it is to be used in combination with CSA, we found significantly
more RCT evidence in the adult population for which it was used in combination with TAC)
l EVL and CSA (with BAS induction) – note that we have modelled this without BAS induction because
there were slightly more patients in adult RCTs receiving this regimen without induction
l TAC-IR (‘specials’ for first 3 years followed by Prograf for remaining life of graft) and MMF
(with BAS induction)
l TAC-IR (Modigraf for first 3 years followed by Prograf for remaining life of graft) and MMF
(with BAS induction).
The last two regimens are for children and adolescents who are unable to swallow Prograf capsules
(although, inconsistently, they are assumed to be able to swallow MMF capsules and prednisolone tablets)
and able to swallow Modigraf suspension (our expert advisory group has suggested some children cannot
swallow Modigraf suspension and require fully liquid formulations, which can be purchased from specialist
manufacturers rather than being prepared as specials by pharmacists or carers).
Time horizon
The time horizon was 50 years for consistency with the parallel HTA in adults and to ensure that all
important differences in costs or outcomes between the technologies are included.
Discount rate
In line with the NICE reference case, the discount rate for costs and health effects was 3.5% per annum.165
Choice of health outcomes
The primary health outcome of the independent economic assessment was QALYs for each comparator
regimen, in line with the NICE reference case.165
Secondary outcomes included:
l undiscounted life-years (life expectancy)
l undiscounted life-years with a functioning graft
l undiscounted life-years on dialysis
l likelihood of experiencing at least one episode of AR
l likelihood of developing NODAT
l likelihood of receiving a second, third or fourth transplant.
Model structure
Owing to the paucity of RCT evidence in the child/adolescent kidney transplant population it was decided
that two types of analyses would be conducted.
The first type of analysis was based on actual RCT evidence in the child/adolescent kidney transplant
population meeting the inclusion criteria for our systematic review of clinical effectiveness evidence
(see Chapter 3, Inclusion and exclusion criteria). For each RCT, a decision tree was used to model the
expected costs incurred and QALYs accrued for the duration of the trial (see Decision tree), followed by
extrapolation using the Markov model (see Markov model), as shown in Figure 15. These analyses allow
for an estimation of the cost-effectiveness of the interventions BAS and TAC-IR while relying on as little
evidence from the adult population as possible, but do not allow for estimation of the cost-effectiveness of
other interventions.
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The second type of analysis was conducted using the Markov model only (see Markov model) and by
assuming effectiveness estimates from adults (relating to death within 12 months, graft loss within
12 months, AR within 12 months, eGFR at 12 months, NODAT within 12 months, CMV infection and
dyslipidaemia within 12 months) apply to children directly. This analysis allows the cost-effectiveness of all
interventions and comparators to be evaluated, but relies on a strong assumption that the effectiveness
estimates will not be biased when applied to a different population.
We do not present either type of analysis as a preferred base case because both have deficiencies.
We attempt to draw conclusions by comparing the results of both types of analyses.
All analyses were constructed in Microsoft Excel 2010.
Decision tree
For each of the three RCTs in children and adolescents, a decision tree was created which calculated the
following outcomes for each arm:
l costs (discounted and undiscounted) of immunosuppression, AR and AEs during the trial duration
l life-years up to the trial duration with functioning graft and with dialysis
l QALYs (discounted and undiscounted) during the trial duration
l for extrapolation using the Markov model
¢ proportion of KTRs alive with functioning graft at the end of the trial duration
¢ proportion of KTRs who are dialysis-dependent at the end of the trial duration
¢ probability of AR within 12 months
¢ probability of NODAT within 12 months
¢ graft function (mean eGFR) at 12 months.
The discounted costs and QALYs from the decision tree and from the Markov model extrapolation were
then combined. Cost-effectiveness results were presented both with ICERs and with incremental net health
benefit figures (calculated at £20,000 and £30,000 per QALY). Cost-effectiveness results were also
calculated by restricting the time horizon to the trial duration, that is, without extrapolating using the
Markov model.
For simplicity, it was assumed that no KTRs losing their graft would be retransplanted within the trial
duration. For Offner et al.,73 with follow-up of only 1 year, this is likely to be a very reasonable assumption.
For Grenda et al.75 and Trompeter et al.,77 with follow-up of 2 and 5 years, respectively, this may result in a
bias against the arm with greater graft loss.
Used to extrapolate
(%AR, %NODAT, eGFR)
(%NODAT)
*Same structure as Arm A
Arm B
Arm A
Functioning graft
Dialysis
Death
FIGURE 15 Simplified diagram of decision tree used for economic analyses based on child/adolescent RCTs.
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Methods for estimating costs
Resource use as reported in the RCTs was used to estimate costs during the trial duration. When the
resource use for certain components was not reported in RCTs, either assumptions were made to
extrapolate from RCT evidence in adults, or if these cost components were small and/or unlikely to vary
between arms, these components were excluded from the analysis.
Immunosuppression resource use was frequently reported as dose per kg body weight or per m2 body
surface area, so these were estimated and were modelled to increase over the course of the trial duration
in line with child/adolescent growth curves. If baseline body weight was not reported, it was estimated
based on age at baseline.
Methods for estimating life-years
For each RCT, we estimated the numbers and times of KTRs losing their grafts (any cause, including
DWFG) and the numbers and times of KTRs dying. It was then assumed that all KTRs not losing their graft
or dying were censored at the end of the trial duration. Restricted mean survival was calculated (restricted
to the trial duration) as shown in Table 58. The estimated life-years with functioning graft was then the
restricted mean graft survival (not censored for DWFG). Restricted mean patient survival minus restricted
mean graft survival gave the estimated life-years on dialysis.
For the probabilistic sensitivity analyses (PSAs), the restricted mean survivals were estimated by fitting a
gamma random variable to the difference between follow-up and restricted mean survival using the
method of moments. More specifically, if Tdiff is the difference between the follow-up duration (Tmax) and
the restricted mean survival (T):
Tdif f = Tmax−T
E½Tdif f  = Tmax−E½T 
SE½Tdif f  = SE½T 
Tdif f ∼Γ(α, β)
α = (E½Tdif f =SE½Tdif f )2
β = (SE½Tdiff )2=E½Tdif f .
(1)
These gamma random variables were sampled separately for each arm and for graft survival and patient
survival. In the event that graft survival was sampled as longer than patient survival (an impossibility) in one
or both arms, graft survival was compressed in both arms by the same factor such that graft survival was
equal to or less than patient survival.
TABLE 58 Restricted mean overall and graft survival in child/adolescent RCTs (years)
Trial Trompeter et al.77 Grenda et al.75 Offner et al.73
Arm TAC+AZA CSA+AZA TAC+AZA BAS+ TAC+AZA BAS+CSA+MMF CSA+MMF
Overall survival
Tmax 4 2 1
E[T] 3.921 3.852 1.996 2.000 0.984 1.000
SE[T] 0.0383 0.0733 0.0018 0.0057
Graft survival
Tmax 4 2 1
E[T] 3.769 3.609 1.840 1.884 0.975 0.994
SE[T] 0.0748 0.1030 0.0550 0.0503 0.0123 0.0055
E, expected value; T, time; Tmax, time at follow-up duration.
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If there were no events in one arm, the SE of restricted mean survival in the total population was assumed
for both arms, and a small constant was added to E[Tdiff] for both arms.
Outcomes for extrapolation
Overall survival (Kaplan–Meier) as reported by the RCTs was used to estimate the proportion of children
and adolescents dead at the end of the trial duration, that is, at the start of extrapolation using the
Markov model (Table 59). Kaplan–Meier graft survival (this time censored for DWFG) was used to estimate
the proportion of those alive who would still have a functioning graft (see Table 59).
Markov model
A Markov model structure was used with three main states: functioning graft, graft loss and death.
The KTRs start in the functioning graft unless they suffer PNF, in which case they start in the graft loss
state. Transitions can occur from functioning graft to graft loss, reflecting disease progression;
transitions are not permitted in the opposite direction except through retransplantation. Up to three
retransplantations are possible and, therefore, there are four substates for functioning graft and graft
loss reflecting the graft number (1–4). As with the initial graft, it is possible that PNF will occur and,
therefore, transitions can occur directly to graft loss following second, third or fourth graft. Pre-emptive
retransplantation can occur from the original functioning graft state, but not from functioning graft states
2–4. Death can occur from any state but the rate of mortality is greater in the graft loss state (see Overall
survival, Mortality after graft loss) and increases with age.
Irrespective of the regimen used for immunosuppression in the first graft, a common regimen was used
for subsequent grafts (BAS+ TAC+MMF), as this was judged the most likely regimen for kidney
transplantation in adults (and most retransplantations are expected to occur after KTRs reach adulthood).
Figure 16 gives the model diagram showing the nine states in the model. Self-links are omitted from all
states in both figures for clarity (there are no tunnel states).
In addition to these health states, for each regimen the incidence of AR, CMV infection, dyslipidaemia and
NODAT was estimated.
TABLE 59 Outcomes from decision trees for extrapolation with Markov models
Trial Trompeter et al.77 Grenda et al.75 Offner et al.73
Arm TAC+AZA CSA+AZA TAC+AZA BAS+ TAC+AZA BAS+CSA+MMF CSA+MMF
Kaplan–Meier
overall survival
0.94 0.92 0.989 1.000 0.972 1.000
Kaplan–Meier
graft survival
(censored
for DWFG)
0.954 0.792 0.896 0.949 0.981 0.989
AR within
12 monthsa
0.43 0.62 0.26 0.24 0.13 0.23
NODAT within
12 months
0.019 0.011 0.011 0.040 0.0 0.0
eGFR at
12 months
(ml/minute/1.73m2)
64.9 57.8 74.9 74.0 79 82
Note
a The proportions with AR in Trompeter et al.77 and Grenda et al.75 are estimated Kaplan–Meier method (i.e. cumulative
incidence) while proportions in Offner et al.72 are estimated as simple proportions.
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For each allowable transition, a transition rate was modelled. The probability of each transition was then
calculated using the following formula:
pi = (ri=R) × (1−e
−RΔt ), (2)
where ri is the hazard rate of the specific transition, R is the sum of allowable transition rates
(including ri) and Δt is the time step (cycle length).
Table 60 gives a summary of how the transition rates were dependent on factors such as age, AR and
NODAT. BAS+ TAC+AZA was assumed to be the baseline regimen for the initial graft, for the
following reasons:
l Only two of the four regimens in current use in the NHS (TAC+AZA and BAS+ TAC+AZA) are
consistent with current NICE guidance TA99.1
l Although the most common regimen in use is TAC+AZA, this is also expected to result in worse
outcomes than BAS+ TAC+AZA, TAC+MMF and BAS+ TAC+MMF (except death within 12 months,
for which it is expected to be superior to TAC+MMF, and eGFR at 12 months, for which it is expected
to be superior to TAC+MMF and BAS+ TAC+MMF) according to network meta-analyses of adult
RCT evidence, and so TAC+AZA may not be as close to average UK outcomes as BAS+ TAC+AZA.
Factors included in the model
Overall survival
Overall survival was not explicitly included as an input to the model and, therefore, emerges from the two
modelled rates of mortality (see Overall survival, Death with functioning graft and Mortality after graft loss).
The exception to this is that the rate of DWFG in the first year was adjusted using an individual HR for
each regimen to achieve the desired OR of patient mortality as derived from the mixed-treatment
comparison (MTC) and head-to-head comparisons.
Although it would be possible to use numerical methods (e.g. Solver add-in for Microsoft Excel) to achieve
exact patient mortality, it was felt it would add significant computational burden, create significant
opportunity for human error (forgetting to rerun Solver every time relevant parameters were changed) and
would greatly slow down PSAs.
FG1
GL1
FG2
GL2
FG3
GL3
FG4
GL4
DEATH
FIGURE 16 Markov model diagram. Note that green arrows indicate pre-emptive retransplantation while dashed
arrows signify PNF of a subsequent retransplantation. FR, functioning graft; GL, graft loss.
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Therefore, a regression approach was used instead, by running different parameter values through the
model and recording the resulting odds of mortality within 12 months. The two factors driving patient
survival at 12 months that could vary between regimens were identified as the OR of graft loss (after
returning to dialysis the mortality rate increases) and the HR of DWFG. The OR of patient mortality within
12 months was plotted against the HR of DWFG for various different ORs of graft loss, and was found to
be linearly dependent on a log-log plot (Figure 17).
For each OR of graft loss, linear regression of ln(odds of patient mortality) versus ln(HR of DWFG) was
performed and the values of the linear regression coefficients were found to be linearly dependent on the
OR of graft loss (Figure 18).
TABLE 60 Summary of determining factors for transition rates within the Markov model
Transition
Corresponding
clinical outcome Dependent on
Functioning graft to graft loss (first graft) Disease progression
(graft loss/survival)
First year
Time since transplantation
Regimen-specific OR of graft loss within
12 months
Subsequent years
Time since transplantation
BPAR within 12 months
NODAT within 12 months
eGFR at 12 months
Functioning graft to graft loss (subsequent graft) Disease progression
(graft loss/survival)
(Constant)
Functioning graft to death (first graft) DWFG First year
Time since transplantation
Regimen-specific HR based on OR of
patient death within 12 months
Subsequent years
Time since transplantation
Age
NODAT
Functioning graft to death (subsequent graft) DWFG Age
NODAT
Graft loss to subsequent functioning graft Retransplantation Age
Graft loss to death Mortality while
receiving dialysis
Age
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The appropriate HR for DWFG to achieve a desired OR of patient mortality is therefore derived as follows
(where ORDCGL,i is the OR of graft loss, HRDWFG,i is the HR of DWFG and ORPD,i is the OR of patient death):
ai=0:8952−0:0936×ORDCGL,i
bi=0:0885×ORDCGL,i−0:083
HRDWFG,i=exp

ln(ORPD,i)−bi
ai

.
(3)
As can be seen in Table 61, the regression formulae perform well in most instances.
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FIGURE 18 Linear regression coefficients for ln(OR of patient death) versus ln(HR of DWFG) plotted versus OR of
graft loss.
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Death with functioning graft
In adult KTRs, DWFG is a significant cause of graft loss. It is a less significant cause of graft loss for children
and adolescents because their life expectancy is much greater.
More KTRs die from infection and malignancy than dialysis recipients and the risk of both is increased by
greater immunosuppression.175 CVD is also a significant cause of mortality in people who have transplants.
As with members of the general population, the mortality rate increases with age, plus there are a number
of additional risks factors affecting patient survival that are adjusted for when comparing survival across
different centres.96
Crude estimates of DWFG will vary according to immunological risk and donor kidney type (i.e. living donor,
DCD, DBD) because of differences in baseline demographics (living donor KTRs tend to be younger) and
in immunosuppression (KTRs at greater immunological risk tend to receive greater immunosuppression,
which increases the risk of infection and malignancy).176 The use of steroids is also linked to increased risk of
death from CVD and infection.177
There is also evidence to suggest that the risks of cardiovascular and infectious causes of death are
elevated in KTRs with reduced graft function at 1 year post transplantation.177
The modelling framework employed allowed flexibility in the rate of DWFG in the first graft modelled but
less flexibility for subsequent grafts, for which it could not be dependent on time since transplantation.
The baseline rate of DWFG for the first graft was estimated from the UK Transplant Registry standard data
set for each donor type (DBD, DCD, living related, living unrelated) after adjusting for transplant period
(adjusted to 2007–12) and age group (adjusted to 31–50 years). The Kaplan–Meier survival function was
directly used for the first 19 years, followed by an extrapolation based on the estimated rate of DWFG
from 9–19 years. The baseline survivor function is shown in Figure 19.
TABLE 61 Comparison of HRs for DWFG from regression and calculated using Solver
Regimen HR for DWFG from regression HR for DWFG from solver
CSA+MMF 0.724 0.717
TAC+MMF 1.302 1.295
CSA+AZA 0.745 0.739
TAC+AZA 1.129 1.127
CSA+ EVL 1.186 1.183
TAC+ SRL 1.106 1.105
TAC-PR+MMF 1.739 1.696
BAS+CSA+MMF 0.641 0.629
BAS+ TAC+MMF 1.143 1.142
BAS+CSA+AZA 0.661 0.649
BAS+ SRL+MMF 1.308 1.299
BAS+ BEL+MMF 0.284 0.227
BAS+CSA+MPS 0.388 0.349
r-ATG+CSA+MMF 0.429 0.395
r-ATG+ TAC+MMF 0.764 0.760
r-ATG+CSA+AZA 0.439 0.402
r-ATG+ TAC+AZA 0.655 0.642
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The rate of DWFG was then adjusted by sex, donor type and age based on a Cox proportional-hazards
analysis of the UK Transplant Registry data set (Table 62 and see Appendix 10). For the first 12 months an
individual HR was applied for each regimen to achieve a target OR of patient mortality (see Overall survival)
and thereafter a HR for NODAT was applied according to Cole et al.178
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FIGURE 19 Baseline survivor function for DWFG.
TABLE 62 Hazard ratios applied to rate of DWFG
Covariate HR
NODAT 1.41
Sex: female 0.865
Donor type
DBD 1
DCD 1.083
Living related 0.551
Living unrelated 0.703
Age (years)
< 18 0.377
18–30 0.369
31–40 0.712
41–50 1
51–60 2.140
61–70 4.128
71–75 7.583
76–80 8.576
81–85 13.751
> 85 23.552
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Mortality after graft loss
Following graft loss, in the absence of an available kidney for pre-emptive retransplantation, KTRs will be
placed on dialysis. Some KTRs will be waitlisted for retransplantation while others will be judged not fit for
retransplantation owing to unsuitability for surgery or prohibitively great immunological risk. The mortality
rate for dialysis recipients is known to be significantly greater than that for age-matched members of the
general population.154
It was assumed that mortality rates following graft loss would be the same as mortality rates for dialysis
recipients and dependent on age group (Table 63). It is notable that the rate of mortality for children and
adolescents on dialysis is higher than the rates for KTRs aged 18–49 years.
For the PSA, the SE of mortality rate in each group was estimated by dividing the square root of the
number of observed deaths by the estimated exposure.
Graft survival
Graft survival is a key measure of the clinical effectiveness of an immunosuppressive regimen and is critical
also for cost-effectiveness as graft loss necessitates expensive dialysis treatment, which has a detrimental
impact on HRQoL or retransplantation (a costly procedure).
Use of graft survival in the model
In the model regimen-specific graft survival drives transitions from functioning graft to graft loss states for
the first graft, whereas for subsequent grafts a constant rate of graft loss was assumed across all regimens
(see Subsequent grafts).
TABLE 63 Mortality rate for dialysis recipients
Age group (years) Hazard rate of mortality (SE)
< 18 0.034 (0.011)
18–24 0.010 (0.003)
25–29 0.012 (0.003)
30–34 0.009 (0.002)
35–39 0.015 (0.002)
40–44 0.021 (0.002)
45–49 0.027 (0.002)
50–54 0.041 (0.003)
55–59 0.053 (0.003)
60–64 0.079 (0.004)
65–69 0.107 (0.005)
70–74 0.149 (0.006)
75–79 0.211 (0.007)
80–84 0.275 (0.011)
> 85 0.408 (0.019)
Note
Calculated from results in table 8.18 of Pruthi et al.154
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The transitions for the first graft are calculated by first estimating a graft survival curve (censored for
DWFG) for each regimen, then multiplying this with a curve estimating patient survival (censored for graft
loss) to obtain an estimate for how many KTRs should be alive and in the functioning graft state in each
cycle. The rate of graft loss for cycle, i, is then calculated as:
rGL(ti) = ½ln(S(ti))− ln(S(ti+1))=Δt, (4)
where S(ti) is the product of survival curves for the start of cycle i and Δt= ti+1 – ti is the cycle length.
The details for how the survival curves are estimated were given earlier (see Overall survival), but briefly:
l Graft survival censored for DWFG is estimated by adjusting baseline graft survival from the UK
Transplant Registry standard data set in the first year according to the OR of graft loss within
12 months and thereafter according to a surrogate relationship based on AR within 12 months,
NODAT within 12 months and eGFR at 12 months.
l Death with functioning graft is estimated by adjusting baseline patient survival estimated from the UK
Transplant Registry standard data set in the first year according to the OR of patient death within
12 months and thereafter according to a surrogate relationship based on NODAT within 12 months.
To account for the possibility of pre-emptive retransplantation, the rate of graft loss is partitioned between
transitions from first functioning graft to graft loss following first graft; first functioning graft to second
functioning graft (successful pre-emptive retransplantation); and first functioning graft to graft loss
following second graft (unsuccessful pre-emptive retransplantation). It was assumed that 20% would
receive pre-emptive retransplantation,179 of which 1.6% would result in PNF (based on the UK Transplant
Registry standard data set, see Appendix 10).
Estimation of graft survival
It has been established in adults that AR, NODAT and graft function measured at 12 months are predictive
of graft survival.178,180–184
For children and adolescents we identified far fewer studies estimating the relationship between the
potentially predictive attributes identified for adults (AR, NODAT and graft function at 12 months) and
graft survival.
Muscheites et al.185 considered a number of potentially predictive factors for death-censored graft loss in
104 children and adolescents receiving kidney transplants in one out of four German centres: recipient age
(< 6 years, 6–12 years, > 12 years); recipient gender; donor type; number of HLA mismatches; number of
rejection episodes; underlying renal disease; transplant period (1989–95, 1996–2000); change in GFR
(between 30 days and 12 months; between 6 and 12 months); and GFR at 30 days, 6 months and
12 months. KTRs with graft survival of < 1 year were excluded and the mean follow-up was 8.3 years.
They found that in univariate Cox analyses only the absolute GFR values at 30 days, 6 months and
12 months were predictive of graft survival with a significance level of 0.05. Furthermore, when
considering a multivariate Cox analysis only GFR at 12 months was predictive of long-term graft survival.
This study concludes that AR is not predictive (in univariate or multivariate analyses, significance level 0.05),
but does not report any central estimates for the HR due to AR. It is possible that the study was
insufficiently powered to estimate the effect of AR on graft survival with precision and it is also possible
that excluding patients with graft survival < 1 year would also limit the predictive power of AR. The study
also does not include NODAT as a covariate.
Tejani and Sullivan186 considered the relationship between AR and ‘chronic rejection graft loss’
(which accounted for 30.8% of failed grafts). Although they found that AR is a significant predictor of
chronic rejection graft loss, they do not report the relationship between AR and graft loss overall.
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It was decided that the relationship between eGFR and graft survival would be estimated based on the
results of Muscheites et al.185 as these appear to be in the relevant population and estimated using
appropriate statistical methodology. It was decided that for AR and NODAT, the same relationship as used
for the adult population would be used, as this is consistent with TA991 (where the Committee in their
consideration of the evidence accepted an AR surrogate relationship based on adult evidence).
It could be argued that as no statistically significant evidence for a relationship between AR and graft
survival was found by Muscheites et al.,185 that no such relationship should be included in the model,
but it was felt that if two regimens were predicted to result in the same eGFR but one regimen was
predicted to reduce the rate of AR, that this should be reflected in the predicted graft survival. In addition,
as Muscheites et al.185 did not report the central estimate for the HR according to AR, it is possible that the
central estimate may not be too different from the HR for adults.
It may also be noted that the HR of graft loss (for KTRs experiencing BPAR in the first 12 months versus
KTRs not experiencing BPAR) assumed in this model (1.60 on the basis of adult evidence) is less than
the HR assumed to inform TA85 and TA99 (1.96), although it is greater than a HR proposed by the
Assessment Group for TA99 and rejected by the NICE Appraisal Committee at that time (a value of 1.41).
Throughout this section it should be noted that graft survival (and the underlying event, graft failure) does
not include DWFG, that is, only considering people who are alive and who become dependent on dialysis
or require retransplantation.
Baseline Baseline graft survival for the first year was estimated from the UK Transplant Registry standard
data set using the Kaplan–Meier method, restricting to the first graft for each recipient and adjusting to
the year 2012 (using Cox proportional hazards on transplant year). Graft survival was estimated separately
for DBD and living related donors (DCD and living unrelated donors are very rare in child/adolescent
transplantation). KTRs with graft failure on the day of transplant were assumed to have PNF and were
excluded. Any KTRs dying with a functioning graft were censored at the time of death. Figure 20 gives the
baseline graft survival.
Baseline graft survival was extrapolated by fitting a Weibull curve to conditional survival from 1 year for
first graft (i.e. fitted to KTRs whose first grafts survived at least 1 year), with proportional hazards
covariates for donor type and transplant year. The fit of this Weibull curve was verified with a graphical
test of the Cox–Snell residuals (Figure 21), which demonstrated that the fit was good as there was little
deviation from the diagonal except for long follow-up (when censoring tends to cause such deviations).
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FIGURE 20 Graft survival in first year according to donor type. LRD, living related donors.
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Other parametric survival distributions were not explored owing to the adequacy of the Weibull fit and for
consistency with the parallel HTA (in which a Weibull curve was further indicated owing to the need to
apply HRs derived from a separate Weibull fit reported by Levy et al.182).
The baseline model for conditional graft survival from 1 year is then:
S(t) = expf− λtγg, (5)
where t is time after 1 year, λ is the rate parameter and γ is the shape parameter (with a value of 1.103,
implying increasing hazard rate with time).
A different rate parameter is obtained for different covariate values (proportional hazards model), the
baseline rate parameter was obtained by assuming the following covariate values: donor type= [(DBD,
0.638), (living related, 0.362)]; transplant year= 2012. These led to a baseline rate parameter value
of 0.02187.
The resulting baseline graft survival in the PenTAG model is shown in Figure 22.
Results presented by Hudson and Collett187 at the British Transplantation Society Congress (February 2014)
suggest that for deceased donors the median graft survival (death censored) for DBD grafts is 21–22 years
(and higher for grafts from living donors), while estimated 30-year graft survival is 36% for DBD grafts
(and expected to be higher for living donor grafts). These results serve as external validation of the
extrapolation in the PenTAG model.
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FIGURE 21 Graphical verification of the fit to graft survival.
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FIGURE 22 Baseline graft survival in the PenTAG model.
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Adjustments during the first year Graft survival for the first year was adjusted using the proportional
odds method such that for each regimen the ORs of graft loss (excluding death and PNF) throughout the
first year matched the ORs of graft loss as detailed in Based on adult randomised controlled trial evidence.
Adjustments after the first year Graft survival for the first graft after the first year was modelled using
the surrogate end points renal function at 12 months, AR within 12 months and NODAT within
12 months.
The surrogate relationship was implemented using proportional hazards and summarised in Table 64
and expanded in sections below. The rate parameters for all regimens (after adjusting according to the
surrogate relationship) are given in Table 65. The resulting graft survival (excluding DWFG) at 1, 3, 5 and
10 years for each regimen is given in Table 66.
TABLE 64 Surrogate relationship HRs for graft survival
Relationship HR Source
AR within 12 months 1.60 Cole et al.178
Renal function (eGFR ml/minute/1.73m2) at 12 months 1 for eGFR > 80
1.59 for 45 < eGFR ≤ 80
55.9 for eGFR ≤ 45
Muscheites et al.185
NODAT within 12 months 1.12 Cole et al.178
TABLE 65 Rate parameters for graft survival after 1 year
Regimen Rate parameter (λ)
CSA+MMF 0.0391
TAC+MMF 0.0300
CSA+AZA 0.0461
TAC+AZA 0.0269
CSA+ EVL 0.0331
TAC+ SRL 0.0424
TAC-PR+MMF 0.0303
BAS+CSA+MMF 0.0323
BAS+ TAC+MMF 0.0247
BAS+CSA+AZA 0.0375
BAS+ TAC+AZA 0.0219
BAS+ SRL+MMF 0.0286
BAS+ BEL+MMF 0.0210
BAS+CSA+MPS 0.0272
r-ATG+CSA+MMF 0.0346
r-ATG+ TAC+MMF 0.0267
r-ATG+CSA+AZA 0.0397
r-ATG+ TAC+AZA 0.0236
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Graft function at 12 months The average graft function (eGFR) at 12 months for each regimen was
estimated by estimating the baseline average eGFR at 12 months. We were unable to find these figures in
the UK Renal Registry annual reports; the best available estimate is 82ml/minute/1.73m2 (SD 27ml/minute/
1.73m2) from a German multicentre observational study.185 This study, by Muscheites et al.,185 also informs the
surrogate relationship between graft function at 12 months and graft survival. Dividing eGFR into three
categories (< 45ml/minute/1.73m2, 45–80ml/minute/1.73m2 and > 80ml/minute/1.73m2) the authors found
that compared with KTRs in the highest eGFR category at 12 months, those in the lowest had significantly
worse graft survival (HR 55.9, 95% CI 5.29 to 591), and those in the middle category had worse graft survival,
but this was not shown to be statistically significant (HR 1.59, 95% CI 0.52 to 4.87).
The regimen-specific proportion of KTRs in each eGFR category at 12 months was estimated by first
calculating the expected mean eGFR for the regimen by adding the regimen-specific mean eGFR difference
(see Based on adult randomised controlled trial evidence) to the baseline mean eGFR, then assuming a
normal distribution with a SD of 27ml/minute/1.73 m2.
Acute rejection within 12 months Acute rejection rates within 12 months were estimated using
effectiveness estimates as described in Based on adult randomised controlled trial evidence and a baseline
AR rate for BAS+ TAC+AZA.
The baseline AR rate for BAS+ TAC+AZA was estimated as 19 out of 99= 19.2% from Grenda et al.75
TABLE 66 The 1-, 3-, 5- and 10-year graft survival for each regimen
Regimen
Graft survival (excluding DWFG and PNF) (%)
1 year 3 years 5 years 10 years
CSA+MMF 97.01 89.19 80.97 62.34
TAC+MMF 97.24 91.16 84.65 69.27
CSA+AZA 96.02 86.97 77.62 57.06
TAC+AZA 95.47 90.10 84.30 70.42
CSA+ EVL 97.51 90.81 83.69 67.09
TAC+ SRL 95.37 87.06 78.40 59.06
TAC-PR+MMF 96.70 90.60 84.07 68.66
BAS+CSA+MMF 97.47 90.94 83.98 67.69
BAS+ TAC+MMF 97.66 92.61 87.14 73.88
BAS+CSA+AZA 96.63 89.15 81.27 63.27
BAS+ TAC+AZA 96.16 91.74 86.92 75.11
BAS+ SRL+MMF 96.52 90.76 84.56 69.84
BAS+ BEL+MMF 97.91 93.59 88.87 77.26
BAS+CSA+MPS 97.81 92.25 86.26 71.92
r-ATG+CSA+MMF 97.67 90.66 83.23 66.04
r-ATG+ TAC+MMF 97.85 92.39 86.49 72.36
r-ATG+CSA+AZA 96.88 88.96 80.66 61.88
r-ATG+ TAC+AZA 96.45 91.69 86.51 73.91
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The effect of AR on graft survival after the first year was estimated using the HR of 1.60 from Cole et al.178
A regimen-specific raw HR was then calculated according to the weighted average of the HRs for AR
(1.60) and no rejection (1.00) with the weights equal to the AR rate for each regimen. These were then
normalised to give HRs versus the baseline (BAS+ TAC+AZA), as shown in Table 67.
NODAT within 12 months The methods for estimating the incidence of NODAT within the first 12 months
since transplantation are described in the section Diabetes mellitus.
The effect of NODAT on graft survival after the first year was estimated using the HR of 1.12 from Cole
et al.178 (based on the adult population) and incorporated using the same methodology as for graft
function and AR. Table 68 demonstrates that the impact of NODAT on graft survival is fairly small, which is
to be expected given the conclusions of Cole et al.178 that NODAT primarily increases the rate of DWFG,
which is not considered here.
Adverse events
Synthesis of AE data is rarely conducted across studies owing to typically low incidence (resulting in low
statistical power to detect differences) and heterogeneity of reporting. The challenge of synthesising such
data is impossible in the case of child/adolescent kidney transplantation owing to the paucity of RCT
evidence. Even so, for this model and in the model for the adult population it was judged important to
consider the possible impact of different regimens on AE rates because the profile of AEs is considered
highly clinically relevant.
TABLE 67 Acute rejection rates and HR for graft survival due to AR for each regimen
Regimen AR rate Raw HR HR vs. baseline
CSA+MMF 27.83% 1.167 1.046
TAC+MMF 24.57% 1.147 1.029
CSA+AZA 44.98% 1.270 1.139
TAC+AZA 32.09% 1.193 1.069
CSA+ EVL 27.19% 1.163 1.043
TAC+ SRL 23.89% 1.143 1.025
TAC-PR+MMF 24.11% 1.145 1.026
BAS+CSA+MMF 16.24% 1.097 0.984
BAS+ TAC+MMF 14.07% 1.084 0.972
BAS+CSA+AZA 29.13% 1.175 1.053
BAS+ TAC+AZA (baseline) 19.19% 1.115 1.000
BAS+ SRL+MMF 15.22% 1.091 0.979
BAS+ BEL+MMF 24.88% 1.149 1.031
BAS+CSA+MPS 22.37% 1.134 1.017
r-ATG+CSA+MMF 11.98% 1.072 0.961
r-ATG+ TAC+MMF 10.31% 1.062 0.952
r-ATG+CSA+AZA 22.40% 1.134 1.017
r-ATG+ TAC+AZA 14.30% 1.086 0.974
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Owing to the lack of RCT evidence in children and adolescents, it was decided that in the analysis for
which effectiveness estimates are drawn from adult RCT evidence, the impact of regimens on AEs should
also be drawn from those adult RCTs. However, in the analyses based on child/adolescent RCTs, estimates
of incidence were taken from those child/adolescent RCTs when possible, even when this meant a
different set of AEs was included.
In this section and subsections we describe how the incidences of NODAT, CMV infection, dyslipidaemia
and anaemia are estimated in the analysis based on adult RCT evidence.
Cytomegalovirus infection is assumed to be a one-off event occurring in the first year, whereas NODAT,
dyslipidaemia and anaemia are chronic conditions modelled for the full time horizon while patients are
alive. All AEs incur costs while NODAT additionally results in a utility decrement (see Disutility due to
diabetes mellitus).
Diabetes mellitus
The incidence of diabetes mellitus in individuals receiving dialysis is higher than that in the general
population, at around 6% per year, with incidence marginally higher in individuals receiving
haemodialysis.188 Kidney transplantation appears to result in a significant increase in the incidence of
diabetes mellitus in the first year post transplant (and especially in the first 6 months), after which
incidence falls to similar levels to those seen in people on dialysis (see figure 2 of Woodward et al.188).
TAC has been repeatedly associated with the development of NODAT5,178 and the same incidence pattern
is observed of significantly elevated incidence in the first year post transplant.188
TABLE 68 Incidence of NODAT and effect on graft survival for each regimen
Regimen Incidence of NODAT Raw HR HR vs. baseline
CSA+MMF 1.83% 1.002 0.997
TAC+MMF 4.04% 1.005 1.000
CSA+AZA 1.83% 1.002 0.997
TAC+AZA 4.04% 1.005 1.000
CSA+ EVL 1.74% 1.002 0.997
TAC+ SRL 6.33% 1.008 1.003
TAC-PR+MMF 4.75% 1.006 1.001
BAS+CSA+MMF 1.83% 1.002 0.997
BAS+ TAC+MMF 4.04% 1.005 1.000
BAS+CSA+AZA 1.83% 1.002 0.997
BAS+ TAC+AZA (baseline) 4.04% 1.005 1.000
BAS+ SRL+MMF 3.22% 1.004 0.999
BAS+ BEL+MMF 0.79% 1.001 0.996
BAS+CSA+MPS 1.71% 1.002 0.997
r-ATG+CSA+MMF 1.83% 1.002 0.997
r-ATG+ TAC+MMF 4.04% 1.005 1.000
r-ATG+CSA+AZA 1.83% 1.002 0.997
r-ATG+ TAC+AZA 4.04% 1.005 1.000
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Pre-existing diabetes mellitus in the cohort was not modelled, only NODAT within 12 months. Based on a
visual inspection of figure 1 of Woodward et al.,188 it was assumed that 75% of NODAT in the first year
would occur within the first 6 months. Incidence of NODAT after the first year was not modelled, as the
results of Woodward et al.188 suggest that after the first year the incidence of diabetes mellitus returns to
pre-transplantation levels.
As in the model for adult KTRs, we assume that after the first year there is no change in the prevalence of
NODAT in the population.
Baseline 12-month incidence of NODAT for BAS+ TAC+AZA was estimated to be 4.0% from Grenda et al.75
In the model for adult KTRs it was assumed that the effect of changing regimen from baseline
(BAS+ TAC+AZA) could be estimated by multiplying the effects of changing the agents TAC and AZA.
In fact, no RCTs were identified comparing MMF and AZA which reported NODAT and, therefore, it was
assumed that AZA and MMF would lead to the same incidence of NODAT.
Tables 69 and 70 list the studies (RCTs from the systematic review of clinical effectiveness in adults)
informing the impact of replacing TAC-IR and MMF, respectively, on 12-month NODAT incidence.
The corresponding network diagrams are given in Figures 23 and 24.
Mixed-treatment comparisons were conducted for both and in both cases a fixed-effects model was
considered to be more appropriate owing to a lower deviance information criterion (DIC) (58.28 vs. 60.39
and 25.52 vs. 27.04). The results of the MTCs are presented in Tables 71 and 72.
The mean log-ORs were combined from the MTCs to estimate an overall OR for each regimen, as shown
in Table 73, which when combined with the baseline incidence for BAS+ TAC+MMF resulted in the
estimated 12-month incidence of NODAT for each regimen, as shown in Table 74.
TABLE 69 Studies included to estimate the impact on NODAT incidence of replacing MMF
Study Compares NODAT in 12 months
Ciancio et al. 2008189 MMF vs. MPS 7/61 vs. 6/55
aFerguson et al. 2011129 MMF vs. SRL 0/33 vs. 2/26
Takahashi et al. 2013190 MMF vs. EVL 3/61 vs. 7/61
Tedesco Silva et al. 2010191 MMF vs. EVL 19/273 vs. 14/274
Anil Kumar et al. 2005192 MMF vs. SRL 2/75 vs. 2/75
Gonwa et al. 2003193 MMF vs. SRL 9/176 vs. 10/185
Sampaio et al. 2008194 MMF vs. SRL 6/50 vs. 12/50
a TAC+MMF arm excluded.
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TABLE 70 Studies included to estimate the impact on NODAT incidence of replacing TAC-IR
Study Compares NODAT in 12 months
Laskow et al. 1996106 TAC vs. CSA 12/67 vs. 1/20
Mayer et al. 1997107 TAC vs. CSA 17/303 vs. 3/145
Campos and Abbud Filho 2002109 TAC vs. CSA 10/85 vs. 3/81
Hardinger et al. 2005113 TAC vs. CSA 5/134 vs. 1/66
Raofi et al. 1999195 TAC vs. CSA 3/14 vs. 4/21
Yang et al. 1999125 TAC vs. CSA 1/24 vs. 1/21
Krämer et al. 2010139 TAC vs. TAC PR 20/336 vs. 22/331
Tsuchiya et al. 2013196 TAC vs. TAC PR 0/52 vs. 1/50
aVincenti et al. 2005197 CSA vs. BEL 6/73 vs. 1/71
aBENEFIT198 CSA vs. BEL 16/221 vs. 7/226
aBENEFIT-EXT199 CSA vs. BEL 11/184 vs. 7/175
bFerguson et al. 2011129 TAC vs. BEL 1/30 vs. 0/33
Lebranchu et al. 2009200 CSA vs. SRL 2/97 vs. 3/96
Buchler et al. 2007201 CSA vs. SRL 3/74 vs. 9/71
Kreis et al. 2000202 CSA vs. SRL 1/38 vs. 1/40
Guba et al. 2010203 CSA vs. SRL 4/71 vs. 5/69
Martinez-Mier et al. 2006204 CSA vs. SRL 1/21 vs. 1/20
Schaefer et al. 2006205 TAC vs. SRL 5/39 vs. 6/41
Groth et al. 1999206 CSA vs. SRL 1/42 vs. 1/41
Chen et al. 2008126 TAC vs. CSA 1/21 vs. 1/20
Symphony127 TAC vs. CSA vs. SRL 34/403 vs. 17/408 vs. 25/380
a Less intensive BEL arm only (more intensive BEL arm excluded).
b BEL+ SRL arm excluded.
MMF
1
4
2
MPS
SRL
EVL
FIGURE 23 Network diagram for network meta-analysis estimating the impact on NODAT incidence of
replacing MMF.
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FIGURE 24 Network diagram for network meta-analysis estimating the impact on NODAT incidence of replacing
TAC-IR.
TABLE 71 Mixed-treatment comparison estimates of impact on NODAT incidence of replacing TAC-IR [WinBUGS
(version 1.4.3; MRC Biostatistics Unit, Cambridge, UK); fixed-effects model]
Agent
OR vs. baseline (natural logarithmic scale) OR vs. baseline (linear scale)
Mean SD Median 95% CrI Median 95% CrI
TAC (Baseline)
TAC-PR 0.1694 0.3199 0.1687 –0.4546 0.8003 1.184 0.635 2.226
CSA –0.8162 0.2086 –0.8136 –1.231 –0.4129 0.443 0.292 0.662
BEL –1.671 0.381 –1.665 –2.431 –0.9394 0.189 0.088 0.391
SRL –0.2345 0.2239 –0.2339 –0.6734 0.2016 0.791 0.510 1.223
Crl, credible interval.
TABLE 72 Mixed-treatment comparison estimates of impact on NODAT incidence of replacing MMF (WinBUGS;
fixed-effects model)
Agent
OR vs. baseline (natural logarithmic scale) OR vs. baseline (linear scale)
Mean SD Median 95% CrI Median 95% CrI
MMF (Baseline)
MPS –0.07041 0.6122 –0.0656 –1.291 1.126 0.937 0.275 3.083
SRL 0.4739 0.3318 0.4719 –0.1688 1.131 1.603 0.845 3.099
EVL –0.05221 0.3194 –0.05309 –0.6831 0.5742 0.948 0.505 1.776
Crl, credible interval.
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TABLE 73 Calculations for the OR of NODAT in 12 months
Regimen Replace TAC OR Replace MMF OR Overall OR
CSA+MMF CSA 0.442 – 1.000 0.442
TAC+MMF – 1.000 – 1.000 1.000
CSA+AZA CSA 0.442 AZA 1.000 (assumed) 0.442
TAC+AZA – 1.000 AZA 1.000 (assumed) 1.000
CSA+ EVL CSA 0.442 EVL 0.949 0.420
TAC+ SRL – 1.000 SRL 1.606 1.606
TAC-PR+MMF TAC-PR 1.185 – 1.000 1.185
BAS+CSA+MMF CSA 0.442 – 1.000 0.442
BAS+ TAC+MMF – 1.000 – 1.000 1.000
BAS+CSA+AZA CSA 0.442 AZA 1.000 (assumed) 0.442
BAS+ TAC+AZA – 1.000 AZA 1.000 (assumed) 1.000
BAS+ SRL+MMF SRL 0.791 – 1.000 0.791
BAS+ BEL+MMF BEL 0.188 – 1.000 0.188
BAS+CSA+MPS CSA 0.442 MPS 0.932 0.412
r-ATG+CSA+MMF CSA 0.442 – 1.000 0.442
r-ATG+ TAC+MMF – 1.000 – 1.000 1.000
r-ATG+CSA+AZA CSA 0.442 AZA 1.000 (assumed) 0.442
r-ATG+ TAC+AZA – 1.000 AZA 1.000 (assumed) 1.000
TABLE 74 Estimated 12-month incidence of NODAT for each regimen
Regimen NODAT incidence (%)
CSA+MMF 1.83
TAC+MMF 4.04
CSA+AZA 1.83
TAC+AZA 4.04
CSA+ EVL 1.74
TAC+ SRL 6.33
TAC-PR+MMF 4.75
BAS+CSA+MMF 1.83
BAS+ TAC+MMF 4.04
BAS+CSA+AZA 1.83
BAS+ TAC+AZA 4.04
BAS+ SRL+MMF 3.22
BAS+ BEL+MMF 0.79
BAS+CSA+MPS 1.71
r-ATG+CSA+MMF 1.83
r-ATG+ TAC+MMF 4.04
r-ATG+CSA+AZA 1.83
r-ATG+ TAC+AZA 4.04
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Cytomegalovirus infection
Cytomegalovirus infection was judged on the basis of examining the incidence of CMV infection in RCTs
included in the systematic review in the adult population and on the basis of the Cochrane systematic
reviews of maintenance immunosuppression by Webster et al.156,207 that CMV infection could be affected
by the use of mammalian/mechanistic target of rapamycin inhibitor (mTOR-I) (SRL and EVL) and that the
impact could vary depending on whether replacing a CNI or antimetabolite in the ‘standard triple-therapy’.
Table 75 lists the studies (RCTs from the systematic review of clinical effectiveness) that could inform the
estimate of the impact on CMV infection incidence of using mTOR-I. The corresponding network diagram
for these studies is given in Figure 25.
Fixed-effects and random-effects MTCs were conducted and the random-effects model was judged to be
superior on the basis of DIC (54.02 vs. 59.54 for fixed-effects model). The results of the random-effects
MTC are shown in Table 76.
TABLE 75 Studies included to estimate the impact on CMV infection incidence of using mTOR-I (SRL and EVL)
Study Compares CMV infection within 12 months
Vitko et al. 2004208 No mTOR-I vs. mTOR-I replacing antimetabolite 38/196 vs. 10/194
Takahashi et al. 2013190 No mTOR-I vs. mTOR-I replacing antimetabolite 21/61 vs. 3/61
Tedesco Silva et al. 2010191 No mTOR-I vs. mTOR-I replacing antimetabolite 16/273 vs. 2/274
Chadban et al. 2013209 No mTOR-I vs. mTOR-I replacing antimetabolite 2/47 vs. 4/30
Sampaio et al. 2008194 No mTOR-I vs. mTOR-I replacing antimetabolite 6/50 vs. 6/50
Mjörnstedt et al. 2012210 No mTOR-I vs. mTOR-I replacing CNI 13/100 vs. 9/102
Flechner et al. 2002211 No mTOR-I vs. mTOR-I replacing CNI 2/30 vs. 3/31
Lebranchu et al. 2009200 No mTOR-I vs. mTOR-I replacing CNI 6/97 vs. 4/96
Büchler et al. 2007201 No mTOR-I vs. mTOR-I replacing CNI 17/74 vs. 4/71
Kreis et al. 2000202 No mTOR-I vs. mTOR-I replacing CNI 8/38 vs. 2/40
Guba et al. 2010203 No mTOR-I vs. mTOR-I replacing CNI 20/71 vs. 5/69
Martinez-Mier et al. 2006204 No mTOR-I vs. mTOR-I replacing CNI 0/21 vs. 1/20
Symphony127 No mTOR-I vs. No mTOR-I vs. mTOR-I replacing CNI 39/403 vs. 45/408 vs. 23/380
1
7
5
No mTOR-I
mTOR-I
replacing CNI
mTOR-I replacing
antimetabolite
FIGURE 25 Network diagram for network meta-analysis estimating the impact on CMV incidence of mTOR-I use.
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The baseline incidence of CMV infection was estimated from Jongsma et al.212 who found that 25.8% of
transplantations in 159 Dutch children and adolescents were followed by CMV infection within 1 year.
The typical regimens were CSA+MMF and BAS+CSA+MMF.
Combining the baseline incidence with the treatment effects results in the incidence rates for each
regimen as shown in Table 77.
Dyslipidaemia
Dyslipidaemia was judged on the basis of examining the incidence of CMV infection in RCTs in the adult
population and on the basis of the Cochrane systematic reviews of maintenance immunosuppression by
Webster et al.156,207 that the incidence of dyslipidaemia could be increased by the use of mTOR-I in the
immunosuppressive regimen. It was considered that it was not necessary to separately estimate the risk
whether used in combination with a CNI or with an antimetabolite. Therefore, to increase statistical power
the effect of mTOR-I use on dyslipidaemia incidence was estimated as the OR of dyslipidaemia incidence
for mTOR-I use versus no mTOR-I use.
Table 78 details the adult population RCTs that compared regimens with and without mTOR-I and that
reported dyslipidaemia. The direction of effect is consistent across the studies and the corresponding
network diagram of these studies is given in Figure 26. Fixed- and random-effects meta-analyses were
conducted and it was judged on the basis of DIC (28.267 vs. 29.897) that a fixed-effects analysis was
appropriate. The results of the fixed-effects meta-analysis are shown in Table 79.
The baseline incidence of dyslipidaemia (without mTOR-I use) was estimated by Bonthuis et al.213 based on
European registry data for child/adolescent RRT recipients. The incidence of dyslipidaemia was 55.5% (313/564)
for transplant recipients, versus 85.1% and 76.1% for haemodialysis and peritoneal dialysis recipients,
respectively. This study also highlighted that SRL was associated with significantly increased lipid levels versus
TAC and CSA. The incidence of dyslipidaemia with mTOR-I use was therefore estimated as 68.5%.
TABLE 76 Mixed-treatment comparison estimates of impact on CMV infection incidence of using mTOR-I
(WinBUGS; random-effects model)
mTOR-I use
OR vs. baseline (natural logarithmic scale) OR vs. baseline (linear scale)
Mean SD Median 95% CrI Median 95% CrI
No mTOR-I (Baseline)
mTOR-I replacing CNI –0.7981 0.3889 –0.806 –1.558 0.01047 0.447 0.211 1.011
mTOR-I replacing antimetabolite –1.153 0.4916 –1.175 –2.091 –0.1184 0.309 0.124 0.888
σ (random effects parameter) 0.7915 0.4085 0.7538 0.08925 1.705
Crl, credible interval.
TABLE 77 CMV infection incidence rates used in the model
Regimen CMV incidence within 12 months (%)
CSA+ EVL 9.88
TAC+ SRL 9.88
BAS+ SRL+MMF 13.53
No mTOR-I 25.79
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Anaemia
Anaemia is an AE that affects KTRs and people on dialysis. As reference costs for dialysis already include
anaemia costs, only anaemia in people with functioning grafts was modelled. It was assumed that there
would be no difference in the prevalence of anaemia between different immunosuppressive regimens.
The prevalence of anaemia requiring treatment with erythropoiesis-stimulating agents (ESAs) was
estimated as 5.2%, based on a study by Vanrenterghem et al.214 This prevalence was assumed to be the
same regardless of time since transplantation, age, or other factors.
Retransplantation
In the parallel HTA to evaluate the cost-effectiveness of immunosuppressive agents for adult KTRs,68 the
rate of retransplantation was estimated for those under 65 years as 0.1037 from the UK Transplant
Registry standard data set. To estimate the rate of retransplantation specifically for children and
adolescents (who generally receive priority in DBD allocation) this rate was multiplied by 3.422 for those
under 18 years, to reflect that median waiting time for adults is 3.422 times greater than median waiting
time for children and adolescents (1160 days vs. 339 days).
Pre-emptive retransplantations were also included, as described in Use of graft survival in the model.
TABLE 78 Studies used to estimate the impact on dyslipidaemia of mTOR-I use
Study Compares Dyslipidaemia within 12 months
Vitko et al. 2004208 No mTOR-I vs. mTOR-I use 24/196 vs. 51/194
Takahashi et al. 2013190 No mTOR-I vs. mTOR-I use 19/61 vs. 28/61
Tedesco Silva et al. 2010191 No mTOR-I vs. mTOR-I use 43/273 vs. 57/274
Sampaio et al. 2008194 No mTOR-I vs. mTOR-I use 8/50 vs. 11/50
Mjörnstedt et al. 2012210 No mTOR-I vs. mTOR-I use 9/100 vs. 13/102
Flechner et al. 2002211 No mTOR-I vs. mTOR-I use 16/30 vs. 20/31
Lebranchu et al. 2009200 No mTOR-I vs. mTOR-I use 4/97 vs. 8/96
Büchler et al. 2007201 No mTOR-I vs. mTOR-I use 38/74 vs. 50/71
Guba et al. 2010203 No mTOR-I vs. mTOR-I use 5/71 vs. 14/69
Symphony127 No mTOR-I vs. mTOR-I use 91/811 vs. 60/380
10
mTOR-I use
No mTOR-I
FIGURE 26 Network diagram for network meta-analysis estimating the impact on dyslipidaemia incidence of
mTOR-I use.
TABLE 79 Fixed-effects meta-analysis of the impact on dyslipidaemia incidence of mTOR-I use
mTOR-I use
OR vs. baseline (natural logarithmic scale) OR vs. baseline (linear scale)
Mean SD Median 95% CrI Median 95% CrI
No mTOR-I (Baseline)
mTOR-I use 0.5566 0.1005 0.5555 0.3604 0.7533 1.743 1.434 2.124
Crl, credible interval.
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Subsequent grafts
Owing to limitations of Markov modelling imposed by the memoryless assumption, there is reduced
flexibility in the modelling of costs and outcomes for subsequent grafts. It was assumed that the hazard
rates of all transitions, costs and utilities are dependent only on time in the model and the arm
under consideration.
Comprehensive information on immunosuppressive regimens used does not appear to be collected;215,216
the UK Renal Registry data set does not include BAS induction and the UK Transplant Registry does not
include any data on immunosuppressive regimens employed.
It was assumed that the same immunosuppressive regimen would be used for all subsequent grafts,
regardless of the immunosuppressive regimen used for the first graft. BAS+ TAC+MMF was chosen as
the immunosuppressive regimen for subsequent grafts as it is believed to be the most common
immunosuppressive regimen in use in the UK. People receiving subsequent grafts are more likely to receive
monoclonal or polyclonal antibody induction as they are likely to be at higher immunological risk. People
can become sensitised to r-ATG if received as induction for first graft or for treatment of steroid-resistant
AR, thus it was judged to be less likely to be used as induction than BAS.
Assuming the same immunosuppressive regimen for subsequent grafts for all regimens has the effect that
the cost-effectiveness of regimens is primarily driven by outcomes for the first graft. Table 80 summarises
the parameters affecting subsequent grafts.
Effectiveness estimates
The key effectiveness parameters driving cost-effectiveness in the model are:
l graft loss within 12 months
l patient death within 12 months
l AR within 12 months
l graft function at 12 months
l NODAT at 12 months
l CMV infection within 12 months
l dyslipidaemia at 12 months.
TABLE 80 Parameters affecting subsequent grafts
Parameter Value Source
Natural history
Baseline rate of DWFG 0.00780 Assumed to be the same as long-running rate of DWFG
for first graft
Rate of graft loss 0.03589 Exponential distribution fitted to UK Transplant Registry
standard data set (see Appendix 10) (first graft and
PNF excluded)
Resource use
TAC dosage 0.10mg/kg/day Assumed to be somewhat higher than the long-running
dosage for first graft (0.08 with AZA/MMF, 0.07 with
SRL) due to increased risk of rejection
MMF dosage 2 g/day Recommended daily dose
Prednisolone dosage 16.3mg/day Assumed to be same as first graft
Monitoring (clinic, TAC TDM, blood
test, renal profile, liver function tests)
Once monthly Assumption
TDM, therapeutic drug monitoring.
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As explained in Model structure, it was not possible to estimate these for all interventions based on RCT
evidence in the child/adolescent kidney transplant population. Therefore, it was decided that separate
analyses would be conducted based on adult RCT evidence (allowing comparison of all interventions) and
on child/adolescent RCT evidence (only allowing a very limited number of comparisons).
The analyses based on child/adolescent RCT evidence differ somewhat from the analyses based on adult
RCT evidence as they utilise a decision tree to estimate costs and QALYs in the trial duration followed by
extrapolation with the Markov model. As such, graft loss and patient death are estimated at the study end
and additionally the restricted mean survival of the patient and the graft are estimated (restricted to the
trial duration), as described in Decision tree.
Based on adult randomised controlled trial evidence
Graft loss, patient death, AR and graft function were primarily estimated from network meta-analyses of
adult RCT evidence for induction and maintenance regimens, assuming independence of treatment effects
(i.e. that the clinical effectiveness for a complete regimen can be decomposed into the effectiveness for the
induction therapy and the maintenance regimen).
Some arms were included in the network meta-analyses which do not correspond to regimens in the
model and the results for these arms were not included, but the arms were not dropped from the network
meta-analyses as they could still contribute indirect effect estimates. The mean treatment effects from the
network meta-analyses are summarised in Table 81.
Head-to-head comparisons for TAC-PR versus TAC-IR and for MPS versus MMF were additionally used to
identify any differences in effectiveness between these agents. In the network meta-analysis, MMF and
MPS were assumed to be the same agent to simplify the analysis and increase the statistical power. The
head-to-head comparisons did not identify any statistically significant differences in clinical effectiveness.
The effectiveness of MMF was assumed to be that of mycophenolate in the network meta-analysis and the
TABLE 81 Summary of mean treatment effects from network meta-analyses of adult RCT evidence
Arm
Mortality within
12 monthsa
(lower is better)
Graft loss within
12 monthsa
(lower is better)
eGFR at
12 monthsb
(higher is better)
BPAR within
12 monthsb
(lower is better)
Induction (vs. no induction)
BAS –0.1168 –0.1712 +2.615 –0.6878
R-ATG –0.4605 –0.2534 +0.7524 –1.041
Maintenance (vs. CSA +AZA)
TAC+AZA +0.3234 +0.1353 +9.304 –0.5484
CSA+MPA –0.0569 –0.2971 +1.609 –0.7516
TAC+MPA +0.4218 –0.3788 +6.531 –0.9205
BEL+MPA –0.7630 –0.4915 +10.55 –0.2159
CSA+ EVL +0.3330 –0.4843 +4.863 –0.7835
TAC+ SRL +0.3248 +0.1587 –0.3523 –0.9574
SRL+MPA +0.5416 +0.0321 +3.846 –0.8283
a Presented as log-ORs.
b Presented as mean difference.
Note
The comparators here are the comparators in the network meta-analysis rather than the baseline used in the model.
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effectiveness of MPS was estimated by combining the network meta-analysis and head-to-head
effectiveness estimates (yMPA and yMPS–MMF, respectively) as follows (on the appropriate scale, i.e. log-odds
for dichotomous outcomes, linear scale for eGFR):
yMMF = yMPA (6)
yMPS = yMPA + ΔyMPS−MMF. (7)
The effectiveness of TAC-PR was similarly estimated:
yTAC−PR = yTAC + ΔyTAC−PR−TAC. (8)
The effectiveness estimates were combined with the following estimated baseline values (for
BAS+ TAC+AZA): mortality within 12 months (odds)= 0.0052 (based on the model with baseline graft
loss and DWFG rates); graft loss within 12 months (odds)= 0.0400 (based on UK Transplant Registry
standard data set); eGFR at 12 months (ml/minute/1.73 m2)= 82 (based on Muscheites et al.185); AR within
12 months (odds)= 0.2375 (based on Grenda et al.75). The resulting absolute effectiveness estimates are
given in Table 82.
The effectiveness estimates for the other outcomes (NODAT, CMV infection and dyslipidaemia) are also
estimated from the RCTs identified in the systematic review of clinical effectiveness (see sections Diabetes
mellitus, Cytomegalovirus infection and Dyslipidaemia in Adverse events).
TABLE 82 Summary of absolute effectiveness estimates for each regimen based on adult RCT evidence
Regimen
Mortality within
12 months (odds)
Graft loss within
12 months (odds)
Mean eGFR
(ml/minute/1.73m2)
BPAR within
12 months (odds)
CSA+MMF 0.0039 0.0245 71.7 0.386
TAC+MMF 0.0063 0.0225 76.6 0.326
CSA+AZA 0.0041 0.0329 70.1 0.818
TAC+AZA 0.0058 0.0376 79.4 0.472
CSA+ EVL 0.0058 0.0203 74.9 0.373
TAC+ SRL 0.0057 0.0384 69.7 0.314
TAC-PR+MMF 0.0082 0.0270 76.4 0.318
BAS+CSA+MMF 0.0035 0.0206 74.3 0.194
BAS+ TAC+MMF 0.0056 0.0190 79.2 0.164
BAS+CSA+AZA 0.0037 0.0277 72.7 0.411
BAS+ TAC+AZA 0.0052 0.0317 82.0 0.238
BAS+ SRL+MMF 0.0064 0.0286 76.5 0.180
BAS+ BEL+MMF 0.0020 0.0170 83.2 0.331
BAS+CSA+MPS 0.0024 0.0178 78.2 0.288
r-ATG+CSA+MMF 0.0026 0.0190 72.4 0.136
r-ATG+ TAC+MMF 0.0040 0.0175 77.4 0.115
r-ATG+CSA+AZA 0.0028 0.0256 70.8 0.289
r-ATG+ TAC+AZA 0.0037 0.0292 80.1 0.167
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Health measurement and valuation
The EQ-5D (3-level version) is the preferred instrument to measure HRQoL in the NICE reference case,165
but it is designed for use in adults. An adapted version of EQ-5D, the European Quality of Life-5
Dimensions Youth version (EQ-5D-Y), has been developed for children and adolescents (aged 8–17 years),
but there is currently no method to value states measured in EQ-5D-Y (except naively applying the EQ-5D
value set which is cautioned against).217 Furthermore, we attempted to systematically identify any HRQoL
studies in the child/adolescent kidney transplant population and did not find any.
In the absence of any studies measuring HRQoL in the child/adolescent population, it was assumed that
the formula estimating the utility of general population health, the utility decrements for the different
methods of RRT and the utility decrement for diabetes mellitus would be the same as for the adult
population, as follows.
Utility was estimated for KTRs by first estimating age-dependent baseline utility for the general population,
then applying a utility decrement according to whether KTRs were in the functioning graft or graft loss
state. In addition, the proportion of the population with NODAT was estimated and a utility decrement
was applied to both functioning graft and graft loss states to reflect the decreased HRQoL for KTRs
with NODAT.
In the PSA utility decrements were drawn from gamma distributions to ensure that they did not result in
increased utility.
With the exception of the source for baseline utility (see Utility of general population), sources of utility
estimates were obtained from sources found through a systematic bibliographic search of the relevant
literature. This search combined established terms and synonyms for identifying studies of utility and
HRQoL, with population search terms for renal transplant, dialysis and ESRD. No study design filter
was used.
The search yielded 1311 titles and abstracts, which were screened by an experienced HTA researcher (RA).
Only 99 were studies that yielded or used EQ-5D scores (the preferred preference-based measure for
informing NICE technology assessments). Studies were sought which yielded EQ-5D derived health state
scores (using UK general population valuations), for health states or clinical events of relevance in our
provisional model structure: functioning renal graft, failing renal graft, chronic allograft injury, acute kidney
rejection, NODAT, malignancy following renal transplant and infection following renal transplant.
Utility of general population
Baseline utility was modelled using the following equation:
Utility = 0:967981−0:001807 × age−0:000010 × age2 + 0:023289 ×male, (9)
where male is equal to 1 for men and 0 for women. This equation was derived from the Health Survey
for England (2012)218 using the well-established methodology of Ara and Brazier.219 The data set includes
16- and 17-year-olds but does not appear to include utility estimates for younger individuals (all of whom
had utility recorded as exactly 1) and, therefore, this is an extrapolation.
Utility with dialysis
A systematic review and meta-analysis by Liem et al.220 reported pooled estimates of utility for various
health states of people undergoing RRT. It reported random-effects meta-analyses of six studies159,221–224
which had produced EQ-5D index scores (either explicitly based on the UK utility tariff or assumed to be so
by the authors) for haemodialysis (range 0.44–0.62) and of four studies159,221,223,224 for peritoneal dialysis
(range 0.53–0.65). The estimates used in our model are shown in Table 83.
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These estimates were then converted into utility decrements from baseline age-related general health
(assuming age 60.4 years and 58% male for haemodialysis, and age 57.9 and 55% male for peritoneal
dialysis) in order that the utility of those on dialysis would always be lower than in people in the general
population of the same age and sex.
The estimated utility decrements were [mean (SE)]: haemodialysis [0.277 (0.034)] and peritoneal dialysis
[0.264 (0.044)].
Utility with functioning graft
The same systematic review and meta-analysis by Liem et al.220 reported pooled estimates of utility
for people living with a functioning renal graft. It reported a random-effects meta-analysis of five
studies159,223,225–227 that had produced EQ-5D index scores (either explicitly based on the UK utility tariff or
assumed to be so by the authors) for people living with a functioning renal graft (range of means, some
medians, 95% CI 0.71 to 0.86; Table 84).
It was assumed that the HRQoL for KTRs would not exceed that of members of the general population
(aged 51.4 years and 60% male), so this absolute estimate was converted into a utility decrement from
baseline of 0.053 (SE 0.049).
Disutility due to diabetes mellitus
Our literature search for utilities revealed one study looking specifically at disutility of NODAT in renal
transplantation patients.228 This is a recent study in the adult RRT population and reports EQ-5D utility
data, with an estimated disutility of 0.06 associated with NODAT. This figure does not adjust for people
with CVD complications and, therefore, is appropriate to how we model NODAT. We note that the study
was conducted in only one hospital in USA and the valuation set for the utility values is US based229 so the
outcomes may not be generalisable to the UK population. It has been demonstrated by Johnson et al.230
that US-valued health states are statistically higher than the UK-valued health states for 31 out of 42
valued EQ-5D health states and that extreme health states are most notably different. However, this does
not necessarily reflect the differences between health states and we believe that having utility data from
a relevant patient population is the most important factor in choosing this value. For example, one
alternative would be to use diabetes mellitus compared with general population using Health Survey for
England data.218 This would be a broader population of comparison and is unlikely to reflect the true utility
impact of diabetes mellitus on someone who has received a kidney transplant.
In their submission to the parallel technology appraisal to evaluate the cost-effectiveness of
immunosuppressive agents for adult KTRs,68 Bristol-Myers Squibb incorporated disutility of 0.041 for
NODAT citing Currie et al.231 as its source, which is a study looking at costs. We believe Bristol-Myers
Squibb intended to cite the other Currie et al. paper from 2005,232 but it is still not clear how it calculated
this value. In its model, the deterministic value for disutility of NODAT appears to be 0.06, which
corresponds with our chosen value.
TABLE 83 The EQ-5D index utility weights for dialysis220
Type of dialysis Pooled mean (95% CI) Number of studies Number of people
Haemodialysis 0.56 (0.49 to 0.62) 6 1315
Peritoneal dialysis 0.58 (0.50 to 0.67) 4 192
TABLE 84 The EQ-5D index utility weights for functioning graft220
Health state Pooled mean (95% CI) Number of studies Number of people
Functioning graft 0.81 (0.72 to 0.90) 5 673
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Astellas (in its submission to this technology appraisal) reports the findings of Wyld et al.233 which does
report utilities, deriving a disutility of 0.10 between no diabetes mellitus and diabetes mellitus groups of
people with CKD. However, this is not restricted to the renal transplant population and it is not clear which
utility elicitation method is used.
Estimating resources and costs
Costs are incurred in the model either in the form of events (e.g. induction therapy, AR, CMV infection,
retransplantation) or in the form of ongoing costs (e.g. maintenance therapy, NODAT, dialysis).
The following costs are incurred exclusively in the functioning graft state (ongoing unless otherwise stated):
l induction therapy (event)
l maintenance therapy
l monitoring
l infection prophylaxis
l AR (event)
l CMV infection (event)
l anaemia.
The following costs are incurred exclusively in the graft loss state:
l dialysis.
The following costs are incurred in both the functioning graft and graft loss states:
l NODAT
l dyslipidaemia.
The following costs are incurred only when transitioning between states:
l from functioning graft to graft loss: explant surgery, dialysis access surgery
l from graft loss to functioning graft (and other retransplantation transitions): retransplantation.
Currency, price date and conversion
Costs are all in 2014/15 pounds sterling. Costs in earlier financial years are inflated based on the Hospital
and Community Health Services pay and prices index (Table 85).234
No costs were included in different currencies so conversion was not necessary.
TABLE 85 HCHS pay and prices index
Year HCHS pay and prices index Inflation factor
2008/9 267.0 1.106
2009/10 268.6 1.099
2010/11 276.7 1.067
2011/12 282.5 1.045
2012/13 287.3 1.028
2013/14 290.5 1.016
2014/15 295.3 (projected based on previous 3 years) 1.000
HCHS, Hospital and Community Health Services.
INDEPENDENT ECONOMIC ASSESSMENT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
124
Resource use
Induction therapy
Basiliximab can be administered by i.v. infusion or i.v. injection but it was assumed that it would be
administered by i.v. infusion in accordance with Brennan et al.235 As i.v. infusion is a more costly method of
administration than i.v. injection, this may overestimate the costs of BAS administration.
Rabbit anti-human thymocyte immunoglobulin is administered only by i.v. infusion and it was assumed it
would be administered as in Brennan et al.,235 which was conducted in adults. We found no RCT evidence
in children or adolescents for r-ATG to inform dosages. We assumed no wastage of r-ATG, which may
result in the costs being underestimated.
The dosage for BAS is 10mg if the recipient’s weight is < 35 kg and 20mg if the recipient’s weight is
≥ 35 kg.63 This cut-off was used by Offner et al.,73 while a higher cut-off of 40 kg was used by Grenda
et al.75 Table 86 describes resource use for induction therapy.
In the base case, recipients are aged 10 years with expected body weight 32 kg and, therefore, they
receive 10mg doses rather than 20mg doses.
TABLE 86 Resource use for induction therapy
Parameter Value Source
BAS induction
BAS 10mg doses 1.964 Brennan et al.235
BAS 20mg doses 0 (Weight < 35 kg)
Administration (i.v. infusion) 1.964 Brennan et al.235
R-ATG induction
R-ATG mg/kg 6.5 Brennan et al.235
Administration (i.v. infusion) 4.525 Assumption based on Brennan et al.235
Number of doses People
1 2
2 6
3 10
4 24
5 97
6 1
7 1
Actual breakdown not reported but given that 87.9%
were initiated before reperfusion, 68.8% received the
intended five doses, one patient received six doses,
also one patient received six doses. At least four doses
were received by 87.2% of people
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Maintenance therapy
Dosages for those under 18 years were estimated from child/adolescent RCTs when possible. When this
was not possible, dosing guidelines for adults were followed when they were already weight based. When
they were not weight based, it was assumed that the dose for children and adolescents would be lower
and would be proportional to their weight or body surface area. Table 87 describes resource use for
maintenance therapy.
Tacrolimus, SRL, EVL and CSA are titrated to achieve target whole blood trough concentrations, as
numerous factors can affect their absorption and removal from the bloodstream and therapeutic windows
can be narrow.
TABLE 87 Resource use for maintenance therapy
Parameter Value Source
TAC-IR
With AZA Those < 18 years
Time Dosage (mg/m2/day)
0–6 months 7.57
6–12 months 5.61
Thereafter 4.89
Trompeter et al.77
Those > 18 years
Time Dosage (mg/kg/day)
12–36 months 0.09
Thereafter 0.08
Margreiter110
With MMF Those < 13 years: 0.18 mg/kg/day Grenda et al.24 (assumed no higher
than AZA)
Those 13–17 years: 0.13 mg/kg/day
Those > 18 years: 0.08 mg/kg/day
With SRL Time Dosage (mg/kg/day)
0–1 month 0.175
1–3 months 0.110
3–6 months 0.104
6–12 months 0.080
12+ months 0.070
Starting dose from Gonwa et al.193
(0–1 month); assumed no higher
than with MMF (1–6 months);
Gonwa et al.,193 Anil Kumar et al.236
(6+ months)
TAC-PR
With MMF As for TAC-IR plus 0.015mg/kg/day for 12 months Wlodarczyk et al.,237 Krämer et al.,139
Tsuchiya et al.196 and Oh et al.238
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TABLE 87 Resource use for maintenance therapy (continued )
Parameter Value Source
CSA
With AZA < 18 years
Time Dosage (mg/m2/day)
0–6 months 251
6–12 months 192
Thereafter 180
Trompeter et al.77
> 18 years
Time Dosage (mg/kg/day)
12–36 months 2.93
Thereafter 2.84
Margreiter110
With MMF or MPS < 18 years (with induction)
Time Dosage (mg/kg/day)
0–3 months 7.80
3–6 months 7.15
6–12 months 6.65
Thereafter 6.20
Offner et al.73
< 18 years (no induction)
Time Dosage (mg/kg/day)
0–3 months 7.67
3–6 months 6.85
6–12 months 6.20
Thereafter 5.90
> 18 years: 2.82mg/kg/day Rowshani et al.239
With EVL Time Dosage (mg/kg/day)
0–12 months 3.9
12+ months 2.1
Vitko et al.208
AZA
With TAC < 18 years: 1.80mg/kg/day Trompeter et al.77
> 18 years: 1.20mg/kg/day Laskow et al.106
With CSA < 18 years: 1.80mg/kg/day (Assumed equal to TAC)
> 18 years: 1.22mg/kg/day Vacher-Coponat et al.240
continued
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TABLE 87 Resource use for maintenance therapy (continued )
Parameter Value Source
MMF
With TAC < 13 years: 0.54 g/m2/day Grenda et al.24
13–17 years: 0.60 g/m2/day
> 18 years: 1.47 g/day Ekberg et al.127
With CSA < 18 years (with induction)
Time Dosage (g/m2/day)
0–3 months 1.06
3–6 months 1.01
6–12 months 0.95
Thereafter 0.93
Offner et al.73
< 18 years (no induction)
Time Dosage (g/m2/day)
0–3 months 1.04
3–6 months 0.93
6–12 months 0.83
Thereafter 0.82
> 18 years: 1.67 g/day Ekberg et al.127
With SRL Time Dosage (g/m2/day)
0–3 months 1.16
3–12 months 1.00
Thereafter 0.85
Ekberg et al.127 (assuming adult
body surface area 1.73m2)
With BEL 1.16 g/m2/day Vincenti et al.198 (assuming adult
body surface area 1.73m2)
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TABLE 87 Resource use for maintenance therapy (continued )
Parameter Value Source
MPS
With CSA Time Dosage (mg/kg/day)
0–3 months 22.8
3–9 months 19.2
9+ months 17.5
Mjörnstedt et al.210 (assuming adult
body weight 63 kg)
SRL
With TAC Time Dosage (mg/kg/day)
0–12 months 0.059
12–60 months 0.044
Thereafter 0.029
Anil Kumar et al.236 (assuming adult
body weight 63 kg)
With MMF Time Dosage (mg/kg/day)
0–3 months 0.082
3–6 months 0.071
6–9 months 0.055
9–12 months 0.051
12–48 months 0.046
48+ months 0.041
Lebranchu et al.200 (assuming adult
body weight 63 kg)
EVL
With CSA Time Dosage (mg/kg/day)
0–3 months 0.047
3–6 months 0.044
6–9 months 0.040
9–12 months 0.041
12–24 months 0.041
24+ months 0.032
Tedesco Silva et al.191 and Lorber
et al.241 (assuming adult body
weight 63 kg)
continued
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Belatacept is administered intravenously according to a prescribed schedule. It was assumed that the
‘less intensive’ regimen from the BENEFIT198 (Belatacept Evaluation of Nephroprotection and Efficacy as
First-line Immunosuppression Trial) and BENEFIT-EXT199 (Belatacept Evaluation of Nephroprotection and Efficacy
as First-line Immunosuppression Trial-Extended criteria donors) studies would be used. We were advised that
vial sharing would most likely not be feasible and, therefore, we assumed full wastage of excess BEL.
Dialysis
Access surgery is required for long-term dialysis. In the case of haemodialysis, the creation of an
arteriovenous fistula is common, which requires time to heal and mature after surgery before use. It was
therefore assumed that all people on haemodialysis would also incur the cost of one temporary tunnelled
central venous catheter.
The mix of haemodialysis and peritoneal dialysis is known to vary over time, with younger people generally
considered better suited to peritoneal dialysis (Table 88). The haemodialysis mix was reflected in incident
and prevalent people on dialysis, but conversion costs (between dialysis modes) were not included.
TABLE 87 Resource use for maintenance therapy (continued )
Parameter Value Source
BEL
Drug acquisition (Round up to nearest 250mg)
Time
Doses per quarter year
10 mg/kg 5 mg/kg
0–3 months 5 0
3–6 months 1 2
Thereafter 0 3.26
Dosing schedule: 10mg/kg on days
1 and 5, weeks 2, 4, 8 and 12, then
5mg/kg every 4 weeks thereafter
Drug administration
(i.v. infusion)
Time Infusions per quarter
0–3 months 5
3–6 months 3
Thereafter 3.26
Prednisolone
With CSA < 18 years
Time Dosage (mg/kg/day)
0–6 months 2.4
Thereafter 0.3
Trompeter et al.77
Without CSA < 18 years
Time Dosage (mg/kg/day)
0–6 months 2.1
Thereafter 0.3
All maintenance
regimens
> 18 years: 16.3mg/day Ekberg et al.127
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Acute rejection
The number of KTRs suffering at least one AR episode was derived as detailed in Acute rejection within
12 months and Based on adult randomised controlled trial evidence.
To account for the fact that some KTRs may experience more than one AR episode, a study112 was
identified that gave both the number of people experiencing at least one AR episode and the total number
of episodes. From this, it was estimated that there would be 1.19 ARs expected per person suffering at
least one AR event.
Grenda et al.75 and Trompeter et al.77 report ARs in the first 6 months according to their response to
treatments as either ‘spontaneously resolving’ (i.e. not requiring changes to treatment), ‘steroid sensitive’
(i.e. resolving after a short course of high-dose CCSs) or ‘steroid resistant’ (i.e. not resolving after a short
course of high-dose CCSs). ARs between 6 and 24 months were not reported by those categories, so it
was assumed that 80% were steroid sensitive and 20% steroid resistant. Table 89 gives the numbers of
ARs in the RCTs in children and adolescents.
Infection prophylaxis
Cytomegalovirus prophylaxis was included for KTRs at high risk of CMV infection (D+/R–; i.e. donor is
seropositive, recipient is seronegative) following the Birmingham Children’s Hospital Renal Unit protocol
(Fiona Gamston, Birmingham Children’s Hospital, 15 July 2014, personal communication). It was assumed
that all high-risk patients would receive valganciclovir (Valcyte®, Roche Products Ltd) at a once-daily dose
calculated using the formula:
Dose (mg)=7× body surface area × eGFR. (10)
Doses are rounded to 450mg or 900mg (whichever is nearest). For example, a KTR with body surface area
of 1.2 m2 and eGFR 40ml/minute/1.73 m2 would have a target dose of 336mg, rounded up to 450mg.
TABLE 88 Proportion of dialysis patients receiving haemodialysis by age group
Age group (years) Proportion receiving haemodialysis (%)
0–1 45.5
2–3 46.4
4–7 55.6
8–11 64.5
12–15 70.5
16–17 62.5
18–24 79.1
25–34 80.4
35–44 84.5
45–54 84.3
55–64 85.2
65–74 85.8
75–84 89.0
85+ 91.5
Source: Reproduced with permission from UK Renal Registry 16th Annual Report (figure 2.7)242 and UK Renal Registry
17th Annual Report (table 4.4).4 The data reported here have been supplied by the UK Renal Registry of the Renal
Association. The interpretation and reporting of these data are the responsibility of the authors and in no way should be
seen as an official policy or interpretation of the UK Renal Registry or the Renal Association.
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According to the Birmingham protocol, prophylaxis is for 3 months, followed by a month at half dose if
quantitative polymerase chain reaction (PCR) at 3 months is negative, followed by discontinuation if
quantitative PCR at 4 months is negative. Relevant data on the proportions having negative PCR at 3 or
4 months were not available and were therefore estimated.
Humar et al.243 report a comparison of 100-day and 200-day CMV prophylaxis in adults (aged ≥ 16 years).
Figure 3 of Humar et al.243 suggests that, at 90 days, approximately 10% of patients have developed CMV
viraemia and in the month after discontinuation (100-day arm), approximately 14% of patients developed
CMV viraemia. It was therefore assumed that 10% would receive 3 months’ prophylaxis plus 2 months’
pre-emptive treatment (at the same dose), 76% of patients would receive 4 months’ planned prophylaxis
while the remaining 14% would receive 4 months’ planned prophylaxis plus 2 months’ pre-emptive
treatment at the full target dose (Table 90).
Half dosage was implemented assuming that alternate day dosing was acceptable, meaning the effective
target daily dose was rounded to 225mg, 450mg or 900mg (whichever is nearest).
Cytomegalovirus prophylaxis was not included for intermediate- or low-risk KTRs (Table 91), except in the
case of intermediate-risk KTRs receiving r-ATG, who were assumed to receive 3 months’ CMV prophylaxis
(based on the Royal and Exeter protocol for adults244).
Pneumocystis jirovecii pneumonia (PJP) and UTI prophylaxis was assumed to be 480mg of co-trimoxazole
(Septrin®, Aspen Pharma Trading Ltd) daily for 3 months.
TABLE 89 Acute rejection and response to treatment in child/adolescent RCTs
Trial Trompeter et al.77 Grenda et al.75 Offner et al.73
Arm
TAC+AZA
(n= 103)
CSA+AZA
(n= 93)
TAC+AZA
(n= 93)
BAS+ TAC+AZA
(n= 99)
BAS+CSA+MMF
(n= 100)
CSA+MMF
(n= 92)
0–6 months 11 19
Spontaneously
resolving
2 0 2 1
Steroid sensitive 45 65 14 15
Steroid resistant 8 26 3 3
6–12 months 4 2 8 4 2 3
12–24 months 7 9
24–36 months 2 6
36–48 months 2 6
TABLE 90 Modelled CMV prophylaxis for high-risk KTRs
Proportion of CMV high-risk patients (%) Time at full dose Time at half dose
10 5 months None
76 3 months 1 month
14 5 months 1 month
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Monitoring
The KTRs receive monitoring on a frequent basis after transplantation, which is gradually tapered for KTRs
with stable grafts.
The following monitoring was included:
l full blood count
l renal profile
l liver function tests
l therapeutic drug monitoring (TAC, CSA, SRL and EVL)
l viral quantitative PCR [CMV, BK virus (BKV), Epstein–Barr virus (EBV)].
In addition, KTRs attend regular outpatient clinics. KTRs with degraded or deteriorating graft function
receive more intensive monitoring to maximise graft survival.
It was assumed that children and adolescents would attend clinics and receive monitoring according to the
Birmingham protocol (Fiona Gamston, Birmingham Children’s Hospital, 15 July 2014, personal
communication), and this was assumed to taper after a number of years to quarterly visits (Table 92).
Kidney transplant recipients at high risk of CMV infection (D+/R–; i.e. donor is seropositive, recipient is
seronegative) were assumed to receive monthly CMV quantitative PCR for 4 months and CMV serology at
3 months, following the Birmingham protocol (Fiona Gamston, Birmingham Children’s Hospital, 15 July
2014, personal communication).
TABLE 91 CMV risk for children and adolescents receiving kidney transplantation212
CMV risk category Proportion of child/adolescent KTRs
High risk (D+/R–) 54/209= 25.8%
Intermediate risk (D±/R+) 84/209= 40.2%
Low risk (D–/R–) 71/209= 34.0%
D–/R–, donor is seronegative, recipient is seronegative; D+/R–, donor is seropositive, recipient is seronegative; D±/R+, donor
is seropositive/seronegative, recipient is seropositive.
TABLE 92 Frequency of attendances at clinic and monitoring
Time Visits per month
Month 1 12
Month 2 8
Month 3 4
Months 4–6 2
Months 7–12 1
Year 2 1 (assumed)
Year 3 2/3 (assumed)
Thereafter 1/3 (assumed)
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According to the Birmingham protocol, all CMV seronegative patients (high risk and low risk) should
receive annual CMV serology until they are seropositive. It was assumed that, on average, this would
require two annual tests for high-risk patients (50.9% of high-risk adult patients in Humar et al.243 were
PCR positive at 12 months) and five annual tests for low-risk patients.
It was also assumed that intermediate-risk patients would receive weekly CMV quantitative PCR for
3 months [based on the Bristol Royal Hospital for Children and the Royal Devon and Exeter protocols244
(Jan Dudley, Bristol Royal Hospital for Children, 25 June 2014, personal communication)] unless they
received induction with r-ATG, in which case they would receive CMV prophylaxis for 3 months.
The BKV quantitative PCR was assumed to be conducted for all children and adolescents at 3, 6 and
12 months (based on the Royal Devon and Exeter protocol244).
The EBV quantitative PCR was assumed to be conducted for children and adolescents at high risk of EBV
infection (Table 93) monthly for months 1–6, then at 9 months and 12 months (based on the Royal Devon
and Exeter protocol244).
Explant surgery
Not all grafts are explanted on failure, with the likelihood of nephrectomy decreasing with time
since transplantation. NHSBT provided data on the probability of nephrectomy as a function of time since
transplantation for the PenTAG assessment report for NICE guidance TA165,18 which we have reproduced
in Table 94 and used to estimate resource use of explant surgery following failure of the initial graft.
For the subsequent graft it was estimated that 5.9% would be explanted on failure by applying the
proportions of grafts explanted for the first graft to the exponential graft survival curve for
subsequent grafts.
TABLE 93 The EBV risk for children and adolescents receiving kidney transplantation245
EBV risk category Proportion of child/adolescent KTRs
High risk (D+/R–) 28/82= 34.1%
Intermediate risk (D±/R+) 48/82= 58.5%
Low risk (D–/R–) 6/82= 7.3%
D–/R–, donor is seronegative, recipient is seronegative; D+/R–, donor is seropositive, recipient is seronegative; D±/R+, donor
is seropositive/seronegative, recipient is seropositive.
TABLE 94 Proportion of failed grafts explanted as a function of time since transplantation
Time since transplantation Proportion of grafts explanted (%)
0–3 months 41
3–12 months 23
12–24 months 9
24+ months 4
Subsequent grafts 5.9
Source: Organ Donation and Transplantation Directorate of NHSBT. Statistics prepared by NHSBT for TA165 (table 33, p.53).18
Contains information licensed under the Non-Commercial Government Licence v1.0.
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Subsequent retransplantation
Based on the NHS Reference Costs 2013 to 2014,58 it was estimated that there would be 1.44 ‘workups
for retransplantation’ for each actual retransplantation (which can include a number of tests for fitness for
transplant surgery, fitness for long-term immunosuppression, immunological assessment and assessment of
risk factors for graft and patient survival) and that living donor costs would be incurred in 34.9% of
retransplantations and deceased donor costs in 65.1%.
Diabetes mellitus medication
It was assumed that KTRs with NODAT would receive three 500-mg metformin tablets daily. Although
this may not be a sophisticated or accurate estimate of the cost of diabetes mellitus medication, it is
considered that the costs of complications incurred in and out of hospital will significantly exceed the cost
of diabetes mellitus medication.
Dyslipidaemia
It was assumed that 60% of people with dyslipidaemia would receive fluvastatin as the evidence base for
this with regards to safety is greatest according to clinical advice. A dosage of 40mg per day was assumed
as this is the starting dose in Riella et al.246
It was assumed that 30% of people would receive pravastatin as the evidence base for safety is smaller.
A dosage of 20mg per day was assumed, again as this is the starting dose in Riella et al.246
It was assumed that 10% of people would receive simvastatin as there have been safety warnings with
respect to CSA. A dosage of 10mg per day was assumed, again as this is the starting dose in Riella et al.246
Medical management for dyslipidaemia was assumed to be one dietetics outpatient attendance per year
and one GP appointment per year.
Post-transplant lymphoproliferative disease
Post-transplant lymphoproliferative disease was not included in the analyses based on adult effectiveness
estimates, but was reported as an outcome in all three paediatric RCTs (Table 95).
Hypomagnesaemia
Trompeter et al.77 reported hypomagnesaemia as an AE occurring significantly more frequently in the TAC
arm than in the CSA arm. Hypomagnesaemia requiring medication occurred within 6 months in 42 out of
103 TAC patients and in 21 out of 93 CSA patients.
Hypomagnesaemia was assumed to last from incidence for the trial duration (4 years).
TABLE 95 Post-transplant lymphoproliferative disease in RCTs in children and adolescents
Trial Trompeter et al.77 Grenda et al.75 Offner et al.73
Arm
TAC+AZA
(n= 103)
CSA+AZA
(n= 93)
TAC+AZA
(n= 93)
BAS+ TAC+AZA
(n= 99)
BAS+CSA+MMF
(n= 100)
CSA+MMF
(n= 92)
PTLD 3 3 2 1 3a 5a
Time to event
(years)
Mean 0.41 Mean 1.09 0–0.5 0.5–1 0–1 0–1
a PTLD/malignancy.
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Hypertension
Hypertension was the most frequent AE reported by Trompeter et al.,77 with 91 out of 103 TAC patients
and 81 out of 93 CSA patients requiring antihypertensive medication within 6 months.
Hypertension was assumed to last from incidence for the trial duration (4 years).
Anaemia
According to Vanrenterghem et al.,214 207 out of 3969 (5.2%) adult KTRs required ESA treatment for
anaemia, with a mean weekly dose of 5832 IU. Therefore, it was assumed that child and adolescent KTRs
would, on average, receive 3967 IU of ESA per quarter-year cycle while they were not dependent
on dialysis.
The NHS Reference Costs 2013 to 201458 indicates that the costs of ESA treatment for anaemia
(and of drug treatments for bone mineral disorders) should be included in Healthcare Resource Group
(HRG) costs. Therefore, it was assumed that additional ESA therapy would not be included for people in
the graft loss state.
Unit costs
The following sources were used to identify unit costs for drug acquisition:
l Commercial Medicines Unit eMIT62
l BNF Volume 68 (January 2015 online update)63
l BNF for Children Volume 68 (January 2015 online update).173
The eMIT national database was the preferred source as it represents the average cost actually paid by
NHS hospitals, including any negotiated discounts.
For procedures, the NHS Reference Costs 2013 to 201458 (inflated to 2014/15 prices) were the preferred
source of unit costs. When unit costs could not be found within the NHS reference costs, a pragmatic
search of England- and UK-wide sources was conducted.
Induction
Drug acquisition costs for induction therapy are given in Table 96.
Maintenance immunosuppression
Although historically the prescribing of maintenance immunosuppression has, in some cases, been
transferred to primary care physicians through shared care arrangements and dispensing in the community,
at present paediatric KTRs are not being transferred out of hospital care and hospital prescribing and
KTRs previously transferred out are being repatriated (Fiona Gamston, Birmingham Children’s Hospital,
10 March 2015, personal communication). A similar process is under way for adult KTRs. As a result, in
this analysis it is assumed that hospital prescribing and dispensing is appropriate and, therefore, eMIT costs
are preferred when available.
TABLE 96 Drug acquisition costs for induction therapy
Agent Pack details Units Unit cost Source
BAS Single 10-mg vial= £758.69 10-mg doses £758.69 BNF 6863
BAS Single 20-mg vial= £842.38 20-mg doses £842.38 BNF 6863
R-ATG Single 25-mg vial= £158.77 mg £6.35 BNF 6863
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For TAC-PR, there is a significant difference in unit price between 5-mg capsules (£1.07 per mg) and
smaller 1-mg and 3-mg capsules (£1.43 per mg). In the absence of data on relative quantities purchased,
it was assumed that virtually all KTRs receiving TAC-PR would receive one 5-mg capsule daily, with some
KTRs also taking one or more lower dose capsules to achieve their target daily dose. The appropriate unit
cost would therefore lie between £1.07 and £1.43 per mg. It was further considered that there may be
scope for negotiated discounts on the more expensive capsules. Therefore, it was assumed that the lower
unit price (£1.07 per mg) would be used in the base-case analyses. Drug acquisition costs for maintenance
therapy are given in Table 97.
Dialysis
Costs of haemodialysis and peritoneal dialysis are broken down in NHS Reference Costs by mode
(haemodialysis, peritoneal dialysis), age (≥ 19 years, ≤ 18 years), location for haemodialysis (hospital,
satellite, home), access method for haemodialysis (haemodialysis catheter, arteriovenous fistula or graft),
complications for haemodialysis (blood-borne virus, no blood-borne virus), specific modality for peritoneal
dialysis (continuous ambulatory, automated, assisted automated) and overall location (at base, away from
base). There are 40 Healthcare Resource Group version 4 (HRG4) codes (and corresponding currencies in
the NHS Reference Costs) for dialysis in total (including four for acute kidney injury).
The costs of haemodialysis and peritoneal dialysis were estimating by dividing the HRG4s currencies by
mode and age, making assumptions about the number of currency units per week and then calculating a
weighted average cost based on activity.
Haemodialysis was assumed to be performed three times weekly unless at home, in which case it was
assumed to be performed 3.23 times per week on average (based on inspection of reported average
number of sessions per week after removing clearly erroneous outliers). Peritoneal dialysis is explicitly
costed per day according to the Reference Costs Guidance247 and, therefore, was assumed to be
performed seven times weekly.
The currencies for acute kidney injury were included but these make up a vanishingly small proportion of
activity and do not have a significant impact on overall cost estimates.
It was estimated for adults (in 2013/14 prices) that haemodialysis would cost £459.59 per week and
peritoneal dialysis £452.57 per week. These costs correspond to £6093 and £6000 per quarter-year cycle,
in 2014/15 prices, for haemodialysis and peritoneal dialysis, respectively.
It was estimated for children and adolescents (in 2013/14 prices) that haemodialysis would cost £1529.53
per week and peritoneal dialysis £793.09 per week. These costs correspond to £20,278 and £10,515 per
quarter-year cycle, in 2014/15 prices, for haemodialysis and peritoneal dialysis, respectively.
Dialysis access surgery Dialysis access costs were estimated per procedure from NHS Reference Costs
2013 to 2014 and inflated to 2014/15 prices (Table 98).
Acute rejection
The only estimates of the cost of treating AR in children and adolescents are:
l Yao et al.:2 £4644 (price year not stated), which appears to be based on an amalgamation of the
company submitted costs for TA85 (i.e. for the adult population).
l Astellas (estimate for TA99):2 ‘around £1000’ (price year not reported).
l Astellas (estimate for current appraisal): £889 [£38.40 for steroid-sensitive AR (80% of cases), £4292
for steroid-resistant AR (20% of cases)] (presumed 2012/13 prices).
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TABLE 97 Drug acquisition costs for maintenance therapy
Agent Pack details Units Unit cost Source
TAC-IR 50 × 1mg= £28.81 mg £0.5201 (based on eMIT market share) CMU eMIT62
100 × 1mg= £55.05
50× 0.5mg= £24.90
50× 5mg= £88.57
TAC-PR 50× 0.5mg= £35.79 mg £1.0677 (based on 50 × 5-mg pack) BNF 6863
50 × 1mg= £71.59
100× 1mg= £143.17
50× 3mg= £214.76
50× 5mg= £266.92
CSA 30× 100mg= £46.15 mg £0.0165 (based on eMIT market share) CMU eMIT62
60 × 10mg= £16.61
30× 25mg= £14.55
30× 50mg= £25.26
MMF 50× 500mg= £9.17 g £0.3774 (based on eMIT market share) CMU eMIT62
100 × 250mg= £10.94
MPS 120× 180mg= £96.72 mg £0.004478 (based on 120 × 180-mg pack) BNF 6863
120 × 360mg= £193.43
AZA 28× 25mg= £1.63 mg £0.001075 (based on eMIT market share) CMU eMIT62
100 × 25mg= £9.43
56× 50mg= £2.53
100× 50mg= £5.03
SRL 30 × 0.5mg= £69.00 mg £2.8830 (based on 30 × 2-mg pack) BNF 6863
30 × 1mg= £86.49
30× 2mg= £172.98
EVL 60 × 0.25mg= £148.50 mg £9.9000 Novartis’ submission
BEL Single 250-mg vial= £354.52 Vial £354.52 BNF 6863
Prednisolone 28 × 1mg= £0.15 mg £0.003286 (based on eMIT market share) CMU eMIT62
30 × 2.5mg= £1.65
100× 2.5mg= £5.33
30× 5mg= £1.61
100× 5mg= £5.41
28× 5mg= £0.39
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It was decided that none of these estimates were appropriate because they were not recent, in the wrong
patient population or omitted important cost components (such as the cost of administration and
hospitalisation for steroid-sensitive AR in the more recent estimate by Astellas). In the absence of any
appropriate costs for children and adolescents, it was decided that the cost estimated by Bristol–Myers
Squibb in its submission to the parallel technology appraisal to update NICE guidance TA85 (kidney
transplantation in adults) would be used, as it was judged the most appropriate cost for the PenTAG
assessment in that technology appraisal. The cost of AR was estimated as £3217 in 2009 Great British
pounds, which was inflated to £3557 in 2014/15 prices.
It is possible that the cost of treating AR could be greater in children and adolescents than in adults
because often hospitalisation costs are greater in children and adolescents. On the other hand, it may
be that reduced drug costs (owing to reduced dosage requirements) counter this. Furthermore, it may be
that some expensive treatments are also deemed to be inappropriate for children and adolescents.
Nevertheless, £3557 is deemed to be an appropriate central estimate for the cost of treating AR in children
and adolescents.
By response to treatment Grenda et al.75 and Trompeter et al.77 report ARs in the first 6 months
according to their response to treatments, as either ‘spontaneously resolving’ (i.e. not requiring changes to
treatment), ‘steroid sensitive’ (i.e. resolving after a short course of high-dose CCSs), or ‘steroid resistant’
(i.e. not resolving after a short course of high-dose CCSs).
We assumed that the cost of spontaneously resolving AR would be £145 (the cost of a clinic visit) and that
the cost of steroid-sensitive AR could be approximated by HRG4 currency LA07P (acute kidney injury
without treatment complication and comorbidity score 0–3),48 as the cost of high-dose CCSs is not
significant (in 2014/15 prices, this is £1274).
We assumed that steroid-resistant AR would be treated by a course of 7 days’ r-ATG infusion at 1.5mg/kg,
plus the cost of steroid-sensitive AR. The total medical management cost for steroid-resistant AR was
estimated to be £3456 and the drug acquisition cost to be £44.46 per kg body weight. This may be an
underestimate of the true cost of AR.
New-onset diabetes mellitus after transplantation
To our knowledge the only estimated costs for NODAT are:
l Astellas/Fujisawa, in their submission for NICE guidance TA99, proposed a one-off cost of £533 for
diabetes mellitus followed by treatment switching (although notably this switching was mostly from
CSA+AZA to TAC+AZA or from TAC+AZA to TAC+MMF).2
l Yao et al.2 did not specifically cost for NODAT, but do include a one-off cost for side effects (including
NODAT) of £200 followed by treatment switching.
l Astellas, in its submission for this appraisal, propose a yearly cost of £17.38 for NODAT, comprising
metformin tablets only.
TABLE 98 Unit costs for dialysis access surgery in 2014/15 prices
Procedure Unit cost (< 19 years) Unit cost (≥ 19 years)
Temporary access for haemodialysis £1747 £823
Long-term access for haemodialysis £1946 £1946
Long-term access for peritoneal dialysis £1101 £1101
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We considered that the costs estimated for NICE guidance TA99 are not appropriate as sources are not
given and the costs are not recent. We also considered that the costs estimated by Astellas for this
appraisal are not appropriate as they do not include any possible complications resulting from NODAT.
We assumed that the costs estimated for NODAT in the adult population could be a reasonable
approximation to costs in children and adolescents. Although these costs would be likely to include certain
costs that are unlikely to be incurred in young patients (particularly cardiovascular complications), there
would also be likely to be increased costs of medical management for children and adolescents with
NODAT and greater costs in the event of any complications requiring hospitalisation. The cost of diabetes
mellitus in adults in the general population was estimated as £2028 per year (£1352 inpatient costs,
£676 non-inpatient costs).248 This was inflated to £2084 per year in 2014/15 prices.
Dyslipidaemia
Statin acquisition costs for the treatment of dyslipidaemia are given in Table 99 and medical management
costs are given in Table 100.
Infection prophylaxis
Drug acquisition costs for infection prophylaxis are given in Table 101. Costs for CMV prophylaxis
(valganciclovir) are clearly much higher than costs for PJP and UTI prophylaxis.
TABLE 101 Drug acquisition costs for infection prophylaxis
Agent Pack details Units Unit cost Source
Co-trimoxazole (Septrin) 100 × 480mg= £15.52 Per 480-mg tablet £0.1552 BNF 6863
Valganciclovir (Valcyte) 60 × 450mg= £1081.46 Per 450-mg tablet £18.02 BNF 6863
TABLE 100 Medical management unit costs for dyslipidaemia
Attendance Source
Unit cost
2013/14 prices 2014/15 prices
Dietetics outpatient NHS Reference Costs 2013 to 2014:58 dietetics
outpatients service (service code 654)
£61.69 £62.70
General practice PSSRU unit costs 2014:234 GP (excluding direct care staff
costs, without qualification costs, per 17.2-minute clinic)
£50.00 £50.82
TABLE 99 Medication (statin) unit costs for dyslipidaemia
Statin Pack details Units Unit cost Source
Fluvastatin 28 × 20mg= £1.59 mg £0.002216 (weighted by eMIT market share) CMU eMIT62
28 × 40mg= £1.79
Pravastatin 28 × 10mg= £4.32 mg £0.002561 (weighted by eMIT market share) CMU eMIT62
28 × 20mg= £1.85
28× 40mg= £0.79
Simvastatin 28 × 10mg= £0.15 mg £0.000339 (weighted by eMIT market share) CMU eMIT62
28 × 20mg= £0.24
28× 40mg= £0.34
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Cytomegalovirus infection treatment
In the parallel HTA to inform the update to NICE guidance TA85,68 Bristol–Myers Squibb submitted a
microcosting study249 in which the cost of CMV infection was estimated to be £2271 in 2009 prices.
This was inflated to £3009 in 2014/15 prices.
Astellas, in its submission for this appraisal, proposes a cost of £221–1151 depending on body weight.
This cost includes drug acquisition [ganciclovir (Cymevene®, Roche Products Ltd)] but does not include any
other costs, including drug administration and other medical management (e.g. hospitalisation costs).
It was decided that the costs derived from adults would be more appropriate because, if anything, the
costs of treating CMV infection could be greater in children and adolescents than in adults.
Post-transplant lymphoproliferative disease
Post-transplant lymphoproliferative disease was assumed to incur £1206 in drug administration (four i.v.
infusions) and £3040/m2 body surface area in drug acquisition [four × 375mg/m2 rituximab (Mabthera®,
Roche Products Ltd), £1.7463/mg].
Hypomagnesaemia
The cost of hypomagnesaemia requiring treatment was estimated to be £290.18 per year (one sachet of
Magnaspartate daily, £0.80 per sachet).173
Hypertension
The annual cost of hypertension requiring medication was estimated to be £120.10 (Table 102), based on
resource use in John and Domingo.250
Anaemia
Costs of ESA therapy were estimated assuming that the ESA with lowest acquisition cost would be used
(following NICE guidance TA323 which relates to cancer-treatment induced anaemia; Table 103). Based on
the BNF list prices epoetin alfa (Binocrit®, Sandoz) is the cheapest ESA, although it is possible that local
pharmacy negotiations may result in reduced costs to the NHS in practice.
Drug administration
All maintenance agents except BEL are administered orally (unless people are unable to take medication
orally) and this was assumed to not incur any cost.
Basiliximab is administered by i.v. infusion or injection and r-ATG is administered by i.v. infusion. BAS is
administered on the day of transplantation and 4 days after transplantation. It is very likely that KTRs will
still be inpatients for the latter administration. R-ATG is administered by i.v. infusion for 3–9 days. It is likely
that KTRs will be inpatients for all of these infusions (a typical adult patient is estimated to require 10 days’
inpatient stay251 and children and adolescents are unlikely to require significantly shorter duration).
TABLE 102 Costs of hypertension
Item Resource use Unit cost Item cost (per year)
Dietetics clinic 1 per year £62.70 £62.70
Amlodipine 5mg per day £0.0071 per mg £13.04
Bendroflumethiazide 1 tablet per day £0.0344 per 2.5-mg tablet £12.56
Captopril 25mg per day £0.0035 per mg £31.81
Total £120.10
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Belatacept is administered by i.v. infusion in an outpatient setting after the KTR is discharged from
hospital. It is possible that there would be some efficiency savings by combining administration
attendances with regular attendances for monitoring and clinics in early months but, thereafter,
administrations are likely to be more frequent than other visits.
The NHS reference costs do not estimate a cost of i.v. infusion for inpatients as it is assumed to be a part
of standard care and costs assigned to procedures taking precedence (e.g. kidney transplant). Nevertheless
it was considered important to estimate the cost of administration separately for induction therapies to
enable fair comparison against no induction and potential future comparisons against other induction with
alternative modes of administration.
We believe that the most appropriate HRG4 currencies for i.v. administration of BAS, r-ATG and BEL are
SB12Z (deliver simple parenteral chemotherapy at first attendance) and SB15Z (deliver subsequent
elements of a chemotherapy cycle), which when inflated to 2014/15 prices have unit costs of £228.95 and
£325.59, respectively.
Kidney transplant recipient follow-up
The unit cost of follow-up clinics was estimated from outpatient attendance costs in the nephrology
service, using a weighted average of the different types of attendance (with weights based on national
activity). When inflated to 2014/15 prices, the unit cost of a follow-up clinic was estimated to be £145.27
(Table 104). First face-to-face attendances were included as well as follow-up clinics on the basis that some
people receive follow-up at a different centre to where they received their transplant and the relative
weight of these clinics in calculating the average is small.
Monitoring
The unit cost of viral quantitative PCR was assumed to be the same for CMV, EBV and BKV. The most
appropriate recent cost estimate that could be found was from University College London Hospitals
provider-to-provider service 2013/14 tariff.252 This is a recent cost from an NHS provider. The tariffs are
likely to be slightly higher than the costs of in-house laboratory tests but this was assumed to be a small
effect and it was also considered that some centres might not have in-house quantitative PCR facilities.
The tariff for CMV quantitative PCR was £46 in 2013/14 prices and this was inflated to £46.75 in 2014/15
prices for use in the model. The cost of CMV serology was estimated from the same source which, when
inflated to 2014/15 prices, is £18.29.
The unit costs of therapeutic drug monitoring were estimated from the Department of Biochemistry and
Immunology, University Hospital of Wales, therapeutic drug monitoring test repertoire. CSA, TAC and SRL
therapeutic drug monitoring all incurred charges of £26.28, which was inflated to £26.71 in 2014/15 prices
for use in the model. The cost of therapeutic drug monitoring was assumed to be the same as that for SRL.
TABLE 103 Drug acquisition costs for anaemia
Agent Pack details Units Unit cost Source
Epoetin alfa (Binocrit) 1000 IU= £4.33 Per 1000 IU £4.33 (based on 1000-IU prefilled syringe) BNF 6863
2000 IU= £8.65
3000 IU= £12.98
4000 IU= £17.31
5000 IU= £21.64
6000 IU= £25.96
8000 IU= £40.73
10,000 IU= £43.27
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Other tests (full blood count, renal profile and liver function tests) were estimated based on the costing
template produced by NHS Kidney Care to assist in the costing of renal transplantation,251 as shown in
Table 105.
Explant surgery
The cost of explant surgery was estimated using NHS Reference Costs 2013 to 2014. The appropriate
HRG4 currencies were identified using the 2013/14 Reference Cost Grouper Code to Group workbook,253
by mapping from NHS Classification of Interventions and Procedures (OPCS-4) code M026 (excision of
rejected transplanted kidney) to groups LB61, LB62 and LB63.
The average cost (weighted by activity) for adults (from HRGs LB61 and LB62) was £4886 in 2013/14
prices (£4966 in 2014/15 prices). The average cost (weighted by activity) for children and adolescents
(from HRG LB63) was £4751 in 2013/14 prices (£4829 in 2014/15 prices).
Subsequent transplant
Living donor costs fall under three HRG4 currencies:
1. LA10Z: live donor kidney screening
2. LA11Z: kidney pre-transplantation workup of live donor
3. LB46Z: live donation of kidney.
The total living donor costs per live kidney donation were calculated by dividing the total cost for each
currency by the activity for actual live donation, resulting in a combined cost of £8770.60 per live kidney
donation in 2013/14 prices (Table 106).
TABLE 104 Unit costs of follow-up clinics
Type of attendance Number of attendances
National average unit
cost (2013/14 prices)
Consultant led Non-admitted
face to face
First 85,206 £185.95
Follow-up 652,678 £146.59
Non-admitted
non-face to face
First 1124 £143.13
Follow-up 3033 £109.24
Non-consultant led Non-admitted
face to face
First 7770 £140.42
Follow-up 109,174 £94.15
Non-admitted
non-face to face
First 246 £60.38
Follow-up 5810 £42.06
Weighted average £142.93
(In 2014/15 prices) £145.27
TABLE 105 Unit costs for other monitoring tests
Test Unit cost (2008/9 prices) Unit cost (2014/15 prices)
Full blood count £4.57 £5.05
Renal profile £4.11 £4.54
Liver function test £4.20 £4.64
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Deceased donor costs comprise the cost of retrieval, which may be divided into staffing, consumables and
transport. NHSBT performed a service evaluation of the National Organ Retrieval Service and reported
various costs.254 Staffing costs were reported separately for abdominal retrieval teams and these were used
to estimate the staffing cost of retrieval at £6093.49 in 2012/13 prices (Table 107). The average cost of
consumables per retrieval was reported as £1770.30, although it should be noted that this also included
cardiothoracic retrievals. The total cost of transport was reported as £4,098,473.94 and this was divided by
the total number of retrievals (abdominal and cardiothoracic) for a unit cost of £2005.12 per retrieval.
The total cost of retrieval was therefore estimated to be £9869 in 2012/13 prices, which was inflated to
£10,142 in 2014/15 prices for the model. The average cost of retransplantation was estimated as £20,576
(Table 108) and Table 109 gives a summary of all costs relating to subsequent retransplantation.
Summary of model parameters
See Appendix 7 for base-case values and PSA distributions for the parameters in the model.
Model verification
The decision model was tested by an independent academic decision modeller (AS). Extreme value testing
and other black box testing techniques were applied to ensure the model performed as expected.185
TABLE 106 Reference costs informing the unit cost of live kidney donation
HRG4 currency Frequency Unit cost Total cost
LA10Z: live kidney donor screening 801 £659.61 £528,351
LA11Z: kidney pre-transplantation workup of live donor 1524 £477.95 £728,398
LB46Z: live donation of kidney 805 £7209.43 £5803,587
Total cost £7060,337
(Per live donation of kidney) £8770.60
TABLE 107 Abdominal retrieval team staffing costs
Abdominal retrieval team Number of retrievals
Average staffing
cost per retrieval
University Hospitals Birmingham NHS Foundation Trust 215 £4440.56
Cambridge University Hospitals NHS Foundation Trust 245 £4082.34
University Hospital of Wales 72 £5979.36
King’s College Hospital NHS Foundation Trust 246 £2865.03
Leeds Teaching Hospitals NHS Trust/Central Manchester and
Manchester Children’s Foundation Hospitals NHS Trust
251 £8645.29
Newcastle upon Tyne NHS Foundation Trust 179 £5158.09
Oxford Radcliffe Hospitals NHS Trust 126 £6912.76
Royal Free Hampstead NHS Trust 122 £10,800.90
Royal Infirmary of Edinburgh (SORT) 117 £10,366.39
Average £6093.49
SORT, Scottish Organ Retrieval Team.
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Results
Summary cost-effectiveness results are presented in the following form throughout, with regimens sorted
in order of ascending effectiveness (total discounted QALYs):
l total costs
l incremental costs versus previous regimen
l total QALYs
l incremental QALYs versus previous regimen
l ICER (vs. the previous regimen on the cost-effectiveness frontier unless the regimen is dominated or
extended dominated)
l incremental net health benefit at £20,000 and £30,000 per QALY versus the referent regimen
(the regimen on the cost-effectiveness frontier with the lowest total QALYs)
l for probabilistic cost-effectiveness results the following is also presented:
¢ the probability that each regimen is cost-effective (i.e. gives the greatest net health benefit of all
regimens being compared) at £20,000 and £30,000 per QALY
TABLE 109 Reference costs informing the unit cost of transplant surgery
HRG4 currency Activity Unit cost Total cost
LA01A: kidney transplant, 19 years and over, from cadaver
non-heart-beating donor
553 £13,603.01 £7,522,463
LA02A: kidney transplant, 19 years and over, from cadaver
heart-beating donor
991 £15,520.53 £15,380,850
LA03A: kidney transplant, 19 years and over, from live donor 826 £17,526.91 £14,477,231
Average (adults) £15,772.38
LA01B: kidney transplant, 18 years and under, from cadaver
non-heart-beating donor
11 £27,496.72 £302,464
LA02B: kidney transplant, 18 years and under, from cadaver
heart-beating donor
47 £18,502.00 £869,594
LA03B: kidney transplant, 18 years and under, from live donor 55 £20,964.49 £1,153,047
Average (children and adolescents) £20,576.15
TABLE 108 Unit costs for subsequent transplants
Procedure HRG4 currency
Unit cost
2013/14 prices 2014/15 prices
Recipient workup LA12A: Kidney Pre-Transplantation
Workup of Recipient, 19 years and over
Adults: £835.06 Adults: £848.72
LA12B: Kidney Pre-Transplantation
Workup of Recipient, 18 years and under
Children and adolescents:
£496.61
Children and adolescents:
£504.73
Living donor costs See Table 106 £8,770.60 £8,914.05
Deceased donor
costs
See Unit costs, Subsequent transplant £9,868.92 £10,142.05
Transplant surgery See Table 108 Adults: £15,772.38
Children and adolescents:
£20,576.15
Adults: £16,030.35
Children and adolescents:
£20,912.68
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Based on child/adolescent randomised controlled trials
Trompeter et al.77
In the deterministic analysis based on Trompeter et al.77 we found that TAC-IR dominated CSA whether
restricting attention to the reported duration of the trial (4 years) or additionally extrapolating to a
maximum time horizon of 50 years using the Markov decision model (Table 110).
During the trial period, costs were predicted to be lower in the TAC arm owing to significant savings in
dialysis costs (£5897 savings) as well as in the costs of immunosuppression and AR (£638 and £1508
savings, respectively), offset in part by increased costs of AEs (£225 greater). Table 111 gives
further details.
Costs were also predicted to be lower in the TAC arm during the extrapolation period, mainly owing to
savings in dialysis (Table 112).
Discounted QALYs were predicted to be greater in the TAC arm in both the trial duration and
extrapolation periods, due, in part, to extended life expectancy (3.92 and 39.51 years with 4- and 50-year
time horizons, respectively, vs. 3.85 and 38.68 years for CSA). Increased graft survival also contributed to
QALY gains for TAC versus CSA.
TABLE 110 Cost-effectiveness results based on Trompeter et al.77 (deterministic analysis)
Regimen TAC+AZA CSA+AZA
Trial duration (4 years)
Discounted costs £17,731 £25,550
Discounted QALYs 3.3290 3.2530
ICER (cost/QALY) Dominant –
INHB at £20,000/QALY 0.4669 –
INHB at £30,000/QALY 0.3366 –
Extrapolation (46 years)
Discounted costs £159,214 £195,939
Discounted QALYs 13.3895 12.9169
Combined (50 years)
Discounted costs £176,946 £221,489
Discounted QALYs 16.7185 16.1698
ICER (cost/QALY) Dominant –
INHB at £20,000/QALY 2.7758 –
INHB at £30,000/QALY 2.0334 –
INHB, Incremental Net Health Benefit.
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Probabilistic analysis
When the average costs and QALYs from the probabilistic analysis are considered, as in the deterministic
analysis TAC-IR is dominant over CSA (Table 113). Costs are predicted to be lower with TAC-IR, particularly
those of dialysis, and QALYs are predicted to be greater.
As shown in the scatter cloud (Figure 27), the vast majority of probabilistic simulations predict that TAC-IR
is cost saving when compared with CSA, and a significant number also predict that TAC-IR results in
greater QALYs. TAC-IR is predicted to be cost-effective at £20,000 per QALY in 100.0% of simulations and
at £30,000 per QALY in 100.0% of simulations (Figure 28).
Scenario analyses
Below average weight for KTRs Assuming that body weight in the extrapolation period follows the
ninth centile for age (rather than the median) results in marginally reduced costs of maintenance
immunosuppression in both arms.
Immediate-release tacrolimus remains dominant over CSA. The incremental net health benefit for TAC-IR
versus CSA is marginally increased at £20,000 and £30,000 per QALY (2.7773 and 2.0344, respectively).
TABLE 111 Predicted costs during trial duration of Trompeter et al.77 (deterministic analysis)
Regimen TAC+AZA CSA+AZA
Undiscounted costs
Immunosuppression £5965 £6652
AR £1232 £2756
AEs £1158 £921
Dialysis £10,710 £17,167
Total £19,065 £27,496
Discounted costs
Immunosuppression £5650 £6288
AR £1219 £2728
AEs £1082 £857
TABLE 112 Extrapolated discounted costs following Trompeter et al.77 (deterministic analysis)
Regimen TAC+AZA CSA+AZA
Maintenance immunosuppression (initial graft) £8277 £5914
Monitoring (initial graft) £5145 £3096
Dialysis £105,979 £136,719
Retransplantation £14,703 £18,717
Maintenance immunosuppression (subsequent grafts) £8684 £11,220
Monitoring (subsequent grafts) £13,122 £16,973
Other costs £3304 £3299
Total £159,214 £195,939
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TABLE 113 Cost-effectiveness results based on Trompeter et al.77 (probabilistic analysis)
Regimen TAC+AZA CSA+AZA
Trial duration (4 years)
Discounted costs £17,979 £25,749
Discounted QALYs 3.3267 3.2512
ICER (cost/QALY) Dominant –
INHB at £20,000/QALY 0.4640 –
INHB at £30,000/QALY 0.3345 –
Extrapolation (46 years)
Discounted costs £156,878 £192,962
Discounted QALYs 13.3755 12.8957
Combined (50 years)
Discounted costs £174,857 £218,711
Discounted QALYs 16.7022 16.1469
ICER (cost/QALY) Dominant –
INHB at £20,000/QALY 2.7480 –
INHB at £30,000/QALY 2.0171 –
INHB, incremental net health benefit.
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FIGURE 27 Probabilistic sensitivity analysis scatter cloud for Trompeter et al.77 (TAC vs. CSA). Note: dashed line
indicates £20,000 per QALY threshold; points to south-east of this line indicate that TAC is cost-effective vs. CSA at
£20,000 per QALY. The black dot indicates mean incremental costs and QALYs.
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Surrogate relationship between AR and graft survival removed When the surrogate relationship
between AR and graft survival is removed (leaving eGFR at 12 months as the dominant determinant of
graft survival), TAC-IR continues to dominate CSA in the deterministic analysis.
Trial duration outcomes are not affected (as the surrogate relationship is only used for extrapolation).
The effect of removing the surrogate relationship is to increase the extrapolated graft survival in both arms,
but more so for the CSA arm. This consequently leads to reduced total costs and increased QALYs in
both arms.
The incremental net health benefit for TAC-IR versus CSA is reduced but remains positive at £20,000 and
£30,000 per QALY (2.6762 and 1.9665, respectively).
Grenda et al.75
In the deterministic analysis based on Grenda et al.,75 we found that induction with BAS was more
effective and less costly than no induction, whether looking at just the trial duration (2 years) or
extrapolating to a 50-year time horizon. BAS dominated no induction with a 2- or 50-year time horizon
(Table 114).
The additional £2481 cost of induction in the BAS arm (and the £269 additional cost of AEs) in the trial
duration are marginally outweighed by savings (£2776 from dialysis and £99 from AR costs), as shown in
Table 115.
Cost savings are also realised in the extrapolation period by reducing future expenditure on dialysis and
subsequent grafts, partially offset by increased cumulative immunosuppression costs for the initial graft
and increased costs associated with NODAT (Table 116).
Basiliximab was predicted to give greater QALYs in the trial duration owing to better graft survival (overall
survival was very similar in both arms). In the extrapolation, BAS was predicted to give greater QALYs and
greater life expectancy.
Probabilistic analysis
When the average costs and QALYs from the probabilistic analysis are considered, as in the deterministic
analysis BAS is dominant over no induction (Table 117).
As shown in the scatter cloud (Figure 29), the majority of probabilistic simulations predict that BAS results
in greater QALYs than no induction and 59% of simulations predicting cost savings with BAS. BAS is
predicted to be cost-effective at £20,000 per QALY in 67.4% of simulations and at £30,000 per QALY in
69.7% of simulations (Figure 30).
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FIGURE 28 Cost-effectiveness acceptability curves for Trompeter et al.77
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TABLE 114 Cost-effectiveness results based on Grenda et al.75 (deterministic analysis)
Regimen TAC+AZA BAS+ TAC+AZA
Trial duration (2 years)
Discounted costs £13,757 £13,631
Discounted QALYs 1.7319 1.7436
ICER (cost/QALY) – Dominant
INHB at £20,000/QALY – 0.0179
INHB at £30,000/QALY – 0.0159
Extrapolation (48 years)
Discounted costs £127,256 £121,684
Discounted QALYs 15.7609 15.9309
Combined (50 years)
Discounted costs £141,012 £135,315
Discounted QALYs 17.4928 17.6745
ICER (cost/QALY) – Dominant
INHB at £20,000/QALY – 0.4665
INHB at £30,000/QALY – 0.3716
INHB, incremental net health benefit.
TABLE 115 Predicted costs during trial duration of Grenda et al.75 (deterministic analysis)
Regimen TAC+AZA BAS+ TAC+AZA
Undiscounted costs
Immunosuppression £2266 £4758
AR £531 £428
AEs £242 £515
Dialysis £11,264 £8361
Total £14,304 £14,063
Discounted costs
Immunosuppression £2220 £4702
AR £525 £426
AEs £240 £508
Dialysis £10,772 £7996
Total £13,757 £13,631
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TABLE 116 Extrapolated discounted costs following Grenda et al.75 (deterministic analysis)
Regimen TAC+AZA BAS+ TAC+AZA
Maintenance immunosuppression (initial graft) £13,334 £14,021
Monitoring (initial graft) £9167 £9630
Dialysis £75,689 £69,730
Retransplantation £10,567 £9799
Maintenance immunosuppression (subsequent grafts) £6121 £5640
Monitoring (subsequent grafts) £9279 £8538
NODAT £424 £1611
Other costs £2676 £2715
Total £127,256 £121,684
TABLE 117 Cost-effectiveness results based on Grenda et al.75 (probabilistic analysis)
Regimen TAC+AZA BAS+ TAC+AZA
Trial duration (2 years)
Discounted costs £13,751 £13,636
Discounted QALYs 1.7302 1.7419
ICER (cost/QALY) – Dominant
INHB at £20,000/QALY – 0.0174
INHB at £30,000/QALY – 0.0155
Extrapolation (48 years)
Discounted costs £129,696 £124,073
Discounted QALYs 15.6259 15.8008
Combined (50 years)
Discounted costs £143,447 £137,708
Discounted QALYs 17.3562 17.5427
ICER (cost/QALY) – Dominant
INHB at £20,000/QALY – 0.4734
INHB at £30,000/QALY – 0.3778
INHB, incremental net health benefit.
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Scenario analyses
Below average weight for KTRs Assuming that body weight follows the ninth centile for age
(as opposed to the median) results in reduced costs of immunosuppression in both arms.
Basiliximab remains dominant over no induction in the deterministic analysis. The incremental net health
benefit for BAS versus no induction increases slightly at £20,000 and £30,000 per QALY (0.4725 and
0.3755, respectively).
Surrogate relationship between AR and graft survival removed Removing the surrogate relationship
between AR and graft survival marginally increases graft survival in both arms, reducing costs and
increasing QALYs.
Basiliximab remains dominant over no induction in the deterministic analysis. The incremental net health
benefit for BAS versus no induction decreases slightly at £20,000 and £30,000 per QALY (0.4446 and
0.3559, respectively).
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FIGURE 29 Probabilistic sensitivity analysis scatter cloud for Grenda et al.75 (BAS vs. no induction). Note: dashed line
indicates £20,000 per QALY threshold; points to south-east of this line indicate that BAS is cost-effective versus no
induction at £20,000 per QALY. The black dot indicates mean incremental costs and QALYs.
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FIGURE 30 Cost-effectiveness acceptability curves for Grenda et al.75
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Offner et al.73
Contrary to analyses based on Grenda et al.,75 analyses based on Offner et al.73 suggest that BAS is more
costly and less effective than no induction, whether with a time horizon of 1 year (trial duration) or
50 years (Table 118).
During the trial duration BAS was predicted to result in lower AR costs (saving of £387) but also increased
costs of immunosuppression, AEs and dialysis (increases of £2203, £19 and £276, respectively), as shown
in Table 119.
When extrapolated beyond the trial duration, BAS was expected to result in greater costs of dialysis and
costs associated with retransplantation (Table 120).
In the trial duration, BAS is predicted to give worse graft survival and overall survival, resulting in fewer
QALYs. When extrapolated to 50 years, BAS is still expected to give fewer QALYs and reduced life
expectancy (40.6 years vs. 41.8 years for no induction).
TABLE 118 Cost-effectiveness results based on Offner et al.73 (deterministic analysis)
Regimen BAS+CSA+MMF CSA+MMF
Trial duration (2 years)
Discounted costs £5408 £3297
Discounted QALYs 0.8839 0.8992
ICER (cost/QALY) Dominated –
INHB at £20,000/QALY –0.1208 –
INHB at £30,000/QALY –0.0857 –
Extrapolation (48 years)
Discounted costs £129,804 £123,387
Discounted QALYs 16.9461 17.4765
Combined (50 years)
Discounted costs £135,212 £126,684
Discounted QALYs 17.8300 18.3757
ICER (cost/QALY) Dominated –
INHB at £20,000/QALY –0.9721 –
INHB at £30,000/QALY –0.8299 –
INHB, incremental net health benefit.
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Probabilistic analysis
Results from the probabilistic analysis are consistent with the deterministic analysis; BAS is still expected to
be dominated by no induction (Table 121).
As shown in the scatter cloud (Figure 31), BAS is predicted to result in QALY loss in a significant majority
of simulations; it is also predicted to increase costs in the majority of simulations. BAS is predicted to be
cost-effective in 10.3% and 7.4% of simulations at £20,000 and £30,000 per QALY, respectively (Figure 32).
Scenario analyses
Below average weight for KTRs Assuming that body weight follows the ninth centile for age
(as opposed to the median) results in reduced costs of immunosuppression in both arms.
Basiliximab remains dominated by no induction in the deterministic analysis. The incremental net health
benefit for BAS versus no induction decreases slightly at £20,000 and £30,000 per QALY (–0.9743 and
–0.8314, respectively).
TABLE 119 Predicted costs during trial duration of Offner et al.73 (deterministic analysis)
Regimen BAS+CSA+MMF CSA+MMF
Undiscounted costs
Immunosuppression £3795 £1591
AR £462 £851
AEs £500 £481
Dialysis £683 £401
Total £5441 £3323
Discounted costs
Immunosuppression £3778 £1575
AR £461 £849
AEs £500 £481
Dialysis £669 £393
Total £5408 £3297
TABLE 120 Extrapolated discounted costs following Offner et al.73 (deterministic analysis)
Regimen BAS+CSA+MMF CSA+MMF
Maintenance immunosuppression (initial graft) £15,715 £16,481
Monitoring (initial graft) £9807 £10,606
Dialysis £73,825 £68,017
Retransplantation £11,706 £10,770
Maintenance immunosuppression (subsequent grafts) £6003 £5522
Monitoring (subsequent grafts) £9933 £9093
Other costs £2815 £2899
Total £129,804 £123,387
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FIGURE 31 Probabilistic sensitivity analysis scatter cloud for Offner et al.73 (BAS vs. no induction). Note: dashed line
indicates £20,000 per QALY threshold; points to south-east of this line indicate that BAS is cost-effective versus no
induction at £20,000 per QALY. The black dot indicates mean incremental costs and QALYs.
TABLE 121 Cost-effectiveness results based on Offner et al.73 (probabilistic analysis)
Regimen BAS+CSA+MMF CSA+MMF
Trial duration (2 years)
Discounted costs £5423 £3301
Discounted QALYs 0.8789 0.8941
ICER (cost/QALY) Dominated –
INHB at £20,000/QALY –0.1212 –
INHB at £30,000/QALY –0.0859 –
Extrapolation (48 years)
Discounted costs £130,442 £124,886
Discounted QALYs 16.8328 17.3400
Combined (50 years)
Discounted costs £135,865 £128,187
Discounted QALYs 17.7117 18.2341
ICER (cost/QALY) Dominated –
INHB at £20,000/QALY –0.9062 –
INHB at £30,000/QALY –0.7783 –
INHB, incremental net health benefit.
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Surrogate relationship between AR and graft survival removed Removing the surrogate relationship
between AR and graft survival marginally decreases graft survival in the BAS arm, increasing costs and
reducing QALYs, while increasing graft survival in the no induction arm.
Basiliximab remains dominated by no induction in the deterministic analysis. The incremental net health
benefit for BAS versus no induction decreases at £20,000 and £30,000 per QALY (–1.1409 and
–0.9474, respectively).
Summary of results from analyses based on child/adolescent randomised
controlled trials
The analysis based on Trompeter et al.77 suggested that TAC-IR would be cost-effective versus CSA at
£20,000 or £30,000 per QALY as it was more effective and cost-saving both in the trial duration and
when extrapolated.
The analyses based on Grenda et al.75 and Offner et al.73 produced contradictory results for the
cost-effectiveness of BAS versus no induction. The analyses based on Grenda et al.75 suggested that BAS
would result in reduced costs and increased QALYs (i.e. BAS was dominant) while the analyses based on
Offner et al.73 suggested that BAS would result in increased costs and decreased QALYs (i.e. BAS was
dominated). These results were robust to scenario analyses.
Using effectiveness estimates from adult studies
Further results for these analyses are given in Appendix 9.
Deterministic results
Induction agents
Basiliximab and r-ATG were both simultaneously compared with no induction with four different
maintenance combinations (CSA+MMF, TAC+MMF, CSA+AZA and TAC+AZA).
Basiliximab was found to be less costly and more effective (and, therefore, dominant) over no induction
and r-ATG in all comparisons (Table 122). R-ATG was also found to be more costly and effective than no
induction (i.e. no induction dominated r-ATG).
The differences in QALYs from r-ATG to no induction and from no induction to BAS are explained by
increased life expectancy overall and by more projected time with functioning graft and less projected time
dependent on dialysis (Table 123). Graft life expectancy for the first graft was greater for BAS than for
r-ATG and no induction. The gains in graft survival for the first graft do not fully translate to gains in
projected time with functioning graft or life expectancy because when a graft is lost later in life there is
less time to achieve retransplantation and the mortality rate while on dialysis is greater.
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FIGURE 32 Cost-effectiveness acceptability curves for Offner et al.73
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TABLE 122 Summary of cost-effectiveness results for induction agents when adult RCTs are used to
estimate effectiveness
Induction
agent
Discounted costs Discounted QALYs
ICER (cost
per QALY)
Incremental net health benefit
Total Incremental Total Incremental £20,000/QALY £30,000/QALY
With CSA +AZA vs. BAS
R-ATG £216,114 – 17.9721 – Dominated –1.0123 –0.7278
No induction £210,097 –£6017 18.0031 +0.0310 Dominated –0.6804 –0.4962
BAS £199,042 –£11,055 18.1308 +0.1277 – – –
With CSA +MMF vs. BAS
R-ATG £209,097 – 18.0702 – Dominated –1.0887 –0.7846
No induction £199,910 –£9188 18.1269 +0.0567 Dominated –0.5726 –0.4217
BAS £190,856 –£9053 18.2468 +0.1200 – – –
With TAC +AZA vs. BAS
R-ATG £183,191 – 18.2468 – Dominated –1.1228 –0.8082
No induction £174,989 –£8202 18.2970 +0.0502 Dominated –0.6625 –0.4846
BAS £164,316 –£10,673 18.4259 +0.1288 – – –
With TAC +MMF vs. BAS
R-ATG £189,637 – 18.1763 – Dominated –1.1560 –0.8317
No induction £179,719 –£9918 18.2398 +0.0635 Dominated –0.5966 –0.4377
BAS £170,182 –£9537 18.3596 +0.1198 – – –
TABLE 123 Projections of expected life-years for induction agents when adult RCTs are used to
estimate effectiveness
Induction agent
Graft life expectancy
(first graft; years)
Life expectancy
(years)
Projected years with
functioning graft
Projected years
receiving dialysis
Total Incremental Total Incremental Total Incremental Total Incremental
With CSA +AZA
R-ATG 14.421 – 43.136 – 33.557 – 9.578 –
No induction 15.098 +0.677 43.175 +0.039 33.784 +0.226 9.391 –0.187
BAS 17.229 +2.131 43.378 +0.203 34.490 +0.706 8.888 –0.503
With CSA +MMF
R-ATG 15.983 – 43.294 – 34.059 – 9.236 –
No induction 17.110 +1.126 43.374 +0.080 34.445 +0.386 8.929 –0.306
BAS 19.171 +2.062 43.566 +0.191 35.159 +0.714 8.407 –0.523
With TAC +AZA
R-ATG 20.068 – 43.582 – 35.474 – 8.109 –
No induction 21.263 +1.194 43.649 +0.067 35.925 +0.451 7.724 –0.385
BAS 23.597 +2.334 43.858 +0.209 36.785 +0.860 7.073 –0.651
With TAC +MMF
R-ATG 18.881 – 43.467 – 34.994 – 8.473 –
No induction 20.304 +1.423 43.553 +0.086 35.502 +0.508 8.051 –0.422
BAS 22.449 +2.145 43.746 +0.193 36.286 +0.784 7.460 –0.591
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Finally, we compared these analyses to the analyses based on Grenda et al.75 and Offner et al.73
(reported in Based on child/adolescent RCTs). The analyses based on Grenda et al.75 suggested that BAS
(with TAC+AZA) was dominant compared with no induction regimen, while the analyses based on Offner
et al.73 suggested that BAS (with CSA+MMF) was dominated by no induction regimen. In summary, the
deterministic results based on adult data were consistent with the analyses based on Grenda et al.75 but
not with the analyses based on Offner et al.73
Maintenance agents
Table 124 shows the summary of cost-effectiveness results for maintenance agents. It shows that TAC-IR is
dominant over CSA, TAC-PR and SRL, but is less effective and less costly than BEL. Because the ICER of BEL
versus TAC-IR is > £500,000 per QALY, only TAC-IR is cost-effective in these comparisons at £20,000 and
£30,000 per QALY. Comparing these results to the results based on Trompeter et al.,77 the regimen of
TAC+AZA (vs. TAC+CSA) was dominant in both analyses (see Tables 110 and 124).
Table 124 also shows that when considering AZA, MMF, MPS, EVL and SRL, the results are less simple. SRL
is dominated by MMF and AZA, but EVL and MPS are both the most effective and most costly treatments
in their comparisons. The ICER for EVL is > £600,000 per QALY and, therefore, EVL is not predicted to be
cost-effective at £20,000 or £30,000 per QALY, while the ICER for MPS is slightly > £50,000 per QALY.
The cost-effectiveness of MMF appears to be dependent on the concomitant treatments: when MMF is
used in combination with CSA it is dominant over AZA (and cost-effective at £20,000 and £30,000 per
QALY), while when it is used in combination with TAC-IR, AZA is dominant (and MMF is therefore not
cost-effective at £20,000 or £30,000 per QALY).
Table 125 gives further details in terms of projected life-years (overall and in certain health states).
TABLE 124 Summary of cost-effectiveness results for maintenance agents when adult RCTs are used to
estimate effectiveness
Maintenance
agent
Discounted costs Discounted QALYs
ICER (cost
per QALY)
Incremental net health benefit
Total Incremental Total Incremental £20,000/QALY £30,000/QALY
With MMF vs. TAC
CSA £199,910 – 18.1269 – Dominated –1.1224 –0.7859
TAC-PR £196,165 –£3744 18.1854 +0.0586 Dominated –0.8767 –0.6026
TAC £179,719 –£16,446 18.2398 +0.0544 – – –
With AZA vs. TAC
CSA £210,097 – 18.0031 – Dominated –2.0494 –1.4642
TAC £174,989 –£35,108 18.2970 +0.2940 – – –
With BAS +MMF vs. TAC
SRL £198,631 – 18.2423 – Dominated –1.5397 –1.0655
CSA £190,856 –£7,775 18.2468 +0.0045 Dominated –1.1464 –0.8019
TAC £170,182 –£20,674 18.3596 +0.1127 – – –
BEL £293,175 +£122,993 18.5901 +0.2306 £533,449 –5.9191 –3.8692
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TABLE 124 Summary of cost-effectiveness results for maintenance agents when adult RCTs are used to
estimate effectiveness (continued )
Maintenance
agent
Discounted costs Discounted QALYs
ICER (cost
per QALY)
Incremental net health benefit
Total Incremental Total Incremental £20,000/QALY £30,000/QALY
With BAS +AZA vs. TAC
CSA £199,042 – 18.1308 – Dominated –2.0314 –1.4526
TAC £164,316 –£34,726 18.4259 +0.2951 – – –
With r-ATG +MMF vs. TAC
CSA £209,097 – 18.0702 – Dominated –1.0791 –0.7548
TAC £189,637 –£19,460 18.1763 +0.1061 – – –
With r-ATG +AZA vs. TAC
CSA £216,114 – 17.9721 – Dominated –1.9209 –1.3722
TAC £183,191 –£32,923 18.2468 +0.2748 – – –
With CSA vs. MMF
AZA £210,097 – 18.0031 – Dominated –0.6332 –0.4634
MMF £199,910 –£10,188 18.1269 +0.1238 – – –
EVL £259,327 +£59,417 18.2209 +0.0940 £632,246 –2.8769 –1.8866
With TAC vs. AZA
SRL £222,300 – 17.9553 – Dominated –2.7073 –1.9187
MMF £179,719 –£42,581 18.2398 +0.2844 Dominated –0.2938 –0.2149
AZA £174,989 –£4730 18.2970 +0.0572 – – –
With BAS +CSA vs. MMF
AZA £199,042 – 18.1308 – Dominated –0.5254 –0.3889
MMF £190,856 –£8186 18.2468 +0.1161 – – –
MPS £198,303 +£7447 18.3907 +0.1438 £51,770 –0.2285 –0.1044
With BAS + TAC vs. AZA
MMF £170,182 – 18.3596 – Dominated –0.3596 –0.2618
AZA £164,316 –£5866 18.4259 +0.0663 – – –
With r-ATG +CSA vs. MMF
AZA £216,114 – 17.9721 – Dominated –0.4490 –0.3321
MMF £209,097 –£7017 18.0702 +0.0982 – – –
With r-ATG + TAC vs. AZA
MMF £189,637 – 18.1763 – Dominated –0.3928 –0.2853
AZA £183,191 –£6446 18.2468 +0.0705 – – –
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TABLE 125 Projections of expected life-years for maintenance agents when adult RCTs are used to
estimate effectiveness
Maintenance
agent
Graft life expectancy
(first graft; years)
Life expectancy
(years)
Projected years with
functioning graft
Projected years
receiving dialysis
Total Incremental Total Incremental Total Incremental Total Incremental
With MMF
CSA 17.110 – 43.374 – 34.445 – 8.929 –
TAC-PR 20.038 +2.929 43.452 +0.077 35.370 +0.925 8.082 –0.848
TAC 20.304 +0.266 43.553 +0.102 35.502 +0.132 8.051 –0.031
With AZA
CSA 15.098 – 43.175 – 33.784 – 9.391 –
TAC 21.263 +6.164 43.649 +0.474 35.925 +2.141 7.724 –1.667
With BAS +MMF
SRL 20.376 – 43.534 – 35.533 – 8.001 –
CSA 19.171 –1.204 43.566 +0.032 35.159 –0.374 8.407 +0.406
TAC 22.449 +3.277 43.746 +0.180 36.286 +1.127 7.460 –0.947
BEL 24.625 +2.176 44.125 +0.379 37.236 +0.950 6.889 –0.571
With BAS +AZA
CSA 17.229 – 43.378 – 34.490 – 8.888 –
TAC 23.597 +6.367 43.858 +0.480 36.785 +2.295 7.073 –1.815
With r-ATG +MMF
CSA 15.983 – 43.294 – 34.059 – 9.236 –
TAC 18.881 +2.898 43.467 +0.173 34.994 +0.935 8.473 –0.763
With r-ATG +AZA
CSA 14.421 – 43.136 – 33.557 – 9.578 –
TAC 20.068 +5.647 43.582 +0.447 35.474 +1.916 8.109 –1.470
With CSA
AZA 15.098 – 43.175 – 33.784 – 9.391 –
MMF 17.110 +2.011 43.374 +0.200 34.445 +0.661 8.929 –0.462
EVL 19.183 +2.074 43.499 +0.124 35.118 +0.673 8.380 –0.549
With TAC
SRL 15.862 – 43.139 – 33.979 – 9.160 –
MMF 20.304 +4.442 43.553 +0.415 35.502 +1.524 8.051 –1.109
AZA 21.263 +0.959 43.649 +0.096 35.925 +0.423 7.724 –0.327
With BAS +CSA
AZA 17.229 – 43.378 – 34.490 – 8.888 –
MMF 19.171 +1.942 43.566 +0.188 35.159 +0.669 8.407 –0.481
MPS 21.364 +2.193 43.810 +0.244 35.983 +0.824 7.827 –0.579
With BAS + TAC
MMF 22.449 – 43.746 – 36.286 – 7.460 –
AZA 23.597 +1.148 43.858 +0.111 36.785 +0.498 7.073 –0.387
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Immediate-release tacrolimus Immediate-release tacrolimus was compared with CSA (six comparisons),
TAC-PR (one comparison), SRL (one comparison) and BEL (one comparison).
Immediate-release tacrolimus was found to be less costly and more effective than all comparators except
BEL in all comparisons. BEL was predicted to be more costly and more effective than TAC-IR with an ICER
of > £500,000 per QALY.
As demonstrated in Table 125, TAC-IR is predicted to result in prolonged survival of the initial graft by
3.2–6.4 years compared with CSA, as well as to prolong overall survival by 0.2–0.5 years. TAC-IR is
predicted to give greater graft and overall survival than CSA, TAC-PR and SRL, but reduced graft and
overall survival than BEL.
Prolonged-release tacrolimus Prolonged-release tacrolimus was compared with CSA and TAC-IR, in
combination with MMF and CCSs.
Prolonged-release tacrolimus was predicted to be less costly and more effective than CSA but was also
predicted to be more costly and less effective than TAC-IR and was therefore dominated and not
cost-effective at any cost-effectiveness threshold.
Belatacept BEL was compared with CSA, TAC-IR and SRL, in combination with BAS induction, MMF
and CCSs.
Belatacept was predicted to be more costly and more effective than all comparators. As CSA and SRL were
predicted to be dominated by TAC-IR, the relevant comparator for BEL is TAC-IR. The ICER of BEL was
predicted to be > £500,000 per QALY.
Mycophenolate mofetil Mycophenolate mofetil was compared with AZA (six comparisons), MPS
(one comparison), SRL (one comparison) and EVL (one comparison).
When used in combination with CSA (three comparisons), MMF was predicted to be less costly and more
effective than AZA. However, when used in combination with TAC-IR (three comparisons), MMF was
predicted to be more costly and less effective than AZA. To summarise, MMF was dominant when used in
combination with CSA but was dominated when used in combination with TAC-IR.
When compared with EVL in combination with CSA and CCSs, MMF was predicted to be less costly and
less effective, with the ICER of EVL predicted to be > £600,000 per QALY.
TABLE 125 Projections of expected life-years for maintenance agents when adult RCTs are used to
estimate effectiveness (continued )
Maintenance
agent
Graft life expectancy
(first graft; years)
Life expectancy
(years)
Projected years with
functioning graft
Projected years
receiving dialysis
Total Incremental Total Incremental Total Incremental Total Incremental
With r-ATG +CSA
AZA 14.421 – 43.136 – 33.557 – 9.578 –
MMF 15.983 +1.562 43.294 +0.159 34.059 +0.501 9.236 –0.343
With r-ATG + TAC
MMF 18.881 – 43.467 – 34.994 – 8.473 –
AZA 20.068 +1.187 43.582 +0.115 35.474 +0.480 8.109 –0.365
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When compared with SRL in combination with TAC and CCSs, MMF was predicted to be less costly and
more effective than SRL, but was itself dominated by AZA in this comparison.
When compared with MPS in combination with BAS induction, CSA and CCSs, MMF was predicted to be
less costly and less effective, with the ICER of MPS predicted to be > £50,000 per QALY.
At a cost-effectiveness threshold between £20,000 and £30,000 per QALY, MMF is predicted to be
cost-effective in regimens containing CSA but not in regimens containing TAC-IR.
Mycophenolate sodium Mycophenolate sodium was compared with AZA and MMF in combination with
BAS induction, CSA and CCSs. It was found to dominate AZA and was predicted to be more costly and
more effective than MMF with an ICER of > £50,000 per QALY.
Sirolimus Sirolimus was compared with CSA, TAC-IR and BEL, in combination with BAS induction,
MMF and CCSs, and was also compared with AZA and MMF, in combination with TAC-IR and CCSs.
When compared with CSA, TAC-IR and BEL, SRL was predicted to be dominated by CSA and TAC-IR.
When compared with AZA and MMF, SRL was predicted to be dominated by AZA and MMF.
Everolimus Everolimus was compared with AZA and MMF in combination with CSA and CCSs. EVL was
predicted to be more costly and more effective than AZA and mycophenolate, with the appropriate ICER
of EVL (vs. MMF) predicted to be > £600,000 per QALY.
Regimens
When all 18 regimens were simultaneously compared, all regimens were predicted to be dominated by
BAS+ TAC+AZA, except for BAS+ BEL+MMF, which was predicted to have an ICER of > £700,000 per
QALY (Table 126).
Summary
At cost-effectiveness thresholds between £20,000 and £30,000 per QALY, BAS was predicted to be
cost-effective when compared with no induction and to r-ATG.
At cost-effectiveness thresholds between £20,000 and £30,000 per QALY, TAC-IR was predicted to be
cost-effective when compared with CSA, TAC-PR, SRL and BEL.
At cost-effectiveness thresholds between £20,000 and £30,000 per QALY, AZA was predicted to be
cost-effective (vs. MMF and SRL) when used in combination with TAC while MMF was predicted to
be cost-effective (vs. AZA, MPS and EVL) when used in combination with CSA.
At cost-effectiveness thresholds between £20,000 and £30,000 per QALY, the only regimen predicted to
be cost-effective when compared with all other regimens was BAS+ TAC+AZA, which dominated all
other regimens except BAS+ BEL+MMF (which was more costly and more effective with an ICER of
> £700,000 per QALY).
TABLE 126 Summary cost-effectiveness results of regimens not dominated
Regimen
Discounted
total costs
Discounted
total QALYs
ICER
(cost per QALY)
INHB at
£20,000/QALY
INHB at
£30,000/QALY
BAS+ TAC+AZA £164,316 18.4259 – – –
BAS+ BEL+MMF £293,175 18.5901 £784,515 –6.2787 –4.1310
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Probabilistic results
Probabilistic results were obtained after running 10,000 iterations. As demonstrated in Figure 33 (which
compares the discounted costs for each regimen) there is good agreement between deterministic and
probabilistic total discounted costs, with no significant non-linearities observed. Figure 34 suggests that
total discounted QALYs overall are slightly lower when estimated in probabilistic analyses. Two regimens
appear to have dropped more QALYs than the others in the probabilistic analyses: TAC-PR+MMF
and BAS+ TAC+MMF.
Induction agents
Summary cost-effectiveness results are shown in Table 127. In all four comparisons BAS is expected to
dominate no induction, which is in turn expected to dominate r-ATG. The same pattern was observed in
deterministic analyses.
There is limited uncertainty predicted in the cost-effectiveness results as a result of parameter uncertainty.
The probability of BAS being cost-effective at £20,000–30,000 per QALY is predicted to range from 91.4%
to 91.9%. It is predicted that it is possible (though much less likely) that r-ATG could be cost-effective at
£20,000–30,000 per QALY. It is predicted to be very unlikely that no induction could be cost-effective.
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Maintenance agents
Table 128 shows the summary cost-effectiveness results for maintenance agents in the probabilistic analysis.
As in the deterministic analysis, it is predicted that TAC-IR dominates CSA (as well as TAC-PR and SRL),
but is less costly and less effective than BEL (ICER £530,421 per QALY).
In addition, matching the results of the deterministic analysis it is again predicted that MMF is
cost-effective when used in combination with CSA, but not when used in combination with TAC-IR.
Mycophenolate sodium is still not predicted to be cost-effective and, in fact, its estimated ICER is £130,080
per QALY in the probabilistic analysis, compared with £51,770 per QALY in the deterministic analysis.
Sirolimus is still not predicted to be cost-effective. As in the deterministic analyses, SRL is dominated by
CSA and TAC-IR when used in combination with BAS and MMF, and is dominated by MMF and AZA
when used in combination with TAC-IR.
Everolimus is still not predicted to be cost-effective. It is predicted to be more expensive and more effective
than MMF and AZA when in combination with CSA with an ICER > £900,000 per QALY (compared with
an ICER of > £600,000 per QALY in the deterministic analysis).
Cost-effectiveness acceptability curves
Cost-effectiveness acceptability curves show, for each regimen, the probability that regimen is
cost-effective at various thresholds. In this context, the probability of a regimen being cost-effective is the
proportion of PSA iterations in which the regimen gives the greatest net health benefit.
No crossovers are observed in the cost-effectiveness acceptability curves and it was verified that in all cases
the regimen with the greatest probability of being cost-effective at each threshold also gave the greatest
expected net health benefit.
Induction agents All treatment combinations with BAS induction were predicted to be cost-effective at
£20,000 per QALY in at least 91.4% of the simulations and at £30,000 per QALY in at least 91.4% of
simulations (Figures 35–38).
Maintenance agents All treatment combinations with TAC were predicted to be cost-effective at
£20,000 per QALY in over 99% of the simulations and at £30,000 per QALY in over 98% of simulations
(Figures 39–44).
Mycophenolate mofetil (in combination with CSA and no induction) was predicted to be cost-effective in
99.9% of the simulations at £20,000 and £30,000 per QALY (Figure 45).
Azathioprine (in combination with TAC and no induction) was predicted to be cost-effective at £20,000
per QALY in 74.1% of the simulations and at £30,000 per QALY in 74.9% of simulations (Figure 46).
Mycophenolate mofetil (in combination with BAS and CSA) was predicted to be cost-effective at £20,000
per QALY in 74.0% of the simulations and at £30,000 per QALY in 69.8% of simulations (Figure 47).
Azathioprine (in combination with BAS and TAC) was predicted to be cost-effective at £20,000 per QALY
in 79.6% of the simulations and at £30,000 per QALY in 80.1% of simulations (Figure 48).
Azathioprine (in combination with r-ATG and CSA) was predicted to be cost-effective at £20,000 per
QALY in 99.6% of the simulations and at £30,000 per QALY in 99.7% of simulations (Figure 49).
Azathioprine (in combination with r-ATG and TAC) was predicted to be cost-effective at £20,000 per
QALY in 81.7% of the simulations and at £30,000 per QALY in 82.0% of simulations (Figure 50).
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FIGURE 35 Cost-effectiveness acceptability curves for induction agents in combination with CSA and AZA.
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FIGURE 38 Cost-effectiveness acceptability curves for induction agents in combination with TAC-IR and MMF.
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FIGURE 36 Cost-effectiveness acceptability curves for induction agents in combination with CSA and MMF.
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FIGURE 37 Cost-effectiveness acceptability curves for induction agents in combination with TAC-IR and AZA.
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FIGURE 39 Cost-effectiveness acceptability curves for maintenance agents in combination with MMF.
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FIGURE 40 Cost-effectiveness acceptability curves for maintenance agents in combination with AZA.
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FIGURE 41 Cost-effectiveness acceptability curves for maintenance agents in combination with BAS and MMF.
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FIGURE 42 Cost-effectiveness acceptability curves for maintenance agents in combination with BAS and AZA.
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FIGURE 43 Cost-effectiveness acceptability curves for maintenance agents in combination with r-ATG and MMF.
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FIGURE 44 Cost-effectiveness acceptability curves for maintenance agents in combination with r-ATG and AZA.
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FIGURE 46 Cost-effectiveness acceptability curves for maintenance agents in combination with TAC-IR.
0.00
0.25
0.50
0.75
1.00
Pr
o
b
ab
ili
ty
 t
re
at
m
en
t 
is
co
st
-e
ff
ec
ti
ve
0 10 20 30 40 50
Cost-effectiveness threshold (cost per QALY, £000)
AZA
MMF
EVL
FIGURE 45 Cost-effectiveness acceptability curves for maintenance agents in combination with CSA.
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FIGURE 47 Cost-effectiveness acceptability curves for maintenance agents in combination with BAS and CSA.
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FIGURE 48 Cost-effectiveness acceptability curves for maintenance agents in combination with BAS and TAC-IR.
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FIGURE 49 Cost-effectiveness acceptability curves for maintenance agents in combination with r-ATG and CSA.
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FIGURE 50 Cost-effectiveness acceptability curves for maintenance agents in combination with r-ATG and TAC-IR.
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Scenario analyses
Below average weight for kidney transplant recipients
When body weight was assumed to follow the ninth centile for age (rather than the median) the
immunosuppression costs of most arms decreased. QALYs were unaffected.
The incremental net health benefits at £20,000 per QALY did not change sign (i.e. no agents previously
not cost-effective became cost-effective or vice versa). At £30,000 per QALY the incremental net health
benefit for MPS became positive, suggesting that in this scenario MPS is cost-effective at £30,000 per
QALY (but not at £20,000 per QALY). The ICER for MPS in this scenario is £27,006 per QALY.
Surrogate relationship between acute rejection and graft survival removed
When the surrogate relationship between AR and graft survival was removed, the result was increased
graft survival for all regimens except BAS+CSA+MMF, BAS+ TAC+MMF, BAS+ SRL+MMF,
r-ATG+CSA+MMF, r-ATG+ TAC+MMF, and r-ATG+ TAC+AZA (for which graft survival was
decreased). Increased graft survival usually results in reduced overall costs and increased QALYs and this
was observed across regimens as expected.
No incremental net health benefits changed sign at £20,000 or £30,000 per QALY, although the ICER for
MPS dropped to £33,157 per QALY.
Subgroup analyses
The only subgroup analyses which were conducted were based on the age of KTRs. The age at time of
transplantation was varied from 2 years to 17 years.
For most regimens, discontinuities in total discounted costs were observed at age 6 years and age
13 years, which are explained by the HRs for graft survival according to age, taken from Muscheites
et al.,185 in which graft survival was predicted to be worse for children aged 6–12 years at the time of
transplantation than for younger children or older adolescents. Reduced graft survival results in greater
total costs as more recipients lose their grafts earlier and require dialysis.
For all regimens, the total discounted QALYs decreased with increasing age, except at age 13 years, when
discounted QALYs were greater than for age 12 years (due to the changing HR for graft survival indicated
above). The cause of decreasing total discounted QALYs is likely to be greater exposure to higher rates
of DWFG.
The total discounted costs and QALYs are shown for BAS, TAC-IR and AZA in Figure 51. Across the
age range, BAS+ TAC+AZA was the most cost-effective regimen at £20,000 and £30,000 per QALY
(Figures 52 and 53). When the weighted average total discounted costs and QALYs (weighted by number
of KTRs at each age) are calculated, BAS+ TAC+AZA is the cost-effective regimen at £20,000 and
£30,000 per QALY (Table 129).
Summary of results from analyses based on extrapolating effectiveness
estimates from adults
Basiliximab was predicted to be cost-effective at £20,000–30,000 per QALY.
R-ATG and no induction were not predicted to be cost-effective at £20,000–30,000 per QALY compared
with BAS.
Immediate-release tacrolimus was predicted to be cost-effective at £20,000–30,000 per QALY.
Prolonged-release tacrolimus, SRL, BEL and CSA were not predicted to be cost-effective at
£20,000–30,000 per QALY compared with TAC-IR and each other.
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TABLE 129 Net health benefit of regimens when averaged across age range
Regimen
Net health benefit
£20,000 per QALY £30,000 per QALY
CSA+MMF 9.08 12.11
TAC+MMF 9.99 12.74
CSA+AZA 8.32 11.55
TAC+AZA 10.25 12.93
CSA+ EVL 5.60 9.81
TAC+ SRL 7.50 10.99
TAC-PR+MMF 9.10 12.13
BAS+CSA+MMF 9.59 12.49
BAS+ TAC+MMF 10.65 13.23
BAS+CSA+AZA 9.08 12.11
BAS+ TAC+AZA 10.95 13.45
BAS+ SRL+MMF 9.02 12.10
BAS+ BEL+MMF 2.33 7.76
BAS+CSA+MPS 9.23 12.29
r-ATG+CSA+MMF 9.28 12.28
r-ATG+ TAC+MMF 10.34 13.02
r-ATG+CSA+AZA 8.83 11.94
r-ATG+ TAC+AZA 10.69 13.27
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MMF was predicted to be cost-effective at £20,000–30,000 per QALY when used in combination with
CSA, but not when used in combination with TAC-IR.
Azathioprine was predicted to be cost-effective at £20,000–30,000 per QALY when used in combination
with TAC-IR, but not when used in combination with CSA.
Mycophenolate sodium was not predicted to be cost-effective at £20,000–30,000 per QALY compared
with MMF and AZA, but was cost-effective at £30,000 per QALY in a scenario analysis in which body
weight followed the ninth centile rather than median weight for age.
Sirolimus and EVL were not predicted to be cost-effective at £20,000–30,000 per QALY compared with
MMF and AZA.
Summary of results from Peninsula Technology Assessment Group
economic assessment
Basiliximab was predicted to be cost-effective at £20,000–30,000 per QALY compared with no induction
in one analysis based on a RCT in children and adolescents,75 but was not predicted to be cost-effective in
an analysis based on another RCT in children and adolescents.73 BAS was predicted to be cost-effective at
£20,000–30,000 per QALY compared with no induction and r-ATG in analyses based on extrapolating
effectiveness estimates from the adult population.
Rabbit anti-human thymocyte immunoglobulin was not predicted to be cost-effective at £20,000–30,000
compared with BAS in analyses based on extrapolating effectiveness estimates from the adult population.
Immediate-release tacrolimus was predicted to be cost-effective at £20,000–30,000 per QALY compared
with CSA in an analysis based on a RCT in children and adolescents77 and was also predicted to be
cost-effective compared with CSA, TAC-PR, SRL and BEL in analyses based on extrapolating effectiveness
estimates from the adult population.
Mycophenolate mofetil was predicted to be cost-effective at £20,000–30,000 per QALY when used in
combination with CSA in analyses based on extrapolating effectiveness estimates from the adult
population, but was not predicted to be cost-effective when used in combination with TAC-IR.
Prolonged-release tacrolimus, SRL, BEL, MPS and EVL were not predicted to be cost-effective at
£20,000–30,000 per QALY compared with TAC-IR in analyses based on extrapolating effectiveness
estimates from the adult population.
Comparison of the Peninsula Technology Assessment Group,
Astellas and previous Assessment Group’s model-based
analyses
In this section, we compare the model-based analysis of maintenance regimens by the independent
Assessment Group (PenTAG) with relevant analyses in the company submission (from Astellas) and with
the previous analyses2 which informed NICE’s current guidance1 on these technologies. Table 130 shows
which specific immunosuppression agents have been evaluated by the three models.
Table 131 summarises which combination regimens have been compared by the PenTAG and Astellas
models in the child/adolescent kidney transplant populations. The Astellas submission did not provide
cost-effectiveness analysis of induction therapies and only one comparison in the previous technology
assessment for NICE compared induction therapies (BAS vs. no induction).
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Fully explaining the differences between the different model cost-effectiveness outputs is more challenging
than usual, because
l the main assumptions in the Astellas model are different in very many respects, including:
¢ 10-year time horizon versus 50 years in PenTAG analyses
¢ basing effectiveness differences only on BPAR at 12 months post transplant
¢ omission of CSA as a relevant comparator for maintenance therapies
¢ large difference between the assumed utility of living with a functioning graft (0.71) and being on
dialysis (haemodialysis 0.44, peritoneal dialysis 0.53)
¢ drug unit costs were all based on BNF list prices in the Astellas analyses, whereas in the PenTAG
analyses we used prices from the eMIT database, when possible, to reflect nationally available
discounted prices (i.e. for TAC-IR, CSA, AZA, MMF, prednisolone)
¢ drug consumption values for SRL regimens were based on treatment guidelines rather than trial
evidence of actual dosage intensity.
TABLE 130 Immunosuppressive agents evaluated for cost-effectiveness in PenTAG analysis, Astellas’ analysis and
NICE guidance TA99
Agent TA99 PenTAG Astellas
BAS Y Y N
R-ATG N Y N
(No induction) Y Y N
TAC-IR Y Y Y
TAC-PR N Y Y
MMF Y Y N
MPS Y Y N
SRL Y Y Y
EVL N Y Y
BEL N Y Y
(CSA) Y Y N
(AZA) Y Y N
N, no; Y, yes.
Brackets denote comparator regimens rather than interventions.
TABLE 131 Regimens compared by the PenTAG and Astellas models
PenTAG Astellas
TAC (+AZA) vs. CSA (+AZA) (based on one
child/adolescent RCT)
TAC (granules for oral solution) vs. TAC ‘specials’ (liquid preparations) vs.
BEL vs. EVL vs. SRL+ low-dose CSA (=CNI minimisation) vs. SRL+MMF
(=CNI avoidance)
In addition, based on adult RCT evidence
following BAS induction:
TAC (+MMF) vs. CSA (+MMF) vs. SRL
(+MMF) vs. BEL (+MMF)
TAC vs. PR-TAC (based on adult RCT) TAC vs. PR-TAC
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l the Yao et al.2 model assumptions and parameters are not fully described in any one report (and we
were also unable to obtain the model files to assess it). The model used in the Yao et al.2 analysis is:
¢ a child-/adolescent-adapted version of an adult post-transplant immunosuppression model, which
was based on:
¢ a ‘meta-model’ developed for the previous technology assessment for NICE of
immunosuppression following kidney transplantation255 which was, in turn, based on:
¢ the Novartis model submitted to the previous technology appraisal process for these drugs.
Therefore, it was not possible to know with certainty what the input parameters and other main
assumptions were in the Yao et al.2 model. In addition, the incremental cost-effectiveness analyses
produced by the Yao et al.2 model used different discount rates for costs (6% per year) and QALYs (1.5%
per year), according to the NICE methods guidance at that time.256 Like the current Astellas model, it also
had a limited time horizon of 10 years. Without access to the original model, and no reporting of the
model outputs for each comparator or as undiscounted costs or QALYs, it is impossible to adjust for these
differences. The results, which are most different between the Yao et al.2 and PenTAG modelling, are
those that relied on adult RCT data – and for which the PenTAG has substantially updated the
effectiveness estimates from more recent trials (Table 132). In contrast, the cost-effectiveness result for BAS
versus no induction – which does use available child/adolescent RCT evidence in both models – arrives at
the same conclusion as Yao et al.2 did in 2006, that is, that BAS is both more effective and cheaper than
no induction.
TABLE 132 Regimens and main results of the PenTAG and Yao et al. models compared
Compared regimens
Table 56 in Yao et al.2 PenTAGa
Estimateb ICER (£ per QALY)b Estimateb ICER (£ per QALY)b
CAS vs. TAS (=CSA +AZA vs. TAC +AZA)
Incremental costs (£) 13,716 145,540 –35,267 TAS dominant
Incremental QALYs 0.09 +0.2888
CAS vs. CMS (=CSA +AZA vs. CSA +MMF)
Incremental costs (£) 9543 194,559 –10,202 CMS dominant
Incremental QALYs 0.049 +0.1232
CAS vs. BCAS (=CSA +AZA vs. BAS +CSA +AZA)
Incremental costs (£) –1103 BCAS dominant –12,726 BCAS dominant
Incremental QALYs 0.074 +0.1522
CAS vs. DCAS (=CSA +AZA vs. DAC +CSA +AZA)c
Incremental costs (£) –417 DCAS dominant N/A
Incremental QALYs 0.05 N/A
TAS vs. BTAS (= TAC +AZA vs. BAS + TAC +AZA)
Incremental costs (£) –451 BTAS dominant –12,335 BTAS dominant
Incremental QALYs 0.038 +0.1584
B, BAS; D, DAS.
a These PenTAG analyses all based on effectiveness data from RCTs in adults.
b Note that these incremental estimated are presented as in Yao et al.,2 with second regimen cost or QALY minus the first.
c DAC (D) is no longer used; the marketing authorisation has been withdrawn at the request of the manufacturer.
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For reference, three larger tables in Appendix 8 compare the main cost parameters, effectiveness
parameters and main cost and effectiveness results for the three models, where they are known (see
Tables 142–144). These show, for example, that the PenTAG model assumptions tended to include fuller
costing of the administration of the maintenance therapies. In addition, although applied differently in the
models, the utility difference between living with a functioning graft and living on dialysis was greater in
the Astellas model (difference of between ≈0.25 and ≈0.3) than in the PenTAG and Yao et al.2 models
(≈0.2 difference).
Peninsula Technology Assessment Group’s and Astellas’ model-based
analyses compared
Table 133 shows the company’s and the Assessment Group’s analysis of the cost-effectiveness of the two
types of TAC. While the Astellas analysis estimates that TAC-PR dominates TAC-IR (estimating it to be
> £5000 cheaper over 10 years and to generate 0.035 extra discounted QALYs, the PenTAG analysis
produces the opposite result – based on effectiveness evidence from adult RCTs), TAC-PR is dominated by
both TAC-IR and CSA. In the PenTAG analysis, TAC-PR is > £18,000 more costly than TAC-IR and
generates 0.06 fewer discounted QALYs (both over a time horizon of 50 years).
This opposite result in incremental QALYs mostly arises because of the different trial data used within the
two models and the fact that long-term outcomes in the Astellas model are driven entirely by rates of AR.
For informing the effectiveness parameters of the drugs on BPAR, mortality, graft loss and renal function,
the PenTAG analysis uses meta-analysis of two direct head-to-head trials of the two comparators.139,196
None of the pooled ORs is statistically significant and all except the comparison for BPAR favour the
TAC-IR. In contrast, the Astellas review reports using three trials;97,139,152 including two meta-analyses of
BPAR (each including two unspecified trials) which they conclude show the two types of TAC to be of
‘similar efficacy and safety’. However, in their model, these data sources are then used to justify TAC-IR
having a 2 percentage point higher rate of AR than TAC-PR, which then drives differences in long-term
graft survival (and costs). In their modelling, they also factor in greater adherence to treatment with
TAC-PR, which departs from the ITT analysis of the trials.
TABLE 133 PenTAG’s and Astellas’ analysis of TAC-PR compared
Agent
Discounted costs Discounted QALYs
ICERTotal Incremental Total Incremental
PenTAG
CSA £202,424 – 18.1018 – Dominated
TAC-PR £198,433 –£3992 18.1503 +0.0485 Dominated
TAC £182,163 –£16,270 18.2085 +0.0581 –
Astellas
TAC-PR £53,395 – 5.604 –
TAC £58,471 +£5,076 5.569 –0.035 Dominated
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Table 134 shows the company’s and the Assessment Group’s analysis of the cost-effectiveness of TAC,
BEL, SRL and CSA. In particular, it shows the impact of the very different time horizons of the two models
on the accumulated costs and QALYs. The other main differences are that in the Astellas model BEL is the
least effective treatment (but the most effective in the PenTAG model) and only about £20,000 more
expensive than TAC (compared with £153,000 more expensive in the PenTAG model). The omission of
CSA from the Astellas modelling does not invalidate comparisons between the two analyses, because in
the PenTAG model the CSA regime is dominated (less effective and more costly) than TAC – and so
effectively ruled out of further consideration.
Despite these substantial differences in assumptions and included comparators, in both model-based
analyses TAC (immediate release) is found to be the most cost-effective regimen.
TABLE 134 PenTAG’s and Astellas’ analysis of TAC, BEL and SRL
Agent
Discounted costs Discounted QALYs
ICERTotal Incremental Total Incremental
PenTAG (all with BAS +MMF)
SRL £199,145 – 18.2423 – Dominated
CSA £191,679 –£7466 18.2468 +0.0045 Dominated
TAC £170,915 –£20,763 18.3596 +0.0485 –
BEL £324,708 +£153,792 18.5901 +0.0581 £667,031
Astellas vs. TAC
SRL I (CNI minimisation) £52,339 –£6132 5.565 –0.004 £1,576,937
SRL II (CNI avoidance) £61,490 +£3019 5.553 –0.016 Dominated by TAC
TAC £58,471 – 5.569 – –
TAC ‘specials’ £72,945 +£14,474 5.564 –0.001 Higher cost similar QALYs
BEL £75,726 +£17,255 5.551 –0.014 Dominated by TAC
INDEPENDENT ECONOMIC ASSESSMENT
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Chapter 6 Discussion
Statement of principal findings
Aim
The remit for this report was to review and update the evidence used to inform the current NICE guidance
(TA99)1 on the clinical effectiveness and cost-effectiveness of immunosuppressive therapies in renal
transplantation in children and adolescents. The systematic review and economic evaluation developed to
support current NICE guidance TA99 was published by Yao et al.2 in 2006. We have incorporated relevant
evidence presented in this previous report and report new evidence. This includes a new decision analytic
model of kidney transplantation outcomes to investigate which regimen is the most cost-effective option.
In this section, we do not restate the previous evidence, but assume that the discussion is read in the
context of the previous evidence summaries and the decisions which followed from them. The conclusions
focus on implications of the new clinical effectiveness and cost-effectiveness evidence for service provision.
Clinical effectiveness systematic review
Three RCTs are included in the clinical effectiveness systematic review presented in this report: one new
RCT73 and two RCTs from the previous assessment.75,77
Four non-RCTs are included in our review.80–83 All of these were also included in the previous assessment
by Yao et al. 2006.2 No new non-randomised studies were identified in our searches.
Induction therapy
Two RCTs of induction therapy (reported in four publications and one abstract) evaluating BAS in children
and adolescents were identified in the review.73,75 No RCTs were identified that evaluated r-ATG in children
and adolescents.
No non-RCTs in the child and adolescents population evaluated induction therapies.
We found no significant difference in survival, graft loss, graft function, incidence of BPAR or time to BPAR
between BAS and PBO/no induction.73,75
The results of the current review are similar to those of the previous HTA.2
Maintenance therapy
Randomised controlled trial evidence
One RCT of maintenance therapy (reported in three publications) evaluating TAC (compared with CSA) in
children and adolescents was identified.77 No RCTs were identified that evaluated TAC-PR, MMF, MPA,
SRL, EVL or BEL in children and adolescents.
From the RCT, we found no significant difference in survival or graft loss between TAC and CSA.77
However, a significantly higher graft function [mean eGFR of 71.5ml/minute/1.73m2 (SD 22.9ml/minute/
1.73m2) in TAC vs. mean eGFR of 53.0ml/minute/1.73m2 (SD 21.6ml/minute/1.73 m2) in CSA;
t-test= 4.03; p< 0.01 at 4-year follow-up), and less BPAR (OR= 0.29, favours TAC, 95% CI 0.15 to 0.57
at 6-month follow-up)] was found in TAC compared with AZA at up to 4 years’ follow-up.77
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The results of the current review for survival, graft function and BPAR are similar to those of the previous
HTA.2 However, the RCT child and adolescent evidence identified in the previous HTA review2 concluded
that TAC lowered graft loss at 2- and 4-year follow-ups. The difference in these results is because we
excluded graft loss due to death from all analyses. This was, first, to avoid double counting with another
key outcome (mortality) and, second, because death-censored graft survival is a well-established clinical
outcome, to which DWFG is intrinsically related. After the removal of graft loss due to death from the
analyses, the evidence from Trompeter et al.77 suggested a borderline (statistically non-significant) lower
graft loss with TAC than CSA (OR= 0.41, favours TAC; 95% CI 0.16 to 1.00; and OR= 0.43, favours TAC;
95% CI 0.18 to 1.01 at 2- and 4-year follow-ups, respectively). In addition, although there were
statistically significant treatment group differences in BPAR and AR at 6 months, the annual differences in
AR were not statistically significant for years 2, 3 and 4.77,79
Non-randomised controlled trial evidence
Three non-RCTs evaluating MMF (compared with AZA) in children and adolescents were identified.81–83
One non-RCT compared TAC+AZA with CSA+MMF.80 No non-RCTs were identified that evaluated
TAC-PR, MPA, SRL, EVL or BEL in children and adolescents.
We found no statistically significant difference in survival between MMF and AZA in the non-RCTs.81,83
Similarly, no statistically significant difference in BPAR between MMF and AZA in the non-RCTs was
identified.81–83 A significantly lower graft loss was found in MMF than AZA at 1- to 5-year follow-ups in
one of the two non-RCTs83 (OR= 0.24 at 5-year follow-up; favours MMF; 95% CI 0.09 to 0.63). However,
this was not confirmed by the other non-RCT at 1-year follow-up.81 In addition, we found no statistically
significant difference in survival, graft loss, BPAR, graft function and DGF between TAC+AZA and
CSA+MMF in the non-RCTs.80
Adverse events
Induction
More infections were found in children treated with BAS than in those treated with PBO (OR= 2.23,
favours PBO; 95% CI 1.03 to 4.68).73 In addition, Grenda et al.75 found that toxic nephropathy and
abdominal pain were higher in the BAS arm than no induction (p= 0.03 and p= 0.02, respectively).75
The previous HTA reported only post-transplant diabetes mellitus,90 the rest of the data they found were
confidential and excluded from the report.2
Maintenance therapy
There were no statistically significant differences between TAC and CSA for a range of AEs (any infections,
UTIs, bacterial infections, viral infections, PTLD, solid tumour, hypertension, any AE and NODAT).77
This is similar to the conclusions of the previous HTA.2 In addition, there were no statistically significant
differences between MMF and AZA for UTI, CMV infections, respiratory infections, herpes simplex, oral
thrush and diarrhoea identified in the non-randomised evidence.81 Similarly, no statistically significant
differences between TAC+AZA and CSA+MMF in CMV infections and NODAT were identified in the
non-randomised evidence.80
Previous technology assessment
The previous assessment (TA99) in 20061 found scarce RCT evidence on the clinical effectiveness of
immunosuppressive agents in renal transplantation in children and adolescents. Only three child and
adolescent RCTs were identified,77,90 including the Wyeth submission 2005. Child and adolescent RCT
evidence was identified for TAC,77 BAS90 and SRL (Wyeth submission 2005). Only non-RCT evidence was
identified for MMF.81,83,95 Finally, no child and adolescent evidence was identified for MPS and DAC
(since the previous assessment, the marketing authorisation of DAC has been withdrawn at the request of
the manufacturer). In addition, three non-RCTs were identified for BAS,91–93 one non-RCT for TAC,94 and
one non-RCT compared TAC+AZA with MMF+CSA.80
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The addition of induction therapy (BAS) was not found to be beneficial. The only child and adolescent
induction therapy RCT found that the addition of BAS failed to significantly improve BPAR, graft function,
graft loss, mortality and AE. Similarly, a meta-analysis of adult RCTs, found no significant difference in
graft loss, mortality or AE. In general, compared with a triple regimen of CSA+AZA+CCS, the newer
immunosuppressive agents were found to lead to lower rates of BPAR. One included child and adolescent
RCT found that TAC led to lower BPAR at 6-month follow-up (RR= 0.42, favours TAC; 95% CI 0.26 to 0.69)
and higher eGFR at 1-year follow-up (p= 0.003; 6-month follow-up data were not statistically significantly
different) than CSA. This lower rate of BPAR with TAC was also shown in the meta-analysis of six adult RCTs
at 1-year follow-up (RR= 0.61, favours TAC; 95% CI 0.53 to 0.71). The total level of withdrawal in children
and adolescents was reduced in those receiving TAC compared with CSA (RR= 0.61, favours TAC; 95% CI
0.39 to 0.96). Pooled results of two adult RCTs found that compared with AZA, SRL reduced BPAR
(RR= 0.60, favours SRL; 95% CI 0.45 to 0.80), improved eGFR (MD= 28.7, favours SRL; 95% CI 18.8 to
38.5) and increased the level of hyperlipidaemia (RR= 1.57, favours AZA; 95% CI 1.19 to 2.07).257,258
In summary, important gaps in the evidence concerning the impact of the newer immunosuppressants on
AEs, long-term outcomes (including graft loss and survival), growth and overall health-related quality were
identified by the previous technology assessment.
Published economic evaluations
Only one previous cost-effectiveness study of immunosuppressive regimens in children and adolescents
was identified.2 It was conducted by the Technology Assessment Group at the University of Birmingham
as part of the previous NICE technology appraisal process. The study evaluated the cost-effectiveness of
adding BAS induction to CNI maintenance therapy with TAC or CSA combined with AZA and steroids.
The study also compared CSA with TAC when given in combination with AZA and steroids, and
separately, MMF compared with AZA as part of the triple therapy containing CSA and steroids.
The analysis was conducted using a Markov model of a cohort with starting age ranging between 3 years
and 13 years and a 10-year horizon. The study found that BAS induction resulted in higher costs and more
QALYs than the alternative of no induction in both the TAC- and CSA-containing regimens. TAC was
found to have a base-case ICER (incremental cost per QALY) of £145,000 relative to CSA, while MMF had
an ICER of £195,000 relative to AZA when given as part of CSA-containing triple therapy. Although some
of the methodological details were not provided in the study report,2 the sensitivity analysis showed that
these results were subject to a high degree of uncertainty. In particular, when the costs of dialysis were
increased to reflect high possible levels of staff requirements of dialysis treatment in children and
adolescents and the estimated treatment effects on AR based on data from adults were used, the ICER for
the comparison of TAC compared with CSA triple therapy reduced to £35,000. This uncertainty, and the
fact that the underlying model used in this analysis accounted for BPAR only as the surrogate measure of
effectiveness (ignoring the role of renal function), suggests that new evidence on the cost-effectiveness of
immunosuppressive regimens in children and adolescents is warranted.
Independent economic assessment
The PenTAG economic assessment included two types of analyses.
The first type of analysis used effectiveness estimates only from RCTs in children and adolescents and,
therefore, can only evaluate the cost-effectiveness of BAS (vs. no induction) and TAC-IR (vs. CSA).
The second type of analysis extrapolated effectiveness estimates from RCTs in adults and allows for the
cost-effectiveness of all interventions to be evaluated. Although effectiveness estimates in these analyses
were restricted to adults, a significant amount of evidence from children and adolescents was used,
including baseline characteristics, costs, baseline graft and overall survival, and the relationship between
graft function and graft survival. The analysis produced different results to those in the parallel HTA for
adults to inform an update of NICE guidance TA85.
Neither type of analysis is presented as a preferred base case because both have their deficiencies.
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Induction agents
Using effectiveness estimates from randomised controlled trials in children
and adolescents
Analyses based on evidence from RCTs in children and adolescents led to contradictory conclusions
regarding the cost-effectiveness of BAS versus no induction.
In the analysis based on Grenda et al.,75 BAS was predicted to be more effective and less costly than no
induction (in combination with TAC-IR and AZA) using either a 2-year time horizon (corresponding to the
trial follow-up) or 50-year time horizon. BAS was therefore dominant over no induction using a 2- or
50-year time horizon. The probability of BAS being cost-effective at £20,000–30,000 per QALY was
67.3–69.3% (50-year time horizon).
In the analysis based on Offner et al.,73 BAS was predicted to be more costly and less effective than no
induction (in combination with CSA and MMF) using either a 1-year time horizon (corresponding to the
trial follow-up) or 50-year time horizon. BAS was therefore dominated by no induction at either time
horizon. The probability of BAS being cost-effective at £20,000–30,000 per QALY was 6.7–9.4%
(50-year time horizon).
The results of both analyses were robust to scenario analyses in which the surrogate relationship between
AR and graft survival was removed, and the ninth centile for body weight for age was used (instead of
median weight).
No economic analyses of r-ATG could be conducted based on RCTs in children and adolescents because
no such RCTs were identified.
Using effectiveness estimates from randomised controlled trials in adults
Analyses based on evidence from RCTs in the adult population suggested that BAS induction is likely to be
cost-effective at £20,000–30,000 per QALY compared with no induction and r-ATG induction.
Depending on the maintenance regimen used, the probability of BAS being cost-effective at
£20,000–30,000 per QALY was 67.6–72.8%, while the probability of r-ATG being cost-effective
at £20,000–30,000 per QALY was 27.0–32.4%. The probability of no induction being cost-effective at
£20,000–30,000 per QALY was 0.0–0.2%.
Results were robust to removal of the surrogate relationship between AR and graft survival and/or
assuming ninth centile weight according to age rather than median weight.
Maintenance agents
Using effectiveness estimates from randomised controlled trials in children
and adolescents
An analysis based on a RCT in children and adolescents suggested that TAC-IR is likely to be cost-effective
at £20,000–30,000 per QALY. In the analysis based on Trompeter et al.,77 TAC-IR in combination with
AZA was predicted to be more effective and less costly than CSA, whether using a 4-year time horizon
(corresponding to the trial follow-up) or a 50-year time horizon. The probability of BAS being cost-effective
at £20,000–30,000 per QALY was over 99.9% (50-year time horizon).
Results were robust to removal of the surrogate relationship between AR and graft survival, and to
assuming ninth centile weight according to age rather than median weight.
No economic analyses of TAC-PR, MMF, MPS, SRL, EVL or BEL could be conducted based on RCTs in
children and adolescents because no such RCTs were identified.
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Using effectiveness estimates from RCTs in adults
Analyses using effectiveness estimates from RCTs in adults suggested that:
l TAC-IR is likely to be cost-effective at £20,000–30,000 per QALY (99.3–100.0% of PSA simulations)
l TAC-PR is unlikely to be cost-effective at £20,000–30,000 per QALY (expected to be dominated by
TAC-IR and cost-effective in only 0.2–0.3% of PSA simulations)
l MMF is likely to be cost-effective at £20,000–30,000 per QALY when used with or without induction
and in combination with CSA (cost-effective in 71.1–99.9% of PSA simulations)
l MMF is unlikely to be cost-effective at £20,000–30,000 per QALY when used with or without
induction and in combination with TAC-IR (expected to be dominated by AZA and cost-effective in only
17.8–24.9% of PSA simulations)
l MPS is unlikely to be cost-effective at £20,000–30,000 per QALY when used in combination with BAS
induction and CSA (ICER over £50,000 per QALY and cost-effective in 24.8–28.8% of PSA simulations)
l SRL is unlikely to be cost-effective at £20,000–30,000 per QALY when used in combination with BAS
induction and MMF (expected to be dominated by CSA and TAC-IR and cost-effective in only 0.1% of
PSA simulations)
l SRL is unlikely to be cost-effective at £20,000–30,000 per QALY when used in combination with
TAC-IR (expected to be dominated by MMF and AZA and cost-effective in 0.0% of PSA simulations)
l EVL is unlikely to be cost-effective at £20,000–30,000 per QALY when used in combination with CSA
(ICER over £600,000 per QALY and cost-effective in 0.0% of PSA simulations)
l BEL is unlikely to be cost-effective at £20,000–30,000 per QALY when used in combination with BAS
induction and MMF (ICER over £600,000 per QALY and cost-effective in 0.0% of PSA simulations).
If ninth centile weight according to age is assumed (instead of median weight), in the deterministic analysis
MPS becomes cost-effective in the deterministic analysis at £30,000 per QALY but not at £20,000 per
QALY (ICER £27,000 per QALY). However, the assumed weight–dose relationship may not be accurate
(the relationship was assumed to be directly proportional, e.g. patients weighing 50% of median adult
weight would require 50% of the average adult dose). In addition, this assumes that kidney transplant
patients do not move from the ninth centile of weight.
Results are robust to removal of the surrogate relationship between AR and graft survival, although the
deterministic ICER for MPS is lowered to £33,000 per QALY.
Company submissions
The only cost-effectiveness analysis submitted by pharmaceutical companies was that of Astellas, the
sponsor of two TAC-IR formulations (Prograf and Modigraf) and TAC-PR (Advagraf). It compared TAC-IR
(Prograf) with TAC oral solutions (specials), SRL with MMF (CNI avoidance regimen), SRL with CSA (CNI
minimisation regimen), EVL and BEL. TAC-IR was found to have an ICER relative to SRL CNI minimisation of
£1,600,000. However, the company concluded that, given the minimal use of SRL in maintenance
immunosuppression for kidney transplantations in England and Wales since the publication of the
Symphony study, SRL is not a relevant comparator in these countries. As TAC dominated all other
regimens it was deemed to be cost-effective. In a separate analysis, TAC-IR (Prograf) was compared with
TAC-PR (Advagraf) by modelling the effects of the different adherence profiles between the two regimens
on BPAR and, independently, on graft survival. Advagraf was found to result in lower costs and more
QALYs than Prograf and was therefore recommended as the cost-effective treatment option.
Although these analyses were set out to meet the specification of the NICE reference case, they are
subject to limitations that question the validity of the results and conclusions derived from them. The most
important problem is that the model uses efficacy data from RCTs conducted in adult patients. The triple
regimen of CSA+MMF+CCS was an important omission from the list of comparators and for which no
reason was given in the submission. The unit cost values adopted for the analysis reflect drug list prices as
opposed to prices actually paid by hospitals at a discount, as evidenced from eMIT data. Moreover, the
drug dosages used for regimens other than MMF and EVL in the cost analysis were derived from those
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specified by national prescribing guidelines for adults (BNF). In addition, by truncating the analysis at age
18 years, the sensitivity analysis conducted by Astellas based on starting age becomes meaningless. The
model ignored important recent evidence about renal graft function as an important outcome for both
costs and HRQoL. Further, the Markov model structure used by Astellas was based on annual cycles and
assumed that within the first year after transplantation some patients would experience graft failure and
retransplantation. Although some patients may experience this in reality, the way the model implemented
this effectively assumed that all such patients would experience failure and retransplantation on day 1.
This suggests that the cycle length chosen by Astellas inadequately reflected the patient experience that
it sought to model. These limitations cast more uncertainty on the results than seems justified by the
available data and knowledge of the disease, and suggest that more evidence addressing some of those
limitations would benefit NICE recommendations in this area.
Comparison of the Peninsula Technology Assessment Group, Astellas and
previous assessment group’s model-based analyses
We attempted to compare and explain the main differences in cost, clinical effectiveness and
cost-effectiveness estimates between the three models. In the case of the Astellas analyses this was
hampered by the substantial number of important differences in modelling assumptions [such as the much
shorter time horizon (10 years) and reliance on data from different trials and different outcome measures
from those trials to drive effectiveness differences].
For comparing TAC-IR with TAC-PR, the PenTAG and Astellas analyses arrive at opposite conclusions
(the Astellas analysis in favour of TAC-PR). This is primarily because of reliance on BPAR at 12 months post
transplant as the main surrogate outcome driving QALY differences, different unit cost sources, and using
outcome data from different trials to those on which the PenTAG analysis is based. The other analysis by
Astellas, comparing a larger range of maintenance therapies (but omitting CSA), showed that SRL would
be the most cost-effective treatment (although its report does not highlight this) whereas the PenTAG
analysis shows TAC-IR to be the most cost-effective. However, there is considerable uncertainty and the
Astellas analysis is based on very small differences in estimated QALYs.
It was virtually impossible to compare our model-based analyses with those by Yao et al.,2 which informed
NICE’s current guidance on these drugs for children and adolescents (TA99).1 This is because the Yao
et al.2 model is not fully described in a single report, the model itself is not available and even the results
were reported only at the level of incremental costs and QALYs (i.e. no separately reported total costs
and QALYs by model comparator). Their cost-effectiveness results also reflect differential discounting of
future QALYs (1.5% per year) and costs (6%), and a limited 10-year time horizon. Despite these major
differences, the findings in favour of the use of BAS as an induction therapy were similar between the
Yao et al.2 and current PenTAG analyses. In contrast, based on more adult RCT evidence and a 50-year
time horizon, the PenTAG analysis found that TAC (with AZA) was more effective and less costly than
CSA, and that MMF (with CSA) was more effective and less costly than AZA.
Strengths and limitations
Systematic review of studies of clinical effectiveness
Strengths
l The systematic review is conducted by an independent research team using the latest evidence.
l The literature searches were not restricted to child/adolescent populations so as to preserve the
sensitivity of the searches and enable identifying RCTs for which mixed populations may have been
recruited, but outcomes were reported according to age.
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Limitations
l The number of included RCTs is low; child/adolescent-specific evidence was identified only for BAS and
TAC-IR. No RCT evidence from children or adolescents was identified for r-ATG, TAC-PR, MMF, MPS,
SRL, EVL and BEL.
l Databases were searched to identify systematic reviews of non-RCTs; however, individual non-RCTs
were not searched for directly. It is likely that some non-RCT comparative evidence was missed. In
addition, results from non-randomised studies may differ from RCT evidence. It can be argued that
large, prospective and comprehensive case series may achieve high external validity, but we did not
search for such studies.
l There is a possibility of spuriously positive tests for statistical significance arising from conducting
multiple tests; we did not formally make adjustments for multiple testing. In addition, owing to a small
number of included studies, publication bias were not assessed.
l For all included studies, less than half of the items constituting the quality appraisal assessment were
adequately addressed in the research articles.
l No studies reporting on quality of life, adherence and growth were identified.
l No RCTs were found to support the subgroup analyses specified in the review protocol.
In addition, this report highlights some methodological issues. Some of the newer immunosuppressive
drugs, such as EVL and SRL, would normally be given to children and adolescents after an initial
maintenance therapy that consists of more conventional drugs. This makes it challenging to compare the
clinical effectiveness of such regimens as only children and adolescents who are well maintained on their
initial maintenance therapy would be given such drugs.
Economic model by the Peninsula Technology Assessment Group
Strengths
l This is an analysis conducted by an independent academic group, adhering to the NICE reference case
when possible.
l All interventions and relevant allowable comparators are included and evaluated for cost-effectiveness.
l The natural history of disease is based on UK data, either published by the UK Renal Registry or from
new analyses of the UK Transplant Registry standard data set.
l Important differences in the costs of dialysis between those under 19 years of age and adults have
been included.
l Analyses have been conducted based on all available RCTs in children and adolescents eligible
for inclusion.
l Additional analyses have been conducted based on a systematic review and network meta-analysis of
RCTs in the adult population to allow comparison of all interventions even when no relevant RCTs in
children and adolescents were identified.
l The surrogate relationship between graft function (eGFR) at 12 months and graft survival has been
estimated from a study of children and adolescents.
l Pre-emptive retransplantations are included for a minority of KTRs following failure of the initial graft
(avoiding dialysis which is costly and reduces HRQoL).
l Unit costs are those relevant to the NHS (e.g. CMU eMIT costs were used when available).
l Dosages for those under 18 years of age are based, when possible, on RCTs in children and
adolescents, while dosages for those over 18 years of age are estimated from RCTs in adults.
l Probabilistic sensitivity analyses are presented to reflect the possible impact of parameter uncertainty.
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Limitations
l Graft function has not been modelled over time, but is only estimated at 12 months in order to
estimate graft survival thereafter. Reduced graft function can have an impact on HRQoL, but this is a
limited effect until graft function is significantly reduced. For most regimens this would slightly reduce
total QALYs (owing to reduced utility near the end of the graft life). For non-CNI regimens, it is possible
that graft function would be better sustained and these regimens would not suffer a QALY loss and
would therefore become more cost-effective (but this would be unlikely to lead to them being
cost-effective at £20,000–30,000 per QALY).
l The cost-effectiveness of reducing or eliminating CCSs has not been evaluated. Some regimens
(particularly those with antibody induction) could make it more possible to reduce or eliminate CCSs
and the side effects associated with them. Given that significant effort is already invested to minimise
maintenance dosage of CCSs, and that the cost of CCSs is minimal, it may be that avoidance would
have only a small impact on cost-effectiveness.
l The cost of NHS-funded transport for haemodialysis patients has not been included. Kerr et al.57
estimated transport costs of £2792 per year per haemodialysis patient (almost certainly mainly
estimated from adults – costs may be higher for children as they may be more likely to be reimbursed
and transport for parents is also reimbursed). Including transport costs would improve
cost-effectiveness for regimens with better graft survival, as this delays and reduces time on dialysis.
l Treatment discontinuation and treatment switching are not modelled except in the events of graft
failure (treatment discontinuation) and retransplantation (treatment switched to BAS+ TAC+MMF
regardless of previous treatment). Given the uncertainty about which treatments would be switched it
is difficult to predict the effect of this on cost-effectiveness.
l Independence of AR, NODAT and eGFR at 12 months was assumed when predicting graft survival. It is
possible that there would be correlation between these outcomes and that the proportion of patients
with particularly unfavourable outcomes at 12 months (e.g. AR, NODAT and low eGFR) is
underestimated, and likewise the proportion of patients with favourable 12-month outcomes.
The impact of this on cost-effectiveness is uncertain.
l The surrogate relationships from AR and NODAT to graft survival are based on the adult population.
It is not possible to estimate the impact of this on cost-effectiveness.
l Continuing immunosuppression following graft loss was not modelled, although it may occur in clinical
settings. This would lead to slightly increased total costs, particularly for more expensive
immunosuppressive agents, and would probably improve cost-effectiveness for less expensive agents.
l A proportional hazards assumption was made for the graft survival surrogate relationship. As a Weibull
model was used, this is also equivalent to an accelerated failure time assumption. Alternative
assumptions could have the HR being time dependent. We have not estimated the impact of
alternative assumptions for graft survival on cost-effectiveness.
l No attempt was made to explicitly model adherence to immunosuppressive agents owing to the
absence of evidence on this outcome in identified RCTs; it is thought that non-adherence is a
significant cause of late AR and graft loss, but any gains in clinical effectiveness owing to improved
adherence attributable to any individual agent or regimen are considered speculative. If any regimen
robustly demonstrated improved long-term graft survival owing to improved adherence, this would
result in improved cost-effectiveness for that regimen.
l It was assumed that there would be no treatment interactions between induction and maintenance
therapies affecting clinical effectiveness outcomes; however, it is known that there is a pharmacokinetic
interaction between BAS and MMF that results in prolonged BAS half-life (and similar interactions may
exist between other induction and maintenance therapies). It is not possible to estimate the impact of
such interactions on cost-effectiveness.
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l Owing to inconsistent reporting of AEs in RCTs included in our systematic review, a limited range of
AEs were modelled: NODAT, CMV infection, dyslipidaemia and anaemia (of these, anaemia was
assumed not to vary between regimens). Malignancy, PTLD, proteinuria, hypertension, EBV infection,
BKV infection, other infections and other AEs were not modelled. In addition, induction agents were
assumed not to affect the incidence of AEs. Cost-effectiveness has been overestimated for regimens
with increased risk of AEs (as these generally increase costs and lower quality of life).
l No drug wastage (e.g. part used packs/vials) was assumed for any intervention except BEL; the other
agent for which wastage may be likely to occur is r-ATG. The cost-effectiveness of r-ATG may have
been somewhat overestimated, but given the uncertainty in dosages in children and adolescents it is
unlikely to be very significant.
l The generalisability of cost-effectiveness results hinges on the generalisability of the clinical
effectiveness evidence. Most of the interventions being considered (except BAS and TAC-IR) have not
been evaluated in RCTs of children and adolescents, but only in adults.
Areas of uncertainty
This technology assessment was conducted by an independent academic group, builds on existing
secondary research and economic evaluations and adheres to the NICE reference case when possible.
However, there are some important sources of uncertainty that impact on the conclusions:
l Most of the interventions being considered (except BAS and TAC-IR) have not been evaluated in
published RCTs in children and adolescents.
l Follow-up in RCTs is limited and, therefore, it has not been possible to externally validate predicted
survival differences between regimens.
l Randomised controlled trials have not provided evidence to support pre-specified subgroup analyses.
l There was no evidence to support analyses of the cost-effectiveness of interventions for children and
adolescents unable to swallow tablets, for whom the following may or may not be appropriate:
¢ TAC-IR oral suspension (Modigraf)
¢ TAC-IR liquid (from specials manufacturers)
¢ CSA solution (Neoral)
¢ SRL solution (Rapamune)
¢ AZA oral suspension (from specials manufacturers)
¢ MMF oral suspension (CellCept).
l The costs for diabetes mellitus are highly uncertain, especially as the costs relate to the general adult
diabetic population.
l It is not known whether or not NHS hospitals might secure discounts from list prices when these were
assumed in the model (i.e. for BAS, r-ATG, TAC-PR, MPS, SRL, EVL and BEL).
l Combinations of immunosuppressive agents other than those considered could be used in clinical
practice (the PenTAG model can be extended to include additional combinations).
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Chapter 7 Conclusion
Cost-effectiveness estimates for immunosuppressive agents in children and adolescents based oneffectiveness estimates in children and adolescents are available only for BAS and TAC-IR. For TAC-IR,
the economic analysis based on one RCT77 suggests that TAC-IR is cost-effective (vs. CSA, in combination
with AZA) at £20,000–30,000 per QALY. For BAS, the analysis based on one RCT75 found BAS to be
dominant, while the analysis based on the other RCT73 found BAS to be dominated.
Consideration of the cost-effectiveness of immunosuppressive agents in children and adolescents by
extrapolating effectiveness estimates from the adult population (when there is considerable RCT evidence)
suggests that, at a cost-effectiveness threshold of £20,000–30,000 per QALY, BAS and TAC-IR are
cost-effective in all considered combinations, while MMF is cost-effective only if used in combination with
CSA. BAS induction, TAC-IR and AZA were predicted to be cost-effective at £20,000–30,000 per QALY
when all regimens were compared.
Implications for service provision
Basiliximab is used regularly as induction therapy for child/adolescent kidney transplant patients in the
NHS, but is not routinely used in all centres. BAS is recommended as an option for induction therapy by
current NICE guidance (TA99).1 Conflicting results from the new economic analyses conducted mean that
it is not possible to conclude whether induction with BAS is more or less costly than no induction, but the
magnitude of the cost difference is unlikely to be great because induction therapy is administered only at
the time of transplantation and is not an ongoing cost.
Rabbit anti-human thymocyte immunoglobulin is not currently used routinely in the NHS and was not
considered by current NICE guidance TA99.1 Economic analyses based on extrapolation from adult
effectiveness estimates suggest that induction with r-ATG is more costly than induction with BAS, but less
costly than no induction.
For maintenance therapy, TAC-IR is the current standard of care in the NHS and was recommended as an
option for maintenance therapy by current NICE guidance TA99.1 If TAC-PR, SRL or BEL were to be used in
place of TAC-IR this would be likely to increase costs. It is also predicted that if CSA were to be used in
place of TAC-IR this would lead to increased costs.
Azathioprine and MMF are both widely and routinely used in the NHS, although current NICE guidance
(TA99) recommended only MMF as an option for maintenance therapy in a restricted population.1
Economic analyses based on extrapolation from adult effectiveness estimates suggest that MMF is likely to
be more costly than AZA in combination with TAC-IR. These analyses also suggest that replacing AZA or
MPS with SRL, EVL or MMF would lead to increased costs.
Belatacept, which is administered intravenously, would be expected to add an extra burden to service
providers although, given the limited number of children and adolescents receiving kidney transplantation,
the additional burden of drug administration may be able to be accommodated without significant
changes to staffing levels.
Suggested research priorities
It is recommended that high-quality primary research into the effectiveness of immunosuppressive agents
for kidney transplantation in children and adolescents is conducted. This could be experimental or
observational research.
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In particular, a prospective study using the UK Renal Registry data set would be beneficial. Such a study
would ideally include longitudinal recording of immunosuppression (combination and doses, reflecting
changes as soon as they are made), as well as recording AR episodes and regular graft function
measurements. A study would also need to ensure that all covariates for effectiveness outcomes (especially
potential confounders) were recorded. Such a study could also include HRQoL measurements, preferably
using a generic instrument validated in the child and adolescent population such as EQ-5D-Y or Child
Health Utility 9 dimensions (CHU9D), and measurements of growth.
In addition, given the perceived importance of adherence to immunosuppression, it may also be desirable
to establish an objective and practical measure of adherence so that any differences in adherence between
regimens can be identified, as well as any effect this has on outcomes.
Finally, although limitations of non-RCT evidence were noted above, a systematic review of non-RCTs
(not limited to search for systematic reviews of non-RCTs) to map all available child and adolescents’
evidence on this topic is needed.
CONCLUSION
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Appendix 1 Literature searching strategies
Clinical effectiveness searches
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and
Ovid MEDLINE(R)
Host: Ovid.
Data parameters: 1946 to present.
Date searched: Wednesday 7 January 2015.
Hits: 95.
Search strategy
# Searches Results
1 Kidney Transplantation/ 81,673
2 (Kidney$ adj3 transplant$).ti,ab,kw,ot. 34,747
3 (Renal adj3 transplant$).ti,ab,kw,ot. 41,731
4 ((kidney or renal) adj3 (recipient$ or dono$ or donation$ or replac$)).ti,ab,kw,ot. 36,959
5 ((graft$ or allograft$ or homograft$ or allogeneic) and (kidney$ or renal)).ti,ab,kw,ot. 46,496
6 1 or 2 or 3 or 4 or 5 115,157
7 (Basiliximab or Basiliximabum or Simulect or “interleukin 2 receptor antibody”).ti,ab,kw,ot. 1080
8 ((rabbit$ adj3 Anti-thymocyte$1) or (rabbit$ adj3 Antithymocyte$1) or (rabbit$ adj3 thymocyte$1)
or (rabbit$ adj3 polyclonal) or (rabbit$ and ATG) or RATG or thymoglobulin$2).ti,ab,kw,ot.
6436
9 (Tacrolimus or Fujimycin or Prograf or Advagraf or Adoport or Capexion or Modigraf or Perixis
or Tacni or Vivadex or Protopic or Tsukubaenolide or “FK 506” or “FK-506” or “FK506” or
“fr-900506”).ti,ab,kw,ot.
17,526
10 Tacrolimus/ 13,172
11 (Belatacept or Nulojix or “lea29y” or “lea 29y” or “bms 224818”).ti,ab,kw,ot. 228
12 (“Mycophenolic acid” or MPA or Mycophenolate or Arzip or CellCep$1 or Myfenax or Myfortic or
Mofetil).ti,ab,kw,ot.
28,566
13 (Sirolimus or Rapamune or Rapamycin or “ay 22-989”).ti,ab,kw,ot. 22,525
14 Sirolimus/ 14,642
15 (Everolimus or Zortress or Certican or Afinitor or Evertor or “SDZ RAD”).ti,ab,kw,ot. 3203
16 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 75,480
17 6 and 16 9696
18 Randomized Controlled Trial.pt. 405,805
19 (random$ or RCT or placebo$ or single blind$ or double blind$ or triple blind$).ti,ab,ot. 863,332
20 clinical trial.pt. 503,357
21 (“controlled trial$” or “clinical trial$”).ti,ab,ot. 356,127
22 18 or 19 or 20 or 21 1,343,010
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# Searches Results
23 6 and 16 and 22 2481
24 limit 23 to yr=“2014 -Current” 95
Notes: N/A.
File: N/A.
Database: EMBASE
Host: Ovid.
Data parameters: 1974 to 5 January 2015.
Date searched: Wednesday 7 January 2015.
Hits: 272.
Search strategy
# Searches Results
1 kidney transplantation/ 97,857
2 (Kidney$ adj3 transplant$).ti,ab,kw,ot. 51,138
3 (Renal adj3 transplant$).ti,ab,kw,ot. 56,254
4 ((kidney or renal) adj3 (recipient$ or dono$ or donation$ or replac$)).ti,ab,kw,ot. 52,314
5 ((graft$ or allograft$ or homograft$ or allogeneic) and (kidney$ or renal)).ti,ab,kw,ot. 66,083
6 1 or 2 or 3 or 4 or 5 154,370
7 basiliximab/ 6754
8 (Basiliximab or Basiliximabum or Simulect or “interleukin 2 receptor antibody”).ti,ab,kw,ot. 2323
9 thymocyte antibody/ 20,451
10 ((rabbit$ adj3 Anti-thymocyte$1) or (rabbit$ adj3 Antithymocyte$1) or (rabbit$ adj3 thymocyte$1)
or (rabbit$ adj3 polyclonal) or (rabbit$ and ATG) or RATG or thymoglobulin$2).ti,ab,kw,ot.
8932
11 tacrolimus/ 54,178
12 (Tacrolimus or Fujimycin or Prograf or Advagraf or Adoport or Capexion or Modigraf or Perixis or
Tacni or Vivadex or Protopic or Tsukubaenolide or “FK 506” or “FK-506” or “FK506” or
“fr-900506”).ti,ab,kw,ot.
26,496
13 belatacept/ 1003
14 (Belatacept or Nulojix or “lea29y” or “lea 29y” or “bms 224818”).ti,ab,kw,ot. 555
15 mycophenolic acid/ 10,124
16 (“Mycophenolic acid” or MPA or Mycophenolate or Arzip or CellCep$1 or Myfenax or Myfortic or
Mofetil).ti,ab,kw,ot.
36,223
17 rapamycin/ 36,866
18 (Sirolimus or Rapamune or Rapamycin or “ay 22-989”).ti,ab,kw,ot. 29,130
19 everolimus/ 14,653
20 (Everolimus or Zortress or Certican or Afinitor or Evertor or “SDZ RAD”).ti,ab,kw,ot. 7135
21 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 149,906
22 6 and 21 25,851
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# Searches Results
23 randomized controlled trial/ 358,007
24 (random$ or placebo$ or single blind$ or double blind$ or triple blind$).ti,ab,ot. 1,039,570
25 (“controlled trial$” or “clinical trial$”).ti,ab,ot. 434,667
26 23 or 24 or 25 1,314,663
27 22 and 26 3526
28 limit 27 to yr=“2014 -Current” 272
Notes: N/A.
File: N/A.
Database: Cochrane CENTRAL
Host: Wiley Online Library.
Data parameters: Issue 12 of 12, December 2014.
Date searched: Wednesday 7 January 2015.
Hits: 75.
# Searches Results
1 MeSH descriptor: [Kidney Transplantation] this term only 3313
2 (Kidney* near/3 transplant*) 5959
3 (Renal near/3 transplant*) 4492
4 ((kidney or renal) near/3 (recipient* or dono* or donation* or replac*)) 3839
5 ((graft* or allograft* or homograft* or allogeneic) and (kidney* or renal)) 5192
6 #1 or #2 or #3 or #4 or #5 9188
7 (Basiliximab or Basiliximabum or Simulect or “interleukin 2 receptor antibody”) 522
8 ((rabbit* near/3 Anti-thymocyte*) or (rabbit* near/3 Antithymocyte*) or (rabbit* near/3 thymocyte*) or
(rabbit* near/3 polyclonal) or (rabbit* and ATG) or RATG or thymoglobulin*)
364
9 (Tacrolimus or Fujimycin or Prograf or Advagraf or Adoport or Capexion or Modigraf or Perixis or Tacni or
Vivadex or Protopic or Tsukubaenolide or “FK 506” or “FK-506” or “FK506” or “fr-900506”)
2587
10 MeSH descriptor: [Tacrolimus] this term only 1181
11 (Belatacept or Nulojix or “lea29y” or “lea 29y” or “bms 224818”) 87
12 (“Mycophenolic acid” or MPA or Mycophenolate or Arzip or CellCep* or Myfenax or Myfortic or Mofetil) 3477
13 (Sirolimus or Rapamune or Rapamycin or “ay 22-989”) 2199
14 MeSH descriptor: [Sirolimus] this term only 1071
15 (Everolimus or Zortress or Certican or Afinitor or Evertor or “SDZ RAD”) 939
16 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 7471
17 #6 and #16 Publication Year from 2014 to 2015 102
Notes: this search strategy represents the whole of The Cochrane Library but only CENTRL was
downloaded in this instance (CENTRAL 75, EED 2, Groups 2, CDSR 20, DARE 3).
File: N/A.
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Database: Web of Science
Host: ISI Thompson Reuters.
Data parameters: 1900–2014.
Date searched: Wednesday 7 January 2015.
Hits: 183.
# Results Searches
16 183 #14 AND #13
Refined by: PUBLICATION YEARS: ( 2014 )
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
15 2,702 #14 AND #13
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
14 1,421,223 TOPIC: ((((random* or rct* or “controlled trial*” or “clinical trial*”))))
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
13 13,127 #12 AND #5
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
12 142,824 #11 OR #10 OR #9 OR #8 OR #7 OR #6
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
11 5570 TOPIC: (((Everolimus or Zortress or Certican or Afinitor or Evertor or “SDZ RAD”)))
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
10 111,240 TOPIC: (((“Mycophenolic acid” or MPA or Mycophenolate or Arzip or CellCep* or Myfenax or
Myfortic or Mofetil)))
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
9 486 TOPIC: (((Belatacept or Nulojix or “lea29y” or “lea 29y” or “bms 224818”)))
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
8 23,942 TOPIC: (((Tacrolimus or Fujimycin or Prograf or Advagraf or Adoport or Capexion or Modigraf or
Perixis or Tacni or Vivadex or Protopic or Tsukubaenolide or “FK 506” or “FK-506” or “FK506” or
“fr-900506”)))
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
7 6468 TOPIC: ((((rabbit* near/3 Anti-thymocyte*) or (rabbit* near/3 Antithymocyte*) or (rabbit* near/3
thymocyte*) or (rabbit* near/3 polyclonal) or (rabbit* and ATG) or RATG or thymoglobulin*)))
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
6 1475 TOPIC: (((Basiliximab or Basiliximabum or Simulect or “interleukin 2 receptor antibody”)))
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
5 125,548 #4 OR #3 OR #2 OR #1
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
4 53,666 TOPIC: ((((graft* or allograft* or homograft* or allogeneic) and (kidney* or renal))))
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
3 50,443 TOPIC: ((((kidney or renal) near/3 (recipient* or dono* or donation* or replac*))))
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
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# Results Searches
2 60,478 TOPIC: (((Renal near/3 transplant*)))
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
1 47,055 TOPIC: (((Kidney* near/3 transplant*)))
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH Timespan=All years
Notes: auto suggest was turned off. No records for 2015 on date of search.
File: N/A.
Database: Health Management Information Consortium (HMIC)
Host: Ovid.
Data parameters: 1979 to November 2014.
Date searched: Wednesday 7 January 2015.
Hits: 0.
Search strategy
# Searches Results
1 Kidney Transplantation/ 121
2 (Kidney$ adj3 transplant$).ti,ab,kw,ot. 84
3 (Renal adj3 transplant$).ti,ab,kw,ot. 81
4 ((kidney or renal) adj3 (recipient$ or dono$ or donation$ or replac$)).ti,ab,kw,ot. 152
5 ((graft$ or allograft$ or homograft$ or allogeneic) and (kidney$ or renal)).ti,ab,kw,ot. 28
6 1 or 2 or 3 or 4 or 5 314
7 (Basiliximab or Basiliximabum or Simulect or “interleukin 2 receptor antibody”).ti,ab,kw,ot. 2
8 ((rabbit$ adj3 Anti-thymocyte$1) or (rabbit$ adj3 Antithymocyte$1) or (rabbit$ adj3 thymocyte$1)
or (rabbit$ adj3 polyclonal) or (rabbit$ and ATG) or RATG or thymoglobulin$2).ti,ab,kw,ot.
1
9 (Tacrolimus or Fujimycin or Prograf or Advagraf or Adoport or Capexion or Modigraf or Perixis or
Tacni or Vivadex or Protopic or Tsukubaenolide or “FK 506” or “FK-506” or “FK506” or “fr-
900506”).ti,ab,kw,ot.
8
10 Tacrolimus/ 0
11 (Belatacept or Nulojix or “lea29y” or “lea 29y” or “bms 224818”).ti,ab,kw,ot. 0
12 (“Mycophenolic acid” or MPA or Mycophenolate or Arzip or CellCep$1 or Myfenax or Myfortic or
Mofetil).ti,ab,kw,ot.
23
13 (Sirolimus or Rapamune or Rapamycin or “ay 22-989”).ti,ab,kw,ot. 11
14 Sirolimus/ 0
15 (Everolimus or Zortress or Certican or Afinitor or Evertor or “SDZ RAD”).ti,ab,kw,ot. 2
16 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 33
17 6 and 16 3
18 Randomized Controlled Trial.pt. 0
19 (random$ or RCT or placebo$ or single blind$ or double blind$ or triple blind$).ti,ab,ot. 10,914
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# Searches Results
20 clinical trial.pt. 0
21 (“controlled trial$” or “clinical trial$”).ti,ab,ot. 5640
22 18 or 19 or 20 or 21 12,174
23 6 and 16 and 22 1
24 limit 23 to yr=“2014 -Current” 0
Notes: N/A.
File: N/A.
Systematic reviews search strategy: clinical effectiveness searches
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and
Ovid MEDLINE(R)
Host: Ovid.
Data parameters: 1946 to present.
Date searched: Thursday 8 January 2015.
Hits: 10.
Search strategy
# Searches Results
1 Kidney Transplantation/ 81,679
2 (Kidney$ adj3 transplant$).ti,ab,kw,ot. 34,743
3 (Renal adj3 transplant$).ti,ab,kw,ot. 41,731
4 ((kidney or renal) adj3 (recipient$ or dono$ or donation$ or replac$)).ti,ab,kw,ot. 36,952
5 ((graft$ or allograft$ or homograft$ or allogeneic) and (kidney$ or renal)).ti,ab,kw,ot. 46,489
6 1 or 2 or 3 or 4 or 5 115,148
7 (Basiliximab or Basiliximabum or Simulect or “interleukin 2 receptor antibody”).ti,ab,kw,ot. 1080
8 ((rabbit$ adj3 Anti-thymocyte$1) or (rabbit$ adj3 Antithymocyte$1) or (rabbit$ adj3 thymocyte$1)
or (rabbit$ adj3 polyclonal) or (rabbit$ and ATG) or RATG or thymoglobulin$2).ti,ab,kw,ot.
6435
9 (Tacrolimus or Fujimycin or Prograf or Advagraf or Adoport or Capexion or Modigraf or Perixis or
Tacni or Vivadex or Protopic or Tsukubaenolide or “FK 506” or “FK-506” or “FK506” or
“fr-900506”).ti,ab,kw,ot.
17,524
10 Tacrolimus/ 13,170
11 (Belatacept or Nulojix or “lea29y” or “lea 29y” or “bms 224818”).ti,ab,kw,ot. 228
12 (“Mycophenolic acid” or MPA or Mycophenolate or Arzip or CellCep$1 or Myfenax or Myfortic or
Mofetil).ti,ab,kw,ot.
28,558
13 (Sirolimus or Rapamune or Rapamycin or “ay 22-989”).ti,ab,kw,ot. 22,498
14 Sirolimus/ 14,646
15 (Everolimus or Zortress or Certican or Afinitor or Evertor or “SDZ RAD”).ti,ab,kw,ot. 3201
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# Searches Results
16 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 75,448
17 6 and 16 9694
18 (systematic adj3 review$).ti,ab,kw,ot. 67,562
19 17 and 18 50
20 limit 19 to yr=“2014 -Current” 10
Notes: N/A.
File: N/A.
Database: EMBASE
Host: Ovid.
Data parameters: 1974 to 7 January 2015.
Date searched: Thursday 8 January 2015.
Hits: 19.
Search strategy
# Searches Results
1 kidney transplantation/ 97,867
2 (Kidney$ adj3 transplant$).ti,ab,kw,ot. 51,145
3 (Renal adj3 transplant$).ti,ab,kw,ot. 56,258
4 ((kidney or renal) adj3 (recipient$ or dono$ or donation$ or replac$)).ti,ab,kw,ot. 52,323
5 ((graft$ or allograft$ or homograft$ or allogeneic) and (kidney$ or renal)).ti,ab,kw,ot. 66,091
6 1 or 2 or 3 or 4 or 5 154,387
7 basiliximab/ 6757
8 (Basiliximab or Basiliximabum or Simulect or “interleukin 2 receptor antibody”).ti,ab,kw,ot. 2323
9 thymocyte antibody/ 20,454
10 ((rabbit$ adj3 Anti-thymocyte$1) or (rabbit$ adj3 Antithymocyte$1) or (rabbit$ adj3 thymocyte$1)
or (rabbit$ adj3 polyclonal) or (rabbit$ and ATG) or RATG or thymoglobulin$2).ti,ab,kw,ot.
8933
11 tacrolimus/ 54,192
12 (Tacrolimus or Fujimycin or Prograf or Advagraf or Adoport or Capexion or Modigraf or Perixis or
Tacni or Vivadex or Protopic or Tsukubaenolide or “FK 506” or “FK-506” or “FK506” or
“fr-900506”).ti,ab,kw,ot.
26,500
13 belatacept/ 1004
14 (Belatacept or Nulojix or “lea29y” or “lea 29y” or “bms 224818”).ti,ab,kw,ot. 555
15 mycophenolic acid/ 10,128
16 (“Mycophenolic acid” or MPA or Mycophenolate or Arzip or CellCep$1 or Myfenax or Myfortic or
Mofetil).ti,ab,kw,ot.
36,231
17 rapamycin/ 36,874
18 (Sirolimus or Rapamune or Rapamycin or “ay 22-989”).ti,ab,kw,ot. 29,138
19 everolimus/ 14,659
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# Searches Results
20 (Everolimus or Zortress or Certican or Afinitor or Evertor or “SDZ RAD”).ti,ab,kw,ot. 7137
21 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 149,945
22 6 and 21 25,858
23 (systematic adj3 review$).ti,ab,kw,ot. 79,043
24 22 and 23 127
25 limit 24 to yr=“2014 -Current” 19
Notes: N/A.
File: N/A.
Database: Cochrane CDSR and Database of Abstracts of Review of Effects
Host: Wiley Online Library.
Data parameters: CDSR Issue 1 of 12, January 2015, DARE and HTA Issue 4 of 4, October 2014.
Date searched: Thursday 8 January 2015.
Hits: 23 (102 in total – CDSR 20, DARE 3, CENTRAL 75, NHS EED 2, Groups 2, HTA 0).
Search strategy
# Searches Results
1 MeSH descriptor: [Kidney Transplantation] this term only 3313
2 (Kidney* near/3 transplant*) 5959
3 (Renal near/3 transplant*) 4492
4 ((kidney or renal) near/3 (recipient* or dono* or donation* or replac*)) 3839
5 ((graft* or allograft* or homograft* or allogeneic) and (kidney* or renal)) 5192
6 #1 or #2 or #3 or #4 or #5 9188
7 (Basiliximab or Basiliximabum or Simulect or “interleukin 2 receptor antibody”) 522
8 ((rabbit* near/3 Anti-thymocyte*) or (rabbit* near/3 Antithymocyte*) or (rabbit* near/3 thymocyte*) or
(rabbit* near/3 polyclonal) or (rabbit* and ATG) or RATG or thymoglobulin*)
364
9 (Tacrolimus or Fujimycin or Prograf or Advagraf or Adoport or Capexion or Modigraf or Perixis or Tacni
or Vivadex or Protopic or Tsukubaenolide or “FK 506” or “FK-506” or “FK506” or “fr-900506”)
2587
10 MeSH descriptor: [Tacrolimus] this term only 1181
11 (Belatacept or Nulojix or “lea29y” or “lea 29y” or “bms 224818”) 87
12 (“Mycophenolic acid” or MPA or Mycophenolate or Arzip or CellCep* or Myfenax or Myfortic or Mofetil) 3477
13 (Sirolimus or Rapamune or Rapamycin or “ay 22-989”) 2200
14 MeSH descriptor: [Sirolimus] this term only 1071
15 (Everolimus or Zortress or Certican or Afinitor or Evertor or “SDZ RAD”) 940
16 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 7472
17 #6 and #16 Publication Year from 2014 to 2015 102
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Notes: the search strategy represents the whole of The Cochrane Library. CDSR and DARE results
downloaded but not CENTRAL or NHS EEDS as hits/results would have been picked up in the effectiveness
and cost-effectiveness searches.
File: N/A.
Database: Health Management Information Consortium (HMIC)
Host: Ovid.
Data parameters: 1979 to November 2014.
Date searched: Thursday 8 January 2015.
Hits: 0.
Search strategy
# Searches Results
1 Kidney Transplantation/ 121
2 (Kidney$ adj3 transplant$).ti,ab,kw,ot. 84
3 (Renal adj3 transplant$).ti,ab,kw,ot. 81
4 ((kidney or renal) adj3 (recipient$ or dono$ or donation$ or replac$)).ti,ab,kw,ot. 152
5 ((graft$ or allograft$ or homograft$ or allogeneic) and (kidney$ or renal)).ti,ab,kw,ot. 28
6 1 or 2 or 3 or 4 or 5 314
7 (Basiliximab or Basiliximabum or Simulect or “interleukin 2 receptor antibody”).ti,ab,kw,ot. 2
8 ((rabbit$ adj3 Anti-thymocyte$1) or (rabbit$ adj3 Antithymocyte$1) or (rabbit$ adj3 thymocyte$1) or
(rabbit$ adj3 polyclonal) or (rabbit$ and ATG) or RATG or thymoglobulin$2).ti,ab,kw,ot.
1
9 (Tacrolimus or Fujimycin or Prograf or Advagraf or Adoport or Capexion or Modigraf or Perixis or Tacni or
Vivadex or Protopic or Tsukubaenolide or “FK 506” or “FK-506” or “FK506” or “fr-900506”).ti,ab,kw,ot.
8
10 Tacrolimus/ 0
11 (Belatacept or Nulojix or “lea29y” or “lea 29y” or “bms 224818”).ti,ab,kw,ot. 0
12 (“Mycophenolic acid” or MPA or Mycophenolate or Arzip or CellCep$1 or Myfenax or Myfortic or
Mofetil).ti,ab,kw,ot.
23
13 (Sirolimus or Rapamune or Rapamycin or “ay 22-989”).ti,ab,kw,ot. 11
14 Sirolimus/ 0
15 (Everolimus or Zortress or Certican or Afinitor or Evertor or “SDZ RAD”).ti,ab,kw,ot. 2
16 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 33
17 6 and 16 3
18 16 and 17 3
19 limit 18 to yr=“2014 -Current” 0
Notes: N/A.
File: N/A.
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Ongoing studies
(Basiliximab OR Basiliximabum OR Simulect OR “interleukin 2 receptor antibody”) AND (kidney* OR renal)
((rabbit AND Anti-thymocyte*) OR (rabbit AND Antithymocyte*) OR (rabbit AND thymocyte*) OR (rabbit*
AND polyclonal) OR (rabbit* AND ATG) OR RATG OR thymoglobulin*) AND (kidney* OR renal)
(Tacrolimus OR Fujimycin OR Prograf OR Advagraf OR Adoport OR Capexion OR Modigraf OR Perixis OR
Tacni OR Vivadex OR Protopic OR Tsukubaenolide OR “FK 506” OR “FK-506” OR “FK506” OR
“fr-900506”) AND (kidney* OR renal)
(Belatacept OR Nulojix OR “lea29y” OR “lea 29y” OR “bms 224818”) AND (kidney* OR renal)
(“Mycophenolic acid” OR MPA OR Mycophenolate OR Arzip OR CellCep* OR Myfenax OR Myfortic OR
Mofetil) AND (kidney* OR renal)
(Sirolimus OR Rapamune OR Rapamycin OR “ay 22-989”) AND (kidney* OR renal)
(Everolimus OR Zortress OR Certican OR Afinitor OR Evertor OR “SDZ RAD”) AND (kidney* OR renal)
Cost-effectiveness searches
Database: MEDLINE
Host: Ovid.
Data parameters: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1946
to present.
Date searched: Thursday 15 January 2015.
Hits: 34.
Search strategy
# Searches Results
1 Kidney Transplantation/ 79,778
2 (Kidney$ adj3 transplant$).ti,ab,kw,ot. 34,082
3 (Renal adj3 transplant$).ti,ab,kw,ot. 40,996
4 ((kidney or renal) adj3 (recipient$ or dono$ or donation$ or replac$)).ti,ab,kw,ot. 35,985
5 ((graft$ or allograft$ or homograft$ or allogeneic) and (kidney$ or renal)).ti,ab,kw,ot. 45,333
6 1 or 2 or 3 or 4 or 5 112,264
7 (Basiliximab or Basiliximabum or Simulect or “interleukin 2 receptor antibody”).ti,ab,kw,ot. 1054
8 ((rabbit$ adj3 Anti-thymocyte$1) or (rabbit$ adj3 Antithymocyte$1) or (rabbit$ adj3 thymocyte$1)
or (rabbit$ adj3 polyclonal) or (rabbit$ and ATG) or RATG or thymoglobulin$2).ti,ab,kw,ot.
6278
9 (Tacrolimus or Fujimycin or Prograf or Advagraf or Adoport or Capexion or Modigraf or Perixis or
Tacni or Vivadex or Protopic or Tsukubaenolide or “FK 506” or “FK-506” or “FK506” or “fr-
900506”).ti,ab,kw,ot.
16,989
10 Tacrolimus/ 12,817
11 (Belatacept or Nulojix or “lea29y” or “lea 29y” or “bms 224818”).ti,ab,kw,ot. 217
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# Searches Results
12 (“Mycophenolic acid” or MPA or Mycophenolate or Arzip or CellCep$1 or Myfenax or Myfortic or
Mofetil).ti,ab,kw,ot.
27,735
13 (Sirolimus or Rapamune or Rapamycin or “ay 22-989”).ti,ab,kw,ot. 20,509
14 Sirolimus/ 13,403
15 (Everolimus or Zortress or Certican or Afinitor or Evertor or “SDZ RAD”).ti,ab,kw,ot. 3038
16 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 71,697
17 6 and 16 9482
18 Economics/ 26,539
19 exp Economics, Pharmaceutical/ 2535
20 exp Economics, Medical/ 13,480
21 exp Economics, Hospital/ 19,774
22 (pharmacoeconomic* or socioeconomics or economic$).ti,ab,kw. 180,610
23 ec.fs. 339,974
24 exp “Costs and Cost Analysis”/ 183,530
25 Cost of Illness/ 18,219
26 (cost* or cba or cea or cua or (value adj2 money) or pric$ or fiscal or funding or financial or finance
or budget$ or (expenditure$ not Energy)).ti,ab,kw.
517,055
27 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 872,822
28 17 and 27 431
29 limit 28 to yr=“2014 -Current” 34
Notes: N/A.
File: N/A.
Database: EMBASE
Host: Ovid.
Data parameters: EMBASE 1974 to 14 January 2015.
Date searched: Thursday 15 January 2015.
Hits: 139.
Search strategy
# Searches Results
1 kidney transplantation/ 97,901
2 (Kidney$ adj3 transplant$).ti,ab,kw,ot. 51,174
3 (Renal adj3 transplant$).ti,ab,kw,ot. 56,282
4 ((kidney or renal) adj3 (recipient$ or dono$ or donation$ or replac$)).ti,ab,kw,ot. 52,361
5 ((graft$ or allograft$ or homograft$ or allogeneic) and (kidney$ or renal)).ti,ab,kw,ot. 66,121
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# Searches Results
6 1 or 2 or 3 or 4 or 5 154,466
7 basiliximab/ 6765
8 (Basiliximab or Basiliximabum or Simulect or “interleukin 2 receptor antibody”).ti,ab,kw,ot. 2325
9 thymocyte antibody/ 20,465
10 ((rabbit$ adj3 Anti-thymocyte$1) or (rabbit$ adj3 Antithymocyte$1) or (rabbit$ adj3 thymocyte$1) or
(rabbit$ adj3 polyclonal) or (rabbit$ and ATG) or RATG or thymoglobulin$2).ti,ab,kw,ot.
8936
11 tacrolimus/ 54,246
12 (Tacrolimus or Fujimycin or Prograf or Advagraf or Adoport or Capexion or Modigraf or Perixis or Tacni
or Vivadex or Protopic or Tsukubaenolide or “FK 506” or “FK-506” or “FK506” or “fr-900506”).ti,ab,
kw,ot.
26,521
13 belatacept/ 1006
14 (Belatacept or Nulojix or “lea29y” or “lea 29y” or “bms 224818”).ti,ab,kw,ot. 555
15 mycophenolic acid/ 10,141
16 (“Mycophenolic acid” or MPA or Mycophenolate or Arzip or CellCep$1 or Myfenax or Myfortic or
Mofetil).ti,ab,kw,ot.
36,267
17 rapamycin/ 36,926
18 (Sirolimus or Rapamune or Rapamycin or “ay 22-989”).ti,ab,kw,ot. 29,195
19 everolimus/ 14,696
20 (Everolimus or Zortress or Certican or Afinitor or Evertor or “SDZ RAD”).ti,ab,kw,ot. 7151
21 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 150,139
22 6 and 21 25,879
23 exp Economics/ 220,609
24 models, economic/ 105,274
25 exp health economics/ 636,555
26 exp “Costs and Cost Analysis”/ 263,409
27 Cost of illness/ 14,621
28 resource allocation/ 15,767
29 pe.fs. 62,540
30 (cost$ or cba or cea or cua or (value adj2 money) or pric$ or fiscal or funding or financial or finance or
budget$ or (expenditure$ not Energy)).ti,ab,kw.
673,305
31 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 1,300,678
32 22 and 31 1475
33 limit 32 to yr=“2014 -Current” 139
Notes: N/A.
File: N/A.
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Database: Cochrane NHS EED
Host: Wiley Online Library.
Data parameters: Issue 4 of 4, October 2014.
Date searched: Thursday 15 January 2015.
Hits: 2.
Search strategy
ID Search Hits
1 MeSH descriptor: [Kidney Transplantation] this term only 3313
2 (Kidney* near/3 transplant*) 5959
3 (Renal near/3 transplant*) 4493
4 ((kidney or renal) near/3 (recipient* or dono* or donation* or replac*)) 3839
5 ((graft* or allograft* or homograft* or allogeneic) and (kidney* or renal)) 5193
6 #1 or #2 or #3 or #4 or #5 9189
7 (Basiliximab or Basiliximabum or Simulect or “interleukin 2 receptor antibody”) 522
8 ((rabbit* near/3 Anti-thymocyte*) or (rabbit* near/3 Antithymocyte*) or (rabbit* near/3 thymocyte*) or
(rabbit* near/3 polyclonal) or (rabbit* and ATG) or RATG or thymoglobulin*)
364
9 (Tacrolimus or Fujimycin or Prograf or Advagraf or Adoport or Capexion or Modigraf or Perixis or Tacni or
Vivadex or Protopic or Tsukubaenolide or “FK 506” or “FK-506” or “FK506” or “fr-900506”)
2587
10 MeSH descriptor: [Tacrolimus] this term only 1181
11 (Belatacept or Nulojix or “lea29y” or “lea 29y” or “bms 224818”) 87
12 (“Mycophenolic acid” or MPA or Mycophenolate or Arzip or CellCep* or Myfenax or Myfortic or Mofetil) 3477
13 (Sirolimus or Rapamune or Rapamycin or “ay 22-989”) 2200
14 MeSH descriptor: [Sirolimus] this term only 1071
15 (Everolimus or Zortress or Certican or Afinitor or Evertor or “SDZ RAD”) 941
16 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 7473
17 #6 and #16 Publication Year from 2014 to 2015 102
Notes: this search strategy represents the whole of The Cochrane Library (NHS EED 2, Groups 2,
CENTRAL 75, CDSR 20, DARE 3).
File: N/A.
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Database: Web of Science
Host: ISI Thompson Reuters.
Data parameters: 1900–current.
Date searched: Thursday 15 January 2015.
Hits: 55.
Search strategy
# Results Searches
16 55 #14 AND #13
Refined by: PUBLICATION YEARS: ( 2014 )
Timespan=All years
Search language=Auto
15 697 #14 AND #13
Timespan=All years
Search language=Auto
14 Approximately
3,354,783
TOPIC: (((pharmacoeconomic* or socioeconomics or economic* or pric* or cost* or cba or cea
or cua or “health utilit*” or “value for money”)))
Timespan=All years
Search language=Auto
13 Approximately
30,726
#12 AND #5
Timespan=All years
Search language=Auto
12 Approximately
261,400
#11 OR #10 OR #9 OR #8 OR #7 OR #6
Timespan=All years
Search language=Auto
11 Approximately
12,458
TOPIC: (((Everolimus or Zortress or Certican or Afinitor or Evertor or “SDZ RAD”)))
Timespan=All years
Search language=Auto
10 Approximately
175,118
TOPIC: (((“Mycophenolic acid” or MPA or Mycophenolate or Arzip or CellCep* or Myfenax or
Myfortic or Mofetil)))
Timespan=All years
Search language=Auto
9 554 TOPIC: (((Belatacept or Nulojix or “lea29y” or “lea 29y” or “bms 224818”)))
Timespan=All years
Search language=Auto
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# Results Searches
8 Approximately
65,143
TOPIC: (((Tacrolimus or Fujimycin or Prograf or Advagraf or Adoport or Capexion or Modigraf or
Perixis or Tacni or Vivadex or Protopic or Tsukubaenolide or “FK 506” or “FK-506” or “FK506”
or “fr-900506”)))
Timespan=All years
Search language=Auto
7 Approximately
21,632
TOPIC: ((((rabbit* near/3 Anti-thymocyte*) or (rabbit* near/3 Antithymocyte*) or (rabbit* near/3
thymocyte*) or (rabbit* near/3 polyclonal) or (rabbit* and ATG) or RATG or thymoglobulin*)))
Timespan=All years
Search language=Auto
6 2,283 TOPIC: (((Basiliximab or Basiliximabum or Simulect or “interleukin 2 receptor antibody”)))
Timespan=All years
Search language=Auto
5 Approximately
332,469
#4 OR #3 OR #2 OR #1
Timespan=All years
Search language=Auto
4 Approximately
158,169
TOPIC: ((((graft* or allograft* or homograft* or allogeneic) and (kidney* or renal))))
Timespan=All years
Search language=Auto
3 Approximately
122,313
TOPIC: ((((kidney or renal) near/3 (recipient* or dono* or donation* or replac*))))
Timespan=All years
Search language=Auto
2 Approximately
145,513
TOPIC: (((Renal near/3 transplant*)))
Timespan=All years
Search language=Auto
1 Approximately
163,622
TOPIC: (((Kidney* near/3 transplant*)))
Timespan=All years
Search language=Auto
Notes: auto suggest was turned off.
File: N/A.
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Database: EconLit
Host: EBSCOhost.
Data parameters: 1886–current.
Date searched: Thursday 15 January 2015.
Hits: 0.
Search strategy
(Basiliximab or Basiliximabum or Simulect or Tacrolimus or Fujimycin or Prograf or Advagraf or Adoport or
Capexion or Modigraf or Perixis or Tacni or Vivadex or Protopic or Tsukubaenolide or Belatacept or Nulojix
or “Mycophenolic acid” or MPA or Mycophenolate or Arzip or CellCep or Myfenax or Myfortic or Mofetil
or Sirolimus or Rapamune or Rapamycin or Everolimus or Zortress or Certican or Afinitor or Evertor) AND
(kidney or renal)
Notes: N/A.
File: N/A.
Database: Health Economic Evaluations Database (HEED)
Host: via The Cochrane Library.
Date searched: Monday 14 April 2014.
Hits: 35.
(Basiliximab or Basiliximabum or Simulect or Tacrolimus or Fujimycin or Prograf or Advagraf or Adoport or
Capexion or Modigraf or Perixis or Tacni or Vivadex or Protopic or Tsukubaenolide or Belatacept or Nulojix
or “Mycophenolic acid” or MPA or Mycophenolate or Arzip or CellCep or Myfenax or Myfortic or Mofetil
or Sirolimus or Rapamune or Rapamycin or Everolimus or Zortress or Certican or Afinitor or Evertor) AND
(kidney or renal)
Notes: the search recorded here was our initial search. HEED had closed by the time we updated the
searches, so we were unable to update our HEED searches.
File: N/A.
Searches for utility data: search strategy
The searches for utility data are recorded below. These searches took the following form: (terms for kidney
or renal transplant or kidney or renal graft or renal dialysis) AND (terms for utility questionnaires such as
SF36 or CHU 9D) and were run from database inception.
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and
Ovid MEDLINE(R)
Host: Ovid.
Data parameters: 1946 to present.
Date searched: 3 September 2014.
Volume: 714.
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Search strategy
# Searches Results
1 Kidney Transplantation/ 79,870
2 (Kidney$ adj3 transplant$).ti,ab,kw. 33,553
3 (Renal adj3 transplant$).ti,ab,kw. 40,747
4 ((kidney or renal) adj3 (recipient$ or dono$ or donation$ or replac$)).ti,ab,kw. 35,663
5 ((graft$ or allograft$ or homograft$ or allogeneic) and (kidney$ or renal)).ti,ab,kw. 45,183
6 1 or 2 or 3 or 4 or 5 112,067
7 Renal Dialysis/ 73,812
8 Peritoneal Dialysis/ 14,950
9 ((kidney or renal or peritoneal) and (dialysis or dialyses)).ti,ab,kw. 48,847
10 7 or 8 or 9 107,010
11 6 or 10 201,694
12 (euroqol or euro qol or eq5d or eq 5d or EQ-5D or EQ-5D-Y).ti,ab,kw. 4481
13 (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).ti,ab,kw. 1391
14 (sf10 or sf 10 or short form 10 or shortform 10 or sf ten or sften or shortform ten or short form ten).ti,
ab,kw.
77
15 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve of sftwelve or shortform twelve or short form
twelve).ti,ab,kw.
3016
16 (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or short
form sixteen).ti,ab,kw.
24
17 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty of sftwenty or shortform twenty of short
form twenty).ti,ab,kw.
341
18 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirstysix or
shortform thirty six or short form thirty six or short form thirtysix or short form thirty six).ti,ab,kw.
17,026
19 (health utilities index$ or (hui or hui1 or hui2 or hui3 or hui4 or hui-4 or hui-1 or hui-2 or hui-3)).ti,ab,kw. 1172
20 (“time trade off” or “time tradeoff” or TTO).ti,ab,kw. 1234
21 standard gamble$.ti,ab,kw. 697
22 (CHU9D or CHU 9D or “Child Health Utility”).ti,ab,kw. 13
23 “discrete choice”.ti,ab,kw. 713
24 (AQoL or “Assessment of Quality of Life”).ti,ab,kw. 1274
25 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 28,980
26 11 and 25 766
27 limit 26 to english language 714
Notes: N/A.
File name: MEDLINE.txt.
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Database: EMBASE
Host: Ovid.
Data parameters: 1974 to 2014 week 34.
Date searched: 3 September 2014.
Volume: 915
Search strategy
# Searches Results
1 kidney transplantation/ 96,703
2 (Kidney$ adj3 transplant$).ti,ab,kw. 50,181
3 (Renal adj3 transplant$).ti,ab,kw. 55,376
4 ((kidney or renal) adj3 (recipient$ or dono$ or donation$ or replac$)).ti,ab,kw. 51,117
5 ((graft$ or allograft$ or homograft$ or allogeneic) and (kidney$ or renal)).ti,ab,kw. 64,806
6 1 or 2 or 3 or 4 or 5 151,605
7 renal replacement therapy/ 36,722
8 peritoneal dialysis/ 23,371
9 ((kidney or renal or peritoneal) and (dialysis or dialyses)).ti,ab,kw. 64,637
10 7 or 8 or 9 97,785
11 6 or 10 224,149
12 (euroqol or euro qol or eq5d or eq 5d or EQ-5D or EQ-5D-Y).ti,ab,kw. 7316
13 (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).ti,ab,kw. 1533
14 (sf10 or sf 10 or short form 10 or shortform 10 or sf ten or sften or shortform ten or short form ten).ti,
ab,kw.
109
15 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve of sftwelve or shortform twelve or short form
twelve).ti,ab,kw.
4428
16 (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or short
form sixteen).ti,ab,kw.
35
17 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty of sftwenty or shortform twenty of short
form twenty).ti,ab,kw.
333
18 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirstysix or
shortform thirty six or short form thirty six or short form thirtysix or short form thirty six).ti,ab,kw.
23,918
19 Short Form 36/ 12,496
20 (health utilities index$ or (hui or hui1 or hui2 or hui3 or hui4 or hui-4 or hui-1 or hui-2 or hui-3)).ti,ab,kw. 1547
21 (“time trade off” or “time tradeoff” or TTO).ti,ab,kw. 1599
22 standard gamble$.ti,ab,kw. 812
23 (CHU9D or CHU 9D or “Child Health Utility”).ti,ab,kw. 13
24 “discrete choice”.ti,ab,kw. 958
25 (AQoL or “Assessment of Quality of Life”).ti,ab,kw. 1812
26 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 43,846
27 11 and 26 991
28 limit 27 to english language 915
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Notes: N/A.
File name: EMBASE.txt.
Database: The Cochrane Library (CENTRAL, HTA and NHS EED)
Host: Wiley Online Library.
Data parameters: CENTRAL Issue 8 of 12, August 2014; HTA and NHS EED Issue 3 of 4 July 2014.
Date searched: 3 September 2014.
Volume: 174.
Search strategy
ID Search Hits
1 MeSH descriptor: [Kidney Transplantation] this term only 3298
2 (Kidney* near/2 transplant*) 5497
3 (Renal near/2 transplant*) 3841
4 ((kidney or renal) near/2 (recipient* or dono* or donation* or replac*)) 3399
5 ((graft* or allograft* or homograft* or allogeneic) and (kidney* or renal)) 4785
6 #1 or #2 or #3 or #4 or #5 8307
7 MeSH descriptor: [Renal Dialysis] this term only 3496
8 MeSH descriptor: [Peritoneal Dialysis] this term only 417
9 ((kidney or renal or peritoneal) and (dialysis or dialyses)) 8888
10 #7 or #8 or #9 8888
11 #6 or #10 15,502
12 (euroqol or euro qol or eq5d or eq 5d or EQ-5D or EQ-5D-Y) 2221
13 (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six) 11,746
14 (sf10 or sf 10 or short form 10 or shortform 10 or sf ten or sften or shortform ten or short form ten) 12,533
15 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve of sftwelve or shortform twelve or short
form twelve)
9569
16 (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or short
form sixteen)
6668
17 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty of sftwenty or shortform twenty of short
form twenty)
7393
18 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirstysix or
shortform thirty six or short form thirty six or short form thirtysix or short form thirty six)
9081
19 (health utilities index* or (hui or hui1 or hui2 or hui3 or hui4 or hui-4 or hui-1 or hui-2 or hui-3)) 6541
20 (“time trade off” or “time tradeoff” or TTO) 512
21 standard gamble* 521
22 (CHU9D or CHU 9D or “Child Health Utility”) 3
23 “discrete choice” 47
24 (AQoL or “Assessment of Quality of Life”) 302
25 #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 22,511
26 #11 and #25 847
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Notes: N/A.
File name: Cochrane.txt.
Resource: ScHARRHUD
URL: (http://update-sbs.update.co.uk/scharr11/index.php?recordsN1&m=search).
Date searched: 3 September 2014.
Volume: 9.
Search strategy
kidney* or renal or dialysis
Notes: N/A.
File name: N/A.
Resource: EuroQoL website
URL: www.euroqol.org/eq-5d-references/reference-search.html.
Date searched: 3 September 2014.
Volume: 24.
Search strategy
kidney or renal or dialysis
Notes: 5 out of 24 were unique when de-duplicated against the EMBASE search.
File name: N/A.
Resource: HERC database of mapping studies
URL: www.herc.ox.ac.uk/downloads/mappingdatabase.
Date searched: 3 September 2014.
Volume: 0.
Search strategy
A hand-search of the Excel database was performed.
Notes: Dakin H. Review of studies mapping from quality of life or clinical measures to EQ-5D: an online
database. Health and Quality of Life Outcomes. 11:151. HERC database of mapping studies, Version 3.0
(Last updated: 26th June 2014). 2013. URL: www.herc.ox.ac.uk/downloads/mappingdatabase.
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Appendix 2 Excluded studies
TABLE 135 Excluded studies
Study Reason
Health Technology Assessment database. Immunosuppressive therapy for renal transplantation in
children and adolescents. In NICE 2006. HTA database Accession Number: 32006000316
Abstract
Health Technology Assessment database. Belatacept for prophylaxis of organ rejection in renal
transplantation. In National Horizon Scanning Centre 2008. HTA database Accession
Number: 32010000604
Abstract
Health Technology Assessment database. Everolimus (Certican) for prophylaxis of organ rejection in renal
or cardiac transplantation. In National Horizon Scanning Centre 2008. HTA database Accession
Number: 32010000590
Abstract
Health Technology Assessment database. Rapid HTA on the use of everolimus to prevent renal transplant
rejection. In Department of Science and Technology - Brazilian Health Technology Assessment General
Coordination (DECIT-CGATS) 2009. HTA database Accession Number: 32011000271
Abstract
Health Technology Assessment database. Tacrolimus (Advagraf®) for the prophylaxis of
transplantrejection in adult kidney or liver allograft recipients and the treatment of allograft rejection
resistant to treatment with other immunosuppressive medicinal products in adult patients. In All Wales
Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group
(AWMSG) 2009. HTA database Accession Number: 32012000410
Abstract
Health Technology Assessment database. Tacrolimus (Advagraf®). In All Wales Therapeutics and
Toxicology Centre (AWTTC) 2011. HTA database Accession Number: 32012000361
Abstract
Health Technology Assessment database. Belatacept (Nulojix®). In All Wales Therapeutics and Toxicology
Centre (AWTTC) 2012. HTA database Accession Number: 32012000600)
Abstract
Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, et al. Everolimus-based,
calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised,
controlled trial. Lancet 2011;377:837–47. [Erratum published in Lancet 2012;380:1994.]
No data
Albano L, Banas B, Klempnauer JL, Glyda M, Viklicky O, Kamar N, Optimising immunoSuppression
After Kidney transplantation with ADVAGRAF Study Group. OSAKA trial: a randomized, controlled trial
comparing tacrolimus QD and BD in kidney transplantation. Transplantation 2013;96:897–903
[Erratum published in Transplantation 2014;97:e38.]
No data
Silva AP, Tonato E, Durao Jr M, Requiao-Moura L, Arruda E, Chinen R, et al. A randomized clinical trial
of early conversion from tacrolimus to everolimus in deceased donor kidney transplantation. Transpl
Int 2013;26:277–78
Abstract
Abou-Jaoude MM, Ghantous I, Almawi WY. Tacrolimus (FK506) versus cyclosporin A microemulsion
(Neoral) maintenance immunosuppression: effects on graft survival and function, infection, and
metabolic profile following kidney transplantation (KT). Mol Immunol 2003;39:1095–100
Population
Abou-Jaoude MM, Irani-Hakime N, Ghantous I, Najm R, Afif C, Almawi WY. Cyclosporine microemulsion
(Neoral) versus tacrolimus (FK506) as maintenance therapy in kidney transplant patients. Transplant
Proc 2003;35:2748–9
Study design
Abou-Jaoude MM, Najm R, Shaheen J, Nawfal N, Abboud S, Alhabash M, et al. Tacrolimus (FK506)
versus cyclosporine microemulsion (neoral) as maintenance immunosuppression therapy in kidney
transplant recipients. Transplant Proc 2005;37:3025–8
Study design
Abramowicz D, Del Carmen Rial M, Vitko S, del Castillo D, Manas D, Lao M, et al. Cyclosporine
withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year,
prospective, randomized study. J Am Soc Nephrol 2005;16:2234–40
Population
Adu D, Cockwell P, Ives NJ, Shaw J, Wheatley K. Interleukin-2 receptor monoclonal antibodies in renal
transplantation: meta-analysis of randomised trials. BMJ 2003;326:789
Study design
Agha IA, Brennan DC. BK virus and current immunosuppressive therapy. Graft 2002;5:S65–72 Study design
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TABLE 135 Excluded studies (continued )
Study Reason
Ahlenstiel-Grunow T, Koch A, Großhennig A, Frömke C, Sester M, Sester U, et al. A multicenter,
randomized, open-labeled study to steer immunosuppressive and antiviral therapy by measurement
of virus (CMV, ADV, HSV)-specific T cells in addition to determination of trough levels of
immunosuppressants in pediatric kidney allograft recipients (IVIST01-trial): study protocol for a
randomized controlled trial. Trials 2014;15:324
Study design
Ahsan N, Holman MJ, Jarowenko MV, Razzaque MS, Yang HC. Limited dose monoclonal IL-2R antibody
induction protocol after primary kidney transplantation. Am J Transplant 2002;2:568–73
Intervention
Akalin E, Ames S, Sehgal V, Murphy B, Bromberg JS, Fotino M, Friedlander R. Intravenous
immunoglobulin and thymoglobulin induction treatment in immunologically high-risk kidney transplant
recipients. Transplantation 2005;79:742
Abstract
Al Najjar A, Etienne I, Le Pogamp P, Bridoux F, Le Meur Y, Toupance O, et al. Long-term results of
monoclonal anti-Il2-receptor antibody versus polyclonal antilymphocyte antibodies as induction therapy
in renal transplantation. Transplant Proc 2006;38:2298–9
Abstract
Al Najjar A, Etienne I, Toupance O, Westeel PF, Hurault De Ligny B, Rerolle JP, et al. Long term follow-up
of a multicenter randomized trial comparing a CNI-free regimen with sirolimus (SRL) to a cyclosporine
based regimen: the spiesser study. Am J Transplant 2010;10:505
Abstract
Albano L, Alamartine E, Toupance O, Moulin B, Merville P, Rerolle JP, et al. Conversion from everolimus
with low-exposure cyclosporine to everolimus with mycophenolate sodium maintenance therapy in
kidney transplant recipients: a randomized, open-label multicenter study. Ann Transplant 2012;17:58–67
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Albano L, Banas B, Kamar N. Safety and renal function in tacrolimus prolonged release vs tacrolimus
immediate release-based therapy in renal transplantation – The OSAKA study. Am J Transplant
2011;11:125
Abstract
Albano L, Banas B, Kamar N. Outcomes with tacrolimus-based immunosuppression after kidney
transplantation with standard-or extendedcriteria donor organsthe osaka study. Transpl Int 2013;26:59
Abstract
Albano L, Banas B, Rostaing L. Efficacy and optimised dosing in tacrolimus prolonged release vs
tacrolimus immediate release-based therapy in renal transplantation – The OSAKA study. Am J
Transplant 2011;11:125
Abstract
Albano L, Banas B, Klempnauer JL, Glyda M, Viklicky O, Kamar N, Optimising immunoSuppression
After Kidney transplantation with ADVAGRAF Study Group. OSAKA trial: a randomized, controlled trial
comparing tacrolimus QD and BD in kidney transplantation. Transplantation 2013;96:897–903
Population
Alberú J, Pascoe MD, Campistol JM, Schena FP, Rial Mdel C, Polinsky M, et al. Lower malignancy rates
in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy:
24-month results from the CONVERT trial. Transplantation 2011;92:303–10
Population
Alemi M, Samadzadeh B, Bardideh A, Heidarnejadiyan J, Torkaman Asadi F. The effect of preoperative
induction therapy with mycophenolate mofetil in early outcomes of living-donor renal allograft
transplantation. Int J Urol 2012;19:163
Abstract
Alloway R, Mulgaonkar S, Ueda K, Cohen D, Kaplan B. A Phase 2 randomized study of the
pharmacokinetics, safety and efficacy of LCP-Tacro tablets once-a-day vs Prograf capsules twice-a-day in
de novo kidney transplants. Am J Transplant 2011;11:355
Abstract
Alloway R, Steinberg S, Khalil K, Gourishankar S, Miller J, Norman D, et al. Conversion of stable kidney
transplant recipients from a twice daily Prograf-based regimen to a once daily modified release
tacrolimus-based regimen. Transplant Proc 2005;37:867–70
Study design
Alloway RR, Mulgaonkar S, Bowers VD, Stevenson KRU, Cohen DJ, Katz E, et al. A phase 2b, open-label,
multi-center, prospective, randomized study to compare the pharmacokinetics and safety of lcp-tacro
(TM) tablets once-a-day to prograf (R) capsules twice-a-day in de novo kidney transplant patients. Am J
Transplant 2009;9:414
Abstract
Alloway RR, Sadaka B, Trofe-Clark J, Wiland A, Bloom RD. Pharmacokinetic comparison of generic
tacrolimus (hecoria (TM)) versus prograf (R) in stable kidney transplant recipients: a randomized,
crossover study. Am J Transplant 2012;12:406
Abstract
Alpay N. Conversion from calcineurin inhibitors to everolimus resulted in decrease of serum TGF-beta
and urinary ngal in renal transplant recipients. Nephrol Dial Transplant 2013;28:i500–1
Abstract
Alvarado A, Chhabra D, Wang E, Najafian N, Friedewald J, Ho B, et al. Prospective randomized study
to evaluate the feasability of CNI elimination with conversion to sirolimus in prednisone-free
immunosuppressive regimen. Am J Transplant 2012;12:42
Abstract
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Study Reason
Andrassy J, Hoffmann VS, Rentsch M, Stangl M, Habicht A, Meiser B, et al. Is cytomegalovirus
prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? a systematic
review and meta-analysis. Transplantation 2012;94:1208–17
Duplicate
Andres A, Bloom R, Bunnapradist S, Cassuto E, Chan L, Hart M, et al. Randomized, multicenter study on
the safety and efficacy of enteric-coated mycophenolate sodium combined with basiliximab and low-or
standard dose of tacrolimus in de novo renal transplant patients. Transpl Int 2007;20:217
Abstract
Andrés A, Budde K, Clavien PA, Becker T, Kessler M, Pisarski P, et al. A randomized trial comparing
renal function in older kidney transplant patients following delayed versus immediate tacrolimus
administration. Transplantation 2009;88:1101–8
Study design
Andres A, del Castillo D, Gainza FJ, Purroy A, Bustamante J, Rengel M, et al. Comparison of a secuential
therapy with tacrolimus versusa standar triple therapy in aged kidney transplantation with aged donors:
results of a multicenter, prospective and randomized trial (Estrella Study). Am J Transplant 2007;7:443
Abstract
Andrés A, Delgado-Arranz M, Morales E, Dipalma T, Polanco N, Gutierrez-Solis E, et al. Extended-release
tacrolimus therapy in de novo kidney transplant recipients: single-center experience. Transplant Proc
2010;42:3034–7
Study design
Andres I, Font B, Mora S, Lahoz R, Ortega F. Quality of life of enteric-coated mycophenolate sodium
(EC-MPS) in renal transplant recipients with gastrointestinal tract complaints to mycophenolate mofetil
(MMF)Myvida study. Value Health 2009;12:A311
Abstract
Anil Kumar MS, Heifets M, Fyfe B, Saaed MI, Moritz MJ, Parikh MH, Kumar A. Comparison of steroid
avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney
transplantation monitored by surveillance biopsy. Transplantation 2005;80:807–14
Population
Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.
Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney
recipients monitored by surveillance biopsy: five-year outcomes. Transpl Immunol 2008;20:32–42
Population
Anonymous. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic
review and meta-analysis of individual patient data. BMJ 2014;349:g7543
No data
Perez-Simon J, Sr., Martino R, Parody R, Cabrero M, Lopez-Corral L, Valcarcel D, et al. The combination
of siromilus plus tacrolimus (SiTac) improves the results of cyclosporine plus mycophenolate mofetil
(CsAMMF) after reduced intensity conditioning (RIC) unrelated donor allogeneic transplantation.
Blood 2011;118:406–7
Abstract
Araki M, Flechner SM, Ismail HR, Flechner LM, Zhou L, Derweesh IH, et al. Posttransplant diabetes
mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. Transplantation
2006;81:335–41
Study design
Arns W, Breuer S, Choudhury S, Taccard G, Lee J, Binder V, et al. Enteric-coated mycophenolate sodium
delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant
2005;19:199–206
Outcome
Arns W, Neumayer HH, Lehner F, Witzke O, Sommerer C, Kliem V, et al. Herakles at month 24:
follow-up results on efficacy and safety of three different treatment regimens in de novo renal transplant
patients demonstrate options for individualized immunsosuppression. Transpl Int 2013;26:21
Abstract
Arns W, Sommerer C, Witzke O, Lehner F, Zeier M, Neumayer HH, et al. Efficacy and safety of three
different treatment regimens in de novo renal transplant patients: results of the herakles trial.
Transplantation 2012;94:995
Abstract
Arora S, Tangirala B, Osadchuk L, Sureshkumar KK. Belatacept : a new biological agent for maintenance
immunosuppression in kidney transplantation. Expert Opin Biol Ther 2012;12:965–79
Study design
Artz MA, Boots JM, Ligtenberg G, Roodnat JI, Christiaans MH, Hené RJ, et al. Randomized conversion
from cyclosporine to tacrolimus in renal transplant patients: improved lipid profile and unchanged
plasma homocysteine levels. Transplant Proc 2002;34:1793–4
Population
Artz MA, Boots JM, Ligtenberg G, Roodnat JI, Christiaans MH, Vos PF, et al. Improved cardiovascular risk
profile and renal function in renal transplant patients after randomized conversion from cyclosporine to
tacrolimus. J Am Soc Nephrol 2003;14:1880–8
Population
Artz MA, Boots JM, Ligtenberg G, Roodnat JI, Christiaans MH, Vos PF, et al. Conversion from
cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk
profile. Am J Transplant 2004;4:937–45
Population
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TABLE 135 Excluded studies (continued )
Study Reason
Åsberg A, Apeland T, Reisaeter AV, Foss A, Leivestad T, Heldal K, et al. Long-term outcomes after
cyclosporine or mycophenolate withdrawal in kidney transplantation - results from an aborted trial.
Clin Transpl 2013;27:E151–6
Population
Asberg A, Midtvedt K, Line PD, Narverud J, Holdaas H, Jenssen T, et al. Calcineurin inhibitor avoidance
with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant
recipients. Transplantation 2006;82:62–8
Comparator
Baas MC, Gerdes VE, Ten Berge IJ, Heutinck KM, Florquin S, Meijers JC, Bemelman FJ. Treatment with
everolimus is associated with a procoagulant state. Thromb Res 2013;132:307–11
Outcome
Baas MC, Kers J, Florquin S, de Fijter JW, van der Heide JJ, van den Bergh Weerman MA, et al.
Cyclosporine versus everolimus: effects on the glomerulus. Clin Transplant 2013;27:535–40
Study design
Baas MC, Kers J, Florquin S, Van Den Bergh Weerman MA, Ten Berge IJM, Bemelman FF. Prolonged
treatment with everolimus does not induce podocyte damage and leaves the glomerular basement
membrane intact. Am J Transplant 2011;11:317
Abstract
Baboolal K, Zaiac M, Zamauskaite A, Newstead C. This multicentre, randomised study comparing
conversion from calcineurin inhibitors (CNIs) to sirolimus versus standard therapy in renal allograft
recipients showed a lower rate of development of subsequent malignant disease in the group receiving
sirolimus. Am J Transplant 2009;9:238
Abstract
Baczkowska T, Perkowska-Ptasin´ska A, Sadowska A, Lewandowski Z, Nowacka-Cieciura E, Cieciura T,
et al. Serum TGF-beta1 correlates with chronic histopathological lesions in protocol biopsies of kidney
allograft recipients. Transplant Proc 2005;37:773–5
Intervention
Bakker RC, Hollander AA, Mallat MJ, Bruijn JA, Paul LC, de Fijter JW. Conversion from cyclosporine to
azathioprine at three months reduces the incidence of chronic allograft nephropathy. Kidney Int
2003;64:1027–34
Intervention
Bakr MA, Gheith OA, Ismael AM, Baz ME, Shehab El-Dein AB, Ghoneim MA. Rescue immunosuppressive
therapies in living-related renal allotransplant: a long-term prospective randomized evaluation. Exp Clin
Transplant 2008;6:48–53
Population
Balbontin FG, Kiberd B, Belistky P, Singh D, Fraser A, Lawen JG. One year randomized study comparing
cyclosporine microemulsion with C2 monitoring and tacrolimus in de novo kidney transplantation.
Am J Transplant 2004;4:236–7
Abstract
Balbontin FG, Kiberd B, Belitsky P, Singh D, Fraser A, Lawen JG. Six month randomized study comparing
cyclosporine microemulsion with C2 monitoring and tacrolimus in de novo kidney transplantation.
J Urol 2004;171:515
Outcome
Banas B, Albano L, Cassuto E, Glyda M, Klempnauer J, Lehner F, et al. The impact of acute rejection on
renal function-perspectives from the OSAKA study. Transplantation 2012;94:983
Abstract
Banas B, Boger CA, Lehner F. Efficacy, safety and optimised dosing in tacrolimus prolonged release vs
tacrolimus immediate release-based therapy in renal transplantation-the Osaka study. Transpl Int
2011;24:35
Abstract
Banas B, Cassuto E, Glyda M, Kamar N, Klempnauer J, Lehner F, et al. Selection of appropriate
composite endpoints is critical for assessing efficacy failure-perspectives from the OSAKA study.
Transplantation 2012;94:3
Abstract
Banas B, Kamar N, Lehner F, Albano L, Glyda M, Viklicky O. Acute rejection in renal transplantation
recipients treated with tacrolimus prolonged release-and immediate release-based therapy – The osaka
study (optimizing immunosuppression after kidney transplantationwith advagraf). Transpl Int
2011;24:38–9
Abstract
Banas B, Kruger B, Viklicky O. Tacrolimus prolonged release optimises exposure during the immediate
postoperative period. Transplantation 2012;94:81–2
Abstract
Bansal D, Yadav AK, Kumar V, Minz M, Sakhuja V, Jha V. Deferred pre-emptive switch from calcineurin
inhibitor to sirolimus leads to improvement in GFR and expansion of T regulatory cell population:
a randomized, controlled trial. PLOS ONE 2013;8:e75591
Study design
Barsoum RS, Morsey AA, Iskander IR, Morgan MM, Fayad TM, Atalla NT, et al. The Cairo kidney center
protocol for rapamycin-based sequential immunosuppression in kidney transplant recipients: 2-year
outcomes. Exp Clin Transplant 2007;5:649–57
Population
Bataille S, Moal V, Gaudart J, Indreies M, Purgus R, Dussol B, et al. Cytomegalovirus risk factors in renal
transplantation with modern immunosuppression. Transpl Infect Dis 2010;12:480–8
Outcome
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Study Reason
Becker LE, Xue Y, Gross ML, Waldherr R, Schwenger V, Zeier M, et al. Evolution of allograft fibrosis
and related markers in kidney transplant patients under treatment with cyclosporine and everolimus.
NDT Plus 2010;3:iii527
Abstract
Bemelman FJ, de Maar EF, Press RR, van Kan HJ, ten Berge IJ, Homan van der Heide JJ, de Fijter HW.
Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
Transplantation 2009;88:421–8
Population
Benfield MR, Tejani A, Harmon WE, McDonald R, Stablein DM, McIntosh M, Rose S, CCTPT Study
Group. A randomized multicenter trial of OKT3 mAbs induction compared with intravenous cyclosporine
in pediatric renal transplantation. Pediatr Transplant 2005;9:282–92
Study design
Bertoni E, Carta P, Salvadori M. Cyclosporine very low dose with everolimus high dose is associated with
excellent outcomes in renal transplant patients. Transpl Int 2011;24:112
Abstract
Bertoni E, Larti A, Rosso G, Zanazzi M, Di Maria L, Salvadori M. Good outcomes with cyclosporine very
low exposure with everolimus high exposure in renal transplant patients. J Nephrol 2011;24:613–8
Population
Birnbaum LM, Lipman M, Paraskevas S, Chaudhury P, Tchervenkov J, Baran D, et al. Management of
chronic allograft nephropathy: a systematic review. Clin J Am Soc Nephrol 2009;4:860–5
Population
Blydt-Hansen TD, Gibson IW, Birk PE. Histological progression of chronic renal allograft injury comparing
sirolimus and mycophenolate mofetil-based protocols. A single-center, prospective, randomized,
controlled study. Pediatr Transplant 2010;14:909–18
No data
Boggi U, Danesi R, Vistoli F, Del Chiaro M, Signori S, Marchetti P, et al. A benefit-risk assessment of
basiliximab in renal transplantation. Drug Saf 2004;27:91–106
Study design
Bolin P, Shihab FS, Mulloy L, Henning AK, Gao J, Bartucci M, et al. Optimizing tacrolimus therapy in the
maintenance of renal allografts: 12-month results. Transplantation 2008;86:88–95
Study design
Borda B, Lengyel C, Várkonyi T, Kemény E, Ottlakán A, Kubik A, et al. Side effects of the calcineurin
inhibitor, such as new-onset diabetes after kidney transplantation. Acta Physiol Hung 2014;101:388–94
Population
Bouwes Bavinck J. Prevention of skin cancer in organ transplant recipients. Br J Dermatol 2012;167:e2 Abstract
Bowman LJ, Edwards A, Brennan DC. The role of rabbit antithymocyte globulin in renal transplantation.
Exp Opin Orphan Drug 2014;2:971–87
Study design
Brar JE, Nader ND. Immune minimization strategies in renal transplantation. Immunol Invest
2014;43:807–18
Study design
Brennan DC, Koch MJ. Is mycophenolate mofetil really necessary in renal transplantation? A review of
the MYSS follow-up study. Nat Clin Pract Nephrol 2007;3:602–3
Abstract
Brennan DC, Agha I, Bohl DL, Schnitzler MA, Hardinger KL, Lockwood M, et al. Incidence of BK with
tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J
Transplant 2005;5:582–94
Population
Brennan DC, Daller JA, Lake KD, Cibrik D, Castillo D. Rabbit antithymocyte globulin versus basiliximab in
renal transplantation. N Engl J Med 2006;355:1967–77
Population
Bresnahan B, Vincenti F, Grinyo J, Charpentier B, Russo GD, Garg P, et al. Renal benefit of belatacept
versus cyclosporine in kidney transplant patients is not impacted by acute rejection (BENEFIT study).
Am J Transplant 2010;10:14
Abstract
Brian Stevens R, Skorupa JY, Rigley TH, Sandoz JP, Kellogg A, Miller N, et al. Calcineurin-inhibitor
withdrawalvs. Minimization after kidney transplantation is safe but does not improve renalfunction;
5-year results of a prospective, randomized trial. Am J Transplant 2010;10:505
Abstract
Budde K, Arns W, Sommerer C, Reinke P, Eisenberger U, Fischer W, et al. Improved renal function of an
everolimus/enteric-coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in
de novo renal transplant patients: 2 years follow-up of the zeus trial. Am J Transplant. 2010;10:503
Abstract
Budde K, Arns W, Sommerer C, Reinke P, Eisenberger U, Vogel EM, et al. Improved renal function of an
Everolimus/Enteric-Coated Mycophenolate Sodium regimen after calcineurin inhibitor withdrawal in
de novo renal transplant patients: 3 years follow-up of the ZEUS trial. Am J Transplant 2011;11:66
Abstract
Budde K, Arns W, Sommerer C, Lehner F, Zeier M, Neumayer H, et al. Superior renal function in an
everolimus-based calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate
and low cyclosporine/everolimus: follow-up of the herakles study at month 24. Am J Transplant
2013;13:310–1
Abstract
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Study Reason
Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, et al. Analysis of renal function in
everolimus/enteric-coated mycophenolate sodium treated de novo renal transplant recipients after
calcineurin inhibitor withdrawal: the ZEUS study. Am J Transplant 2009;9:259
Abstract
Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, et al. Everolimus-based,
calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised,
controlled trial. Lancet 2011;377:837–47
Population
Budde K, Bunnapradist S, Rostaing L. A phase III randomized trial of conversion to once-daily extended
release meltdose tacrolimus tablets (LCP-tacro) from twice-daily tacrolimus capsules (prograf): efficacy
results from an analysis of specific patient sub-populations. Transplantation 2012;94:984
Abstract
Budde K, Bunnapradist S, Grinyo JM, Ciechanowski K, Denny JE, Silva HT, Rostaing L, Envarsus study
group. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo
kidney transplants: one-year results of Phase III, double-blind, randomized trial. Am J Transplant
2014;14:2796–806
Population
Budde K, Curtis J, Knoll G, Chan L, Neumayer HH, Seifu Y, Hall M, ERL B302 Study Group.
Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant
patients: results of a 1-year study. Am J Transplant 2004;4:237–43
Population
Budde K, Glander P, Diekmann F, Dragun D, Waiser J, Fritsche L, et al. Enteric-coated mycophenolate
sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients. Transpl
Proc 2004;36:524S–7S
Population
Budde K, Knoll G, Curtis J, Kahana L, Pohanka E, Seifu Y, Neumayer HH. Safety and efficacy after
conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium: results of a 1-year
extension study. Transplant Proc 2005;37:912–5
Study design
Budde K, Knoll G, Curtis J, Chan L, Pohanka E, Gentil M, et al. [Long-term safety and efficacy
after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to
enteric-coated mycophenolate sodium (EC-MPA, myfortic).] Nieren- und Hochdruckkrankheiten
2006;35:454–64
Study design
Budde K, Knoll G, Curtis J, Chan L, Pohanka E, Gentil M, et al. Long-term safety and efficacy after
conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to
enteric-coated mycophenolate sodium (EC-MPA, myfortic). Clin Nephrol 2006;66:103–11
Language
Budde K, Lehner F, Arns W, Reinke P, Eisenberger U, Paulus EM, et al. Improved renal function of an
everolimus/enteric-coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in
de novo renal transplant patients: 4 years follow-up of the zeus trial. Am J Transplant 2012;12:298
Abstract
Budde K, Lehner F, Sommerer C, Arns W, Reinke P, Eisenberger U, et al. Conversion from cyclosporine
to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study. Am J
Transplant 2012;12:1528–40
Population
Budde K, Sommerer C, Haller H, Arns W, Kramer S, Vogel EM, et al. Renal function of an Everolimus
based therapy after Calcineurin Inhibitor withdrawal in maintenance renal transplant recipients: 2 year
data of the APOLLO trial. Am J Transplant 2011;11:411
Abstract
Budde K, Sommerer C, Haller H, Suwelack B, May C, Paulus EM, et al. Renal function of an everolimus
based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 3 year
data of the apollo trial. Am J Transplant 2012;12:298
Abstract
Budde K, Sommerer C, Reinke P, Haller H, Arns W, Witzke O, et al. Outcome on renal function of an
everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant
recipients: 4 year data of the apollo trial. Am J Transplant 2013;13:311–2
Abstract
Budde K, Witzke O, Sommerer C, Reinke P, Eisenberger U, Paulus E, et al. Improved renal function of
an everolimus/enteric-coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in
de novo renal transplant patients: 5 years follow-up of the zeus trial. Am J Transplant 2013;13:35–6
Abstract
Budde K, Zeier M, Haller H, Arns W, Kramer S, E MV, et al. Renal function of an everolimus based
therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients. Am J
Transplant 2010;10:504
Abstract
Büchler M, Caillard S, Barbier S, Thervet E, Toupance O, Mazouz H, et al. Sirolimus versus cyclosporine in
kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids.
Am J Transplant 2007;7:2522–31
Population
Bunnapradist S, Danovitch GM. Minimizing ciclosporin in renal transplant recipients on daclizumab,
mycophenolate and steroids. Nat Clin Pract Nephrol 2007;3:426–7
Abstract
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Bunnapradist S, Ciechanowski K, West-Thielke P, Mulgaonkar S, Rostaing L, Vasudev B, Budde K, MELT
investigators. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT):
the phase III randomized MELT trial. Am J Transplant 2013;13:760–9
Population
Burke GW. Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols Accompanied by
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2011;89:A16–7
Abstract
Campbell SB, Walker R, Tai SS, Jiang Q, Russ GR. Randomized controlled trial of sirolimus for renal
transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 2012;12:1146–56
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squamous cell cancer permits potential protective changes in immune phenotype. Transplantation
2012;94:167
Abstract
continued
DOI: 10.3310/hta20610 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 61
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Haasova et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
245
TABLE 135 Excluded studies (continued )
Study Reason
Carroll RP, Hester J, Wood KJ, Harden PN. Conversion to sirolimus in kidney transplant recipients with
squamous cell cancer and changes in immune phenotype. Nephrol Dial Transplant 2013;28:462–5
Population
Cataneo-Davila A, Zuniga-Varga J, Correa-Rotter R, Alberu J. Renal function outcomes in kidney
transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI
reduction or elimination. Transpl Proc 2009;41:4138–46
Population
Cerezo O, Bravo MG, Jimenez Aranda P, Lemus EA. Clinical benefits of immunosuppression therapy in
renal trasplant Patients. Systematic review and meta-analysis. Value Health 2013;16:A697
Abstract
Cerezo O, Bravo MG, Jimenez Aranda P, Lemus EA. Clinical benefits of immunosuppression therapy in
renal trasplant Patients. Systematic review and meta-analysis. Value Health 2013;16:A697
Duplicate
Chadban S, Campbell S, Russ G, Walker R, Chapman J, Pussell B, et al. A one-year, randomised, open
label, parallel group study to investigate the safety and efficacy of enteric-coated Mycophenolate sodium
(EC-MPS) in combination with full dose or reduced dose cyclosporine microemulsion (CSA-ME),
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profile of belatacept in kidney transplant recipients from the benefit and BENEFIT-EXT studies. Transpl
Int 2011;24:68–9
Abstract
Charpentier B, Groth CG, Bäckman L, Morales JM, Calne R, Kreis H, et al. Bicêtre hospital experience
with sirolimus-based therapy in human renal transplantation: the Sirolimus European Renal Transplant
Study. Transplant Proc 2003;35(Suppl. 3):58–61
Population
Charpentier B, Medina Pestana JO, Del C Rial M, Rostaing L, Grinyó J, Vanrenterghem Y, et al.
Long-term exposure to belatacept in recipients of extended criteria donor kidneys. Am J Transplant
2013;13:2884–91
Population
Charpentier B, Rostaing L, Berthoux F, Lang P, Civati G, Touraine JL, et al. A three-arm study comparing
immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or
cyclosporine A in adult renal transplant recipients. Transplantation 2003;75:844–51
Population
Charpentier B, Vincenti F, Rice K, Budde K, Campistol J, Duan T, et al. Three-year outcomes in patients
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2008;107:533–9
Population
Cheung CY, Chan HW, Liu YL, Chau KF, Li CS. Long-term graft function with tacrolimus and
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exposure and to withdraw steroids in pediatric renal transplant recipients. Pediatr Nephrol 2014;29:1755
Abstract
Chun DXY, Alexandre H, Sandrine GS, Olivier T, Isabelle E, Christophe L, et al. The phenotype of tubular
epithelial cells does not recover after a conversion from cyclosporine a to siroliumus. Nephrol Dial Transpl
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versus mycophenolate (MPA) in kidney transplant recipients receiving tacrolimus (TAC). Transplantation
2014;98:141
Abstract
Cruzado JM, Bestard O, Riera L, Torras J, Gil-Vernet S, Serón D, et al. Immunosuppression for dual
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transplantation: a country subset analysis of the Symphony study. Transpl Int 2009;22:1172–81
Population
Dharnidharka VR, Fiorina P, Harmon WE. Kidney transplantation in children. N Engl J Med
2014;371:549–58
Study design
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
248
TABLE 135 Excluded studies (continued )
Study Reason
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Facundo C, Diaz JM, Guirado L, Duran F, Herreros MA, Diaz M, Sola R. Results of a triple induction
regime with tacrolimus, mycophenolate mofetil, and prednisone in renal transplantation. Transplant
Proc 2002;34:98
Study design
Favi E, Citterio F, Spagnoletti G, Gargiulo A, Delreno F, Romagnoli J, Castagneto M. Prospective clinical
trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus
everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months
follow-up. Transplant Proc 2009;41:1152–5
Study design
Favi E, Citterio F, Spagnoletti G, Gargiulo A, Romagnoli J, Castagneto M. A prospective clinical trial
comparing tacrolimus-mmf to cyclosporine-everolimus in de novo renal transplant recipients: 2 years
results. Transpl Int 2009;22:241
Abstract
Favi E, Silvestrini N, Pedroso J, Salerno M, Spagnoletti G, Bianchi V, et al. Extended-release tacrolimus
plus everolimus vs extended-release tacrolimus plus micophenolate mofetil in primary deceased donor
kidney transplant recipients: 1-year results of an open label, randomized phase 2 clinical trial. Am J
Transpl 2013;13:316
Abstract
Favi E, Silvestrini N, Pedroso JA, Salerno MP, Spagnoletti G, Romagnoli J, et al. Er-tacrolimus plus
everolimus vs ertacrolimus plus MMF in primary deceased donor kidney transplantation: 1-year results of
single center, open label, prospective, randomized clinical trial. Transpl Int 2013;26:241
Abstract
Favi E, Silvestrini N, Salerno MP, Romagnoli J, Citterio F. Extended-release tacrolimus plus everolimus or
micophenolate mofetil in deceased donor kidney transplant recipients: 6-month results of a prospective
randomized clinical trial. Am J Transpl 2012;12:42–3
Abstract
Favi E, Silvestrini N, Spagnoletti G, Castagneto M, Citterio F. Thymoglobulin and basiliximab vs
basiliximab as induction therapy in deceased donor kidney transplantation: 1-year results of a prospective
clinical trial. Am J Transpl 2011;11:147
Abstract
Favi E, Silvestrini N, Valente I, Salerno MP, Castagneto M, Citterio F. Lower acute rejection with basiliximab
and short course, low dose thymoglobulin vs basiliximab as induction therapy in deceased donor renal
transplant recipients: 6-month results of a prospective clinical trial. Am J Transpl 2010;10:321
Abstract
Favi E, Spagnoletti G, Salerno MP, Pedroso JA, Romagnoli J, Citterio F. Tacrolimus plus mycophenolate
mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of
a single-center prospective clinical trial. Clin Transpl 2013;27:E359–67
Study design
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Study Reason
Favi E, Spagnoletti G, Silvestrini N, Salerno MP, Pedroso JA, Romagnoli J, et al. Thymoglobulin plus
basiliximab versus basiliximab induction in deceased donor kidney transplant recipients treated with
tacrolimus and MMF: 1-year results of a prospective clinical trial. Transpl Int 2013;26:83
Abstract
Favi E, Spagnoletti G, Silvestrini N, Salerno M, Pedroso J, Romagnoli J, et al. Thymoglobulin plus
basiliximab vs basiliximab as induction therapy in deceased donor kidney transplant recipients treated
with tacrolimus and mycophenolate mofetil: 1-year results of a prospective clinical trial. Am J Transpl
2013;13:426
Abstract
Felix M, Felipe C, Tedesco H, Medina-Pestana J. Safety profile after planned conversion from tacrolimus
(TAC) to sirolimus (SRL) based immunosuppressive therapy in kidney transplant recipients (KTR).
Transplantation 2014;98:544–5
Abstract
Fellstrom B, Holdas H, Holme I, Jardine A, Soveri I. Cardiovascular risk calculator for renal transplant
recipients: applications to BENEFIT and BENEFIT-EXT trials. Am J Transpl 2012;12:409–10
Abstract
Feng XF, Min M, Zuo FJ, Zhou MS, Wang LM. Conversion from tacrolimus to cyclosporine A improves
new-onset diabetes mellitus after transplantation. Chinese Journal of Tissue Engineering Research
2013;17:9176–81
Language
Ferguson R, Grinyó J, Vincenti F, Kaufman DB, Woodle ES, Marder BA, et al. Immunosuppression with
belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J
Transplant 2011;11:66–76
Population
Ferguson R, Vincenti F, Kaufman DB, Woodle ES, Marder BA, Citterio F, et al. Immunosuppression with
belatacept-based, CNI-avoiding and steroid-avoiding regimens vs a tacrolimus-based, steroid-avoiding
regimen in kidney transplant patients: results of a 1-year, randomized study. Am J Transpl 2010;10:150
Abstract
Ferrer F, Machado S, Alves R, Macário F, Bastos C, Roseiro A, Mota A. Induction with basiliximab in renal
transplantation. Transplant Proc 2010;42:467–70
Study design
Filipe R, Mota A, Alves R, Bastos C, Macário F, Figueiredo A, et al. Kidney transplantation with
corticosteroid-free maintenance immunosuppression: a single center analysis of graft and patient
survivals. Transplant Proc 2009;41:843–5
Study design
Filler G. Randomised clinical trial in paediatric renal transplantation: tacrolimus (tac) vs cyclosporine
neoral (cya) - 3-year data [abstract]. JASN 2003;14:65a
Abstract
Filler G. Finding the optimal therapeutic window for tacrolimus. Pediatr Transplant 2014;18:783–5 Study design
Fisher G, Rocha V, dos Santos M, Devergie A, Robin M, de Latour RP, et al. Myeophenolate mofetil
(MMF) with or without tracolimus (FK506) as a second line treatment for steroid-resistant acute
graft-versus-host disease. The experience of Saint Louis Hospital. Blood 2006;108:819A–A
Abstract
Flechner S, Friend P, Campistol J, Weir M, Diekmann F, Russ G. De novo immunosuppression with
mammalian target of rapamycin inhibitors and posttransplantation malignancy in focus. Transplant Proc
2009;41(Suppl. 6):42–4
Study design
Flechner S, Glyda M, Steinberg S, Harler MB, Invest OT. A randomized, open-label study to compare the
safety and efficacy of two different sirolimus (SRL) regimens with a tacrolimus (TAC) and mycophenolate
mofetil (MMF) regimen in de novo renal allograft recipients: renal function results from the Orion study.
Transplant Int 2007;20:25
Abstract
Flechner S, Glyda M, Steinberg S, Harler MB, Investigators OT. A randomized, open-label study to
compare the safety and efficacy of two different sirolimus (SRL) regimens with a tacrolimus (TAC) and
mycophenolate mofetil regimen (MMF) in De novo renal allograft recipients: acute rejection and graft
survival results from the orion study. Transplant Int 2007;20:209–10
Abstract
Flechner SM, Cockfield S, Grinyo J, Russ G, Wissing KM, Legendre C, et al. A randomized, open-label
study to compare the safety and efficacy of two different sirolimus (SRL) regimens with tacrolimus (TAC)
plus mycophenolate mofetil (MMF) in De Novo renal allograft recipients: preliminary 2-year safety results
from the ORION trial. Am J Transplant 2008;8:582
Abstract
Flechner SM, Glyda M, Tai SS. Delayed graft function (DGF) in two sirolimus (SRL)-based regimens
compared with tacrolimus (TAC) and mycophenolate mofetil (MMF) in de novo renal allograft recipients.
Am J Transplant 2009;9:277–8
Abstract
Flechner SM, Glyda M, Cockfield S, Grinyó J, Legendre Ch, Russ G, et al. The ORION study: comparison
of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft
recipients. Am J Transplant 2011;11:1633–44
Population
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TABLE 135 Excluded studies (continued )
Study Reason
Flechner SM, Goldfarb D, Modlin C, Feng JY, Krishnamurthi V, Mastroianni B, et al. Kidney
transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus
cyclosporin. Transplantation 2002;74:1070–6
Population
Flechner SM, Goldfarb D, Solez K, Modlin CS, Mastroianni B, Savas K, et al. Kidney transplantation with
sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized
prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007;83:883–92
Population
Flechner SM, Gurkan A, Hartmann A, Legendre CM, Russ GR, Campistol JM, et al. A randomized,
open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients.
Transplantation 2013;95:1233–41
Population
Flechner SM, Gurkan A, Tai SS, Schulman SL. Incidence of delayed graft function (DGF) in a sirolimus
(SRL)-based versus cyclosporine (CsA)-based regimen in de novo renal allograft recipients Am J
Transplant 2009;9:278
Abstract
Flechner SM, Kurian SM, Solez K, Cook DJ, Burke JT, Rollin H, et al. De novo kidney transplantation
without use of calcineurin inhibitors preserves renal structure and function at two years. Am J
Transplant 2004;4:1776–85
Population
Florman S, Becker T, Bresnahan B, Chevaile-Ramos A, Carvalho D, Muehibacher F, et al. Three year
outcomes by donor type in phase III studies of belatacept vs cyclosporine in kidney transplantation
(benefit and benefit-EXT). Transplant Int 2011;24:51
Abstract
Florman S, Becker T, Bresnahan B, Chevaile-Ramos A, DeCarvalho D, Muehlbacher F, et al. Three-year
outcomes by donor type in phase III studies of belatacept vs cyclosporine in kidney transplantation
(BENEFIT & BENEFIT-EXT). Am J Transplant 2011;11:100
Abstract
Florman S, Bresnahan B, Chan L, Helderman H, Dong Y, Harler MB, et al. Three year outcomes in
Black/African American kidney transplant recipients from the BENEFIT and BENEFIT-EXT studies. Am J
Transplant 2011;11:350
Abstract
Florman S, Durrbach A, Grinyo J, Pestana JOM, Rial MDC, Vitko S, et al. 4-year results from the
long-term extension of the belatacept BENEFIT-EXT study. Am J Transplant 2012;12:82
Abstract
Florman S, Durrbach A, Larsen C, Pestana JM, Vanrenterghem Y, Vincenti F, et al. Outcomes as a
function of donor criteria from a phase III study of belatacept vs cyclosporine in kidney transplantation
(benefitext). Am J Transplant 2010;10:150
Abstract
Florman S, Rice K, Chan L, Steinberg S, Pearson T, Duan T, et al. Four-year outcomes in black/African
American kidney transplant recipients from the long-term extension of the belatacept BENEFIT and
BENEFIT-EXT studies. Am J Transplant 2012;12:404
Abstract
Florman S, Rice K, Chan L, Zhang R, Abouljoud M, Steinberg S, et al. Outcomes at five years in
black/African-American kidney transplant recipients from the long-term extension of the belatacept
benefit and BENEFIT-EXT studies. Am J Transplant 2013;13:311
Abstract
Foroncewicz B, Mucha K, Ciszek M, Małkowski P, Durlik M, Szmidt J, et al. A comparison between
two tacrolimus-based immunosuppression regimens in renal transplant recipients: 7-year follow-up.
Ann Transplant 2013;18:384–92
Study design
Forsythe J. A phase II open label single centre randomized study of tacrolimus plus sirolimus and
corticosteroids compared with tacrolimus plus azathioprine and corticosteroids in de novo renal allografts
recipients. 2002. National Research Register, UK. URL: www.nrr.nhs.uk/ (accessed 25 July 2014)
Unobtainable
Franz S, Regeniter A, Hopfer H, Mihatsch M, Dickenmann M. Tubular toxicity in sirolimus- and
cyclosporine-based transplant immunosuppression strategies: an ancillary study from a randomized
controlled trial. Am J Kidney Dis 2010;55:335–43
Study design
Frei U, Daloze P, Vítko S, Klempnauer J, Reyes-Acevedo R, Titiz I, et al. Acute rejection in low-toxicity
regimens: clinical impact and risk factors in the Symphony study. Clin Transplant 2010;24:500–9
Population
Friend PJ. Thymoglobulin induction and steroid-free immunosuppression in kidney transplantation from
deceased donors after cardiac death – an open label randomised controlled trial to evaluate the role of
thymoglobulin as induction immunosuppression in kidney transplants from deceased donors after cardiac
death. 2011. URL: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/711/CN-00796711/frame.
html (accessed 25 July 2014)
No data
Frimat L, Cassuto-Viguier E, Charpentier B, Noël C, Provôt F, Rostaing L, et al. Impact of cyclosporine
reduction with MMF: a randomized trial in chronic allograft dysfunction. The ‘reference’ study. Am J
Transplant 2006;6:2725–34
Population
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Study Reason
Frimat L, Cassuto-Viguier E, Provôt F, Rostaing L, Charpentier B, Akposso K, et al. Long-Term Impact of
Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year
Follow Up. J Transplant 2010;2010:402750
Population
Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft
recipients: results from an open-label, randomized trial. Transplantation 2008;86:1187–95
Population
Gallon L, Monica G, Friedewald J, Cabral B, Miller J, Najafaian N, et al. Prospective randomized study to
evaluate feasibility of conversion of CNI to SRL in a pred-free immunosuppressive regimen. Impact on
treg generation. Am J Transplant 2009;9:260
Abstract
Gallon L, Perico N, Dimitrov BD, Winoto J, Remuzzi G, Leventhal J, et al. Long-term renal allograft
function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs.
MMF. Am J Transplant 2006;6:1617–23
Population
Gamboa O, Montero C, Mesa L, Benavides C, Reino A, Torres RE, Castillo JS. Cost-effectiveness analysis
of the early conversion of tacrolimus to mammalian target of rapamycin inhibitors in patients with renal
transplantation. Transplant Proc 2011;43:3367–76
Population
Martin Garcia D, Martin Gago J, Mendiluce A, Gordillo R, Bustamente J. Tacrolimus-Basiliximab versus
Cyclosporine-Basiliximab in renal transplantation “de novo”: acute rejection and complications.
Transplant Proc 2003;35:1694–6
Study design
Garcia I, Spanish-Italian Tacrolimus Study Group. Efficacy and safety of dual versus triple
tacrolimus-based therapy in kidney transplantation: two-year follow-up. Transplant Proc 2002;34:1638–9
Comparator
Garcia R, Machado PG, Felipe CR, Park SI, Spinelli GA, Franco MF, et al. Exploratory calcineurin
inhibitor-free regimens in living-related kidney transplant recipients. Braz J Med Biol Res 2007;40:457–65
Study design
van Gelder T, Silva HT, de Fijter H, Budde K, Kuypers D, Mamelok RD, et al. How delayed graft function
impacts exposure to mycophenolic acid in patients after renal transplantation. Ther Drug Monit
2011;33:155–64
Population
van Gelder T, Silva HT, de Fijter JW, Budde K, Kuypers D, Tyden G, et al. Comparing mycophenolate
mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial.
Transplantation 2008;86:1043–51
Comparator
van Gelder T, Tedesco Silva H, de Fijter JW, Budde K, Kuypers D, Arns W, et al. Renal transplant patients
at high risk of acute rejection benefit from adequate exposure to mycophenolic acid. Transplantation
2010;89:595–9
Comparator
Gelder T, ter Meulen CG, Hené R, Weimar W, Hoitsma A. Oral ulcers in kidney transplant recipients
treated with sirolimus and mycophenolate mofetil. Transplantation 2003;75:788–91
Study design
Gelens MA, Christiaans MH, van Heurn EL, van den Berg-Loonen EP, Peutz-Kootstra CJ, van Hooff JP.
High rejection rate during calcineurin inhibitor-free and early steroid withdrawal immunosuppression in
renal transplantation. Transplantation 2006;82:1221–3
Population
Gheith O, Al-Otaibi T, Mansour H. Next-generation calcineurin inhibitors in development for the
prevention of organ rejection. Transplant Research and Risk Management 2014;6:23–30
Study design
Glotz D, Charpentier B, Abramovicz D, Lang P, Rostaing L, Rifle G, et al. 6 months preliminary results of
a randomized trial comparing sirolimus (SRL) versus tacrolimus (FK) in 141 transplant patients receiving a
cadaveric renal graft. Am J Transplant 2005;5:460
Study design
Glotz D, Charpentier B, Abramovicz D, Lang P, Rostaing L, Rifle G, et al. Thymoglobulin induction and
sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids.
Transplantation 2010;89:1511–7
Abstract
Gonwa T, Johnson C, Ahsan N, Alfrey EJ, Halloran P, Stegall M, et al. Randomized trial of tacrolimus plus
mycophenolate mofetil or azathioprine versus cyclosporine plus mycophenolate mofetill after cadaveric
kidney transplantation: results at three years. Transplantation 2003;75:2048–53
Population
Gonwa T, Mendez R, Yang HC, Weinstein S, Jensik S, Steinberg S, Prograf Study Group. Randomized
trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation:
results at 6 months. Transplantation 2003;75:1213–20
Population
Gonzalez F, Espinoza M, Herrera P, Rocca X, Reynolds E, Lorca E, et al. Everolimus versus azathioprine
in a cyclosporine and ketoconazole-based immunosuppressive therapy in kidney transplant: 3-year
follow-up of an open-label, prospective, cohort, comparative clinical trial. Transplant Proc 2010;42:270–2
Study design
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Study Reason
Gonzalez Molina M, Morales JM, Marcen R, Campistol JM, Oppenheimer F, Serón D, et al. Renal
function in patients with cadaveric kidney transplants treated with tacrolimus or cyclosporine. Transplant
Proc 2007;39:2167–9
Study design
Graeme R, Mamta A, Thomas B, Bresnahan B, Campistol JM, Darji P, et al. Belatacept associated with
preserved renal function and structure compared with cyclosporine (CSA) in kidney transplant patients.
Immunol Cell Biol 2010;88(6):A11–12
Abstract
Graeme R, Steve C, Scott C, Brian H, John K, Philip O, et al. Everolimus plus reduced-dose cyclosporine:
results from a randomized, phase iii study in 833 De-novo renal transplant recipients. Immunol Cell Biol
2010;88:A22
Study design
Grafals M. Low Dose Thymoglobulin as Induction Agent on Prednisone-Free Regimens of Renal
Transplant Recipients. 2011. URL: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/457/
CN-00794457/frame.html (accessed 25 July 2014)
Comparator
Grannas G, Richter N, Klempnauer J, Lehner F. 10 years’ experience with belatacept (nulojix).
Transplantation 2012;94:964
Abstract
Grannas G, Schrem H, Klempnauer J, Lehner F. Ten years experience with belatacept-based
immunosuppression after kidney transplantation. J Clin Med Res 2014;6:98–110
Study design
Gregoor P, De Sevaux RGL, Ligtenberg G, Hoitsma AJ, Hene RJ, Weimar W, et al. Withdrawal of
cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy:
a randomized, prospective, multicenter study. J Am Soc Nephrol 2002;13:1365–73
Study design
Grinyo J, Abouljoud M, Germain M, Manfro R, Morales J, Legendre C, et al. Improving or sustaining
renal function over 3 years with belatacept or cyclosporine a (CSA): insights from the benefit study.
Transplant Int 2011;24:250
Abstract
Grinyo J, Abouljoud M, Germain M, Manfro R, Morales J, Legendre C, et al. Likelihood of improving or
sustaining renal function over three years with belatacept or CsA: insights from the BENEFIT study. Am J
Transplant 2011;11:349
Abstract
Grinyo J, Alberu J, Contieri FL, Manfro RC, Mondragon G, Nainan G, et al. Improvement in renal
function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year
results from the long-term extension of a phase II study. Transplant Int 2012;25:1059–64
Population
Grinyo J, Charpentier B, Medina Pestana J, Vanrenterghem Y, Vincenti F, Shi R, et al. Safety profile of
belatacept in kidney transplant recipients from a pooled analysis of phase II and phase III studies. NDT
Plus 2010;3:iii270
Abstract
Grinyo J, Durrbach A, Rostaing L, Bresnahan B, Helderman J, Rice K, et al. Likelihood of improving or
maintaining renal function over five years with belatacept or CSA: insights from the benefit long-term
extension study. Am J Transplant 2013;13:182
Abstract
Grinyo J, Florman S, Medina Pestana JO, Del Carmen Rial M, Muehlbacher F, Durrbach A, et al.
Long-term extension of the belatacept BENEFIT-EXT study: results at month 48. Transplantation
2012;94:974
Abstract
Grinyo J, Nainan G, Del Carmen Rial M, Steinberg S, Vincenti F, Dong Y, et al. Renal function at 2 years
in kidney transplant recipients switched from cyclcosporine or tacrolimus to belatacept: results from the
long-term extension of a phase II study. Transplant Int 2011;24:70
Abstract
Grinyo J, Nainan G, Rial M, Steinberg S, Vincenti F, Dong Y, et al. Renal function at 2 years in kidney
transplant recipients switched from cyclosporine or tacrolimus to belatacept: results: from the long-term
extension of a phase II study. Am J Transplant 2011;11:99
Abstract
Grinyo J, Pestana JM, Becker T, Rial MC, Dong Y, Block A, et al. Likelihood of improving or sustaining
renal function over three years with belatacept or CsA: insights from the BENEFIT-EXT study. Am J
Transplant 2012;12:82
Abstract
Grinyo J, Rial M, Alberu J, Steinberg S, Manfro R, Nainan G, et al. Outcomes of switching to belatacept
from a calcineurin inhibitor in kidney transplant recipients: 3 year results from the long-term extension of
a phase ii study. Am J Transplant 2013;13:182
Abstract
Grinyo J, Vanrenterghem Y, Durrbach A, Rial M, Charpentier B, Matas A, et al. Likelihood of improving
or maintaining renal function in recipients of extended-criteria donor kidneys over five years with
belatacept or CsA (benefit-ext long-term extension study). Am J Transplant 2013;13:310
Abstract
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Study Reason
Grinyo JM, Campistol JM, Paul J, García-Martínez J, Morales JM, Prats D, et al. Pilot randomized study
of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation.
Am J Transplant 2004;4:1308–14
Study design
Grinyo JM, Ekberg H, Mamelok RD, Oppenheimer F, Sanchez-Plumed J, Gentil MA, et al. The
pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or
low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic
substudy. Nephrol Dial Transplant 2009;24:2269–76
Population
Grinyo JM, Marks W, Vincenti F, Kaufman DB, Marder BA, Woodle S, et al. Immunosuppression with
belatacept-based, CNI-free, steroid-avoiding regimens in kidney transplant recipients: 6 month, interim
results. Am J Transplant 2009;9:382
Abstract
Grinyo JM, Mondragon-Ramirez G, Darji P, Bresnahan B, Pearson T, Di Russo GB, et al. Belatacept is
associated with preservation of renal function and structure at 1 year compared to cyclosporine in kidney
transplant patients (BENEFIT Study). Am J Transplant 2009;9:258–9
Abstract
Grinyo JM, Paul J, Novoa P, Errasti P, Franco A, Aldana G, et al. Better renal function in renal-transplant
recipients treated with everolimus plus cyclosporine elimination compared with cyclosporine
minimisation. Am J Transplant 2010;10:503
Abstract
Grushkin C, Mahan JD, Mange KC, Hexham JM, Ettenger R. De novo therapy with everolimus and
reduced-exposure cyclosporine following pediatric kidney transplantation: a prospective, multicenter,
12-month study. Pediatr Transplant 2013;17:237–43
Population
Gu YH, Du JX, Ma ML. Sirolimus and Non-melanoma Skin Cancer Prevention After Kidney
Transplantation: A Meta-analysis (Provisional Abstract). DARE; 2012. DARE Accession Number:
12013033631. URL: http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?AccessionNumber=
12013033631&UserID=0 (accessed 25 July 2014)
Population
Gu YH, Du JX, Ma ML. Sirolimus and non-melanoma skin cancer prevention after kidney transplantation:
a meta-analysis. Asian Pac J Cancer Prev 2012;13:4335–9
Population
Guba M, Pratschke J, Hugo C, Kraemer B, Burmeister D, Brockmann J, et al. A randomized multicenter
trial of early conversion to sirolimus/mycophenolate/steroids versus cyclosporine/mycophenolate/steroids
in renal transplantation: one-year analysis (SMART-study). Am J Transplant 2009;9:497
Abstract
Guba M, Pratschke J, Hugo C, Kraemer B, Nohr-Westphal C, Brockmann J, et al. Renal function, efficacy
and safety of sirolimus and mycophenolat mofetil therapy after early calcineurin-inhibitor withdrawal in
de novo renal transplant patients: one-year analysis of a randomized multicenter trial. Transplant Int
2009;22:78
Abstract
Guba M, Pratschke J, Hugo C, Krämer BK, Nohr-Westphal C, Brockmann J, et al. Renal function,
efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based
quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter
trial. Transplantation 2010;90:175–83
Population
Guba M, Witzke O, Lehner F, Arns W, Sommerer C, Neumayer HH, et al. The herakles study at
24 month: superior renal function in an everolimus-based cnifree regimen. Transplant Int 2013;26:110
Abstract
Guerra G, Ciancio G, Gaynor JJ, Zarak A, Brown R, Hanson L, et al. Randomized trial of
immunosuppressive regimens in renal transplantation. JASN 2011;22:1758–68
Study design
Guerra G, Gaynor JJ, Ciancio G, Zarak A, Sageshima J, Roth D, et al. Randomized trial of
tacrolimus/sirolimus versus tacrolimus/mycophenolate versus cyclosporine (neoral (r))/sirolimus in renal
transplantation: seven year results. Am J Transplant 2009;9:325
Abstract
Gupta D. Design of a randomized study evaluating everolimus in pediatric renal transplant recipients.
Transplant Int 2013;26:328
Abstract
Gürkan A, Kaçar S, Erdogdu U, Varilsüha C, Kandemir G, Karaca C, et al. The effect of sirolimus in the
development of chronic allograft nephropathy. Transplant Proc 2008;40:114–6
Population
Hakemi M, Shahebrahimi K, Ganji MR, Najafi I, Broumand B. Side effects of mycophenolate mofetil
versus azathioprine in iranian renal transplant recipients (single-center experience). Transplant Proc
2002;34:2091–2
Study design
Hamdy AF, Bakr MA, Ghoneim MA. Long-term efficacy and safety of a calcineurin inhibitor-free regimen
in live-donor renal transplant recipients. J Am Soc Nephrol 2008;19:1225–32
Population
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Study Reason
Hamdy AF, Bakr MA, Ghoneim MA. Proteinuria among primarily sirolimus treated live-donor renal
transplant recipients' long-term experience. Exp Clin Transplant 2010;8:283–91
Population
Hamdy AF, El-Agroudy AE, Bakr MA, Mostafa A, El-Baz M, El-Shahawy el-M, Ghoneim MA. Comparison
of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live
donor renal transplantation. Am J Transplant 2005;5:2531–8
Population
Han D, Kim Y-S, Park KT, Kim S-J, Ha J-W, Kim H-C, et al. A Phase III, Randomized, open-label,
comparative, multicenter study to assess the safety and efficacy of prograf (R) (tacrolimus) and extended
release (XL) Tacrolimus in asian de novo kidney transplants from living donors: 6 month results. Am J
Transplant 2009;9:413
Abstract
Han DJ, Park JB, Kim YS, Kim SJ, Ha J, Kim HC, et al. A 39-month follow-up study to evaluate the safety
and efficacy in kidney transplant recipients treated with modified-release tacrolimus (FK506E)-based
immunosuppression regimen. Transplant Proc 2012;44:115–7
Study design
Han F, Wu J, Huang H, Zhang X, He Q, Wang Y, et al. Conversion from cyclosporine to sirolimus in
chronic renal allograft dysfunction: a 4-year prospective study. Exp Clin Transplant 2011;9:42–9
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Hanaway M, Woodle ES, Mulgaonkar S, Peddi R, Harrison G, Vandeputte K, et al. 12 month results of
a multicenter, randomized trial comparing three induction agents (alemtuzumab, thymoglobulin and
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transplantation. Am J Transplant 2008;8:215
Abstract
Hardinger KL, Bohl DL, Schnitzler MA, Lockwood M, Storch GA, Brennan DC. A randomized,
prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with
thymoglobulin in renal transplant recipients. Transplantation 2005;80:41–6
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Harold Y. A phase III, randomized, open-label, comparative, multi-center study to assess the safety
and efficacy of Prograf (R) (Tacrolimus)/MMF, extended release (XL) Tacrolimus/MMF and Neoral (R)
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Abstract
Havenith SH, Yong SL, Donselaar-van der Pant KA, Lier RA, Berge IJ, Bemelman FJ. Everolimus-treated
renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with
cyclosporine- or mycophenolate-treated patients. Transplantation 2013;95:184–91
Study design
Hazzan M, Buob D, Labalette M, Provot F, Glowacki F, Hoffmann M, et al. Assessment of the risk of
chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial.
Transplantation 2006;82:657–62
Outcome
Hazzan M, Labalette M, Copin MC, Glowacki F, Provôt F, Pruv FR, Noël C. Predictive factors of acute
rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate
mofetil: results from a prospective, randomized trial. J Am Soc Nephrol 2005;16:2509–16
Outcome
Heilman RL, Cortese C, Geiger XJ, Younan K, Wadei HM, Mai ML, et al. Impact of early conversion from
tacrolimus to sirolimus on chronic allograft changes in kidney recipients on rapid steroid withdrawal.
Transplantation 2012;93:47–53
Population
Heilman RL, Younan K, Wadei HM, Mai ML, Reddy KS, Chakkera HA, Gonwa TA. Results of a
prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid
withdrawal. Transplantation 2011;92:767–73
Population
Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin
inhibitors: a systematic review and meta-analysis. Am J Transplant 2004;4:583–95
Population
Heller T, Gelder T, Budde K, Fijter JW, Kuypers D, Arns W, et al. Plasma concentrations of mycophenolic
acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. Am J Transplant
2007;7:1822–31
Outcome
Hernández D, Miquel R, Porrini E, Fernández A, González-Posada JM, Hortal L, et al. Randomized
controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based
immunosuppression. Transplantation 2007;84:706–14
Population
Hertig A, Kamar N, Anglicheau D, Moulin B, Hazzan M, Hurault De Ligny B, et al. Epithelial to
mesenchymal transition markers in kidney transplant recipients: the certitem trial. Transplant Int
2013;26:2
Abstract
Hest RM, Gelder T, Vulto AG, Mathot RA. Population pharmacokinetics of mycophenolic acid in renal
transplant recipients. Clin Pharmacokinet 2005;44:1083–96
Study design
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Hirsch HH, Vincenti F, Friman S, Wiecek A, Pescovitz MD, Jenssen T, et al. Prospective study of
polyomavirus BK viruria and viremia in De Novo renal transplantation comparing cyclosporine and
tacrolimus: a multivariate analysis. Am J Transplant 2009;9:337
Abstract
Hirsch HH, Vincenti F, Friman S, Tuncer M, Citterio F, Wiecek A, et al. Polyomavirus BK replication in de
novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized,
multicenter study. Am J Transplant 2013;13:136–45
Outcome
Ho ETL, Wong G, Chapman JR, Craig J. Once daily extended release versus twice daily standard release
tacrolimus in kidney transplant recipients: a systematic review. Transplantation 2012;94:989
Abstract
Hoerning A, Köhler S, Jun C, Lu J, Fu J, Tebbe B, et al. Cyclosporin but not everolimus inhibits
chemokine receptor expression on CD4+ T cell subsets circulating in the peripheral blood of renal
transplant recipients. Clin Exp Immunol 2012;168:251–9
Outcome
Holdaas H, Rostaing L, Serón D, Cole E, Chapman J, Fellstrøm B, et al. Conversion of long-term kidney
transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter,
24-month study. Transplantation 2011;92:410–8
Duplicate
Holdaas H, Rostaing L, Serón D, Cole E, Chapman J, Fellstrøm B, et al. Conversion of long-term kidney
transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter,
24-month study. Transplantation 2011;92:410–8
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Holdaas H, Rostaing L, Serón D, Cole E, Chapman J, Fellstrøm B, et al. Conversion of long-term kidney
transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter,
24-month study. Transplantation 2011;92:410–8
Population
Holdaas H, Rostaing L, Serón D, Cole E, Chapman J, Fellstrøm B, et al. Conversion of long-term kidney
transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter,
24-month study. Transplantation 2011;92:410–8
Duplicate
Homan Van Der Heide JJ, De Fijter JW, Ten Berge I, De Maar EF, Bemelman FJ. Mecano: mycophenolate
sodium vs everolimus or ciclosporin with allograft nephropathy as outcome study: clinical results.
Transplant Int 2011;24:85
Abstract
Hooff J, Walt I, Kallmeyer J, Miller D, Dawood S, Moosa MR, et al. Pharmacokinetics in stable kidney
transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations. Therapeutic
Drug Monitoring 2012;34:46–52
Study design
van Hooff JP, Squifflet JP, Vanrenterghem Y. Benelux experience with a combination of tacrolimus and
mycophenolate mofetil: 4-year results. Transplant Proc 2002;34:1591–3
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Hooff JP, Squifflet JP, Wlodarczyk Z, Vanrenterghem Y, Paczek L. A prospective randomized multicenter
study of tacrolimus in combination with sirolimus in renal-transplant recipients.
Transplantation 2003;75:1934–9
Comparator
Hoogendijk-van den Akker JM, Harden PN, Hoitsma AJ, Proby CM, Wolterbeek R, Bouwes Bavinck JN,
de Fijter JW. Two-year randomized controlled prospective trial converting treatment of stable renal
transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus. J Clin Oncol
2013;31:1317–23
Study design
Howell M, Yeo R, Tong A, Craig JC, Howard K, Wong G. Adverse events of maintenance
immunosuppression following kidney transplantation reported in randomised controlled trials: a
systematic review. URL: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/360/CN-01009360/
frame.html (accessed 25 July 2014)
Abstract
Huang HF, Yao X, Chen Y, Xie WQ, Shen-Tu JZ, Chen JH. Cyclosporine A and tacrolimus combined with
enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a
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Outcome
Huh W, Lee K, Lee K, Kim S, Joh J, Oh H. Randomized trial of tacrolimus versus cyclosporine in steroid
withdrawal regimen after living kidney transplantation. Clin Pharmacol Ther 2003;73:P26
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Iaria G, Pisani F, Iorio B, Lucchesi C, De Luca L, Ielpo B, et al. Long-term results of kidney transplantation
with cyclosporine- and everolimus-based immunosuppression. Transplant Proc 2006;38:1018–9
Study design
Ibrahim H, Issa N, Spong R, Kukla A, Kandaswamy R, Dunn T, et al. CNI reduction vs. mTOR based
immunosuppression after prednisone discontinuation: four year preliminary results from a large
randomized trial. Am J Transplant 2012;12:302
Abstract
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Study design
Nicholson M. A prospective randomised trial of the use of cellcept to allow early tacrolimus withdrawal
in live donor kidney transplantation. ISRCTN. URL: www.controlled-trials.com/ISRCTN63298320
(accessed 25 July 2014)
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2011;11:410
Abstract
Jevnikar A, Arlen D, Barrett B, Boucher A, Cardella C, Cockfield SM, et al. Five-year study of tacrolimus
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chronic renal allograft failure. Transplantation 2008;86:953–60
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Joannides R, Etienne I, Iacob M, Hurault de Ligny B, Barbier S, Bellien J, et al. Comparative effects of
sirolimus and cyclosporin on conduit arteries endothelial function in kidney recipients. Transpl Int
2010;23:1135–43
Population
Joannidès R, Monteil C, de Ligny BH, Westeel PF, Iacob M, Thervet E, et al. Immunosuppressant regimen
based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine.
Am J Transplant 2011;11:2414–22
Population
Johari Y, Bryson D, Nicholson M. A randomised controlled trial comparing switching to rapamune based
immunosuppression with tacrolimus minimisation for renal transplantation. Br J Surg 2010;97:68–9
Abstract
Johari Y, Bryson D, Barlow A, Nicholson M. Cyclosporine micro-emulsion versus tacrolimus for renal
transplantation: 10-year follow-up for single centre randomised controlled trial. Br J Surg 2010;97:32–3
Abstract
Johari Y, Bryson D, Medcalf J, Nicholson M. Cyclosporine versus tacrolimus for renal transplantation:
10 year follow up of a randomised controlled trial. Br J Surg 2010;97:37
Abstract
Jose M, Caring for Australians with Renal Impairment (CARI). The CARI guidelines. Calcineurin inhibitors
in renal transplantation: adverse effects. Nephrology 2007;12(Suppl. 1):66–74
Study design
Joss N, Rodger RS, McMillan MA, Junor BJ. Randomized study comparing cyclosporine with azathioprine
one year after renal transplantation-15-year outcome data. Transplantation 2007;83:582–7
Population
Junge G, De Simone P, Fung J, Kohler S, Saliba F. Urinary protein excretion in non-renal transplant
patients-does mTOR-inhibitor treatment matter? Am J Transplant 2013;13:531–2
Abstract
Junge G, Tufveson G, Riad H, Cibrik D, Tedesco H, Schwende H, et al. Better renal allograft function
with everolimus facilitated CNI reduction - Graft type, donor criteria and gender analysis. NDT Plus
2010;3:iii540
Abstract
Jungraithmayr TC, Wiesmayr S, Staskewitz A, Kirste G, Bulla M, Fehrenbach H, et al. Five-year outcome
in pediatric patients with mycophenolate mofetil-based renal transplantation. Transplantation
2007;83:900–5
Study design
Jurewicz WA. Tacrolimus versus ciclosporin immunosuppression: long-term outcome in renal
transplantation. Nephrol Dial Transplant 2003;18:i7–i11
Population
Kaabak M, Babenko N, Zokoyev A, Schekaturov S, Sandrikov V. Eculizumab for prevention and
treatment of kidney graft reperfusion injury, preliminary results of RCT. Transplantation 2014;98:257–8
Abstract
Kahan BD. Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to
cyclosporine-based immunosuppressive regimens in renal transplantation. Transplant Proc 2003;
35(Suppl. 3):37–51
Population
Kalil AC, Florescu DF, Sun J. Induction immunosuppression: what is the difference in the risk of serious
infections between interleukin-2RA and polyclonal antibodies? Am J Transplant 2009;9:283
Abstract
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Kalil AC, Florescu MC, Grant W, Miles C, Morris M, Stevens RB, et al. Risk of serious opportunistic
infections after solid organ transplantation: interleukin-2 receptor antagonists versus polyclonal
antibodies. A meta-analysis. Expert Rev Anti Infect Ther 2014;12:881–96
Study design
Kamar N, Allard J, Ribes D, Durand D, Ader JL, Rostaing L. Assessment of glomerular and tubular
functions in renal transplant patients receiving cyclosporine A in combination with either sirolimus or
everolimus. Clin Nephrol 2005;63:80–6
Study design
Kamar N, Lehner F, Banas B, Viklicky O, Albano L, Glyda M. Efficacy and safety of tacrolimus prolonged
release and immediate release in de novo renal transplantation – the osaka study (optimizing
immunosuppression after kidney transplantation with advagraf). Transplant Int 2011;24:39
Abstract
Kamar N, Rial M, Alberu J, Steinberg SM, Manfro R, Nainan G, et al. 3-year outcomes after switching to
belatacept from a calcineurin inhibitor in stable kidney transplant recipients. Transplant Int 2013;26:44
Abstract
Kamar N, Rial M, Alberu J, Steinberg S, Manfro R, Nainan G, et al. Three-years outcomes after switching
to belatacept from calcineurin inhibitor in stable kidney transplant recipients. Transplant Int 2013;26:22
Abstract
Kamar N, Rostaing L, Cassuto E, Villemain F, Moal MC, Ladrière M, et al. A multicenter, randomized trial
of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced
tacrolimus exposure in maintenance kidney transplant recipients. Clin Nephrol 2012;77:126–36
Population
Kandaswamy R, Melancon JK, Dunn T, Tan M, Casingal V, Humar A, et al. A prospective randomized
trial of steroid-free maintenance regimens in kidney transplant recipients – an interim analysis. Am J
Transplant 2005;5:1529–36
Population
Kang MH, Kim HJ, Ko RK, Ko SK. A systematic review of immunosuppressive regimens in lower
immunological risk renal transplant recipients. Value Health 2010;13:A473–4
Abstract
Kang MH, Kim HJ, Ko RK, Ko SK. A systematic review of immunosuppressive regimens in lower
immunological risk renal transplant recipients. Value Health 2010;13:A473–4
Duplicate
Karpe Krishna M, Talaulikar Girish S, Walters G. Calcineurin inhibitor withdrawal or tapering for kidney
transplant recipients. Cochrane Database System Rev 2007;4:CD006750
Study design
Kasiske BL, de Mattos A, Flechner SM, Gallon L, Meier-Kriesche HU, Weir MR, Wilkinson A. Mammalian
target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant
2008;8:1384–92
Study design
Keown P, Balshaw R, Khorasheh S, Chong M, Marra C, Kalo Z, Korn A. Meta-analysis of basiliximab for
immunoprophylaxis in renal transplantation. BioDrugs 2003;17:271–9
Population
Ke-Pu L, Xiao-Min Y, Shuai-Jun M, Zhi-Bin L, Geng Z, Jian-Lin Y. Effects of tacrolimus and cyclosporine A
on inflammatory cytokines and blood lipid after renal transplantation. Journal of Clinical Rehabilitative
Tissue Engineering Research 2011;15:5769–72
Language
Keven K, Sahin M, Kutlay S, Sengul S, Erturk S, Ersoz S, Erbay B. Immunoglobulin deficiency in kidney
allograft recipients: comparative effects of mycophenolate mofetil and azathioprine. Transpl Infect Dis
2003;5:181–6
Outcome
Khosroshahi HT, Tubbs RS, Shoja MM, Ghafari A, Noshad H, Ardalan MR. Effect of prophylaxis with
low-dose anti-thymocyte globulin on prevention of acute kidney allograft rejection. Transplant Proc
2008;40:137–9
Population
Khwaja K, Asolati M, Harmon J, Melancon JK, Dunn T, Gillingham K, et al. Outcome at 3 years with a
prednisone-free maintenance regimen: a single-center experience with 349 kidney transplant recipients.
Am J Transplant 2004;4:980–7
Study design
Kihm LP, Hinkel UP, Michael K, Sommerer C, Seckinger J, Morath C, et al. Contrast enhanced
sonography shows superior microvascular renal allograft perfusion in patients switched from cyclosporine
A to everolimus. Transplantation 2009;88:261–5
Population
Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug
monitoring in clinical practice? A systematic review. Transplantation 2008;85:1675–85
Study design
Knoll GA, Kokolo MB, Mallick R, Beck A, Buenaventura CD, Ducharme R, et al. Effect of sirolimus on
malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual
patient data. BMJ 2014;349:g6679
Duplicate
Knoll GA, Kokolo MB, Mallick R, Beck A, Buenaventura CD, Ducharme R, et al. Effect of sirolimus on
malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual
patient data. BMJ 2014;349:g6679
Study design
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Kobashigawa J, Ross H, Kfoury AG, Van Bakel A, Ewald G, Burton J, et al. CMV infections are less
frequent in de novo heart transplant recipients receiving immunosuppression with everolimus plus
reduced CsA compared to MMF and standard CsA. Am J Transplant 2011;11:131–2
Abstract
Koch M, Becker T, Lueck R, Neipp M, Klempnauer J, Nashan B. Basiliximab induction therapy in kidney
transplantation: benefits for long term allograft function after 10 years? Biologics 2009;3:51–6
Study design
Koukoulaki M, Grispou U, Pistolas D, Balaska K, Apostolou T, Anagnostopoulou M, et al. Monitoring of
BK polyoma virus in renal transplant recipients. Preliminary results of a prospective study. Nephrol Dial
Transplant 2005;20:V177–V
Abstract
Kovac D, Kotnik V, Kandus A. Basiliximab and mycophenolate mofetil in combination with low-dose
cyclosporine and methylprednisolone effectively prevent acute rejection in kidney transplant recipients.
Transplant Proc 2005;37:4230–4
Study design
Kramer B. Significantly better freedom from acute rejection with tacrolimus vs. cyclosporine-based
immunosuppression in renal transplant recipients at 7-year follow-up. Am J Transplant 2010;10:568
Abstract
Kramer B, Kruger B, Banas B, Tomlinson P. Early post-transplant blood levels in de novo renal recipients
on tacrolimus prolonged release (TACQD) versus tacrolimus immediate release (TACBD) in A phase III
double-blind double-dummy study. Transplant Int 2011;24:54
Abstract
Kramer BK. Better tolerability and significantly higher freedom from acute rejection at 7 years with
tacrolimus vs. cyclosporine-based immunosuppression in renal transplant recipients. NDT Plus
2010;3:iii284
Abstract
Krämer BK, Böger C, Krüger B, Marienhagen J, Pietrzyk M, Obed A, et al. Cardiovascular risk estimates
and risk factors in renal transplant recipients. Transplant Proc 2005;37:1868–70
Population
Krämer BK, Del Castillo D, Margreiter R, Sperschneider H, Olbricht CJ, Ortuño J, et al. Efficacy and safety
of tacrolimus compared with ciclosporin A in renal transplantation: three-year observational results.
Nephrol Dial Transplant 2008;23:2386–92
Population
Krämer BK, Charpentier B, Bäckman L, Silva HT, Mondragon-Ramirez G, Cassuto-Viguier E, et al.
Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation:
a randomized phase III study. Am J Transplant 2010;10:2632–43
Population
Krämer BK, Klinger M, Vítko Sˇ, Glyda M, Midtvedt K, Stefoni S, et al. Tacrolimus-based, steroid-free
regimens in renal transplantation: 3-year follow-up of the ATLAS trial. Transplantation 2012;94:492–8
Comparator
Krämer BK, Klinger M, Wlodarczyk Z, Ostrowski M, Midvedt K, Stefoni S, et al. Tacrolimus combined
with two different corticosteroid-free regimens compared with a standard triple regimen in renal
transplantation: one year observational results. Clin Transplant 2010;24:E1–9
Study design
Krämer BK, Montagnino G, Castillo D, Margreiter R, Sperschneider H, Olbricht CJ, et al. Efficacy and
safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year
follow-up results. Nephrology, Dialysis, Transplantation 2005;20:968–73
Study design
Kramer BK, Zulke C, Kammerl MC, Schmidt C, Hengstenberg C, Fischereder M, et al. Cardiovascular risk
factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal
transplantation. Am J Transplant 2003;3:982–7
Outcome
Kreis H. Worse renal transplant outcomes with sirolimus-mycophenolate than with calcineurin inhibitor
regimens. Nat Clin Pract Nephrol 2007;3:424–5
Study design
Krischock L, Marks SD. Induction therapy: why, when, and which agent? Pediatr Transplant
2010;14:298–313
Study design
Kumar A, Zaman W, Chaurasia D, Gupta A, Sharma RK, Gulati S. Prospective randomized trial to
evaluate the efficacy of single low dose ATG induction in renal transplant recipient with spousal kidney.
Indian J Urol 2002;19:58–62
Study design
Kumar N, Manimaran R, Williams C, Ravanan R. Tacrolimus preserves renal function better than
cyclosporin at 10 years – long term results of a randomised controlled trial. Am J Transplant 2009;9:200
Abstract
Kwon O, Cho JH, Choi JY, Park SH, Kim YL, Kim HK, et al. Long-term outcome of azathioprine versus
mycophenolate mofetil in cyclosporine-based immunosuppression in kidney transplantation: 10 years of
experience at a single center. Transplant Proc 2013;45:1487–90
Study design
Kyllönen LE, Eklund BH, Pesonen EJ, Salmela KT. Single bolus antithymocyte globulin versus basiliximab
induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety.
Transplantation 2007;84:75–82
Population
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Langer RM, Hené R, Vitko S, Christiaans M, Tedesco-Silva H, Ciechanowski K, et al. Everolimus plus early
tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation.
Transpl Int 2012;25:592–602
Study design
Langer RM, Pape L, Tonshoff B, Dello Strologo L, Ettenger R, Niaudet P, et al. Evaluation of safety and
efficacy of everolimus with reduced tacrolimus: design of a randomized, multicenter, open-label study in
pediatric renal transplant recipients. Pediatr Transplant 2013;17:80
Abstract
Langone AJ, Chan L, Bolin P, Cooper M. Enteric-coated mycophenolate sodium versus mycophenolate
mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter,
double-blind, randomized study. Transplantation 2011;91:470–8
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Larsen C, Alberu J, Massari P, Acevedo RR, Kamar N, Lin CS, et al. 4-Year results from the long-term
extension of the belatacept BENEFIT study. Am J Transplant 2012;12:82
Abstract
Larsen C, Vincenti F, Grinyo J, Rice K, Steinberg S, Gaite L, et al. Long-term belatacept exposure
maintains efficacy and safety at 5 years: results from the long-term extension (LTE) of the belatacept
evaluation of nephroprotection and efficacy as first-line immunosuppression trial (benefit) study. Am J
Transplant 2013;13:312
Abstract
Larsen C, Vincenti F, Grinyo JM, Charpentier B, Di Russo GB, Garg P, et al. Renal benefit of belatacept vs
cyclosporine in kidney transplant patients is not impacted by acute rejection (BENEFIT Study). Am J
Transplant 2009;9:220
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Larsen CP, Bray R, Gebel H, Ganguly B, Kulbokas E, Brickman D, et al. Evaluation of donor-specific
antibodies in kidney transplant patients treated with belatacept-or cyclosporine-based
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Am J Transplant 2006;6:514–22
Population
Lawen JG, Davies EA, Mourad G, Oppenheimer F, Molina MG, Rostaing L, et al. Randomized
double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor
monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal
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inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/
everolimus. Transplant Internat 2013;26:28
Abstract
Lehner F, Sommerer C, Arns W, Eisenberger U, Reinke P, Pressmar K, et al. A post hoc analysis of
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Study design
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Study design
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Study design
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2010;42:1297–302
Population
Lou HX, Vathsala A. Conversion from mycophenolate mofetil to azathioprine in high-risk renal allograft
recipients on cyclosporine-based immunosuppression. Transplant Proc 2004;36:2090–1
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Study design
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2011;43:1395–404
Study design
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Abstract
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Study design
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Abstract
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Abstract
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Transplant 2005;5:1164
Study design
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Montagnino G, Krämer BK, Arias M, European Tacrolimus vs Cyclosporin Microemulsion Renal
Transplantation Study Group. Efficacy and safety of tacrolimus compared with cyclosporine
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Abstract
Montagnino G, Sandrini S, Casciani C, Schena FP, Carmellini M, Civati G, et al. A randomized trial of
steroid avoidance in renal transplant patients treated with everolimus and cyclosporine. Transplant Proc
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Moore R. New-onset diabetes after renal transplantation: comparing ciclosporin and tacrolimus. Nature
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Morales JM, Andrés A, Dominguez-Gil B, Arriola M, Gutiérrez MJ, Hernández E, et al. Ten years of
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Study design
Morales JM, Campistol JM, Kreis H, Mourad G, Eris J, Schena FP, et al. Sirolimus-based therapy with or
without cyclosporine: long-term follow-up in renal transplant patients. Transplant Proc 2005; 37:693–6
Language
Morales JM, Grinyó JM, Campistol JM, García-Martínez J, Arias M, Paul J, et al. Improved renal function,
with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus
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Study design
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improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with
continuous cyclosporine. Transplant Proc 2009;41:2339–44
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Morales JM, Tedesco-Silva H, Peddi VR, Russ GR, Marder BA, Hahn CM, et al. Planned transition from
tacrolimus to sirolimus versus continued tacrolimus in renal allograft patients. Transplant Int 2013;26:81
Abstract
Moscarelli L, Caroti L, Antognoli G, Zanazzi M, Di Maria L, Carta P, Minetti E. Everolimus leads to
a lower risk of BKV viremia than mycophenolic acid in de novo renal transplantation patients:
a single-center experience. Clin Transplant 2013;27:546–54
Study design
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and steroids. Transplantation 2004;78:584–90
Population
Mourer JS, Hartigh J, Zwet EW, Mallat MJ, Dubbeld J, Fijter JW. Randomized trial comparing late
concentration-controlled calcineurin inhibitor or mycophenolate mofetil withdrawal. Transplantation
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renal allograft patients receiving sirolimus and corticosteroids: results from an open-label comparative
study. Transpl Int 2014;27:176–86
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follow-up. Iran J Kidney Dis 2012;6:300–6
Population
Nashan B, Ivens K, Suwelack B, Arns W, Abbud Filho M, myPROMS DE02 Study Group. Conversion from
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MMF in de novo Kidney Transplant Recipients. URL: www.clinicaltrials.gov/ct2/show/NCT00064701
(accessed 25 July 2014)
No data
NCT. An Open-Label, Concentration Controlled, Randomized, 12 Month Study of Prograf + Rapamune +
Cor [Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients].
URL: www.clinicaltrials.gov/ct2/show/NCT00044720 (accessed 25 July 2014)
Study design
Nguyen C, Shapiro R. New immunosuppressive agents in pediatric transplantation. Clinics
2014;69(Suppl. 1):8–16
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switch to an everolimus-based therapy with cni elimination/minimization does not overall impact graft
function: the ascertain study. Immunol Cell Biol 2011;89:A5
Abstract
O'Connell P, Fassett R, Pilmore H, Chapman J, Hutchison B, Russ G, et al. Post-HOC analysis of the
ascertain trial: everolimus based therapy with CNI elimination improves renal function in select
populations. Immunol Cell Biol 2011;89:A5
Abstract
Oh C, Huh K, Lee J, Lee J, Cho H, Kim Y. Multicenter randomized clinical investigation for the safety and
efficacy of advagraf (R) (extended-release tacrolimus) vs. prograf (R) (twice-daily tacrolimus) in de novo
korean adult kidney recipients. Am J Transplant 2013;13:317
Abstract
Oh CK, Huh KH, Ha J, Kim YH, Kim YL, Kim YS. Safety and efficacy of the early introduction of
everolimus with reduced-exposure cyclosporine a in de novo kidney recipients. Transplantation
2015;99:180–6
Population
Oppenheimer F, Rebollo P, Grinyo JM, Ortega F, Sanchez-Plumed J, Gonzalez-Molina M, et al.
Health-related quality of life of patients receiving low-toxicity immunosuppressive regimens: a substudy
of the Symphony Study. Transplantation 2009;87:1210–3
Intervention
Ortega F, Sanchez-Fructuoso A, Cruzado JM, Gomez-Alamillo JC, Alarcon A, Pallardo M, et al. Quality
of life and tolerability of enteric-coated mycophenolate sodium (EC-MPS) in renal transplant recipients
with gastrointestinal tract complaints to mycophenolate mofetil (MMF): a multicenter, randomized,
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induction therapy followed by tacrolimus conversion to sirolimus at 3 months does not expand treg cells.
Transplantation 2012;94:771
Abstract
Pankewycz O, Leca N, Wallace P, Said M, Feng L, Patel S, et al. Rabbit anti-thymocyte globulin (rATG)
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Ponticelli C, Salvadori M, Scolari MP, Citterio F, Rigotti P, Veneziano A, Bartezaghi M, EVEREST Study.
Everolimus and minimization of cyclosporine in renal transplantation: 24-month follow-up of the
EVEREST study. Transplantation 2011;91:e72–3
Comparator
Prokopenko E, Scherbakova E, Vatazin A, Pasov S, Budnikova N, Agafonova S. Does mycophenolate
mofetil increase the incidence of infections in renal transplant recipients? Drugs Exp Clin Res
2005;31:199–205
Study design
Pussell B, Russ G, Walker R, Campbell S, O'Connell P, Kanellis J, et al. Conversion from calcineurin
inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients:
18-month efficacy and safety results from a large, randomized, open-label, comparative trial.
Immunol Cell Biol 2006;84:A19–20
Abstract
Reinke P, Haller H, Rath T, Arns W, Paulus EM, Scheidf S, et al. Two year data of the apollo trial: renal
function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal
transplant recipients. Transplant Int 2011;24:50
Abstract
Reinke P, Lehner F, Witzke O, Sommerer C, Eisenberger U, Arns W, et al. 5 Years follow-up on renal
function-ZEUS trial: improved renal function of an everolimus/enteric-coated mycophenolate sodium
regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients. Transplant Int
2013;26:21
Abstract
Remuzzi G, Cravedi P, Costantini M, Lesti M, Ganeva M, Gherardi G, et al. Mycophenolate mofetil versus
azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up
randomized, controlled clinical trial. J Am Soc Nephrol 2007;18:1973–85
Population
Remuzzi G, Lesti M, Gotti E, Ganeva M, Dimitrov BD, Ene-Iordache B, et al. Mycophenolate mofetil
versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial.
Lancet 2004;364:503–12
Population
Renner FC, Dietrich H, Bulut N, Celik D, Gaertner ND, Karoui S, et al. The development of BK viremia
after renal transplantation is associated with a reduced CD8 cell IL-2 response. Transplant Int 2011;24:56
Abstract
Renner FC, Dietrich H, Bulut N, Celik D, Freitag E, Gaertner N, et al. The risk of polyomavirus-associated
graft nephropathy is increased by a combined suppression of CD8 and CD4 cell-dependent immune
effects. Transplant Proc 2013;45:1608–10
No data
Rhat T, Sommerer C, Haller H, Reinke P, Witzke O, Suwelack B, et al. Outcome on renal function of
everolimus conversion in maintenance KTX patients: 4 years apollo trial. Transplant Int 2013;26:240
Abstract
Rice K, Vanrenterghem Y, Merville P, Muehlbacher F, Zhang R, Duan T, et al. Three-year outcomes in
elderly kidney transplant recipients treated with belatacept vs cyclosporine in BENEFIT-EXT. Am J
Transplant 2012;12:403
Abstract
Richard MG, Angela W, Ruster Lorenn P, Matheson Sandra L, Higgins Gail Y, Willis Narelle S, et al.
Interleukin-2 receptor antagonists versus atg for kidney transplant recipients: an updated cochrane
review. Immunol Cell Biol 2010;88:A21
Abstract
Riegersperger M, Plischke M, Sengoelge G, Steiner S, Seidinger D, Winkelmayer WC, et al. Effect of
conversion from cyclosporine to tacrolimus on endothelial progenitor cells in stable long-term kidney
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transplantation: prospective trial in once-daily versus twice-daily tacrolimus. Transplantation
2013;96:198–204
Population
Tullius SG, Pratschke J, Strobelt V, Kahl A, Reinke P, May G, et al. ATG versus basiliximab induction
therapy in renal allograft recipients receiving a dual immunosuppressive regimen: one-year results.
Transplant Proc 2003;35:2100–1
Abstract
Turconi A, Rilo LR, Goldberg J, de Boccardo G, Garsd A, Otero A. Open-label, multicenter study on the
safety, tolerability, and efficacy of Simulect in pediatric renal transplant recipients receiving triple therapy
with cyclosporin, mycophenolate, and corticosteroids. Transplant Proc 2005;37:672–4
No data
Urbizu JM, Amenabar JJ, Gomez-Ullate P, Zarraga S, Lampreabe I. Immunosuppression using
tacrolimus/mycophenolate versus neoral/mycophenolate following kidney transplantation: a single-center
experience. Transplant Proc 2002;34:87–8
Study design
Vacher-Coponat H, Brunet C, Moal V, Loundou A, Bonnet E, Lyonnet L, et al. Tacrolimus/mycophenolate
mofetil improved natural killer lymphocyte reconstitution one year after kidney transplant by reference to
cyclosporine/azathioprine. Transplantation 2006;82:558–66
Outcome
Vacher-Coponat H, Moal V, Indreies M, Purgus R, Loundou A, Burtey S, et al. A randomized trial with
steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/
mycophenolate mofetil (CATM2) in renal transplantation. Transplantation 2012;93:437–43
Population
Van Der Giet M, Brakemeier S, Liefeldt L, Glander P, Diekmann F, Hohne M, et al. The impact of
everolimus versus CNI-based immuno suppression on cardiovascular function and stiffness after renal
transplantation. Am J Transplan. 2010;10:506
Abstract
Van Der Heide JJH, De Fijter JW, De Maar EF, Ten Berge I, Bemelman FJ. Low acute rejection rate and
superior renal function 2 years after early CsA with drawal and overnight switch to everolimus. Am J
Transplant 2010;10:508
Abstract
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TABLE 135 Excluded studies (continued )
Study Reason
Van Doesum W, Gard L, Van Son WJ, Sanders JSF, Riezebos A, Niesters BGM, et al. Incidence and
outcome of BK infection in a randomized controlled multicenter study with renal transplant patients
receiving duo-therapy. Transplant Int 2013;26:166
Abstract
Van Gurp E, Bustamante J, Franco A, Rostaing L, Becker T, Rondeau E, et al. Comparable Renal Function
at 6 Months with Tacrolimus Combined with Fixed-Dose Sirolimus or MMF: results of a Randomized
Multicenter Trial in Renal Transplantation. J Transplant 2010;2010:731426
Population
Vanrenterghem Y, Bresnahan B, Campistol J, Durrbach A, Grinyó J, Neumayer HH, et al.
Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors
compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies).
Transplantation 2011;91:976–83
Outcome
Vanrenterghem Y, Hooff JP, Squifflet JP, Salmela K, Rigotti P, Jindal RM, et al. Minimization of
immunosuppressive therapy after renal transplantation: results of a randomized controlled trial.
Am J Transplant 2005;5:87–95
Study design
Vathsala A, Schena FP, Wali RK, Pascoe MD, Alberu J, Del Carmen Rial M, et al. Conversion from
calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft
recipients: a randomized, open-label, comparative trial. Nephrology 2005;10:A217–A
Abstract
Vester U, Kranz B, Wehr S, Boger R, Hoyer PF, RAD B 351 Study Group. Everolimus (Certican) in
combination with neoral in pediatric renal transplant recipients: interim analysis after 3 months.
Transplant Proc 2002;34:2209–10
Study design
Vincenti F, Blancho G, Durrbach A, Friend P, Grinyo J, Halloran PF, et al. Five-year safety and efficacy of
belatacept in renal transplantation. J Am Soc Nephrol 2010;21:1587–96
Population
Vincenti F, Charpentier B, Rostaing L, Reyes-Acevedo R, Massari P, Vitko S, et al. Long-term extension of
the belatacept benefit study: result’s at month 48. Transplantation 2012;94:958
Abstract
Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, et al. A phase III study of
belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients
(BENEFIT study). Am J Transplant 2010;10:535–46
Population
Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, et al. Results of an
international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine
versus tacrolimus. Am J Transplant 2007;7:1506–14
Study design
Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, et al. DIRECT (diabetes
incidence after renal transplantation: neoral (R) C2 monitoring versus tacrolimus) investigators (2007)
results of an international, randomized trial comparing glucose metabolism disorders and outcome with
cyclosporine versus tacrolimus (vol 7, pg 1506, 2007). Am J Transplant 2008;8:908
Study design
Vincenti F, Grinyo JM, Charpentier B, Medina-Pestana JD, Rostaing L, Vanrenterghem Y, et al. Primary
outcomes from a randomized, Phase III study of belatacept vs cyclosporine in kidney transplant recipients
(BENEFIT Study). Am J Transplant 2009;9:191–2
Abstract
Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and
cyclosporine in kidney transplantation: evidence for improved allograft survival at five years.
Transplantation 2002;73:775–82
Population
Vincenti F, Larsen C, Alberu J, Garcia V, Rostaing L, Rice K, et al. Three-year outcomes from benefit: a
phase III-study of belatacept vs cyclosporine in kidney transplant recipients. Transplant Int 2011;24:21
Abstract
Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, et al. Costimulation blockade with
belatacept in renal transplantation. N Engl J Med 2005;353:770–81
Population
Vincenti F, Larsen CP, Alberu J, Bresnahan B, Garcia VD, Kothari J, et al. Three-year outcomes from
BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.
Am J Transplant 2012;12:210–7
Population
Vincenti F, Pescovitz MD, El-Shahawy M. Glucose metabolism disorders in non-white renal transplant
patients receiving cyclosporine or tacrolimus in an international, randomized trial. Transplant Int
2007;20:115
Abstract
Vincenti F, Rostaing L, DIRECT (Diabetes Incidence after REnal Transplantation: Neoral C2 monitoring
versus Tacrolimus) investigators. Rationale and design of the DIRECT study: a comparative assessment of
the hyperglycemic effects of tacrolimus and cyclosporine following renal transplantation. Contemp Clin
Trials 2005;26:17–24
No data
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TABLE 135 Excluded studies (continued )
Study Reason
Vincenti F, Tuncer M, Castagneto M, Klinger M, Friman S, Scheuermann EH, et al. Prospective,
multicenter, randomized trial to compare incidence of new-onset diabetes mellitus and glucose
metabolism in patients receiving cyclosporine microemulsion versus tacrolimus after de novo kidney
transplantation. Transplant Proc 2005;37:1001–4
Duplicate
Vítko S, Klinger M, Salmela K, Wlodarczyk Z, Tydèn G, Senatorski G, et al. Two corticosteroid-free
regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate
mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study.
Transplantation 2005;80:1734–41
Comparator
Vítko S, Klinger M, Salmela K, Wlodarczyk Z, Tydèn G, Senatorski G, et al. Two corticosteroid-free
regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate
mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study.
Transplantation 2005;80:1734–41
Study design
Vítko S, Margreiter R, Weimar W, Dantal J, Viljoen HG, Li Y, et al. Everolimus (Certican) 12-month safety
and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation
2004;78:1532–40
Population
Vítko S, Margreiter R, Weimar W, Dantal J, Kuypers D, Winkler M, et al. Three-year efficacy and safety
results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients.
Am J Transplant 2005;5:2521–30
Population
Vondrak K, Grenda R, Watson A, Janda J, Simkova E, Seeman T, et al. Immunosupression with triple
combination with tacrolimus with or without monoclonal antibody induction: a multicentric randomized
study in children after kidney transplantation. Kidney Blood Press Res 2006;29:381
Abstract
Vondrak K, Grenda R, Watson AR, Webb NJA, Beattie J, Pediat Tacrolimus Study G. Tacrolimus triple
therapy with or without monoclonal antibody administration: a multicentre, randomized study in
pediatric kidney transplantation. Am J Transplant 2005;5:401–2
Abstract
Wagner M, Balk EM, Webster AC, et al. Mycophenolic acid versus azathioprine as primary
immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2009;2:CD007746
No data
Waid T. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic
renal allograft failure. Clin Transplant 2005;19:573–80
Intervention
Walker R, Vathsala A, Zibari GB, Kim YS, Cibrik D, Johnston T, et al. Class related adverse events in renal
transplant recipients treated with everolimus: 24 month results from the A2309 study. Am J Transplant
2011;11:407
Abstract
Walker RG, Cottrell S, Sharp K, Tripodi R, Nicholls KM, Fraser I, et al. Conversion of cyclosporine to
tacrolimus in stable renal allograft recipients: quantification of effects on the severity of gingival
enlargement and hirsutism and patient-reported outcomes. Nephrology 2007;12:607–14
Outcome
Walker RG, Rostaing L, Nainan G, Del CRM, Steinberg S, Vincenti F, et al. A switch to belatacept-based
immunosuppresive regimen in kidney transplant recipients from calcineurin inhibitors (CNI) has a
favourable safety profile and results in improved renal function: 12-month results from a phase II study.
Immunol Cell Biol 2011;89:A3
Abstract
Waller JR, Murphy GJ, Metcalfe MS, Sandford RM, Pattenden CJ, Nicholson ML. Primary
immunosuppression with tacrolimus is associated with a reduction in renal allograft fibrosis compared
with neoral therapy. Transplant Proc 2002;34:1587–8
Population
Wang K, Zhang H, Li Y, Wei Q, Li H, Yang Y, Lu Y. Efficacy of mycophenolate mofetil versus
azathioprine after renal transplantation: a systematic review. Transplant Proc 2004;36:2071–2
Population
Wang K, Zhang H, Li Y, Wei Q, Li H, Yang Y, Lu Y. Safety of mycophenolate mofetil versus azathioprine
in renal transplantation: a systematic review. Transplant Proc 2004;36:2068–70
Population
Wang R, Xu Y, Wu J, Wang Y, He Q, Chen J. Reduced-dose cyclosporine with mycophenolate mofetil
and prednisone significantly improves the long-term glomerular filtration rate and graft survival. Intern
Med 2013;52:947–53
Study design
Warejko JK, Hmiel SP. Single-center experience in pediatric renal transplantation using thymoglobulin
induction and steroid minimization. Pediatr Transplant 2014;18:816–21
Study design
Watorek E, Szymczak M, Boratynska M, Patrzalek D, Klinger M. Cardiovascular risk in kidney transplant
recipients receiving mammalian target of rapamycin inhibitors. Transplant Proc 2011;43:2967–9
Comparator
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TABLE 135 Excluded studies (continued )
Study Reason
Watorek E, Szymczak M, Boratynska M, Patrzalek D, Klinger M. Cardiovascular risk in kidney transplant
recipients receiving mTOR inhibitors. Transplant Int 2011;24:118
Abstract
Watson AR, Grenda R, Vondrak K, European Multicentre Tacrolimus S. A multicentre, randomised trial
of tacrolimus triple therapy with or without basiliximab in paediatric kidney transplantation.
Pediatr Transplant 2005;9:56
Abstract
Watson CJ, Firth J, Williams PF, Bradley JR, Pritchard N, Chaudhry A, et al. A randomized controlled
trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal
transplantation. Am J Transplant 2005;5:2496–503
Population
Weimer R, Süsal C, Yildiz S, Streller S, Pelzl S, Staak A, et al. sCD30 and neopterin as risk factors of
chronic renal transplant rejection: impact of cyclosporine A, tacrolimus, and mycophenolate mofetil.
Transplant Proc 2005;37:1776–8
Population
Weimer R, Süsal C, Yildiz S, Staak A, Pelzl S, Renner F, et al. Post-transplant sCD30 and neopterin as
predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens.
Am J Transplant 2006;6:1865–74
Population
Weir M. Long-term assessment of function in patients completing the spare-the-nephron study with a
functioning graft. Am J Transplant 2013;13:36
Abstract
Weir M, Mulgaonkar S, Pearson T, Patel A, Patel D, Shidban H, et al. Mycophenolate Mofetil/Sirolimus
maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients: 2-Year
Outcomes of the spare-the-nephron (STN) Trial. Am J Transplant 2009;9:200–1
Abstract
Weir MR, Mulgaonkar S, Chan L, Shidban H, Waid TH, Preston D, et al. Mycophenolate mofetil-based
immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron
trial. Kidney Int 2011;79:897–907
Abstract
Welberry Smith MP, Cherukuri A, Newstead CG, Lewington AJ, Ahmad N, Menon K, et al.
Alemtuzumab induction in renal transplantation permits safe steroid avoidance with tacrolimus
monotherapy: a randomized controlled trial. Transplantation 2013;96:1082–8
Population
West-Thielke PM, Bodziak KA, Cohen DJ. Conversion to once-daily extended release meltdose (R)
tacrolimus tablets (lcp-tacro (TM)) from twice-daily tacrolimus capsules (prograf (R)) is safe and efficacious
in african american kidney transplant recipients: results from a phase iii randomized trial. Am J
Transplant 2012;12:405–6
Abstract
Williams P. An open label randomised study of sirolimus in patients with impaired renal function
following renal transplantation. National Research Register, UK. URL: www.nrr.nhs.uk/
(accessed 25 July 2014)
Unobtainable
Wiseman AC, McCague K, Kim Y, Geissler F, Cooper M. The effect of everolimus versus mycophenolate
upon proteinuria following kidney transplant and relationship to graft outcomes. Am J Transplant
2013;13:442–9
Outcome
Wissing KM, Pipeleers L. Obesity, metabolic syndrome and diabetes mellitus after renal transplantation:
prevention and treatment. Transplant Rev 2014;28:37–46
Study design
Wissing KM, Fomegné G, Broeders N, Ghisdal L, Hoang AD, Mikhalski D, et al. HLA mismatches remain
risk factors for acute kidney allograft rejection in patients receiving quadruple immunosuppression with
anti-interleukin-2 receptor antibodies. Transplantation 2008;85:411–6
Study design
Wissing KM, Kuypers D, Abramowicz D, Weekers L, Budde KMD, Rath T, et al. Conversion from
tacrolimus to cyclosporine a improves glucose metabolism in patients with new onset diabetes after renal
transplantation: interim analysis of a prospective and randomized study. Transplant Int 2013;26:37
Abstract
Wlodarczyk Z, Ostrowski M, Mourad M, Krämer BK, Abramowicz D, Oppenheimer F, et al. Tacrolimus
pharmacokinetics of once- versus twice-daily formulations in de novo kidney transplantation: a substudy
of a randomized phase III trial. Ther Drug Monit 2012;34:143–7
Population
Wlodarczyk Z, Squifflet JP, Ostrowski M, Rigotti P, Stefoni S, Citterio F, et al. Pharmacokinetics for
once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized,
open-label trial. Am J Transplant 2009;9:2505–13
Population
Włodarczyk Z, Wałaszewski J, Perner F, Vitko S, Ostrowski M, Bachleda P, et al. Freedom from rejection
and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney
transplant recipients. Ann Transplant 2002;7:28–31
Population
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TABLE 135 Excluded studies (continued )
Study Reason
Wlodarczyk Z, Walaszewski J, Perner F, Vitko S, Ostrowski M, Bachleda P, et al. Steroid withdrawal at
3 months after kidney transplantation: a comparison of two tacrolimus-based regimens. Transpl Int
2005;18:157–62
Population
Woestenburg AT, Peeters P, Sennesael J, Abramowicz D, Wissing KM, Geers C, et al. Interstitial fibrosis
and fibrous intimal thickening in de novo renal allografts under sirolimus or cyclosporine: results of a
randomised, controlled trial (FIBRASIC). Transplant Int 2009;22:79
Abstract
Wohlfahrtova M, Viklicky O. Recent trials in immunosuppression and their consequences for current
therapy. Curr Opin Organ Transplant 2014;19:387–94
Study design
Woodle ES, Grp TS. A randomized, prospective, multicenter study of thymoglobulin in renal
transplantation for induction and minimization of steroids (TRIMS). Am J Transplant 2005;5:571
Abstract
Woodside KJ, Thomas PG, Lappin JA, Vaidya S, Rajaraman S, Gugliuzza KK. An open label, randomized,
controlled trial of a tolerogenic induction protocol using alemtuzumab (Campath 1H) and tacrolimus
monotherapy versus thymoglobulin induction with triple drug therapy in high immunological risk renal
transplantation. Am J Transplant 2007;7:522
Abstract
Wu B, Wu FB, Yu L, Li TP, Tang Y. Effectiveness and safety of calcineurin inhibitor withdrawal from
target-of-rapamycin-inhibitor-based immunosuppression in kidney transplantation: a meta analysis
(Provisional abstract). Chinese Journal of Evidence-Based Medicine 2010;10:33–9
Study design
Wu FL, Tsai MK, Chen RR, Sun SW, Huang JD, Hu RH, et al. Effects of calcineurin inhibitors on sirolimus
pharmacokinetics during staggered administration in renal transplant recipients. Pharmacotherapy
2005;25:646–53
Study design
Wyrley-Birch H, Kanwar A, Vijayanand D, Navarro A, Reddy M, Wilson C, et al. A prospective
randomised paired trial of sirolimus versus tacrolimus as primary immunosuppression following non heart
beating donor kidney transplantation after anti-il2 monoclonal antibody induction. Transplant Int
2010;23:16
Abstract
Xue W, Zhang Q, Xu Y, Wang W, Zhang X, Hu X. Effects of tacrolimus and cyclosporine treatment on
metabolic syndrome and cardiovascular risk factors after renal transplantation: a meta-analysis. Chin Med
J 2014;127:2376–81
Population
Yao G, Albon E, Adi Y, Milford D, Bayliss S, Ready A, et al. A systematic review and economic model of
the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children.
Health Technol Assess 2006;10(49)
Duplicate
Yaqoob M, Pattison J, Riad H, Cornu-Artis C, Wang Z, Shihab F. Cytomegalovirus and BK virus infections
are less frequent with everolimus versus mycophenolate immunosuppression: 24-month update from the
2309 study in de novo renal transplant recipients. Transplant Int 2011;24:40–1
Unobtainable
Yaqoob M, Riad H, Pattison J, Cornu-Artis C, Wang Z, Tedesco Silva H. Efficacy and safety of 24 months
immunosuppression with concentration-controlled everolimus and reduced cyclosporine in de novo renal
transplant recipients. Transplant Int 2011;24:39
Abstract
Yoshimura N, Uchida K, Takahara S, Teraoka S, Kobayashi E, Teshima R, et al. Concentration-controlled
everolimus with reduced cyclosporine concentration in Japanese de novo renal transplant recipients:
efficacy and safety results at 12 months: Japanese multicenter study. Transplantation 2012;94:990
Abstract
Zachariah M, Nader ND, Brar J, Singh N, Venuto R, Patel S, et al. Alemtuzumab and minimization
immunotherapy in kidney transplantation: long-term results of comparison with rabbit anti-thymocyte
globulin and standard triple maintenance therapy. Transplant Proc 2014;46:94–100
Study design
Zadrazil J, Horak P, Strebl P, Krejci K, Kajabova M, Schneiderka P, et al. In vivo oxidized low-density
lipoprotein (ox-LDL) aopp and tas after kidney transplantation: a prospective, randomized one year study
comparing cyclosporine A and tacrolimus based regiments. Biomed Pap Med Fac Univ Palacky Olomouc
Czech Repub 2012;156:14–20
Population
Zeier M, Budde K, Arns W, Guba M, Sommerer C, Neumayer H, et al. Efficacy and safety of three
different treatment regimens in de novo renal transplant patients: follow-up results of the herakles trial
at month 24. Am J Transplant 2013;13:183
Abstract
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TABLE 135 Excluded studies (continued )
Study Reason
Zhang YG, Teng DH, Wang L, et al. Effectiveness and safety of rapamycin-based immunosuppression
regimen with or without CsA in renal transplantation: a systematic review. Chinese Journal of
Evidence-Based Medicine 2006;6:94–106
Study design
Zhong J-y, Qu L-x, Zhang M, Jiao Z, Lu F-m. Application of basiliximab in prevention of acute allograft
rejection in kidney transplantation recipients. Zhongguo Xinyao yu Linchuang Zazhi 2005;24:468–71
Language
Zhu QG, Zhao YK, Liu W, Luo H, Qiu Y, Gao ZZ. Two-year observation of a randomized trial on
tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal
transplantation. Chinese Med Sci J 2008;23:244–8
Study design
TABLE 136 Mixed-population RCTs
Study
Treatment
comparisons
(number of
participants in
each arm)
Eligibility
criteria
Age mean (SD),
median [range] (years)
Ciancio G, Burke GW, Gaynor JJ, Mattiazzi A,
Roth D, Kupin W, et al. A randomized long-
term trial of tacrolimus and sirolimus versus
tacrolimus and mycophenolate mofetil versus
cyclosporine (Neoral) and sirolimus in renal
transplantation. I. Drug interactions and
rejection at one year. Transplantation
2004;77:244–251
TAC+ SRL (50) vs.
TAC+MMF (50) vs.
CSA+ SRL (50)
≥ 13 years 50 (13) vs. 47 (16) vs.
44 (16)
Flechner SM, Gurkan A, Hartmann A,
Legendre CM, Russ GR, Campistol JM, et al.
A randomized, open-label study of sirolimus
versus cyclosporine in primary de novo renal
allograft recipients. Transplantation
2013;95:1233–41
SRL (314) vs.
CSA (161)
≥ 13 years 42.9 (SE 0.8) vs. 42.7
(SE 1.1)
Gaber AO, Kahan BD, Buren C, Schulman SL,
Scarola J, Neylan JF. Comparison of sirolimus
plus tacrolimus versus sirolimus plus
cyclosporine in high-risk renal allograft
recipients: results from an open-label,
randomized trial. Transplantation
2008;86:1187–95
TAC (224) vs.
CSA (224)
≥ 13 years 46.4 [15–73] vs.
44.4 [15–80]
Kahan BD for The Rapamune US Study Group.
Efficacy of sirolimus compared with azathoprine
for reduction of acute renal allograft rejection:
a randomised multicentre study. Lancet
2000;356:194–202a
SRL 2mg (284) vs.
SRL 5mg (274) vs.
AZA (161)
≥ 13 yearsb 44.9 (13.6) vs. 46.8
(13.0) vs. 45.6 (13.0)
MacDonald AS for The Rapamune US Study
Group. A worldwide, phase III ranomized,
controlled, safety and efficacy study of a
sirolimus/cyclosporine regimen for prevention of
acute rejection in recipients of primary
mismatched renal allografts. Transplantation
2001;71:271–80a
SRL 2mg (227) vs.
SRL 5mg (219) vs.
PBO (130)
Included
participants aged
15–71 yearsc
45.6 (12.3) [15–71] vs.
45.1 (12.2) [17–68] vs.
46 (13.1) [16–72]
Lee YJ, Kim B, Lee JE, Kim YG, Kim DJ, Kim SJ,
et al. Randomized trial of cyclosporine and
tacrolimus therapy with steroid withdrawal in
living-donor renal transplantation: 5-year
follow-up. Transplant Int 2010;23:147–54
CSA (55) vs. TAC (62) > 15 years 38.5 (9.5) vs. 38.8 (9.2)
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TABLE 136 Mixed-population RCTs (continued )
Study
Treatment
comparisons
(number of
participants in
each arm)
Eligibility
criteria
Age mean (SD),
median [range] (years)
Machado PG, Felipe CR, Hanzawa NM, Park SI,
Garcia R, Alfieri F, et al. An open-label
randomized trial of the safety and efficacy of
sirolimus vs. azathioprine in living related renal
allograft recipients receiving cyclosporine and
prednisone combination. Clin Transplant
2004;18:28–38
SRL (35) vs. AZA (35) ≥ 13 years 35.8 (10.5) vs.
32.7 (10.4)
Wu FL, Tsai MK, Chen RR, Sun SW, Huang JD,
Hu RH, et al. Effects of calcineurin inhibitors on
sirolimus pharmacokinetics during staggered
administration in renal transplant recipients.
Pharmacotherapy 2005;25:646–53
TAC (11) vs. CSA (10) 13–65 yearsd 40.4 (10.4) vs. 36.9 (8.1)
Silva HT Jr, Yang HC, Abouljoud M, Kuo PC,
Wisemandle K, Bhattacharya P, et al. One-year
results with extended-release tacrolimus/MMF,
tacrolimus/MMF and cyclosporine/MMF in
de novo kidney transplant recipients. Am J
Transplant 2007;7:595–608e
TAC PR (214) vs. TAC
(212) vs. CSA (212)
≥ 12 years 47.8 (13), 48 [17–77] vs.
48.6 (12.9), 50.5
[19–74] vs. 47.6 (13),
48.5 [17–77]
a Identified from Kahan et al.259
b Yao et al.2 states: ’participants between 12–18 years were assigned as 6 vs. 3 vs. 3’.
c Yao et al.2 states: ’participants under 18 years were assigned as 1 vs. 1 vs. 1’.
d This is unclear as the paper also states: ’study recruited 22 adults’.
e The 4-year follow-up data can be found in Silva HT Jr, Yang HC, Meier-Kriesche HU, Croy R, Holman J, Fitzsimmons WE,
et al. Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and
cyclosporine/MMF in de novo kidney transplant recipients. Transplantation 2014;97:636–41
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Appendix 3 Systematic reviews
TABLE 137 Included systematic reviews
Trial Aim
Identified
RCTs
Identified
non-RCTs
Almeida et al. 2013260 To evaluate the safety of the most commonly used
immunosuppressive regimens
0 0
Andrassy et al. 2012261 To summarise clinical trials after solid organ transplantation and
describe potential mechanisms involved in the antiCMV effect of
mTOR-inhibitors
0 0
Brooks et al. 2010262 To evaluate the quality of reporting of transplantation trials in
children published in contemporary biomedical literature
2 0
Ho et al. 2013263 To evaluate the benefits and harms of sustained-release daily
dosing formulation compared with standard twice daily TAC
in KTRs
0 0
Kasiske et al. 2008264 To conduct a systematic review of RCTs to critically examine the
incidence and type of dyslipidemia associated with mTOR-Is
0 0
Knight et al. 2009265 To identify whether or not MMF improves outcomes compared
with AZA in renal transplant recipients, particularly in incidence of
acute rejection, patient and graft survival, and toxicity
0 0
Liu et al. 2010266 To compare the efficacy and safety of BAS with antithymocyte
globulin for induction therapy
0 0
Masson et al. 2014267 To synthesise data from RCTs that compared belatacept with other
primary maintenance immunosuppression regimens
0 0
Moore et al. 2009268 To assess transplant outcomes after CNI sparing with
mycophenolate as sole adjunctive immunosuppression
0 0
Mulay et al. 2006269 To systematically review all clinical studies that evaluated CNI
conversion to SRL in patients with chronic nephropathy
0 0
Peddi et al. 2013270 To evaluate the efficacy and safety of immunosuppressive regimens
containing a mTOR-I with TAC minimisation therapy in solid organ
transplant recipients
0 0
Pengel et al. 2011271 To evaluate the occurrence of wound complications and
lymphoceles in solid organ transplant recipients receiving mTOR-Is
from the time of transplantation compared with patients not
receiving mTOR-I
0 0
Su et al. 2011272 To evaluate clinical consequences of and MMF dose reduction in
renal transplant recipients on TAC based regimens
0 0
Webster et al. 2004273 To systematically identify and summarise the effects of IL-2Ra as
induction agents, as an addition to standard therapy, or as an
alternative to other antibody therapies in common use
(antithymocyte globulins, antilymphocyte globulins,
monomurab-CD3)
0 0
Webster et al. 2004274 To systematically identify and summarise the effects of using an
IL2Ra, as an addition to standard therapy, or as an alternative to
other antibody therapy
0 0
Webster et al. 2005207 To systematically review randomised controlled trials in which TAC
had been compared with ciclosporin as initial immunosuppressive
therapy in the treatment of KTRs
0 0
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TABLE 137 Included systematic reviews (continued )
Trial Aim
Identified
RCTs
Identified
non-RCTs
Webster et al. 2005275 To compare the effects of TAC with ciclosporin as primary therapy
for KTRs
0 0
Webster et al. 2006156 To identify systematically and summarise the current available
evidence of the short- and long-term benefits and harms of SRL
and everolimus when used in primary immunosuppressive regimens
for KTRs
0 0
Webster et al. 2006276 To investigate the benefits and harms of immunosuppressive
regimens containing TOR-I when compared with other regimens as
initial therapy for KTRs
0 0
Webster et al. 2010277
(update of Webster
et al. 2004274)
To systematically identify and summarise the effects of using an
IL2Ra, as an addition to standard therapy, or as an alternative to
another immunosuppressive induction strategy
0 0
Woodroffe et al.
2005255
To examine the clinical effectiveness and cost-effectiveness of the
newer immunosuppressive drugs for renal transplantation: BAS,
daclizumab, TAC, mycophenolate (mofetil and sodium) and SRL
1 0
Yan et al. 2014278 To evaluate the efficacy and safety of CNI avoidance, CNI
withdrawal, and CNI regimens on postoperative patient and graft
survival, acute rejection, renal function and adverse events
0 0
Yao et al. 20062 To establish the clinical effectiveness (harms and benefits) and
cost-effectiveness of four of the newer immunosuppressive drugs
for renal transplantation, namely BAS, daclizumab, TAC and MMF
and sodium) and of SRL in children
2 4
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Appendix 4 Ongoing trials
TABLE 138 Ongoing trials
Study Sponsor/collaborators Trial name n Status
Included in
PenTAG
(reason)
NCT01791491 Bristol-Myers Squibb Phase II Pharmacokinetics,
Efficacy, and Safety of
Belatacept in Paediatric
Renal Transplant Recipients
54 Recruiting N/A
NCT01544491
A2314; Gupta et al.
2013,86 Langer et al.
2013,87 Tonshoff et al.
201289 and Tonshoff
et al. 201388
Novartis Pharmaceuticals Efficacy, Tolerability and
Safety of Early Introduction
of Everolimus, Reduced
Calcineurin Inhibitors and
Early Steroid Elimination
Compared to Standard
CNI, Mycophenolate
Mofetil and Steroid
Regimen in Paediatric Renal
Transplant Recipients
106 Recruiting N/A
NCT01550445
Oh et al. 2012279
Ajou University School
of Medicine
Steroid Withdrawal
Immunosuppression After
Renal Transplantation
30 Unknown Not included
(design)
NCT00023244,
Study 315 (mentioned
in Yao et al. 20062 as
ongoing; Benfield
et al. 2010280)
National Institute of
Allergy and Infectious
Diseases (NIAID),
Cooperative Clinical
Trials in Paediatric
Transplantation; Pfizer
(formerly Wyeth)
Steroid Withdrawal in
Pediatric Kidney
Transplant Recipients
274 Terminated Not included
(steroid
withdrawal)
NCT00137345
Flechner et al. 2013281
Pfizer (formerly Wyeth) Study Comparing Sirolimus
With Cyclosporine in a
Calcineurin Inhibitor
(CNI)-Free Regimen in
Kidney Transplant
Recipients
500 Terminated Not included
(population)
NCT00005113
(included in Yao et al.
20062; 0468E1–217-US)
Children’s Hospital
Boston; Pfizer
(formerly Wyeth)
A Study to Compare
Treatment With Sirolimus
Versus Standard Treatment
in Patients Who Have
Received a Kidney
Transplant
213 Terminated Not included
(no data
available
and population)
NCT00228020
Offner et al. 200873
Novartis Study of Safety and
Efficacy of a Basiliximab,
Mycophenolate Mofetil,
Cyclosporine
Microemulsion and
Prednisone Combination
Treatment Regimen in
Pediatric Renal
Allograft Recipients
212 Completed Included
NCT00141037
Sarwal et al. 2012282
National Institute of
Allergy and Infectious
Diseases (NIAID)
Astellas Pharma Inc.
Hoffmann-La Roche
Steroid-Free Versus
Steroid-Based
Immunosuppression in
Pediatric Renal (Kidney)
Transplantation
130 Completed Not included
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TABLE 138 Ongoing trials (continued )
Study Sponsor/collaborators Trial name n Status
Included in
PenTAG
(reason)
NCT00296348 Astellas Pharma Inc. Comparing Efficacy and
Safety of Steroid
Withdrawal With
Tacrolimus and MMF With
Induction in Children After
Kidney Transplantation
(TWIST)
198 Completed Not included
NCT00166244
van Gelder et al.
2008283
Erasmus Medical
Hoffmann-La
Roche Center
Fixed Dose MMF vs.
Concentration Controlled
MMF After Renal
Transplantation
901 Completed Not included
(population)
ISRCTN89278733
Cransberg et al.
2007284
Erasmus Medical Center Safety and efficacy of
mycophenolate mofetil
in pediatric renal
transplantation
44 Completed Not included
(design)
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Appendix 5 Clinical effectiveness:
additional information
TABLE 139 TA99: included adult RCTs
Study Multiple publications Treatments
Included in
PenTAG (reason)
Vincenti et al. 1998285 Vincenti et al. 1998286 Hengster et al.
1999287 Bumgarden et al. 2001288
DAC vs. PBO No (treatment)
Bingyi et al. 2003104 N/A BAS vs. PBO Yes
Ponticelli et al. 2001102 Ponticelli et al. 2001289 BAS vs. PBO Yes
Sheashaa et al. 200399 N/A BAS vs. NI Yes
Folkmane et al. 2001290 Folkmane et al. 2002291 (a) BAS vs. NI and
MMF vs AZA
No (design)
Shapiro et al. 1991292 N/A TAC vs. CSA No (design)
Mayer et al. 1997107 Mayer et al. 1999293 Mayer et al.
2002294 Mayer et al. 2002295 European
Tacrolimus Multicentre Renal Study
TAC vs. CSA Yes
Radermacher et al. 1998124 N/A TAC vs. CSA No (design)
Van Duijnhoven et al. 2002123 N/A TAC vs. CSA Yes
Jurewicz et al. 1999296 Baboolal et al. 2002121 Jurewicz et al.
2003297 Welsh Transplant Research
group
TAC vs. CSA Yes
Sperschneider et al. 2001298 Krämer et al. 2003299 Dietl et al.
2002300 Margreiter et al. 2002110
TAC vs. CSA Yes
Töz et al. 2004301 N/A TAC vs. CSA Yes
Campost et al. 2003109 Brazilian TAC study TAC vs. CSA Yes
Murphy et al. 2003302 N/A TAC vs. CSA Yes
Mathew et al. 1998303 Tricontinental Mycophenolate Mofetil
Renal Transplantation Study 1996
MMF vs. AZA Yes
Miladipour et al. 2002304 N/A MMF vs. AZA No (design)
Sadek et al. 2002116 N/A MMF vs. AZA Yes
Tuncer et al. 2002118 N/A MMF vs. AZA Yes
Sollinger et al. 1995120 MMF Acute Renal transplantation
Study Group 1996
MMF vs. AZA Yes
Baltar et al. 2002305 N/A MMF vs. AZA No (language)
Salvadori et al. 2004306 N/A MPS vs. MMF Yes
Kahan 2000257 Rapamune US study SRL vs. AZA No (design)
Machado et al. 2004258 N/A SRL vs. AZA No (design)
Groth et al. 1999206 Sirolimus European Renal
transplantation Study group
SRL vs. CSA Yes
Johnson et al. 2001307 Rapamune Maintenance Regimen
(RMR) study
Addition of SRL
and CSA removal
No (design)
N/A, not applicable; NI, no induction.
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TABLE 140 Adverse events, long-term follow-up: Staskewitz et al.83
AE Follow-up CSA+MMF+CCS
n events n participants %
Respiratory infections 1 year 24 69 35
1–2 years 6 57 11
2–3 years 4 44 9
UTIs 1 year 14 69 20
1–2 years 6 57 11
2–3 years 4 44 9
CMV infections 1 year 11 69 16
1–2 years 2 57 4
2–3 years 0 44 0
3–5 years 2 44 5
EBV infections 1 year 2 69 3
1–2 years 8 57 14
2–3 years 2 44 5
3–5 years 3 78 4
Solid tumour 1 year 0 69 0
1–2 years 0 57 0
2–3 years 1 44 2
3–5 years 0 78 0
PTLD 1 year 1 69 1
1–2 years 0 57 0
2–3 years 0 44 0
3–5 years 0 78 0
Herpes simplex 1 year 11 69 16
1–2 years 4 57 7
2–3 years 0 44 0
3–5 years 8 78 10
HPV6 1 year 1 69 1
1–2 years 2 57 4
2–3 years 1 44 2
3–5 years 3 78 4
Oral thrush 1 year 3 69 4
1–2 years 2 57 4
2–3 years 0 44 0
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TABLE 140 Adverse events, long-term follow-up: Staskewitz et al.83 (continued )
AE Follow-up CSA+MMF+CCS
Diarrhoea 1 year 37 69 54
1–2 years 9 57 16
2–3 years 3 44 7
Abdominal pain/nausea 1 year 12 69 17
1–2 years 5 57 9
2–3 years 3 44 7
HPV6, human papillomavirus type 6.
Note
Staskewitz et al.83 did not report any AE for the historic control AZA group; only AE for MMF group were reported. All ORs
were calculated by PenTAG.
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Appendix 6 Astellas’ submission
DOI: 10.3310/hta20610 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 61
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Haasova et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
293
TA
B
LE
14
1
A
st
el
la
s’
tr
ia
ls
in
cl
u
d
ed
in
su
b
m
is
si
o
n
St
u
d
y
A
rm
1
A
rm
2
A
rm
3
A
rm
4
Pa
ra
lle
l
A
d
u
lt
H
TA
(r
ea
so
n
)
Ek
be
rg
et
al
.
20
07
12
7
C
SA
+
M
M
F
+
C
C
S
D
A
C
+
LO
W
C
SA
+
M
M
F
+
C
C
S
D
A
C
+
LO
W
TA
C
+
M
M
F
+
C
C
S
D
A
C
+
LO
W
SR
L
+
M
M
F
+
C
C
S
In
cl
ud
ed
A
bo
u-
Ja
ou
de
et
al
.
20
03
30
8
D
A
C
/r
-A
TG
/N
O
N
+
TA
C
+
A
ZA
+
C
C
S
D
A
C
/r
-A
TG
/N
O
N
+
C
SA
+
A
ZA
+
C
C
S
N
/A
N
/A
Ex
cl
ud
ed
(s
tu
dy
de
si
gn
)
A
bo
u-
Ja
ou
de
et
al
.
20
05
30
9
D
A
C
/Z
EN
A
/N
O
N
E
+
TA
C
+
A
ZA
/M
M
F
+
C
C
S
D
A
C
/Z
EN
A
/N
O
N
E
+
C
SA
+
A
ZA
/M
M
F
+
C
C
S
N
/A
N
/A
Ex
cl
ud
ed
(s
tu
dy
de
si
gn
)
Bu
sq
ue
et
al
.
20
01
31
0
TA
C
+
M
M
F
+
C
C
S
TA
C
+
A
ZA
+
C
C
S
C
SA
+
M
M
F
+
C
C
S
N
/A
Ex
cl
ud
ed
(s
tu
dy
de
si
gn
)
C
am
po
s
et
al
.
20
02
10
9
TA
C
+
A
ZA
+
C
C
S
C
SA
+
A
ZA
+
C
C
S
N
/A
N
/A
In
cl
ud
ed
H
ar
di
ng
er
et
al
.
20
05
11
3
r-
A
TG
+
TA
C
+
A
ZA
+
C
C
S
r-
A
TG
+
C
SA
+
A
ZA
+
C
C
S
N
/A
N
/A
In
cl
ud
ed
Jo
hn
so
n
et
al
.
20
00
31
1
TA
C
+
A
ZA
+
C
C
S
C
SA
+
M
M
F
+
C
C
S
TA
C
+
M
M
F
+
C
C
S
N
/A
Ex
cl
ud
ed
(p
op
ul
at
io
n)
M
ar
gr
ei
te
r
et
al
.
20
02
11
0
TA
C
+
A
ZA
+
C
C
S
C
SA
+
A
ZA
+
C
C
S
N
/A
N
/A
In
cl
ud
ed
G
ar
ci
a
et
al
.
20
03
31
2
C
SA
+
C
C
S
BA
S
+
C
SA
+
C
C
S
BA
S
+
TA
C
+
C
C
S
N
/A
Ex
cl
ud
ed
(s
tu
dy
de
si
gn
)
M
or
ris
-S
tif
f
et
al
.
20
00
31
3
TA
C
+
A
ZA
+
C
C
S
C
SA
+
A
ZA
+
C
C
S
N
/A
N
/A
Ex
cl
ud
ed
(p
op
ul
at
io
n)
M
ur
ph
y
et
al
.
20
03
30
2
TA
C
+
A
ZA
+
C
C
S
C
SA
+
A
ZA
+
C
C
S
N
/A
N
/A
In
cl
ud
ed
Ra
of
ie
t
al
.
19
99
19
5
O
K
T3
+
TA
C
+
C
C
S
O
K
T3
+
C
SA
+
C
C
S
N
/A
N
/A
In
cl
ud
ed
Si
lv
a
et
al
.
20
07
15
2
BA
S
+
TA
C
PR
+
M
M
F
+
C
C
S
BA
S
+
TA
C
+
M
M
F
+
C
S
BA
S
+
C
SA
+
M
M
F
+
C
C
S
N
/A
Ex
cl
ud
ed
(p
op
ul
at
io
n)
To
z
et
al
.
20
04
30
1
TA
C
+
A
ZA
+
C
C
S
C
SA
+
A
ZA
+
C
C
S
N
/A
N
/A
In
cl
ud
ed
V
in
ce
nt
ie
t
al
.
20
07
31
4
BA
S
+
TA
C
+
M
M
F/
M
PS
+
C
C
S
BA
S
+
C
SA
+
M
M
F/
M
PS
+
C
C
S
N
/A
N
/A
Ex
cl
ud
ed
(in
te
rv
en
tio
n)
W
an
g
et
al
.
20
00
31
5
TA
C
+
M
M
F
+
C
C
S
C
SA
+
M
M
F
+
C
C
S
N
/A
N
/A
Ex
cl
ud
ed
(a
bs
tr
ac
t)
APPENDIX 6
NIHR Journals Library www.journalslibrary.nihr.ac.uk
294
St
u
d
y
A
rm
1
A
rm
2
A
rm
3
A
rm
4
Pa
ra
lle
l
A
d
u
lt
H
TA
(r
ea
so
n
)
W
hi
te
et
al
.
20
00
31
6
TA
C
+
C
C
S
C
SA
+
C
C
S
N
/A
N
/A
Ex
cl
ud
ed
(a
bs
tr
ac
t)
W
ill
ia
m
s
et
al
.
19
99
31
7
TA
C
+
C
C
S
C
SA
+
C
C
S
N
/A
N
/A
Ex
cl
ud
ed
(a
bs
tr
ac
t)
Y
an
g
et
al
.
19
99
12
5
TA
C
+
M
M
F
+
C
C
S
C
SA
+
M
M
F
+
C
C
S
N
/A
N
/A
In
cl
ud
ed
Fl
ec
hn
er
et
al
.
20
11
31
8
D
A
C
+
TA
C
+
SR
L
+
C
C
S
D
A
C
+
M
M
F
+
SR
L
+
C
C
S
N
/A
N
/A
In
cl
ud
ed
G
lo
tz
et
al
.
20
10
12
8
TA
C
+
M
M
F
+
C
C
S
r-
A
TG
+
SR
L
+
M
M
F
+
C
C
S
N
/A
N
/A
Ex
cl
ud
ed
(in
te
rv
en
tio
n)
La
rs
on
et
al
.
20
06
31
9
r-
A
TG
+
TA
C
+
M
M
F
+
C
C
S
r-
A
TG
+
SR
L
+
M
M
F
+
C
C
S
N
/A
N
/A
In
cl
ud
ed
V
in
ce
nt
ie
t
al
.
20
10
19
8
BA
S
+
BE
L
LO
W
+
M
M
F
+
C
C
S
BA
S
+
BE
L
H
IG
H
+
M
M
F
+
C
C
S
BA
S
+
C
SA
+
M
M
F
+
C
C
S
N
/A
In
cl
ud
ed
D
ur
rb
ac
h
et
al
.
20
10
19
9
BA
S
+
BE
L
LO
W
+
M
M
F
+
C
C
S
BA
S
+
BE
L
H
IG
H
+
M
M
F
+
C
C
S
BA
S
+
C
SA
+
M
M
F
+
C
C
S
N
/A
In
cl
ud
ed
Be
rt
on
ie
t
al
.
20
11
32
0
BA
S
+
EV
L
+
C
SA
+
C
C
S
BA
S
+
M
PS
+
C
SA
+
C
C
S
N
/A
N
/A
In
cl
ud
ed
Te
de
sc
o
Si
lv
a
et
al
.
20
10
19
1
BA
S
+
EV
L
LO
W
+
C
SA
+
C
C
S
BA
S
+
EV
L
H
IG
H
+
C
SA
+
C
C
S
BA
S
+
M
PA
+
C
SA
+
C
C
S
N
/A
In
cl
ud
ed
A
lb
an
o
et
al
.
20
13
97
TA
C
+
M
M
F
+
C
C
S
TA
C
(0
.2
M
G
)+
M
M
F
+
C
C
S
TA
C
PR
(0
.3
M
G
)+
M
M
F
+
C
C
S
BA
S
+
TA
C
PR
+
M
M
F
+
C
C
S
In
cl
ud
ed
K
rä
m
er
et
al
.
20
10
13
9
TA
C
+
M
M
F
+
C
C
S
TA
C
+
M
M
F
+
C
C
S
N
/A
N
/A
In
cl
ud
ed
C
ia
nc
io
et
al
.
20
04
32
1
SR
L
+
TA
C
+
C
C
S
M
M
F
+
TA
C
+
C
C
S
SR
L
+
C
SA
+
C
C
S
N
/A
Ex
cl
ud
ed
(p
op
ul
at
io
n)
G
on
w
a
et
al
.
20
03
19
3
SR
L
+
TA
C
+
C
C
S
M
M
F
+
TA
C
+
C
C
S
N
/A
N
/A
In
cl
ud
ed
M
en
de
z
et
al
.
20
05
32
2
SR
L
+
TA
C
+
C
C
S
M
M
F
+
TA
C
+
C
C
S
N
/A
N
/A
In
cl
ud
ed
N
/A
,
no
t
ap
pl
ic
ab
le
.
DOI: 10.3310/hta20610 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 61
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Haasova et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
295

Appendix 7 Summary of model parameters
Parameter Value PSA distribution
Study characteristics (clinical effectiveness estimates from adult RCTs)
Patient age (years) 10 Not varied
Patient weight (kg) 31.8 Not varied
Proportion male 0.598 Not varied
Donor type (first graft)
DBD 0.645 Not varied
Living related 0.355 Not varied
Donor type (subsequent grafts)
DBD 0.833 Not varied
Living related 0.167 Not varied
Study characteristics (Trompeter et al.77)
Patient age (years) 10.3 Normal(10.31, 0.325)
Patient weight (kg) 32.6 Normal(32.58, 1.159)
Proportion male 0.612 Beta(120, 76)
Study characteristics (Grenda et al.75)
Patient age (years) 11.4 Normal(11.40, 0.292)
Proportion male 0.620 Beta(119, 73)
Study characteristics (Offner et al.73)
Patient age (years) 10.7 Normal(10.75, 0.342)
Proportion male 0.615 Beta(118, 74)
Surrogate relationships
Graft survival (censored for DWFG)
AR 1.60 Log-normal(0.47, 0.037)
NODAT 1.12 Log-normal(0.113, 0.061)
eGFR (ml/minute/1.73 m2)
≥ 80 1 Not varied
45–80 1.59 Log-normal(0.463, 0.571)
< 45 55.9 Log-normal(4.024, 1.203)
DWFG
NODAT 1.41 Log-normal(0.113, 0.061)
Sex= female 0.865 Log-normal(–0.145, 0.036)
Donor type
DBD 1 Not varied
Living related 0.551 Log-normal(–0.595, 0.071)
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Parameter Value PSA distribution
Age (years)
0–17 0.377 Log-normal(–0.975, 0.186)
18–30 0.369 Log-normal(–0.996, 0.117)
31–40 0.712 Log-normal(–0.339, 0.091)
41–50 1 Not varied
51–60 2.140 Log-normal(0.761, 0.059)
61–70 4.128 Log-normal(1.418, 0.053)
Effectiveness estimates from adult RCTs
Mortality within 12 months [ln(OR)]
Induction agents (vs. no induction) Multivariate normal
BAS –0.117
R-ATG –0.461
Maintenance regimens (vs. CSA+AZA) Multivariate normal
TAC+AZA 0.323
CSA+MMF –0.057
TAC+MMF 0.422
BEL+MMF –0.763
CSA+ EVL 0.333
TAC+ SRL 0.325
SRL+MMF 0.542
Head to head
MPS vs. MMF –0.435 Normal(–0.435, 1.231)
TAC-PR vs. TAC 0.245 Normal(0.245, 0.481)
Graft loss within 12 months [ln(OR)]
Induction agents (vs. no induction) Multivariate normal
BAS –0.171
R-ATG –0.253
Maintenance regimens (vs. CSA+AZA) Multivariate normal
TAC+AZA 0.135
CSA+MMF –0.297
TAC+MMF –0.379
BEL+MMF –0.492
CSA+ EVL –0.484
TAC+ SRL 0.159
SRL+MMF 0.032
Head to head
MPS vs. MMF –0.148 Normal(–0.148, 0.524)
TAC-PR vs. TAC 0.183 Normal(0.183, 0.290)
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Parameter Value PSA distribution
BPAR within 12 months [ln(OR)]
Baseline (BAS+ TAC+AZA) 0.192 Beta(19, 80)
Induction agents (vs. no induction) Multivariate normal
BAS –0.688
R-ATG –1.041
Maintenance regimens (vs. CSA+AZA) Multivariate normal
TAC+AZA –0.548
CSA+MMF –0.752
TAC+MMF –0.921
BEL+MMF –0.216
CSA+ EVL –0.784
TAC+ SRL –0.957
SRL+MMF –0.828
Head to head
MPS vs. MMF 0.396 Normal(0.396, 0.678)
TAC-PR vs. TAC –0.025 Normal(–0.025, 0.383)
Graft function at 12 months [mean difference (ml/minute/1.73 m2)]
Baseline (BAS+ TAC+AZA) 82 (SD 27) Not varied
Induction agents (vs. no induction) Multivariate normal
BAS 2.615
R-ATG 0.752
Maintenance regimens (vs. CSA+AZA) Multivariate normal
TAC+AZA 9.304
CSA+MMF 1.609
TAC+MMF 6.531
BEL+MMF 10.550
CSA+ EVL 4.863
TAC+ SRL –0.352
SRL+MMF 3.846
Head to head
MPS vs. MMF 3.9 Normal(3.9, 2.9)
TAC-PR vs. TAC –0.211 Normal(–0.211, 1.302)
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Parameter Value PSA distribution
Effectiveness estimates (Trompeter et al.77)
Mortality within 4 years
TAC+AZA 0.06 Beta(6, 97)
CSA+AZA 0.08 Beta(7, 86)
Graft loss (excluding DWFG) within 4 years
TAC+AZA 0.046 Beta(5, 98)
CSA+AZA 0.208 Beta(19, 74)
AR within 12 months
TAC+AZA 0.43 Beta(44, 58)
CSA+AZA 0.62 Beta(58, 35)
eGFR at 12 months (ml/minute/1.73 m2)
TAC+AZA 64.9 Normal(64.9, 2.17)
CSA+AZA 57.8 Normal(57.8, 2.27)
Effectiveness estimates (Grenda et al.75)
Mortality within 48 months
TAC+AZA 0.011 Beta(1.5, 92.5)
BAS+ TAC+AZA 0.000 Beta(0.5, 99.5)
Graft loss (excluding DWFG) within 48 months
TAC+AZA 0.104 Beta(10.2, 83.8)
BAS+ TAC+AZA 0.051 Beta(5.5, 94.5)
AR within 12 months
TAC+AZA 0.26 Beta(24, 69)
BAS+ TAC+AZA 0.24 Beta(23.5, 75.5)
eGFR at 12 months (ml/minute/1.73 m2)
TAC+AZA 74.9 Normal(74.9, 2.04)
BAS+ TAC+AZA 74.0 Normal(74.0, 1.98)
Effectiveness estimates (Offner et al.73)
Mortality within 48 months
BAS+CSA+MMF 0.028 Beta(3.3, 97.7)
CSA+MMF 0.000 Beta(0.5, 92.5)
Graft loss (excluding DWFG) within 48 months
BAS+CSA+MMF 0.019 Beta(1.9, 98.1)
CSA+MMF 0.011 Beta(1.0, 91.0)
AR within 12 months
BAS+CSA+MMF 0.13 Beta(13, 87)
CSA+MMF 0.23 Beta(21, 71)
eGFR at 12 months (ml/minute/1.73 m2)
BAS+CSA+MMF 79 Normal(79, 2.3)
CSA+MMF 82 Normal(82, 2.5)
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Parameter Value PSA distribution
NODAT within 12 months
Based on adult evidence
Baseline 0.040 Beta(4, 95)
Maintenance agents (vs. TAC) [ln(OR)] Multivariate normal
TAC-PR 0.169
CSA –0.816
BEL –1.671
SRL –0.234
Maintenance agents (vs. MMF) [ln(OR)] Multivariate normal
MPS –0.070
SRL 0.474
EVL –0.052
Trompeter et al.77
TAC+AZA 0.019 Beta(2,101)
CSA+AZA 0.011 Beta(1, 92)
Grenda et al.75
TAC+AZA 0.011 Beta(1, 92)
BAS+ TAC+AZA 0.040 Beta(4, 95)
Offner et al.73
BAS+CSA+MMF 0.0 Beta(0.5, 100.5)
CSA+MMF 0.0 Beta(0.5, 92.5)
AEs
CMV
Based on adult evidence
Baseline 0.258 Beta(41, 118)
Maintenance agents (vs. no mTOR-I) [ln(OR)] Multivariate normal
mTOR-I replacing CNI –0.798
mTOR-I replacing antimetabolite –1.153
Grenda et al.75
TAC+AZA 0.022 Beta(2, 91)
BAS+ TAC+AZA 0.071 Beta(7, 92)
Offner et al.73
BAS+CSA+MMF 0.128 Beta(14, 95)
CSA+MMF 0.086 Beta(8, 85)
Dyslipidaemia
Based on adult evidence
Baseline 0.555 Beta(313, 251)
Maintenance agents (vs. no mTOR-I) [ln(OR)]
mTOR-I 0.557 Normal(0.557, 0.100)
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Parameter Value PSA distribution
PTLD
Trompeter et al.77
TAC+AZA 0.029 Beta(3, 100)
CSA+AZA 0.032 Beta(3, 90)
Grenda et al.75
TAC+AZA 0.022 Beta(2, 91)
BAS+ TAC+AZA 0.010 Beta(1, 98)
Offner et al.73
BAS+CSA+MMF 0.028 Beta(3, 106)
CSA+MMF 0.054 Beta(5, 88)
Toxic nephropathy
Grenda et al.75
TAC+AZA 0.043 Beta(4, 89)
BAS+ TAC+AZA 0.141 Beta(14, 85)
Abdominal pain
Grenda et al.75
TAC+AZA 0.022 Beta(2, 91)
BAS+ TAC+AZA 0.111 Beta(11, 88)
DGF
Grenda et al.75
TAC+AZA 0.054 Beta(5, 88)
BAS+ TAC+AZA 0.111 Beta(11, 88)
Hypertension
Trompeter et al.77
TAC+AZA 0.883 Beta(91, 12)
CSA+AZA 0.871 Beta(81, 12)
Hypomagnesaemia
Trompeter et al.77
TAC+AZA 0.408 Beta(42, 61)
CSA+AZA 0.226 Beta(21, 72)
Anaemia
Based on adult evidence 0.052 Beta(207, 3762)
Retransplantation
Probability of pre-emptive retransplantation on loss of
first graft
0.2 Beta(3, 12)
Rate of retransplantation (by age)
< 18 years (HR) 3.422 Normal(3.422, 0.397)
18–64 years 0.104 Normal(0.104, 0.0023)
(Rate declines after 65 years)
Baseline rate of DWFG (subsequent grafts) 0.0078 Log-normal(–4.853, 0.472)
Baseline rate of graft loss (subsequent grafts) 0.0359 Log-normal(–3.327, 0.084)
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Parameter Value PSA distribution
Mortality
Rate of death on dialysis following graft loss (by age in years)
0–17 0.034 Normal(0.034, 0.010)
18–24 0.010 Normal(0.010, 0.003)
25–29 0.012 Normal(0.012, 0.003)
30–34 0.009 Normal(0.009, 0.002)
35–39 0.015 Normal(0.015, 0.002)
40–44 0.021 Normal(0.021, 0.002)
45–49 0.027 Normal(0.027, 0.002)
50–54 0.041 Normal(0.041, 0.003)
55–59 0.053 Normal(0.053, 0.003)
60–64 0.079 Normal(0.079, 0.004)
65–69 0.107 Normal(0.107, 0.005)
Other natural history parameters
Probability of PNF
DBD 0.014 Beta(21, 1456)
Living related 0.019 Beta(15, 755)
Proportion of NODAT in first 6 months 0.75 Beta(75, 25)
Risk stratification for CMV infection Dirichlet(54, 84, 71)
High risk (D+/R–) 0.258
Intermediate risk (D±/R+) 0.402
Low risk (D–/R–) 0.340
Risk stratification for EBV infection Dirichlet(28, 48, 6)
High risk (D+/R–) 0.341
Intermediate risk (D±/R+) 0.585
Low risk (D–/R–) 0.073
Utilities
Baseline utility Multivariate normal
Constant 0.9679812
Coefficient for age –0.001807
Coefficient for age2 –0.00000971
Coefficient for sex (male) 0.0232887
Disutilities
Functioning graft 0.053 Gamma(1.179, 0.045)
Haemodialysis 0.277 Gamma(66.90, 0.004)
Peritoneal dialysis 0.264 Gamma(35.73, 0.007)
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Parameter Value PSA distribution
Resource use
Induction therapy
BAS (10mg if weight < 35 kg; 20mg if weight ≥ 35 kg) 1.964 1+ beta(95, 4)
R-ATG drug acquisition (mg/kg) 6.5 Normal(6.5, 0.126)
R-ATG i.v. administration 4.525 Normal(4.525, 0.079)
Maintenance therapy
See Table 87 Unless SE reported or could be
calculated, a log-normal
distribution was fitted using the
method of moments and assuming
coefficient of variation of 10% with
following exceptions:
coefficient of variation= 50% for
TAC-PR vs. TAC resource use
coefficient of variation= 2% for
BEL resource use
Trompeter et al.77
TAC (with AZA) (mg/m2/day) X1 ∼ normal(8.80, 0.240)
X2 ∼ normal(6.33, 0.292)
X3 ∼ normal(4.89, 0.329)
0–6 months 7.565 (X1+X2)/2
6–12 months 5.610 (X2+X3)/2
Thereafter 4.890 X3
CSA (with AZA) (mg/m2/day) X1 ∼ normal(299.4, 10.4)
X2 ∼ normal(203.3, 5.1)
X3 ∼ normal(180.0, 6.6)
0–6 months 251.35 (X1+X2)/2
6–12 months 191.65 (X2+X3)/2
Thereafter 180.00 X3
AZA (mg/kg/day) 1.80 Normal(1.80, 0.04)
Prednisolone (mg/kg/day) X1 ∼ normal(3.9, 0.19)
X2 ∼ normal(4.5, 0.37)
X3 ∼ normal(0.3, 0.02)
0–6 months (with TAC) 2.1 (X1+X3)/2
0–6 months (with CSA) 2.4 (X2+X3)/2
Thereafter (with TAC or CSA) 0.3 X3
Grenda et al.75
TAC (with MMF) (mg/kg/day)
Throughout (prepubertal) 0.180 Normal(0.180, 0.014)
Throughout (pubertal) 0.130 Normal(0.130, 0.010)
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Parameter Value PSA distribution
MMF (with TAC) (g/m2/day)
Throughout (prepubertal) 0.54 Normal(0.54, 0.002)
Throughout (pubertal) 0.60 Normal(0.60, 0.003)
Offner et al.73
CSA (with BAS+MMF) (mg/kg/day)
0–3 months 7.80 Normal(7.80, 0.34)
3–6 months 7.15 Normal(7.15, 0.33)
6–12 months 6.65 Normal(6.65, 0.29)
Thereafter 6.20 Normal(6.20, 0.27)
CSA (with MMF) (mg/kg/day)
0–3 months 7.67 Normal(7.67, 0.34)
3–6 months 6.85 Normal(6.85, 0.30)
6–12 months 6.20 Normal(6.20, 0.28)
Thereafter 5.90 Normal(5.90, 0.26)
MMF (with BAS+CSA) (g/m2/day) X1 ∼ normal(1.06, 0.03)
X2 ∼ normal(1.06, 0.03)
X3 ∼ normal(0.96, 0.04)
X4 ∼ normal(0.93, 0.04)
0–3 months 1.06 (X1+ 2×X2)/3
3–6 months 1.01 (X2+X3)/2
6–12 months 0.95 (X3+X4)/2
Thereafter 0.93 X4
MMF (with CSA) (g/m2/day) X1 ∼ normal(1.11, 0.03)
X2 ∼ normal(1.00, 0.04)
X3 ∼ normal(0.85, 0.04)
X4 ∼ normal(0.82, 0.04)
0–3 months 1.04 (X1+ 2×X2)/3
3–6 months 0.93 (X2+X3)/2
6–12 months 0.83 (X3+X4)/2
Thereafter 0.82 X4
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Parameter Value PSA distribution
Graft loss
Proportion of failed grafts explanted by time since transplantation
0–3 months 0.41 Beta(1.95, 2.81)
3–12 months 0.23 Beta(2.85, 9.54)
12–24 months 0.09 Beta(3.55, 35.9)
24+ months 0.04 Beta(3.80, 91.2)
Proportion of failed grafts explanted (subsequent grafts) 0.056 Linear combination of above
Subsequent transplantation
Workup for retransplantation 1.44 Normal(3423, 58.5)/2370
Living donor costs 0.349 Beta(826, 1544)
Deceased donor costs 0.651 1 minus above
Maintenance immunosuppression
TAC (mg/kg/day) 0.1 Log-normal(–2.31, 0.1)
MMF (g/day) 2 Log-normal(0.688, 0.1)
Prednisolone (mg/day) 16.3 Log-normal(2.79, 0.1)
Infection prophylaxis
Co-trimoxazole (PJP and UTI prophylaxis): Septrin (480-mg
tablets in first three months)
90 Log-normal(4.49, 0.1)
Valganciclovir (CMV prophylaxis) (proportion of affected patients multiplied by time)
Full dose 0–3 months 1 Not varied
Half dose 3–6 months 0.3 Beta(3, 7)
Full dose 3–6 months 0.16 Beta(1.6, 8.4)
Valganciclovir dosage according to target dose (Daily only/alternate
days allowed)
0–337.5 450/225
337.5–675 450/450
675+ 900/900
GFR for target dose calculation 80 Normal(80, 2)
AR
Expected number of AREs per patient
experiencing 1+ARE
1.193 Normal(136, 11.7)/114
CMV infection treatment
Expected number of CMV infections per patient
experiencing 1+ CMV infection
1 Not varied
Diabetes mellitus
Antidiabetic medication: metformin 500-mg tablets per
3 months
273.9 Log-normal(5.61, 0.1)
Complications (inpatient) 0.25 Not varied
Complications (non-inpatient) 0.25 Not varied
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Parameter Value PSA distribution
Dyslipidaemia
Statins (mg per cycle per affected patient)
Fluvastatin 2191 Log-normal(7.66, 0.25)
Pravastatin 548 Log-normal(6.28, 0.25)
Simvastatin 91 Log-normal(4.48, 0.25)
Medical management (attendances per cycle per affected patient)
Dietetics outpatients 0.25 Log-normal(–1.42, 0.25)
GP 0.25 Log-normal(–1.42, 0.25)
Anaemia
Proportion requiring ESA treatment 0.052 Beta(207, 3762)
Mean weekly dose 5.832 Normal(5.832, 0.067)
Monitoring
Clinics (first 3 months) 26.1 Log-normal(3.26, 0.05)
Blood tests (first 3 months) 26.1 Log-normal(3.26, 0.05)
Clinics+ bloods (per cycle)
3–6 months 6.5 Log-normal(1.87, 0.1)
6–12 months 3 Log-normal(1.09, 0.1)
12–24 months 3 Log-normal(1.09, 0.1)
24–36 months 2 Log-normal(0.69, 0.1)
36+ months 1 Log-normal(1.87, 0.1)
Subsequent grafts 3 Log-normal(1.07, 0.25)
Viral PCR
0–3 months (CMV) (if no r-ATG) 6.02 Log-normal(1.76, 0.25)
0–3 months (CMV) (with r-ATG) 1.98 Log-normal(0.65, 0.25)
3–6 months (CMV) 0.26 Log-normal(–1.38, 0.25)
0–6 months (BKV) 1 Log-normal(–0.03, 0.25)
6–12 months (BKV) 0.5 Log-normal(–0.72, 0.25)
0–6 months (EBV) 1.02 Log-normal(–0.01, 0.25)
6–12 months (EBV) 0.34 Log-normal(–1.10, 0.25)
Viral serology (per cycle)
0–3 months (CMV) 0.26 Log-normal(–1.38, 0.25)
At 12 and 24 months (CMV) 0.60 Log-normal(–0.54, 0.25)
At 36, 48 and 60 months (CMV) 0.34 Log-normal(–1.11, 0.25)
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Parameter Value PSA distribution
Dialysis
Proportion of dialysis patients receiving haemodialysis (by age in years)
0–1 0.455 Beta(10, 12)
2–3 0.464 Beta(13, 15)
4–7 0.556 Beta(15, 12)
8–11 0.645 Beta(20, 11)
12–15 0.705 Beta(31, 13)
16–17 0.625 Beta(15, 9)
18–24 0.791 Beta(276, 73)
25–34 0.804 Beta(913, 223)
35–44 0.845 Beta(1853, 340)
45–54 0.843 Beta(3358, 624)
55–64 0.852 Beta(4408, 768)
65–74 0.858 Beta(5824, 967)
75–84 0.890 Beta(5533, 681)
85+ 0.915 Beta(1246, 116)
Access surgery
Temporary access (for HD) 1 Not varied
Long-term access (for HD) 1 Not varied
Long-term access (for PD) 1 Not varied
Unit costs
Dialysis
Access surgery
Long-term access for HD £1946 Normal(1946, 98)
Temporary access for HD (years)
< 19 £1747 Normal(1747, 113)
≥ 19 £823 Normal(823, 40)
Long-term access for PD £1101 Normal(1101, 120)
Ongoing costs (per cycle)
Haemodialysis
< 19 £20,278 Normal(20,278, 3134)
≥ 19 £6093 Normal(6093, 164)
Peritoneal dialysis
< 19 £10,515 Normal(10,515, 881)
≥ 19 £6000 Normal(6000, 183)
Induction agents
BAS and r-ATG See Table 96 Not varied
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Parameter Value PSA distribution
Maintenance agents
TAC-PR, MPS, SRL, EVL and BEL See Table 96 Not varied
TAC-IR, CSA, MMF, AZA and prednisolone See Table 97 Mixture models
AR treatment
AR (per episode) £3557 Log-normal(8.15, 0.25)
Spontaneously resolving £145 Log-normal(4.97, 0.1)
Steroid sensitive £1274 Log-normal(7.14, 0.1)
Steroid resistant (medical management) £3456 Log-normal(8.12, 0.25)
Steroid resistant (drug acquisition per kg) £44.46 Log-normal(0.64, 0.25)
Infection prophylaxis
Septrin (per 480-mg tablet) £0.16 Not varied
Valcyte (per 450-mg tablet) £18.02 Not varied
Infection treatment
CMV infection £3,009 Log-normal(7.98, 0.25)
Anaemia
Binocrit (per 1000 IU) £4.33 Not varied
Diabetes mellitus
Metformin (per 500-mg tablet) £0.0054 Normal(0.0054, 0.00001)
Complications (annual cost)
Inpatient 1389 Normal(1389, 99)
Non-inpatient 695 Normal(695, 19)
Dyslipidaemia
Statins (per mg)
Fluvastatin £0.0022 Mixture model
Pravastatin £0.0026 Mixture model
Simvastatin £0.0003 Mixture model
Medical management
Dietetics £62.70 Normal(62.70, 2.76)
GP £50.82 Normal(50.82, 5.38)
PTLD
MabThera (per mg) £1.75 Not varied
Hypertension
Amlodipine (per mg) £0.0071 Not varied
Bendroflumethiazide (per 2.5-mg tablet) £0.0344 Not varied
Captopril (per mg) £0.0035 Not varied
Hypomagnesaemia
Magnaspartate (per sachet) £0.80 Not varied
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Parameter Value PSA distribution
Drug administration
i.v. infusion (first) £228.95 Normal(228.95, 15.54)
i.v. infusion (subsequent) £325.59 Normal(325.59, 45.74)
Monitoring
Clinic £145 Log-normal(4.97, 0.1)
Viral PCR (CMV, EBV, BKV) £46.75 Log-normal(3.81, 0.25)
CMV serology £18.29 Log-normal(2.88, 0.25)
Therapeutic drug monitoring (CSA, TAC, SRL, EVL) £26.71 Log-normal(3.25, 0.25)
Full blood count £5.05 Log-normal(1.62, 0.1)
Renal profile £4.54 Log-normal(1.51, 0.1)
Liver profile £4.64 Log-normal(1.53, 0.1)
Explant
< 19 £4829 Normal(4829, 483)
≥ 19 £4966 Normal(4966, 497)
Subsequent retransplantation
Recipient workup
< 19 £505 Normal(505, 50)
≥ 19 £849 Normal(849, 84)
Living donor costs £8914 Normal(8914, 891)
Deceased donor costs £10,142 Normal(10142, 1014)
Transplant surgery
< 19 £20,913 Normal(20913, 2091)
≥ 19 £16,030 Normal(16030, 1603)
ARE, acute rejection episode; D–/R–, donor is seronegative, recipient is seronegative; D+/R–, donor is seropositive, recipient is
seronegative; D±/R+, donor is seropositive/seronegative, recipient is seropositive; HD, haemodialysis; PD, peritoneal dialysis.
Note
Normal distributions are reported as mean (SD) and beta distributions are reported as beta(α, β).
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Appendix 8 Comparison of the Peninsula
Technology Assessment Group, Astellas and previous
Assessment Group’s model-based analyses
TABLE 142 Major cost elements in the different analyses
Cost parameter
Previous Assessment
Group model2 (£) PenTAGa (£) Astellasb (£)
TAC therapy
(per year)
(£1.70/mg) 3909 With MMF
l 1114 (first year)
l 1234–1527 (second year to age 17 years)
l 959 (age 18+ years)
With AZA
l 1376 (first year)
l 1115–1579 (second year to age 17 years)
l 959 (age 18+ years)
With SRL
l Year 1: £610
l Year 2 to age 17 years (average cost per
year): £664
l Age 18 years onwards: £839
1559 (first year)
1366 (second year)
TAC administration 0 1031 (first year)
321 (second year)
214 (third year)
107 (fourth year+)
0
MMF therapy
(per year)
2737 With TAC
l 82–141 (first year to age 17 years)
l 203 (age 18+ years)
With CSA
l 138 (first year)
l 135–191 (second year to age 17 years)
l 230 (age 18+ years)
1326
CSA therapy
(per year)
1368 With MMF
l 1317 (first year)
l 1281–2194 (second year to age 17 years)
l 1071 (age 18+ years)
With AZA
l 1466 (first year)
l 1299–1841 (second year to age 17 years)
l 1078 (age 18+ years)
N/A
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TABLE 142 Major cost elements in the different analyses (continued )
Cost parameter
Previous Assessment
Group model2 (£) PenTAGa (£) Astellasb (£)
CSA administration 0 1031 (first year)
321 (second year)
214 (third year)
107 (fourth year+)
N/Ac
BEL (per year) N/A 7276 (first year)
4624 (thereafter for weight ≤ 50 kg)
9249 (thereafter for weight > 50 kg)
4018 (first year)
2374 (second year+)
BEL administration N/A 4632 (first year)
4247 (thereafter)
0
CCSs 0 46 (first year)
13–20 (thereafter)
176 (first year)
139 (second year+)
AR (event) 4644 3557 (4244 per patient experiencing AR) 2536 (first year)
2522 (second year+)
Dialysis (per year) 21,060 < 19 years
l 81,112 (HD)
l 42,058 (PD)
≥ 19 years
l 24,372 (HD)
l 24,000 (PD)
0
Retransplantation N/A < 19 years
l 20,913 (procedure only)
≥ 19 years
l 16,030 (procedure only)
5086
Retransplantation:
organ procurement
N/A 9714 0
HD, haemodialysis; PD, peritoneal dialysis.
a The values are based on applying adult weight-based doses to children and adolescents.
b Adopted a 31.5 kg weight for representative patient in the model
c Astellas does not evaluate CSA as a comparator in their submission. However, the model spreadsheets include
information where the annual costs of CSA are calculated based on market shares to be £3731 for the first and £3514
for subsequent years.
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TABLE 143 Key effectiveness assumptions and outcomes in economic models compared
Effectiveness parameter
Previous Assessment
Group model2 PenTAG Astellas
Time to graft failure (median) NR (To nearest 0.25 years,
excluding DWFG)
CSA+MMF: 14.00
TAC+MMF: 17.50
CSA+AZA: 12.00
TAC+AZA: 18.75
CSA+ EVL: 16.25
TAC+ SRL: 12.75
TAC-PR+MMF: 17.25
BAS+CSA+MMF: 16.50
BAS+ TAC+MMF: 21.00
BAS+CSA+AZA: 14.50
BAS+ TAC+AZA: 22.75
BAS+ SRL+MMF: 18.00
BAS+ BEL+MMF: 24.25
BAS+CSA+MPS: 19.25
r-ATG+CSA+MMF: 15.75
r-ATG+ TAC+MMF: 19.50
r-ATG+CSA+AZA: 13.75
r-ATG+ TAC+AZA: 21.50
Time to 15% failure
(median not achieved
within model horizon)
Without BCAR at
12 months: 7 years
With BCAR at
12 months: 6 yearsa
Time to transplantation from
graft failure (mean unless
otherwise stated)
NR Mean time to transplantation
or death following failure of
initial graft: 4.86 years (range
4.39–5.17 years)
3.5 years (median)
Annual change in GFR N/A N/A N/A
Utility of functioning graft –
first transplant
0.84
(NR, assumed is same
as Woodroffe et al.255)
0.909 (age 10 years)
0.888 (age 20 years)
0.866 (age 30 years)
0.841 (age 40 years)
0.815 (age 50 years)
0.786 (age 60 years)
0.712
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TABLE 143 Key effectiveness assumptions and outcomes in economic models compared (continued )
Effectiveness parameter
Previous Assessment
Group model2 PenTAG Astellas
Utility of functioning
graft –second+ transplants
0.84
(NR, assumed is same
as Woodroffe et al.255)
As first 0.712
Utility of dialysis state 0.65
(NR, assumed is same
as Woodroffe et al.255)
0.691 (age 10 years)
0.668 (age 20 years)
0.645 (age 30 years)
0.619 (age 40 years)
0.592 (age 50 years)
0.564 (age 60 years)
0.483
N/A, not applicable.
a Model was driven by surrogate marker of AR.
APPENDIX 8
NIHR Journals Library www.journalslibrary.nihr.ac.uk
314
TA
B
LE
14
4
R
es
u
lt
s
o
f
th
e
A
st
el
la
s
an
d
Pe
n
TA
G
m
o
d
el
-b
as
ed
an
al
ys
es
co
m
p
ar
ed
M
o
d
el
R
eg
im
en
s
co
m
p
ar
ed
Fu
n
ct
io
n
in
g
fi
rs
t
g
ra
ft
(y
ea
rs
)
Fu
n
ct
io
n
in
g
g
ra
ft
(y
ea
rs
)
Y
ea
rs
w
it
h
g
ra
ft
lo
ss
/d
ia
ly
si
s
Li
fe
-y
ea
rs
Q
A
LY
sa
C
o
st
s
(£
)a
IC
ER
in
cr
em
en
ta
l
co
st
p
er
Q
A
LY
A
st
el
la
s
TA
C
(+
M
M
F
+
C
C
S)
SR
L
I(
+
M
M
F
+
C
C
S)
EV
L
(+
M
M
F
+
C
C
S)
SR
L
II
(+
M
M
F
+
C
C
S)
BE
L
(+
M
M
F
+
C
C
S)
N
R
N
R
N
R
9.
47
2
9.
46
8
9.
46
7
9.
45
6
9.
45
5
5.
56
9
5.
56
5
5.
56
4
5.
55
3
5.
55
1
58
,4
71
52
,3
39
90
,1
68
61
,4
90
75
,7
26
TA
C
TD
vs
.
SR
L
I:
£1
,5
76
,9
37
(o
th
er
op
tio
ns
ar
e
do
m
in
at
ed
by
TA
C
TD
)
TA
C
TD
b
(+
M
M
F
+
C
C
S)
TA
C
O
D
b
(+
M
M
F
+
C
C
S)
N
R
N
R
N
R
9.
47
2
9.
50
2
5.
56
9
5.
60
4
58
,4
71
53
,3
95
TA
C
O
D
do
m
in
at
es
A
ss
es
sm
en
t
G
ro
up
(P
en
TA
G
)
TA
C
(+
M
M
F)
TA
C
(+
BA
S
+
M
M
F)
SR
L
I(
+
BA
S
+
M
M
F)
BE
L
(+
BA
S
+
M
M
F)
C
SA
(+
A
ZA
)
C
SA
(+
M
M
F)
TA
C
(+
A
ZA
)
TA
C
-P
R
(+
M
M
F)
19
.9
4
22
.4
5
20
.3
8
24
.6
2
14
.8
0
16
.7
9
20
.9
1
19
.6
8
35
.3
5
36
.2
9
35
.5
3
37
.2
4
33
.6
7
34
.3
2
35
.7
7
35
.2
1
8.
14
7.
46
8.
00
6.
89
9.
46
9.
01
7.
82
8.
17
43
.4
9
43
.7
5
43
.5
3
44
.1
2
43
.1
3
43
.3
3
43
.5
9
43
.3
8
18
.2
1
18
.3
6
18
.2
4
18
.5
9
17
.9
8
18
.1
0
18
.2
7
18
.1
5
18
2,
16
3
17
0,
91
5
19
9,
14
4
32
4,
70
8
21
2,
62
6
20
2,
42
4
17
7,
36
0
19
8,
43
3
C
SA
vs
.
TA
C
:
TA
C
do
m
in
at
es
A
ZA
vs
.
M
M
F:
A
ZA
do
m
in
at
es
(w
ith
TA
C
)
M
M
F
do
m
in
at
es
(w
ith
C
SA
)
SR
L
vs
.
TA
C
:
TA
C
do
m
in
at
es
BE
L
vs
.
TA
C
:
£6
67
,0
31
O
D
,
on
ce
da
ily
(p
ro
lo
ng
ed
re
le
as
e)
;
TD
,
tw
ic
e
da
ily
(im
m
ed
ia
te
re
le
as
e)
;
N
R,
no
t
re
po
rt
ed
.
SR
L
Ii
s
a
C
N
Im
in
im
is
at
io
n
st
ra
te
gy
(u
si
ng
SR
L)
as
us
ed
in
A
st
el
la
s’
su
bm
is
si
on
.
SR
L
II
is
a
C
N
Ia
vo
id
an
ce
st
ra
te
gy
(u
si
ng
SR
L)
as
us
ed
in
A
st
el
la
s’
su
bm
is
si
on
.
a
D
is
co
un
te
d
at
3.
5%
pe
r
ye
ar
.
b
M
od
el
ad
ju
st
ed
fo
r
co
m
pl
ia
nc
e;
th
is
an
al
ys
is
is
no
t
co
m
pa
ra
bl
e
w
ith
th
e
ab
ov
e
A
st
el
la
s
an
al
ys
es
.
DOI: 10.3310/hta20610 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 61
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Haasova et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
315

Appendix 9 Additional results from the Peninsula
Technology Assessment Group model
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TABLE 148 Total discounted costs and QALYs for scenario analyses
Regimen
Total discounted costs Total discounted QALYs
Base case Scenario 1 Scenario 2 Base case Scenario 1 Scenario 2
CSA+MMF £199,910 £197,252 £195,685 18.1269 18.1554 18.1269
TAC+MMF £179,719 £178,138 £175,974 18.2398 18.2569 18.2398
CSA+AZA £210,097 £202,041 £206,583 18.0031 18.0868 18.0031
TAC+AZA £174,989 £171,128 £171,604 18.2970 18.3387 18.2970
CSA+ EVL £259,327 £258,260 £242,849 18.2209 18.2474 18.2209
TAC+ SRL £222,300 £221,113 £215,947 17.9553 17.9696 17.9553
TAC-PR+MMF £196,165 £194,866 £189,774 18.1854 18.2008 18.1854
BAS+CSA+MMF £190,856 £191,872 £186,442 18.2468 18.2358 18.2468
BAS+ TAC+MMF £170,182 £171,903 £166,389 18.3596 18.3407 18.3596
BAS+CSA+AZA £199,042 £195,682 £195,463 18.1308 18.1663 18.1308
BAS+ TAC+AZA £164,316 £164,316 £160,885 18.4259 18.4259 18.4259
BAS+ SRL+MMF £198,631 £199,792 £191,707 18.2423 18.2277 18.2423
BAS+ BEL+MMF £293,175 £292,935 £283,749 18.5901 18.6097 18.5901
BAS+CSA+MPS £198,303 £197,393 £190,327 18.3907 18.4023 18.3907
r-ATG+CSA+MMF £209,097 £211,660 £204,555 18.0702 18.0432 18.0702
r-ATG+ TAC+MMF £189,637 £192,841 £185,673 18.1763 18.1422 18.1763
r-ATG+CSA+AZA £216,114 £215,070 £212,374 17.9721 17.9827 17.9721
r-ATG+ TAC+AZA £183,191 £184,933 £179,583 18.2468 18.2283 18.2468
Notes
Scenario 1: surrogate relationship between AR and graft survival is removed.
Scenario 2: body weight follows ninth centile for age (instead of median).
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Appendix 10 UK Transplant Registry standard
national organ transplant data set
The UK Transplant Registry maintains a standard data set, which is available on request without the need
for prior approval (URL: www.odt.nhs.uk/uk-transplant-registry/data/; Cathy Hopkinson, Statistics and
Clinical Studies, NHSBT, 15 October 2014, personal communication). The data set contains details of all
solid organ transplants (kidney, liver, pancreas, intestine, heart, lung and multiorgan) between 1995 and
2012. The data set contains limited information about the donor, recipient and match between them.
Key variables in the data set which have been used in analyses supporting the economic modelling:
l RECIP_ID – allows subsequent retransplantations to be identified and graft number to be estimated
l DTYPE (DBD; DCD; living related; living unrelated; domino; living – relationship unspecified; living
unrelated – pooled; living unrelated – altruistic) – classification of donor type (it was assumed that
relationships from domino onwards are living unrelated)
l RAGE_GRP (< 18; 18–30; 31–50; 51–60; 61–70; > 70) – recipient age group
l RSEX (male; female) – recipient sex
l TY_YR (1995; 1996; . . .; 2012) – transplant year
l TX_TYPE (kidney only; . . .) – used to restrict to kidney-only transplants
l KID_GSURV – kidney (graft) survival (days since transplantation)
l KID_GCENS – 0 if graft survival was censored; 1 if graft failed
l KID_PSURV – patient survival following kidney transplant (days since transplantation)
l KID_PCENS – 0 if patient survival was censored; 1 if patient died.
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